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ABSTRACT 
The treatment of tuberculosis (TB) is currently a challenge due to multi- and 
extensively drug resistant strains of Mycobacterium tuberculosis.  Mycobacterium 
bovis and M. tuberculosis cause clinically indistinguishable tuberculosis in humans.  
Both M. bovis and M. tuberculosis have been isolated from humans and animals.  
Plant species contain antimicrobial compounds that may lead to new anti-TB drugs.  
To conduct in vitro antimycobacterial assays, it is important to include current clinical 
isolates as new strains of bacteria might be circulating under the ongoing climate 
change environment.  The overall goal and objectives of this study were to isolate 
and characterize mycobacteria species from South Africa, to test some selected 
plant species of the Anacardiaceae family for antimycobacterial activity using some 
of the newly isolated and reference strains of mycobacteria followed by cytotoxicity 
evaluation of the most active plant species, and finally the isolation and 
characterization of at least one compound from the most active and least toxic plant.  
This study led to the discovery of a new isolate of Mycobacterium Avium Complex 
species from black wildebeest.  Other non-tuberculous mycobacteria and M. bovis 
isolates were identified from other animal species.  Five out of 15 plant species 
screened showed good activity against Mycobacterium species. Five 
antimycobacterial compounds were isolated from Searsia undulata, the most active 
plant species.  Two out of the five compounds were identified, and one compound 
appears to be novel, but both compounds have been isolated for the first time from 
Searsia undulata.  An incidental finding was the potential anticancer property of 
extracts of Searsia undulata.   
Recommended future activities include isolation and identification of more active 
compounds from Searsia undulata which were visible in bioautography analysis, as 
well as synergy evaluation of antimycobacterial activities of the different compounds 
with current anti-tubercular drugs.   
Key words: Characterization, Antimycobacterial, NTM mycobacteria, Black 
wildebeest, MDR-M. bovis, MDR-M. tuberculosis, Anacardiaceae, Searsia 
undulata, Betulonic acid.  
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The project involved the following steps: 
Isolation and characterization of Mycobacterium species 
A total of 80 samples from 44 animals were processed, and included samples from 
12 black wildebeest (Connochaetus gnou) (n=26); 10 cattle (Bos taurus) (n=31), 1 
impala (Aepyceros melampus) (n=1); 1 rabbit (Oryctolagus cuniculus) (n=2) and 20 
warthog (Phacochoerus africanus) (n=20).  These samples namely lymph nodes, 
liver, lung and kidney were obtained from slaughtered animals showing lesions 
suggestive of tuberculosis and positive reactors to tuberculin test (cattle only).  The 
methods used were isolation in liquid medium using the BACTECTM MGITTM 960 
system, solid media and Löwenstein Jensen slants, with glycerol and pyruvate.  The 
isolates were further identified using the commercial kit GenoType CM/AS reverse 
line blot assay and DNA strip Mycobacterium identification species (Hain Life 
Science, Gmbh Nehren, Germany).  The isolates were further characterized by 
multiplex PCR, spoligotyping, Mycobacterial Interspersed Repetitive Units-Variable 
Number of Tandem Repeats (MIRU-VNTR), gene sequencing, phylogenetic analysis 
and antimicrobial susceptibility test of cattle isolates (M. bovis) against first line TB 
drugs using a Genotype MTBDRplus kit (Hain Life Science GmbH, Nehren, 
Germany). 
The samples from cattle yielded 15 isolates of M. bovis; 8 out of the 15 isolates 
(53%) were resistant to isoniazid (INH) and rifampin (MDR-M. bovis), whereas 7 out 
of 15 (47%) were sensitive to both drugs.  The presence of MDR-M. bovis is of 
concern as M. bovis causes tuberculosis in humans which is clinically 
indistinguishable from TB caused by M. tuberculosis.  Added to this, there are very 
few data available in South Africa reporting human tuberculosis caused by M. bovis.  
The isolates from cattle were genotyped and yielded two spoligotypes, namely 
SB0121 (67%) and SB 1235 (33%). The VNTR was type 1.  These isolates were 
from the same origin and most likely belonged to the Kruger National Park cluster as 
reported by Hlokwe et al. 2014.   
The first batch of samples, received in February 2009, from black wildebeest yielded 
non-tuberculous mycobacteria: a novel Mycobacterium Avium Complex species was 
confirmed by gene sequencing and phylogenetic analysis and the second batch, 
received in August 2010, yielded Mycobacterium avium subspecies hominissuis (M. 
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avium subsp. hominissuis).  The sample from a rabbit also yielded M. avium subsp. 
hominissuis.  These findings were of concern as meat from black wildebeest and 
rabbit are used for human consumption.  Non-tuberculous mycobacterial species are 
among emerging mycobacteria of increasing interest as their clinical significance has 
been established in humans but their level of involvement has not yet been 
described in animals.  Additionally, some of the members of MAC have been 
reported as potentially zoonotic which includes M. avium subsp. hominissuis.  
Further investigations are needed to fully establish the pathogenicity of non-
tuberculous mycobacteria in animals and thus the depositing of new isolates at the 
international gene data bank is critical to these endeavours. 
Samples from warthogs yielded a mixture of M. bovis and non-tuberculous 
mycobacteria, namely M. intracellulare and M. avium.  The sample from impala 
yielded M. bovis.  These findings confirm that mixed infection of tuberculous and 
non-tuberculous mycobacteria occurs naturally. 
Quantitative antimycobacterial activity of selected plants, fractions and 
isolated compounds  
In seeking for alternative drugs for the treatment of tuberculosis, plant species are 
easily accessible natural resources that may contain antimicrobial compounds that 
could lead to new anti-TB drugs.  Previous preliminary screening of some tree 
species from the Anacardiaceae family showed that many of these species had good 
activity against M. smegmatis, justifying further investigations on their 
antimycobacterial activity.  Leaves from 15 Anacardiaceae tree species were 
collected, dried and extracted with acetone as a solvent which extracts plant 
compounds of varying polarities.  The leaf extracts were then screened for 
antimycobacterial activity using a two-fold serial microdilution assay against the 
pathogenic multidrug resistant M. bovis and M. tuberculosis and rapidly growing 
mycobacteria, namely M. smegmatis, M. fortuitum and M. aurum.  The vaccine 
strain, M. bovis BCG and an avirulent strain of M. tuberculosis H37Ra were also 
used.  Extraction yield ranged from 0.8% to 18.8%.  The highest percentage yield 
was observed with Searsia magaliesmontana (18.8%) followed by S. undulata 
(12.5%) and Protorhus longifolia (8.3%).  Heeria argentea had the lowest yield of 
0.8%.    
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Four out of 15 crude acetone extracts (Harpephyllum caffrum, Searsia undulata,   
Sclerocarya birrea and Protorhus longifolia) had significant antimycobacterial activity 
with minimum inhibitory concentration (MIC) values varying from 50-100 µg/mL.  
Searsia undulata had the highest activity against most mycobacteria, followed by P. 
longifolia.  Mycobacterium fortuitum was a reasonably good predictor of activity 
against MDR-TB isolates (correlation coefficient =0.65).  Searsia undulata extracts 
had significant antimycobacterial activity with the lowest MIC value of 70 µg/mL for 
M. aurum and M. fortuitum followed by M. smegmatis with MIC = 90 µg/mL.  
Protorhus longifolia also had significant antimycobacterial activity against all three 
non-tuberculous mycobacteria with MIC values of 110 µg/mL for both M. aurum and 
M. fortuitum and 70 µg/mL for M. smegmatis.  Searsia lancea, S. birrea and H. 
caffrum had moderate activity of MIC = 420, 520 and 590 µg/mL against M. aurum, 
respectively, whereas the same plant species (S. lancea, H. caffrum and S. birrea) 
had moderate activity with low MIC values of 110 to 210 µg/mL for M. smegmatis 
and M. fortuitum, respectively.  Searsia undulata had significant activity against all 
mycobacteria including MDR - M. bovis and M. tuberculosis with MIC values ranging 
from 50 to 110 µg/mL and the lowest MIC of 50 µg/mL against M. tuberculosis ATCC 
strain H37Ra.  
Bioautography using M. aurum and M. fortuitum worked well as indicators of the Rf 
values of active compounds yielding strong zones of inhibition.  The leaf extracts of 
S. undulata and P. longifolia had more than 10 different antimycobacterial 
compounds, whereas the other plant species showed none or only one to two active 
compounds depending on the non-tuberculous Mycobacterium spp. involved.  
Based on good antimycobacterial activity and low cytotoxicity, Searsia undulata was 
further processed to isolate the active antimycobacterial compounds.  The amount of 
1.5 kg of dried fine powder of S. undulata leaves was processed for acetone bulk 
extraction, followed by solvent to solvent fractionation and separation by silica gel 
column chromatography.  The isolation was bioassay-guided; fractions collected at 
different stages were tested using two-fold serial dilution to determine the minimum 
inhibitory concentration using the previous isolates of pathogenic MDR - M. bovis, M. 
tuberculosis and rapidly growing mycobacteria, M. aurum, M. fortuitum and M. 
smegmatis.  The active compounds, visible on biautography, were targeted during 
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the bioassay-guided isolation using thin layer chromatography as fingerprints to 
locate those active compounds. 
Solvent to solvent fractionation yielded five fractions, namely chloroform, hexane, 
butanol, 35% H2O-methanol and water fraction.  Chloroform, butanol and 35% H2O-
methanol fractions had clear zones of inhibition on biautography whereas the water 
fraction did not show any clear zones of activity. 
The chloroform fraction was further separated and yielded 55 fractions that were 
combined into 12 fractions (F1-F12), based on similar patterns on TLC fingerprints.  
Three out of the 12 fractions showed similar compounds using bioautography.  
These fractions were tested as already mentioned above under “quantitative 
antimycobacterial of fractions” and F5-F7 had good MIC values. These three semi-
purified fractions were combined and separated further.  
Fractions and compounds collected during different stages of isolation had good 
antimycobacterial activity.  Some of the main fractions obtained during solvent-
solvent fractionation, namely chloroform, butanol and 35% H2O methanol, showed 
similar compounds inhibiting the growth of non-tuberculous Mycobacterium spp. on 
bioautography although TLC fingerprints of the butanol fraction did not show visible 
compounds.  The chloroform fraction revealed the presence of several potential 
active fractions on the bioautogram plate sprayed with M. aurum whereas the plate 
sprayed with M. fortuitum had fewer active fractions which corresponded to a lower 
total activity observed with the combined sub-fractions F5-F7 derived from the 
chloroform fraction.  The variation of activity observed on bioautography could be 
explained by the different sensitivity of mycobacterial species towards the potential 
antimycobacterial phytochemicals present in the fractions.   
Sub-fractions F1-F12 derived from the chloroform fraction had MIC values from 58 to 
468 µg/mL.  Sub-fractions F5, F6 and F7 had significant antimycobacterial activity 
and were selected for further fractionation towards isolation of compounds with MIC 
values of 117 µg/mL for M. aurum, 234 µg/mL for M. fortuitum and 58 µg/mL for M. 
smegmatis for all fractions except F7 with MIC value of 117 µg/mL against M. 
smegmatis.  Fractions F5 and F6 showed the lowest value of 58 µg/mL against M. 
smegmatis.  Fractions F5, F6 and F7 were active against all three non-tuberculous 
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Mycobacterium spp.  The total activity of each fraction (Mass/MIC) was calculated as 
this indicates which fraction could be the best candidate for organic production of the 
compound.  Among all the fractions, F3 showed the highest total activity of 19 765 
mL/g on its own for M. aurum and less for M. fortuitum and M. smegmatis whereas 
F5, F6 and F7 had a combined total activity of 44 181 mL/g against M. smegmatis 
with F6 and F5 showing the highest activity of 19 793 and 17 154 mL/g, respectively, 
against M. smegmatis. F7 had the highest activity of 7 262 mL/g for both M. aurum 
and M. smegmatis and 3 627 mL/g for M. fortuitum.  The total activity of the 
combined fractions F5-F7 was the highest with M. smegmatis followed by total 
combined activity of 25 716 mL/g with M. aurum.   
Three compounds were isolated from the leaves of S. undulata and these had good 
antimycobacterial activity against rapidly growing Mycobacterium spp. with MIC 
values ranging from 23.44 to 250 µg/mL.  Two of the compounds (SLN1 and PK-B) 
had MIC values of 23.44 µg/mL, the lowest value for M. fortuitum, and MIC = 31.25 
µg/mL for M. aurum and M. smegmatis.  In addition, compound 3, had activity 
against all three mycobacteria with MIC = 32.25 µg/mL against M. aurum and M. 
fortuitum with the highest value of 46.88 µg/mL against M. smegmatis. 
Two of the isolated compounds were subjected to MS and NMR spectroscopy.  The 
first compound (SLN1) was identified as betulonic acid.  The second compound (PK-
B) appears to be a novel compound as it did not match with any published records 
using Scifinder search tool.  This compound will be further identified using 
crystallization, melting point determination and Fourier Transform Infrared (FTIR) 
spectroscopy.  This is the first report of isolation of betulonic acid from S. undulata.  
This compound has been reported to have anti-proliferative (anticancer) activity 
which could relate to the high cytotoxicity of the crude extract observed on human 
liver cancer cells.  Other properties reported include antiviral, anti-inflammatory and 
antimicrobial.  Besides the above three compounds, the isolation of the other active 
compounds is still underway, forming the research focus subsequent to this PhD 
study. 
Cytotoxicity of the 15 acetone crude extracts and compounds of S. undulata  
Cytotoxicity was assessed using a tetrazolium colorimetric assay (MTT) against Vero 
monkey kidney, human hepatoma (C3A) and murine macrophage (RAW 264.7) cell 
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lines.  Plants extracts of H. caffrum, L. discolor, P. longifolia, S. undulata and S. 
birrea with good antimycobacterial activity (significant to moderate) and showing one 
or more visible zones of inhibition on bioautograms were selected for cytotoxicity 
testing. All crude extracts from the above-mentioned plant species had low 
cytotoxicity against the three cell lines except S. undulata which had high toxicity 
against C3A cells and relatively low cytotoxicity on Vero kidney cells.  This finding 
deserves further investigation as it may indicate that S. undulata extracts have good 
anticancer activity.  Searsia undulata had moderate cytotoxicity with LC50 = 34 µg/mL 
for C3A and LC50 of 50 and 120 µg/mL for Vero kidney and RAW cells respectively 
with good selectivity indexes of 7.08 on Vero and more than 10 on RAW cells for 
non-tuberculous and MDR-TB mycobacteria.  Protorhus longifolia had LC50 of 620 
µg/mL on C3A cells, 880 µg/mL on Vero cells and more than 1 000 µg/mL on RAW 
cells with the highest selectivity index on Vero cells of 12.6 for M. smegmatis 
followed by 8.02 for M. aurum, M. fortuitum and MDR-TB.  Extracts with SI > 1 may 
indicate better safety as they are less toxic to the mammalian cells but more toxic to 
pathogens but this will need to be confirmed with in vivo tests.   
Only three compounds out of the five which were isolated in sufficient quantity were 
tested for cytotoxicity using Vero cells. PK-B was the least toxic with LC50 of 210 
µg/mL whereas compound 3 and SLN1 showed moderate cytotoxicity of 31.3 µg/mL 
and 47.7 µg/mL, respectively. 
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CHAPTER 1: 
GENERAL INTRODUCTION AND LITERATURE REVIEW 
1.1 GENERAL INTRODUCTION  
Many human diseases that are new, emerging or re-emerging at present, are caused 
by pathogens that originate from animals or products of animal origin (Müller et al., 
2013).  Tuberculosis can be foodborne or airborne and is one of the most important 
human infections in the world with more than 2 million new cases occurring each 
year, mostly in developing countries (WHO, 2015).   
The emergence of multi-drug resistant (MDR) strains of Mycobacterium tuberculosis 
associated with human immunodeficiency virus (HIV) / acquired immunodeficiency 
syndrome (AIDS) is of great epidemiological concern.  Species belonging to the 
Mycobacterium tuberculosis (MTB) complex include M. tuberculosis, M. bovis, M. 
africanum, M. canetti, M. pinnipedii, M. caprae, M. microti, M. mungi, Dassie bacillus, 
Oryx bacillus (M. orygis) and M. surricatae (Alexander et al., 2010; Azé et al., 2015; 
Clarke et al., 2016; Helden et al., 2009).   There are other pathogenic non-
tuberculous mycobacterium (NTM) species for example Mycobacterium avium 
complex (MAC) which consists of two closely related species, M. avium and M. 
intracellulare (Legrand et al., 2000).  The importance of NTM has received much 
attention during the past decade, especially in humans.  They are found widely in 
soil, water, near human settlements and aerosols and can be associated with 
colonization, serious infection or pseudo-outbreaks with a wide variety of 
presentations (Biet et al., 2005; Kankya et al., 2011; Katale et al., 2014). 
The isolation of NTM from human clinical samples of patients (HIV positive or HIV 
negative) with pulmonary symptoms as suspected cases of tuberculosis has 
increased over the years and has been observed in different countries in Africa, 
America and Europe (Kankya et al., 2011; Katale et al., 2014; Mirsaeidi et al., 2014a; 
Moore et al., 2010).  In animals, the clinical significance of NTM has yet to be 
elucidated in the disease-causing process (Chege et al., 2008; Kankya et al., 2011; 
Katale et al., 2014). 
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The management, treatment and infection control measures differ significantly 
between M. tuberculosis and NTM infections.  One hundred and sixty species of 
NTM have been reported worldwide, of which more than 60% are pathogenic to 
animals or humans (BoRam et al., 2014; Tortoli, 2014).  In South Africa, reports on 
the isolation of NTM in animals, humans and the environment and their effects in 
disease-causing processes are limited (Gcebe et al., 2013; Kabongo-Kayoka et al., 
2015; Michel et al., 2007; Müller et al., 2011). 
As far as tuberculosis is concerned in humans, there are several underlying medical 
conditions that are associated with an increased risk of progressing to tuberculosis 
such as HIV infection, diabetes mellitus, renal failure, malnutrition or advanced 
malignancy but the disease can develop in people who do not have any of the 
mentioned risk factors, most likely due to genetic susceptibility (Gopathi et al., 2015). 
South Africa has one of the highest tuberculosis incidence rates in the world (WHO, 
2015).  Twenty one million people are infected with TB of which 5-10% may develop 
active tuberculosis whereas the majority of individuals (90-95%) infected with M. 
tuberculosis will never develop the disease (Lienhardt et al., 2016). The clinical 
manifestation of tuberculosis is worsened when associated with HIV/AIDS due to the 
concomitant immunosuppression (Swaminathan and Chandrasekaran, 2014). 
The most common route of infection (95%) is inhalation of infectious droplet nuclei 
through the air-borne route but the foodborne/alimentary route also plays an 
important role in the dissemination of the disease as does the handling of 
contaminated fomites (Inderlied, 2004; Wani, 2013).  The exposure to M. 
tuberculosis bacilli does not always lead to infection and not all the patients are 
infectious.  Only individuals with active pulmonary or laryngeal tuberculosis are 
infectious.   Infectious individuals propel TB bacilli in the air by coughing, sneezing, 
spitting, talking or singing.   The risk of infection is directly related to the number and 
distribution of tubercle bacilli in the inhaled and respired air (Inderlied, 2004).  
Coughing and talking for 5 minutes can produce 3 000 infectious droplet nuclei and 
sneezing can produce over a million particles (Alland et al., 1994).  Inhaled droplet 
nuclei that are less than 100 nm in diameter usually travel through the airway until 
they reach the alveoli whereas the larger particles that are deposited on the way are 
removed through the normal mechanism of airway clearance (Dannenberg  Jr, 
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1989).  The first step of possible infection is the contact between the bacteria and 
lung alveolar epithelial mucosal cells and attending macrophages. The inhaled bacilli 
are phagocytosed, processed, and presented by alveolar macrophages to the T-
lymphocytes (Gopathi et al., 2015).  The probability of an infection depends on the 
ability of the mycobacterium to survive within the macrophages, in this way evading 
many host defence mechanisms (Figure 1.1).  During this phase, unless a patient 
receives prophylactic treatment, symptomatic disease will eventually occur in 5-10% 
of infected patients (Inderlied, 2004; Lin and Flynn, 2010). 
Several methods have been described for identifying Mycobacterium species. 
Conventional methods continue to be used such as smears, mycobacterial cultures 
and chest radiography but other technologies have emerged that include nucleic acid 
amplification tests, immune based assays, skin path test and rapid culture systems 
(Barnard et al., 2008; Pai et al., 2006).  Mycobacterial cultures and histopathology 
are essential for confirmation of TB infection; molecular characterization is used for 
identification and studying the spatial spread of mycobacteria whereas phylogenetic 
analysis has been used for analysis of morphological and molecular data to define 
relationships of mycobacteria isolates (Barnard et al., 2008; Pai et al., 2006). 
Control measures of TB in animals depend on the primary objectives for the specific 
ecosystem, being wild animals or domestic animals. Currently, control and 
monitoring of infected animals are done using the intradermal tuberculin test.  In 
humans, vaccination remains the ultimate control measure but it has been reported 
that the vaccination is no longer as effective as it was in the past.  There are 15 
vaccines that are currently on trial in different countries (WHO, 2015). 
In general, TB is not treated in animals - the testing and slaughter policy is followed 
whereas in humans, the treatment of tuberculosis has become a challenge due to 
emerging multi-drug resistant strains (MDR). The molecular basis of MDR 
tuberculosis has been well documented (Bosne-David et al., 2000; Cingolani et al., 
1999; Musser, 1995; Sreevatsan et al., 1997).  Mutations that occur in the target 
genes of M. tuberculosis and M. bovis strains are the most common mechanisms of 
resistance encountered for primary antimycobacterial agents such as rifampin, 
isoniazid and streptomycin.  The World Health Organization estimates that up to 50 
million persons worldwide may be infected with drug resistant strains of M. 
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tuberculosis (WHO, 2015).  As far as genetic assessment is concerned, there are 
limited data available on drug resistant M. bovis strains and this species is 
transmissible to humans (Blazquez et al., 1997). 
 
Figure 1.1: Macrophage phacocytosis and evasion of tubercle bacilli (Inderlied, 2004) 
(1). The tubercle bacilli bind via lipoarabinomannan (LAM) or complement receptors (2); 
phagocytosis occurs (3) with the activation of an oxidative burst with superoxide dismutase 
(SOD) (4), glycolipids (GL), sulfatides (ST), thiols and LAM downregulate the oxidative burst 
(5), reactive nitrogen intermediates may play a role in antimycobacterial activity (6), similar 
role is played by the acidic pH of the phagolysosome (7).  The production of ammonia by 
tubercles may diminish the effect of reactive nitrogen intermediates (8) and contribute to the 
failure to form a phagolysosome fusion (9).  The tubercle bacilli may evade the 
antimycobacterial activities of the phagolysosome by producing a hemolysin that releases the 
bacilli into the cytoplasm (10). 
Plants have been used as resources for many traditional medicine systems 
throughout the world for centuries and continue to provide people with new 
remedies.  Numerous useful drugs were developed from compounds isolated from 
medicinal plants.  Up to this day, this strategy remains an essential route to new 
pharmaceuticals (Balunas and Kinghorn, 2005; Jachak and Saklani, 2007).  There 
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are also few publications showing activity of certain plants against the rapidly 
growing mycobacteria, namely M. aurum, M. bovis BCG, M. smegmatis and M. 
fortuitum  (Chimponda and Mukanganyama, 2010; Ghaemi et al., 2011; Mariita et al., 
2010; Nguta et al., 2016).  Further investigation is needed to evaluate activity against 
the pathogenic mycobacteria, namely M. bovis and M. tuberculosis.  
A large proportion of the populations in developing countries use traditional 
medicines for primary health care.  It is estimated that 80% of the world’s population 
utilize plants as their primary source of medicinal agents (Cowan, 1999; Fabricant 
and Farnsworth, 2001).  In South Africa up to 60% of the population consult 
traditional healers as an alternative to or in addition to Western health care providers 
(Van Vuuren, 2008).  The reliance on traditional medicine can be attributed to 
availability, accessibility, affordability, extensive traditional knowledge and expertise 
within communities (Gurib-Fakim, 2006). 
Much therapeutics used daily in South Africa is still derived from plants.  This 
presents a valuable resource for research into the development of new 
pharmaceutical drugs and there has been a growing interest in natural and traditional 
medicines as sources of new medicinal products of commercial value 
(Mahomoodally et al., 2010; Rybicki et al., 2012).  Approximately 30 000 plant 
species of South Africa form a useful potential pool for the screening of new 
therapeutic compounds.  Conventional medicine has been accepting the use of 
traditional medicine once scientifically validated (Mukherjee et al., 2010).  Some 
traditional healers use the different parts of the whole plant depending on the 
disease (Street et al., 2008; Van Wyk, 2008a). 
It is often preferable to screen leaves rather than roots or bark for potential biological 
activity as part of promoting sustainability of the environment.  Traditional health 
practitioners predominantly use water as an extractant but it has been reported that 
some compounds including antimicrobials are not commonly extracted by water 
(Kotzé and Eloff, 2002).  Among other organic solvents, acetone has proven not to 
be bactericidal at the concentration used in the bioassay (Eloff et al., 2007) and 
therefore, it is a solvent of choice as extractant in the investigation of antimicrobial 
activities of plant extracts including antimycobacterial activities (Eloff, 1998a). 
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Isolation and identification of compounds from plants have been explored using 
different research techniques, among others bioassay-guided fractionation, which 
involves repetitive fractionation of extracts in order to determine the biological activity 
of each fraction against a specific organism (Brusotti et al., 2014).  This method is 
time-consuming and labour intensive but provides a rational means to isolate 
bioactive compounds from a complex mixture (Bero et al., 2011). 
Other methods that have been used comprise thin layer chromatography (TLC), gas 
or liquid chromatography, mass spectrometry, open column chromatography on 
silica gel, nuclear magnetic resonance (NMR) spectroscopy and Fourier Transform 
Infra-Red (FTIR) spectroscopy (Harborne, 1998). 
Nuclear magnetic resonance is the most frequently used technique by chemist and 
biochemists to identify the structure of organic molecules.  Samples may be 
analysed with 1-dimensional proton and 2-dimensional carbon 13 NMR spectroscopy 
(Exarchou et al., 2003; Ward et al., 2007). 
1.2 LITERATURE REVIEW 
1.2.1 Tuberculosis epidemiology 
1.2.1.1 Tuberculosis in humans 
Tuberculosis (TB) is one of the major causes of illness and death in the world, 
especially in Asia and Africa (Figure 1.2).  The incidence of this disease may still be 
under-reported in countries with limited laboratory skills.  According to the World 
Health Organization report (2015), 9.6 million of TB cases occurred in 2014, 1.5 
million people died of TB, and among these mortalities, 1.1 million were HIV negative 
and 0.4 million HIV positive.  While life expectancy has been increasing for HIV/AIDS 
individuals due to antiretroviral drugs, the battle against TB is still a challenge.   
Tuberculosis remains one of the world’s biggest threats alongside HIV as a leading 
cause of death.  It has been reported that the ratio of patients under treatment to 
patients newly notified as having MDR-TB or rifampicin resistant TB was 90% 
globally (WHO, 2015).  Only 50% of MDR-TB patients were successfully treated 
globally.  An estimated 9.7% of people with MDR-TB have extensively drug resistant 
(XDR) TB (WHO, 2015).  South Africa has the highest incidence rate of TB per 
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capita of 500 per 100 000 population (Figure 1.2).  South Africa is on the list of 30 
high burden TB countries in the world according to the World Health Organization 
(2015).  A large proportion (59%) of people living with co-infection of HIV and TB has 
been reported in South Africa (WHO, 2015). 
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                            Figure 1.2: Map showing the estimated new TB cases in the world (WHO, 2015) 
Source: courtesy of www.who.int 
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Most of the TB drugs currently in use were introduced more than 50 years ago.  New 
drugs approved for treatment of TB, namely rifabutin and rifapentine, are not yet 
widely available (León-Díaz et al., 2013; Svensson et al., 2014).  After a pilot trial 
conducted in South Africa (Diacon et al., 2012), a treatment programme was 
introduced in March 2014 for XDR-TB patients using the first new drug after more 
than 50 years, bedaquiline, initially known as diarylquinolone TMC 207.  This drug 
has a new mechanism of action which consists of inhibiting ATP synthase 
(Ganihigama et al., 2015).  Another new MDR-TB treatment using delamanid has 
also been tested (Xavier and Lakshmanan, 2014).  Linezolid, an antibiotic 
discovered during the late 1990’s, has been used in combination with bedaquiline 
(Sotgiu et al., 2013; Zumla et al., 2013).  Antibiotic resistance is a continuous threat; 
therefore, research for alternative drugs is ongoing to broaden the range of effective 
and safe potential antimycobacterial drugs.  Indeed, studies conducted in countries 
such as Europe, Africa, America and Canada have led to isolation of different 
chemical compounds, namely allicin, alkaloids, arjunic acid, anthraquinone, 
anthocyanidin, beta-sitosterol, benzophenanthridine alkaloids, crinine, decarine,  
mellagitannin, neolignans, elligitannin, ellagic acids, friedelin, gallic acid, 
galanthimine, glucopyranosides, glycosides, hydroxybenzoic acids, iridoids, 
phenylpropanoids, 1-epicatechol, leucopelargonidol, punicalagin, taraxerol and 
termilignan B (Chinsembu, 2016; Mukanganyama et al., 2015).  Some of these 
compounds may provide leads to the development of new and less toxic drugs to 
lessen the global burden of TB and drug resistant M. tuberculosis strains. 
1.2.1.2 Tuberculosis in animals 
Tuberculosis in cattle is caused mainly by M. bovis and cattle are considered the true 
host; in other words they are the main maintenance host of M. bovis in domestic 
animals.  In South Africa, M. bovis infection  has been confirmed in the following wild 
species: African buffalo (Syncerus caffer), Greater Kudu (Tragelaphus strepsiceros), 
Lion (Panthera leo), Eland (Taurotragus oryx), Warthog (Phacochoerus aethiopicus), 
Bushpig (Potamochoerus porcus), Large spotted genet (Genetta tigrina), Leopard 
(Panthera pardus), Spotted hyena (Crocuta crocuta), Cheetah (Acinonyx  jubatus), 
Chacma baboon (Papio ursinus), Impala (Aepyceros melampus) and Honey badger 
(Mellivora capensis) (Bengis et al., 2002, 1996; Hang’ombe et al., 2012; Hlokwe et 
al., 2013; Palmer et al., 2012).  Mycobacterium bovis has also been isolated from 
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bison, sheep, goats, equines, camels, pigs, wild boars, deer, antelopes, dogs, cats, 
foxes, mink, badgers, ferrets, rats, primates, llamas, elands, tapirs, elks, elephants, 
sitatungas, oryxes, addaxes, rhinoceroses, possums, ground squirrels, otters, seals, 
hares, moles, racoons, coyotes and several predatory felines including tigers and 
lynx (O’Brien et al., 2002 and OIE, 2014). 
Tuberculosis is a zoonotic disease as it occurs in both humans and animals with 
similar clinical features (Cousins, 2001; De la Rua-Domenech, 2006a; Grange, 
2001).   It is primarily a respiratory disease and transmission of infection is mainly by 
the airborne route although the food-borne route is also encountered.  It can also be 
systemic and affect different organs in the body (De la Rua-Domenech, 2006; 
Fanning, 1999). 
Many susceptible species including man are considered spill-over hosts as they 
harbour Mycobacterium bovis as long as the maintenance host is present but still 
can spread the disease.  In some instances, spill overs can become maintenance 
hosts and spill back to the initial hosts.  The African buffalo (Syncerus caffer) in 
South Africa is considered a maintenance host for M. bovis (Bengis et al., 2002; 
Michel et al., 2010; Vos et al., 2001) while there is spill-over to other species (Vos et 
al., 2001).  In Canada, the wapiti (Cervus elaphus) and bison (Bison bison) are 
reservoirs (Nishi et al., 2006); in USA, the white-tailed deer population is the wildlife 
reservoir for M. bovis (de Lisle et al., 2002; O’Brien et al., 2002; Schmitt et al., 2002); 
European badger (Meles meles) are reservoir hosts in Ireland, United Kingdom 
(Corner, 2006); brushtail possums (Trichosurus vulpecula) are the primary 
maintenance host in New Zealand (Nugent, 2011).  Tuberculosis in captive deer or 
wild cervids has been observed in Europe and America; wild boars (Sus scrofa) are 
maintenance hosts for other wildlife and domestic animals in Europe (Naranjo et al., 
2008).  Wildlife may contaminate cattle by direct or indirect contact at the wildlife- 
livestock interface (Michel et al., 2010). 
In South Africa, recent studies have also revealed that interspecies spreading of M. 
bovis is extending to different animal species in different provinces; spoligotyping 
has revealed that some strains are from the same origin which implies that there is 
indeed inter- and intra-species spreading of the disease (Hlokwe et al., 2014).  This 
situation is of concern as it makes the control of TB difficult.  In this study, adding to 
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the animal species mentioned in the first paragraph, M. bovis was also isolated from 
cattle (Bos taurus), bushbuck (Tragelaphus scriptus and Tragelaphus sylvaticus) 
nyala (Tragelaphus angasii), waterbuck (Kobus ellipsiprymnus) and wildebeest  
(Connochaetes gnou and Connochaetes taurinus) (Hlokwe et al., 2014).  Human 
infections with M. bovis have been reported (Cosivi et al., 1998; de Kantor et al., 
2008; De Kantor et al., 2010; De la Rua-Domenech, 2006; Thoen et al., 2009).  A 
study conducted in California confirmed cases of M. bovis in children and adults 
(Gallivan et al., 2015).  Mycobacterium bovis in adults was associated with HIV or 
other immunosuppressive disease such as diabetes, whereas in children the clinical 
picture was usually mainly extra-pulmonary TB.  Human to human transmission of M. 
bovis in immunocompetent patients has also been reported in France (Sunder et al., 
2009).   
Tuberculosis is not treated in animals; the test and slaughter approach is used to 
control the spread of the disease (Cousins, 2001).  In South Africa, eradication of 
tuberculosis in livestock is sometimes compromised due to the lack of tuberculin 
stock (Matt Ekron, personal communication 2010).  Adding to this, the 
implementation of the test and slaughter policy is either non-existent or compromised 
due to lack of farmers’ compensation by the government subsidies and the increase 
of emerging farmers (Personal communication and observation during the course of 
this research 2009-2012;  Department of Agriculture, Forestry and Fisheries; Musoke 
et al., 2015).  In developing countries, human tuberculosis caused by M. bovis is 
probably under-reported as there are limitations of laboratories in identifying and 
differentiating M. bovis from M. tuberculosis.  In countries where there is 
transmission of infection from endemically infected wildlife populations to cattle or 
other farmed animals, eradication is not feasible as wild animals play the role of 
maintenance hosts and control measures must be applied indefinitely,  and this is 
also the case in South Africa (Keet et al., 2001; Michel et al., 2010). 
Bovine TB has been reduced or eliminated in many developed countries but there 
are pockets of infected reservoirs in wildlife in Canada, the United Kingdom, the 
United States of America and New Zealand (Corner et al., 2009; de Lisle et al., 2002; 
Naranjo et al., 2008; Nugent, 2011).  The prevalence of bovine TB has been found to 
be high in certain populations of animals.  In South Africa, the highest prevalence of 
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70% was reported in buffaloes (Kriek et al., 1996) whereas in Zambia, the 
prevalence of 50% has been reported in Kafue where lechwe antelopes are the 
maintenance hosts (Munyeme et al., 2010).  Infected wild animals are a source of 
infections for other animal species through ingestion of infected meat or carcasses 
by lions, cheetah and baboons.  Sharing of extensive grazing land is also a factor in 
the spreading of the disease among animals (Munyeme et al., 2010).  A similar 
situation has been reported in New Zealand where maintenance hosts are mainly 
ferrets (Mustela furo) and stoats (Mustela erminea); ferrets could also infect cattle 
and farmed deers.  
The zoonotic transmission of TB infection in humans is likely to occur by inhalation of 
infected droplets which are expelled from the lungs during coughing of sick animals. 
Calves and humans can also become infected by ingesting raw milk from infected 
cows or by handling contaminated fomites on the farm or premises where infected 
animals are housed or post-mortem in the laboratory (Cosivi et al., 1998).  China 
among others has been identified as a high burden TB country (WHO, 2015).  It has 
been reported that cattle maintain both M. bovis and M. tuberculosis.  Although M. 
tuberculosis was thought to be non-pathogenic to cattle, there has been evidence of 
M. tuberculosis isolated from cattle tissues with and without tuberculous lesions 
(Prasad et al., 2005; Une and Mori, 2007).   
The course of the disease is slow; taking months or years to kill an infected animal, 
thus, an animal can spread the disease to many other animals in the herd before it 
begins to manifest clinical signs. Therefore, movement of undetected infected 
domestic animals and contact with infected wild animals are the major ways of 
spreading the disease (Cosivi et al., 1998; Hlokwe et al., 2014; Michel et al., 2008). 
1.2.2 Mycobacteria 
Bacterial ecology is broad and complex, therefore our knowledge is still limited as 
most bacteria are still unknown, with new enzymatic functions or new products to be 
isolated (Busse et al., 1996).  Mycobacteria belong to the family Mycobacteriaceae 
and the genus Mycobacterium.  The members of the genus Mycobacterium are 
genetically closer to each other than the microorganisms belonging to other genera, 
making identification a difficult and challenging task.  This genus includes species 
 13 
 
that cause tuberculosis and those that cause disease conditions other than 
tuberculosis called “non-tuberculous mycobacteria” or NTM.   
The genus Mycobacterium contains more than 170 species 
(http://www.bacterio.net/mycobacterium.html) most of which are classified as NTM or 
potentially pathogenic mycobacteria (PPM); (BoRam et al., 2014; Chege et al., 2008; 
Malama et al., 2014; Tortoli, 2014) and mycobacteria belonging to the 
Mycobacterium tuberculosis complex (MTC).  The MTC comprises M. tuberculosis, 
M. bovis, M. africanum, M. canetti, M. pinnipedii, M. caprae, M. microti, M. mungi, 
Dassie bacillus, Oryx bacillus (M. orygis), M. surricatae and the attenuated M. bovis 
Bacille Calmette–Guerin (BCG) vaccine strain.  With the exception of BCG, these 
species are obligate parasites, pathogenic and can cause tuberculosis (TB) in 
mammalian hosts (Alexander et al., 2010; Azé et al., 2015; Pittius et al., 2012; Vos et 
al., 2001).  The prominent pathogens in the MTC include M. tuberculosis and M. 
bovis; both species are incriminated in cases of human and bovine tuberculosis 
because M. bovis is transmitted zoonotically.   
Mycobacteria are aerobic, non-motile single cell, non-sporeforming and are straight 
or slightly curved rods. They are considered Gram-positive although they are not 
stained easily by Gram’s stain.  They are grouped in the suprageneric rank of 
actinomycetes that, unusually, have a high content of guanine (61-71%) and 
cytosine (G+C) in the genomic deoxyribonucleic acid (DNA).  The most prominent 
feature of mycobacteria that is uniformly present and distinctive to the genus is the 
complex, lipid-rich cell envelope (Figure 1.3).  The structure of the mycobacterial cell 
envelope comprises a plasma membrane, a peptidoglycan layer, an arabinogalactan 
layer esterified to an uneven mycolate layer, and a glycolipid layer.  
Lipoarabinomannan and a small number of porins traverse the width of the 
mycobacterial envelope (Daffé and Reyrat, 2008).  A common feature of the 
mycobacterial envelope is the lipid shell which is made of a thick, hydrophobic waxy 
cell wall rich in mycolic acids up to 50% (Chatterjee, 1997; Riley, 2006).  This is one 
of the main characteristics of the genus responsible for acid fastness, extreme 
hydrophobicity, and resistance to injury such as desiccation and most disinfectants 
including the drugs (antibiotics) as well as distinctive immunological properties.  It 
also contributes to the slow growth rate of some species by restricting the uptake of 
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nutrients (Hett and Rubin, 2008; Niederweis, 2003).  Based on the growth rate, 
mycobacteria are divided into two groups: rapid growers and slow growers. Rapid 
growers are separated from slowly growing mycobacteria according to the time 
required to produce clearly visible colonies which is about 7 days or less for rapid 
growers (Inderlied, 2004) whereas most pathogenic mycobacteria are slow growing 
organisms.  Mycobacterium smegmatis (rapidly growing) has a generation time of 2-
4 h whereas M. tuberculosis (slow grower) has a generation time of 16-18 h  
(Wayne, 1994).  Adding to the lipids, peptidoglycan is another major component of 
the mycobacterial cell wall.   
 
      Figure 1.3: Mycobacterial cell envelopes (Riley, 2006) 
Source: courtesy of www.jci.org 
When processing samples for isolation, the resistance of the cell wall due to the high 
lipid content allows treatment of samples with acid or alkali to kill microbial 
contaminants without destroying the mycobacteria.  Mycobacteria are acid-fast 
organisms. Ziehl-Neelsen is the stain of choice for their microscopic visualization; 
once stained with carbol fuchsin, they cannot be decolourized by acid-alcohol and 
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hence they are referred to as “acid fast” (Figure 1.4).  With Ziehl-Neelsen stain, the 
bacilli appear as stained dark pink rods against a deep sky-blue background.  
Mycobacterium and other closely related genera namely Corynebacterium, Gordona, 
Tsukamurella, Nocardia, Rhodococcus and Dietzia have similar cell wall compounds 
and structure and show some phenotypic resemblance.   
 
Figure 1.4: Mycobacterium tuberculosis stained by Ziehl-Neelsen method, appearing              
as dark pink straight and curved rods (Brehar, 2015) 
Source: courtesy of www.slideshare.net  
1.2.2.1 Mycobacterium tuberculosis 
In the 1700s and early 1800s, tuberculosis prevalence reached its peak in Western 
Europe and the United States and was the most common cause of death.  A 
hundred years later, it spread to Eastern Europe, Asia, Africa and South America 
(Bloom and Murray, 1992).  Today, tuberculosis has re-emerged as one of the 
prevalent causes of death worldwide.  Mycobacterium tuberculosis can also infect 
animals (Maslow and Mikota, 2015; Michel et al., 2010; Mikota et al., 2001).  It is the 
main cause of human tuberculosis and was first described by Robert Koch in 1882. 
He was able to reproduce the disease in guinea pigs and rabbits and isolated the 
bacillus in pure culture (Mikota et al., 2001).  This microorganism is also known as 
Koch’s bacillus.  As previously mentioned, it belongs to the M. tuberculosis complex.  
In 1891, Koch developed tuberculin, a purified sterile protein extracted from culture 
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of M. tuberculosis, which was used for immunity or treatment of the disease.  It is still 
a valuable diagnostic and control tool for the detection of the disease caused by M. 
tuberculosis or M. bovis; it is used in cattle to identify infected animals that react 
positively on the tuberculin test.  These animals are either slaughtered or isolated in 
control programmes.  Purified protein obtained from cultures of M. bovis or M. avium 
can also be used in the comparative tuberculin test (Corner, 2007; Musoke et al., 
2015; Tweddle and Livingstone, 1994).   
Microscopically, M. tuberculosis appears as a fairly large, slender, non-motile, 
slightly curved or straight, rod shaped bacterium.  The rods are 1.0 to 4.0 µm in 
length and 0.2 to 0.5 µm in width surrounded by a multi-layered cell wall of about 20 
nm thicknesses.  One of the features of this mycobacterium is formation of cords 
(Figure 1.5), which is due to the presence of a glycolipid loosely bound in the outer 
layer of the cell wall (Chan et al., 1991; Glickman et al., 2000).  The cord factor is 
thought to be important as a virulent factor because it inhibits secretion of tumour 
necrosis factor alpha (TNF) by macrophages (Clay et al., 2008; Ryll et al., 2001). 
 
    Figure 1.5: Mycobacterium tuberculosis cord factor.  
Source: courtesy of www.intranet.tdmu.edu.ua  
Macroscopically, M. tuberculosis grows on medium containing egg yolk (Löwenstein-
Jensen) and colonies appear as raised, dry, cream-yellowish coloured colonies.  The 
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colonies are tough and difficult to pick up with a loop from the surface of the agar 
(Figure 1.6). 
 
 Figure 1.6: Colonies of M. tuberculosis on Löwenstein-Jensen agar slope tubes  
Source: courtesy of www.microbiologyinfo.com 
People with compromised immunity due to factors such as malnutrition, physical 
stress, poor access to health services, overcrowded conditions, and other diseases 
namely HIV/AIDS, diabetes etc. are more susceptible to TB.  In general, the natural 
body defences of an individual can prevent the infection from developing into active 
disease.  Besides human infection, M. tuberculosis and M. tuberculosis-like 
organisms have been reported in a wide range of species that include non-human 
primates, elephants and other exotic ungulates, carnivores, marine mammals and 
psittacine birds, and transmission from some of these species namely non-human 
primates, Asian elephants and psittacine birds to humans has been reported  
(Maslow and Mikota, 2015; Ocepek et al., 2005). 
1.2.2.2 Mycobacterium bovis 
Bovine tuberculosis existed in the Mediterranean littoral before classical times.  From 
Northern Italy, it spread to Western Europe and Great Britain then, cattle imported 
from Holland and Great Britain spread the disease to other parts of the world that 
were colonized by those countries (Myers and Steele, 1969).   
 18 
 
The first reference to animal tuberculosis in South Africa was made by Hutcheon in 
1880 after importation of European breeds; in 1902, many animals imported from 
Australia, Argentina, Madagascar and England were destroyed in Durban after a 
positive reaction in the tuberculin test (Henning, 1956).  The spread in South Africa 
was originally confined to dairy farms but more beef herds have been found to be 
infected (Hlokwe et al., 2011; Musoke et al., 2015).  Bovine tuberculosis was first 
recorded in Zimbabwe in 1908 in a heifer imported from the Cape Peninsula.   With 
movement of cattle and animals across the world, Mycobacterium bovis has since 
been isolated in domestic and wild animals and humans in different African countries 
(Ayele et al., 2004; Cosivi et al., 1998; Hlokwe et al., 2014; Marcotty et al., 2013; 
Michel et al., 2010; Munyeme et al., 2010a; Munyeme et al., 2010b; Musoke et al., 
2015; Thoen et al., 2009). 
Bovine tuberculosis has been a notifiable and controlled disease in South Africa 
since 1911.  Under the Animal Diseases Act No 27 of 1903, individual animals and 
herds which had been in contact with cases that tested positive and with infected 
animals based on lesions observed at the abattoir were subjected to compulsory 
tuberculin testing.  Reactors were slaughtered and their owners compensated.  Later 
on, this act was replaced by voluntary accreditation of the herd meaning that farm 
owners voluntarily joined the bovine tuberculosis eradication scheme.  The scheme 
objective of total eradication through a test and slaughter policy was introduced in 
1969 and it has since been in operation to date under the Animal Diseases Act No 
35 of 1984 (www.nda.agric.za).  
Although Mycobacterium bovis is of greatest concern in cattle as the primary host, it 
can occur in humans and many other domesticated and wild animal species.  Goats 
and swine are highly susceptible to infection, while sheep and horses are more 
resistant (Pavlik et al., 2003).  Besides known maintenance reservoir hosts 
previously mentioned, some authors believe that there are species that could be 
spill-over hosts that maintain the organism only when its population density is high.  
Species reported to be spill-over hosts include sheep, goats, horses, pigs, dogs, 
cats, ferrets, camels, Llamas, deer, elk, elephants, rhinoceroses, foxes, coyotes, 
mink, primates, opossums, otters, seals, sea lions, hares, raccoons, bears, 
warthogs, large cats (lions, tigers, leopards, cheetahs and lynx) and several species 
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of rodents (Miller, 2015; Musoke et al., 2015; Nugent, 2011; Palmer et al., 2012; 
Thoen et al., 2014). 
Little is known about the susceptibility of birds to M. bovis, although they are 
generally thought to be resistant.  Experimental infections have been reported in 
pigeon after oral or intra-tracheal inoculation and in crows after intraperitoneal 
inoculation (Fitzgerald et al., 2003).  Some avian species, including mallard ducks, 
appear to be resistant to experimental infection (Clarke et al., 2006; Fitzgerald et al., 
2003). 
Cattle usually infect human beings, but other sources of infection have also been 
reported such as direct contact with a wound during hunting of infected game, and 
also from person to person when a person with pulmonary TB coughs or sneezes. 
Indeed, several cases of human tuberculosis caused by M. bovis have been 
described (Biet et al., 2005; CDC, 2005; Evans et al., 2007; Hlavsa et al., 2008) and 
there are also reports on human to human infection of M. bovis (Gallivan et al., 2015; 
Müller et al., 2013; Sunder et al. 2009).  Human tuberculosis caused by M. bovis is 
clinically, radiologically and pathologically undistinguishable from the disease caused 
by M. tuberculosis (Cosivi et al., 1998; De la Rua-Domenech, 2006; Grange, 2001). 
The disease caused by M. bovis is prevalent in most of Africa, parts of Asia, America 
and Middle Eastern countries.  Nations classified as TB-free in domestic animals 
include Australia, Iceland, Denmark, Sweden, Norway, Finland, Austria, Switzerland, 
Luxembourg, Latvia, Slovakia, Lithuania, Estonia, the Czech Republic, Canada, 
Singapore, Jamaica, Barbados and Israel (OIE, 2014).  Eradication programmes are 
in progress in Japan, New Zealand, United States of America, Mexico and some 
countries of central and South America (OIE, 2014).  In South Africa, the existence 
of tuberculosis infection at the wildlife-livestock interface has complicated the control 
of bovine tuberculosis due to spill-over from wild animals to livestock (Michel et al., 
2010) but spill-back from cattle to wild life is also a possibility.  
1.2.2.3 Non-tuberculous mycobacteria 
The non-tuberculous mycobacteria (NTM) or opportunistic mycobacteria are also 
referred to as atypical mycobacteria, mycobacteria other than tuberculosis (MOTT) 
or potentially pathogenic environmental mycobacteria (PPEM).  They can survive in 
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water and have been isolated in Europe, New Zealand and South Africa (Gcebe et 
al., 2013; van der Werf et al., 2014).  NTM can complicate the interpretation of the 
tuberculin skin test in cattle as they can be responsible for non-specific sensitization 
of cattle to purified protein derivative (PPD) of bovine and avian tuberculin (Gcebe et 
al., 2013; Wagner and Young, 2004; Zeng et al., 2013).  In humans, both M. 
tuberculosis and NTM can induce pulmonary infection with similar symptoms and 
pulmonary radiographic findings; these similarities have led to difficulty in 
distinguishing the infections clinically (Dailloux et al., 2006; Koh et al., 2002; McGrath 
et al., 2008).  Adding to this, in primary health care with limited facilities using Ziehl-
Neelsen as the main bacteriological identification of M. tuberculosis, NTM can easily 
be misdiagnosed as M. tuberculosis, therefore, relying on Ziehl-Neelsen staining 
alone can be misleading (Laifangbam et al., 2009; Padilla et al., 2005). 
Mycobacteria are classified based on growth rate, pigmentation and clinical 
significance.  Diseases caused by the non-tuberculous mycobacteria are named 
mycobacterioses (Han et al., 2007; Shitaye et al., 2009).  They were considered as 
opportunistic pathogens often resistant to chemotherapeutic agents and not 
contagious (Pavlik et al., 2005; Slany et al., 2010; Tortoli, 2009).  Over the past 
years, reports on isolation of the non-tuberculous mycobacteria from clinical samples 
from humans and animals have been increasing (Kabongo-Kayoka et al., 2015; 
Kankya et al., 2011; Malama et al., 2014; Muwonge et al., 2012; Tortoli, 2014). 
NTM have been incriminated in the non-specific reactions observed on cattle 
reactors to tuberculin test during the interpretation process (De la Rua-Domenech et 
al., 2006; Kazda and Cook, 1988; Pavlik et al., 2005).  In South Africa, they have 
been isolated from organs and lymph nodes of animals with lesions suggestive of 
tuberculosis (Gcebe et al., 2013; Kabongo-Kayoka et al., 2015).  They have also 
been isolated from humans presenting clinical conditions suggestive of tuberculosis 
(Tortoli, 2014; Tortoli et al., 2009) in different countries such as the Czech Republic 
(Pavlik et al., 2005); China (Zeng et al., 2013), Zambia (Malama et al., 2014) and 
Uganda (Kankya et al., 2011).  There are reports on the clinical importance of some 
NTM, namely M. fortuitum isolated from non-healing wounds in dogs and cats (Baral 
et al., 2006; Jang and Hirsh, 2002) and diseased fish (Zeng et al., 2013); M. 
marinum from snakes and bullfrogs (Maslow and Mikota, 2015).  Mycobacterium 
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aurum has been reported as the cause of infection in catheter-related blood-stream 
infections in humans (El Helou et al., 2013; Escalonilla et al., 1998; Koranyi and 
Ranalli, 2003).  Mycobacterium smegmatis can also be found in normal human 
genital secretions (Best and Best, 2009). It was first isolated in 1884 by Lustgarden 
from syphilitic chancres but was found to be pathogenic for the first time by Vonmoos 
et al. (1986).  Mycobacterium smegmatis has been identified as the cause of 
disseminated infection (Pierre-Audigier et al., 1997), pneumonia and infection of soft 
tissues (Best and Best, 2009; Ergan et al., 2004).  In animals, M. smegmatis and 
other mycobacterial species were isolated from mastitis cases in cattle (Pardo et al., 
2001; Thomson et al., 1988) and panniculitis pyogranuloma in cats (Ålander-
Damsten et al., 2003).  Different species of NTM have been isolated during 
experimental conditions and natural disease cases (Bercovier and Vincent, 2001).  
These NTM are sometimes referred to as non-pathogenic but it is preferable to refer 
to them as rapidly growing mycobacteria.  The most important group widely spread 
in the environment and causing clinical diseases in various animal species apart 
from the obligate pathogens (M. tuberculosis complex) is the M. avium complex, also 
referred as M. avium-intracellulare.  The M. avium complex includes M. 
intracellulare, M. avium, M. paratuberculosis, M. lepraremurium (pathogenic for 
rodents) and M. avium subsp. silvaticum subsp. Nov, known as wood pigeon 
bacillus. 
Some members of the M. avium complex are saprophytes and others are pathogens 
of birds and mammals, including humans (Biet et al., 2005).  They cause 
opportunistic infection in AIDS sufferers.  There are different serovars involved in the 
disease process: serovars 1, 2 and 3 produce natural progressive disease in poultry 
and birds.  In Europe, “Fowl tuberculosis” has been important and serovars 2 and 3 
have been isolated from pig with lymphadenitis that were in close contact with fowls 
(Bono et al., 1995).  This condition has also been reported in the USA.  In South 
Africa, serovars 1, 4 and 8 are mainly responsible for pig lymphadenitis and serovars 
4 and 8 occur frequently in the environment, in animal feed and bedding and on 
plants.  In the Czech Republic, during a survey study conducted over 4 years by 
Pavlik et al. (2005), it was found that M. avium subsp. avium prevailed in cattle 
whereas M. avium subsp. hominissuis occurred in pigs. 
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Members of the M. avium complex produce visible growth in culture after two to 
three weeks.  They grow at temperatures ranging from 20 to 45°C and form colonies 
that are pearly-grey, lemon-yellow or sometimes bright yellow and which emulsify 
easily (Biet et al., 2005).  Methods to determine the relationship within the 
mycobacteria include immunological techniques, comparison of cell wall 
components, and comparison of homologous enzyme sequences, DNA/DNA 
homology, plasmid profiles, and restriction endonuclease analyses (BumJoon et al., 
2004; Cousins et al., 2003; Roth et al., 2000; Stahl and Urbance, 1990).  
Comparative rRNA sequencing supports the classification of slow and rapid growers 
(Roth et al., 2000; Stahl and Urbance, 1990). 
1.2.3 Pathogenesis of tuberculosis  
Tuberculosis is not treated in animals and therefore, the focus of the pathogenesis 
will be on humans.  Mycobacterium tuberculosis is a slow growing organism which is 
primary transmitted via the respiratory route but other routes can allow the entry of 
this bacterium, namely the oral route when using contaminated items or ingestion of 
contaminated food (gastro intestinal tract).  Generally, the primary focus of infection 
is the lower zones of the lung (respiratory tract).  The bacilli are taken up by lung 
macrophages but they can survive within the macrophages and grow to form the 
primary focus of infection and from there, enter the local lymphatic system and move 
within the body via the blood and lymphatic system.  This phase of the disease is 
clinically silent and it is called “latent infection”; sometimes there is mild fever but in 
most cases, immunity develops within a few weeks and the patient becomes 
tuberculin positive (Leung et al., 2011).   
Mycobacterium tuberculosis has a particular characteristic of being able to multiply 
intracellularly in the macrophages, evading many host defence mechanisms 
(Sakamoto, 2012).  Acute inflammation is initiated by immune cells, macrophages 
which possess specialized receptors known as pattern recognition receptors (PRRs).  
Upon infection, macrophages are activated which enhances the ability of PRRs to 
recognize pathogen-associated molecular patterns (PAMPs) preserved on most 
pathogens (Walsh et al., 2013).  When PRRs bind to PAMPs, the immune cells are 
activated to release inflammatory mediators (cytokines, plasma proteins and growth 
factors) to sustain the inflammatory process and recruit more cells to the site of injury 
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or infection (Castellheim et al., 2009).  Upon successful removal of the causative 
agents, the inflammatory response is quickly stopped and the repair mechanism is 
initiated by an active, coordinated process of resolution of the inflammatory episode 
(Walsh et al., 2013).  In chronic inflammation, the inflammatory response is 
sustained, prolonged and further propagated causing damage to adjacent tissues 
and organs (Walsh et al., 2013). 
Humans are as susceptible to M. bovis as to M. tuberculosis.  Once a tuberculous 
lesion develops in an organ, the appearance and the course of the disease are the 
same irrespective of the causative agent (Cousins, 2001; Grange, 2001).  Some 
mycobacterial infections remain localized, while others cause widely disseminated 
lesions.  In general, depending on the route of infection, primary foci of tuberculosis 
occur in either the respiratory tract (95%) or gastro-intestinal tract.  Other routes of 
infection for M. bovis in humans are percutaneous via damaged skin (for example, a 
meat inspector at an abattoir).  Some factors do influence the length of time required 
for the disease to develop namely immune status, age, route of infection, strain of 
mycobacterium and the dose of mycobacteria (Shanmuganathan and 
Shanmuganathan, 2015). 
The majority of individuals (90-95%) infected with M. tuberculosis, the main cause of 
TB, will never develop any clinical disease.  There are risk predisposing factors that 
may lead to the development of clinical tuberculosis namely HIV infection, diabetes 
mellitus, gastrectomy, jejunoileal bypass surgery, dialysis dependent chronic kidney 
disease, renal failure, malnutrition, immunosuppression after solid organ 
transplantation, long-term corticosteroid treatment, tumour necrosis factor (TNF) 
inhibitors, advanced malignancy and to some extent genetic susceptibility among 
some individuals (Ferrara et al., 2012). 
The most common form of tuberculosis is the chronic pulmonary form that is 
classified into three phases which include primary, post-primary dissemination or 
miliary and cell mediated immunity (Jacob et al., 2009; Sharma et al., 2005).  To 
initiate infection, M. tuberculosis bacilli must be ingested by the macrophages.  
Bacilli that are not killed by the macrophages replicate inside them, killing the host 
macrophages with the help of CD8 lymphocytes; inflammatory cells are attracted to 
the area causing pneumonitis that coalesces into the characteristic tubercles 
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observed histologically.  The ability of the macrophages to kill mycobacteria is 
enhanced only after the development of delayed type hypersensitivity.  The rapid 
development of the immune response following infection inhibits the growth of 
mycobacteria in lesions while they are still very small.  Macrophages at the site of 
infection may be activated by direct contact with mycobacteria or as result of 
lymphokines.   
The debris of necrotic macrophages sensitizes local lymphocytes.  After 
sensitization, lymphocytes release lymphokines that attract, activate and increase 
the number of mononuclear cells at the site of infection.  They also contribute to 
death of cells leading to caseous (cheese-like appearance) necrosis.  Macrophages 
also play an integral part in the processing of mycobacterial antigens and the 
initiation of the immune response.  Cell death caused by the delayed hypersensitivity 
reaction may be the result of lymphokines, toxic components of the bacteria, 
ischaemia, antigen-antibody reactions, hydrolytic enzymes and reactive oxygen 
intermediates released from necrotic macrophages and neutrophils, and tumour 
necrosis factor (Ahmad, 2010; Lee et al., 2011; Leung et al., 2011; Parandhaman 
and Narayanan, 2014; Young, 1993).   
In the early weeks of infection, some infected macrophages can migrate to regional 
lymph nodes where they access the bloodstream.  Organisms may then spread to 
any part of the body.  In the pulmonary form, the lesions occur primarily in the 
lymphoid tissues whereas both the lung parenchyma and the lymph nodes are 
affected in the respiratory system.  Although hematogenous spread of tubercle bacilli 
from the lung is seldom, hematogenous dissemination accounts for the occurrence 
of extrapulmonary involvement of lymph nodes, kidneys, reproductive organs, bones 
and the gastrointestinal tract.  Local features vary according to the organ involved.   
Hematogenous dissemination is less likely in patients with partial immunity due to 
vaccination or to prior natural infection with M. tuberculosis or environmental 
mycobacteria (non-tuberculous).  In 95% of cases, after three weeks of uninhibited 
growth, the immune system suppresses bacillary replication, usually before 
symptoms develop (Leung et al., 2011; Young, 1993).  Foci of bacilli in the lungs or 
other sites resolve into epithelioid cell granulomas, which may have caseous and 
necrotic centres.  Tubercle bacilli can survive in this state for years; the balance 
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between the host’s resistance and microbial virulence determines whether the 
infection ultimately resolves without treatment, remains dormant, or becomes active 
(Delogu et al., 2013; Leung et al., 2011; Sakamoto, 2012; Young, 1993).  Infectious 
foci may leave fibro-nodular scars in the apices of one or both lungs (Simon foci, 
which usually result from hematogenous seeding from another site of infection) or 
small areas of consolidation (Ghon foci).   
The initial possible infection is the contact between the inhaled bacteria and lung 
alveolar epithelial mucosal cells followed by reaching macrophages.  When inhaled, 
droplet nuclei that are less than 100 nm usually travel through the airway until they 
reach the alveoli (Inderlied, 2004; Leung et al., 2011).  Once the bacteria enter the 
macrophage, they locate in the mycobacterial phagosome (Inderlied, 2004; 
Sakamoto, 2012).  Unlike normal phagocytosis, during which the phagosomal 
content is degraded upon fusion with lysosomes, the mycobacteria block this 
process (Inderlied, 2004; Sakamoto, 2012).  The inhaled bacilli are phagocytosed, 
processed and presented by alveolar macrophages to the lymphocytes (Sakamoto, 
2012).  The probability of infection depends on the ability of the mycobacterium to 
survive within the macrophages, in this way evading many host defence mechanism 
(Figure 1.1).  At this stage unless the patient receives prophylaxis, symptomatic 
disease eventually occurs in 5-10% of infected patients. 
The maturation of mycobacterial phagosomes is stopped and therefore, these cells 
are unable to eliminate bacilli by fusion of phagosomes with lysosomes.  The 
inhibition of phagosome maturation by mycobacteria may be reverted by cytokines, 
such as interferon-gamma (IFN-γ) and tumour necrosis alpha (TNF-α) which also 
stimulate microbicidal mechanisms, including the production of reactive oxygen and 
nitrogen intermediates (Chan et al., 1992).  Nitrogen intermediates play a protective 
role to some extent (Nicholson et al., 1996); reactive oxygen intermediates namely 
hydrogen peroxide produced by the macrophages activated by cytokines, have a 
mycobactericidal activity (Walker and Lowrie, 1981).  In addition, the tubercles of 
bacilli present other molecules such as lipoarabinomannan (LAM), phenolic 
glycolipid I and thiols such as mycothiol (MSH) which work as oxygen radical 
scavenger molecules (Chan et al., 1991). 
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A Ghon focus with lymph node involvement is a Ghon complex, which, if calcified, is 
called a Ranke complex.  The tuberculin skin test and interferon-gamma release 
blood assays (IGRA) become positive during the latent stage of infection.  Sites of 
latent infection are dynamic processes.  Extra-pulmonary TB at any site can 
sometimes manifest without evidence of lung involvement.  Lymphadenopathy TB is 
the most common extra pulmonary presentation; however, meningitis is the most 
feared because of its high mortality in the very young and very old (Donald et al., 
2005; Marx and Chan, 2011). 
1.2.4 Clinical signs of tuberculosis 
Clinical signs observed may include a persistent cough, night sweats, lassitude, 
weight loss, malaise, fever and anorexia, dyspneoa, chest pain, signs of chest 
disease (Churchyard et al., 2014; Inderlied, 2004). 
At every stage during the course of the tuberculous process, the character of the 
lesions depends on the fluctuation between cell mediated immunity and the delayed 
type hypersensitivity.  Adding to this, the development of either an exudative or a 
proliferative response depends on the concentration of bacterial antigen, with low 
concentrations causing proliferative lesions, whereas high concentrations result in an 
exudative response (Delogu et al., 2013; Inderlied, 2004). 
1.2.5 Diagnostic tests 
There are different traditional methods for the diagnosis of tuberculosis which include 
the tuberculin skin test, culture and smear microscopy.  Each of these methods has 
limitations.  In humans, one of the challenges of the tuberculin test is that prior 
vaccination with BCG may result in a false positive result even many years later.  
The culture method, although sensitive, is time-consuming, and takes 6-8 weeks to 
obtain results (Cosivi et al., 1998; Cousins, 2001).  In laboratories that only process 
human samples, M. bovis is often missed as the routine growth medium used (LJ 
with glycerol) does not contain pyruvate which is a substrate that enhances the 
growth of M. bovis (de Kantor et al., 2008; Grange, 2001).  Furthermore, the 
suspected cases might be missed due to delay.  Staining of infective organisms by 
the Ziehl-Neelsen (ZN) technique in sputum has both the problems of sensitivity and 
specificity as there are many other organisms that are also acid-fast and therefore 
one cannot rely on ZN staining as the only method of identification.  Although, time-
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consuming, the culture method and ZN staining are still used for the confirmation of 
acid-fast organisms and diagnosis of tuberculosis (Bhalla et al., 2015; Kabongo-
Kayoka et al., 2015; Ryu, 2015). 
Other time-consuming methods include phenotypic tests based on biochemical 
substrates, mycolic acid analysis and narrow spectrum nucleic acid probes.  Bacteria 
are identified based on biochemical and physiological features.  These methods are 
sometimes not able to differentiate between different Mycobacterium species.  
Puttinaowarat et al. (2002) reported on combining PCR followed by reverse cross 
blot hybridisation (RCBH) which was highly specific for Mycobacterium spp. and 
identified bacteria to the species level with a detection limit of 100 fg which is 
equivalent to 20 mycobacterial cfu.  For an improved differentiation of 
Mycobacterium tuberculosis strains, Yokoyama et al. (2007) proposed the use of a 
combination of variable number of tandem repeat loci.   
Chemotaxonomic methods include analysis of the quinone system, fatty acid 
profiles, polar lipid patterns, polyamine patterns, whole cell sugars, peptidoglycan 
diaminoacids, analytical fingerprints methods and cellular protein patterning (Butler 
and Guthertz, 2001; Layre et al., 2011).  Other approaches include PCR and 
sequencing technologies (Cloud et al., 2002).  The microSeq 500 system is a 
commercial kit based on the sequencing and analysis of the gene 16S rRNA; it has 
limitations as it requires the use of additional databases such as the Ribosomal 
Differentiation of Medical Microorganisms (RIDOM) to precisely identify subtypes of 
strains not currently in the MicroSeq library (Fontana et al., 2005).  Gene sequencing 
allows the analysis of phylogenetic relationships of bacteria, nucleic acids 
hybridization, G+C content determination, restriction fragment length polymorphism 
(RFLP), macrorestriction analysis and random amplified polymorphic DNA (RAPD) 
(Jansen et al., 2002; Laurent et al., 1999). 
Advances in the molecular field and understanding of the genetic structure of 
mycobacteria has led to the development of techniques  and tools that can be used 
to confirm the identity of isolates from clinical samples and study of the epidemiology 
of tuberculosis.  PCR-based methods are available as diagnostic and confirmatory 
tests for tuberculosis and are expected to detect as few as 1-10 organisms, but its 
use in surveillance and epidemiological studies might not be possible (Ryu, 2015).  
 28 
 
Molecular typing methods such as IS6110-RFLP and spoligotyping can be used for 
identification of outbreaks and can facilitate contact tracing of tuberculosis.  IS6110-
RFLP is considered a gold standard for the molecular typing of M. tuberculosis but 
this has provided limited discrimination among M. bovis populations where the 
majority of the isolates harbour only one or a few IS copies (Haddad et al., 2004).  
IS6110-RFLP has a high discriminative power and reproducibility but the technique 
requires a large amount of DNA and is therefore restricted to the mycobacterial 
cultures which take around 20-40 days to obtain sufficient DNA needed.  Moreover, 
this technique is also demanding technically, is expensive and requires sophisticated 
software for result analysis.  For M. bovis, PCR-based spoligotyping (Kamerbeek et 
al., 1997) has been widely used to genotype isolates; it is highly reproducible and 
represents the first universally recognized typing system for M. bovis but other 
studies have showed a limited discrimination power of this method (Hilty et al., 2005; 
Roring et al., 2002; Skuce et al., 2002).   
Spoligotyping (spacer oligonucleotide typing) is a method that can be simultaneously 
used for detection as well as typing of the M. tuberculosis complex.  It is a PCR-
based method, which relies on the amplification of the spacers using the primers 
DRa and DRb, which allow the amplification of the highly polymorphic Direct Repeat 
(DR) locus, the whole DR genome (Haddad et al., 2001).  The DR region in M. bovis 
BCG contains direct repeat sequences of 36 bp, which is interspersed by the non-
repetitive DNA spacers of 35-41 bp in length.  In other M. tuberculosis complex 
strains, the number of DR elements varies significantly and the majority of the M. 
tuberculosis strains contain one or more IS6110 elements in the DR region.  A main 
feature for M. bovis is the lack of spacers 39 to 43 (Aranaz et al., 1996). 
Genetic typing of M. bovis has contributed to a greatly improved knowledge of inter-
bovine and inter-species transmission of bovine tuberculosis (Durr et al., 2000).  The 
understanding of genetic typing is important for the effective management of bovine 
tuberculosis control schemes and the wildlife–livestock interface in countries where 
wildlife reservoirs for M. bovis have been identified, including South Africa (Haddad 
et al., 2004; Vos et al., 2001).  The most widely used DNA typing techniques for M. 
bovis include IS6110 and PGRS restriction fragment length polymorphism (RFLP) 
typing, spoligotyping and variable number of tandem repeat (VNTR) typing (Sola et 
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al., 2003; Wirth et al., 2008).  In South Africa, spoligotyping and VNTR typing have 
been used (Hlokwe et al., 2014; Michel et al., 2008). 
Other methods for rapid molecular epidemiology investigation include six VNTR loci, 
A through F (ETR-A,-B, -C, -D, -E and –F), which were reported to be more 
discriminative than spoligotyping (Frothingham and Meeker-O’Connell, 1998).  A 
method with more genetic markers, MIRU-VNTR was described and comprised 
ETRS, mycobacterial interspersed repetitive units (MIRUs) and VNTRS (Roring et 
al., 2002; Skuce et al., 2002).  Combining methods can reduce their respective 
limitations and improve the identification of mycobacteria.  A combination of 
spoligotyping and MIRU-VNTR provides a discrimination power greater than 90% 
(Roring et al., 2002). 
The similarity of mycobacteria can be based on the 16S rDNA most conserved 
region but further differentiation is obtained with the concatenation of all four genes 
namely ITS, 16S rDNA, rpoB and hsp65 gene sequences that require high 
identification resolution (Cloud et al., 2002). 
The whole cell MALDI-TOF (Matrix Assisted Laser Desorption Ionization Time Of 
Flight) aided with diagnostic proteins is robust for Mycobacterium spp. phenotypic 
characterization (Buckwalter et al., 2016; Wang et al., 2012) whereas for genotypic 
characterization, the multiple-locus sequence analysis of all four genes are required 
for the complete identification at the species level of any Mycobacterium spp. (Cloud 
et al., 2002; Kabongo-Kayoka et al., 2015).  Mycobacteria can also be differentiated 
or identified based on the composition of the longer chain alpha mycolic acids of 
their cell wall (C80).  Each mycobacterial species possesses a characteristic profile 
of alpha-mycolic composition and that the use of normal phase liquid 
chromatography with thermally assisted hydrolysis and methylation followed by gas 
chromatography-mass spectrometry could give rapid and very precise information for 
the identification of pathogenic and non-pathogenic mycobacterial species (Mourão 
et al., 2016).  
Phylogenetic analysis is conducted to find similarities between organisms (analysis 
of changes that have occurred in different organisms during evolution), to 
understand or find relationships between an ancestral sequence and its descendant 
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and estimate time of divergence between a group of organisms from a common 
ancestor.  This evolution is illustrated as a phylogenetic tree. There are different 
methods to build phylogenetic trees, namely neighbour joining, the parsimony 
method and maximum likelihood (Tamura et al., 2011). 
1.2.6 Challenges in the treatment of tuberculosis 
Tuberculosis treatment is based on the use of multi-drug treatment where usually 
three to four anti-TB drugs are combined.  The cocktail of rifampin (RIF), isoniazid 
(INH), pyrazinamide (PA) and ethambutol (EMB) are the recommended first line 
drugs.  Second line drugs, in case of organism resistance or heavy side effects, 
include fluoroquinolones, aminoglycosides or streptomycin (CDC and Society, 2003; 
Warner and Mizrahi, 2006).  The emergence of TB strains resistant to more than one 
drug is a concern.  Factors that may lead to the development of resistance include 
patients failing to adhere to the regular administration of the correct dosage due to 
the long duration and toxic effects of the drugs; other factors such as 
immunosuppressed patients may contribute to the development of resistant strains.  
The molecular basis of MDR TB has been well documented (Bosne-David et al., 
2000; Cingolani et al., 1999; Johnson et al., 2007; Musser, 1995; Sreevatsan et al., 
1997).  Mutations that occur in the target genes of M. tuberculosis and M. bovis 
strains are the most common mechanisms of resistance encountered for primary 
antimycobacterial agents such as RIF and INH.  
MDR strains of TB do not respond to treatment with rifampin and isoniazid which are 
the first line drugs in the initial treatment regime of TB whereas XDR-TB strains are 
not only resistant to both first line drugs, rifampin and isoniazid, but also to one of the 
three second line drugs, for example fluoroquinolones.  The normal mechanism of 
activity is either hampered or inhibited (Figure 1.7).  MDR-TB and XDR-TB infections 
are difficult to treat and require a long duration of treatment.  As the disease is 
chronic and develops slowly, lesions might already be established when the disease 
is clinically diagnosed and surgical removal of necrotic tissues is sometimes required 
as permeability of drugs into dead tissues is sometimes not possible (Kaplan et al., 
2003).  The cost to treat such cases is high and requires long courses of antibiotic 
treatment with possible adverse consequences due to toxic side effects of more 
expensive drugs.  According to the World Health Organization (2015), it is estimated 
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worldwide that 3.3% of new TB cases and 20% of previously treated cases are 
MDR-TB.  Eastern European and central Asian countries continue to have the 
highest levels of MDR-TB.  South Africa was among the six countries with the 
highest incident cases in 2014 (WHO, 2015) and it is still on the list of the countries 
with a high TB burden.  Other countries are India, Indonesia, China, Nigeria and 
Pakistan.  There is a need for alternative treatment with fewer toxic effects, possibly 
using natural resources.  
 
Figure 1.7: Mechanism of activity of antiTB drugs  
Source: courtesy of www.slideshare.net  
1.2.7 The use of traditional medicine as an alternative or complementary 
medicine 
Alternative medicine is a term referring to a broad spectrum of healthcare practices, 
namely acupuncture, chiropractic, herbalism, homeopathy and naturopathy, whereas 
complementary medicine refers to the use of treatments drawn from alternative 
medicine to complement allopathic medicine (Cleary-Guida et al., 2001; Ernst and 
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White, 2000).  This is an unfortunate clumping of practices because herbalism is 
based on scientifically understood pharmacological activities of compounds present 
in plants (Craker and Gardner, 2003; Cushman and Hoffman, 2004; Hoffmann, 
2003). 
Despite the advances made in the treatment of many microbial infections caused by 
microorganisms and other diseases with conventional drugs, there has been a global 
cultural revival towards more natural methods of healing.  The use of traditional 
plant-based medicine remains ingrained in the healing practices of many developing 
countries (Makunga et al., 2008).  It has been reported that about 80% of 
communities of African origin rely on herbal medicine for primary health care 
purposes (Dubey et al., 2004; Mahomoodally et al., 2010).  The huge reliance of 
African people on traditional medicine can be attributed to availability, accessibility, 
affordability, extensive traditional knowledge and expertise within local people 
(Gurib-Fakim, 2006).  Conventional medicine has been accepting the use of  
traditional medicine once it has been scientifically validated (Gilani, 2005).   
Prior to modern medicine, people have been using medicinal plants for the treatment 
of various ailments for centuries (Briskin, 2000).  Plant-derived medicines are used 
for primary health care to treat diseases such as cancer, diabetes, infectious 
diseases and many others (Zahin et al., 2010).  In South Africa, both Western and 
traditional systems of medicines co-exist.  Three hundred years ago, the Western 
system was introduced by European settlers and traditional medicine was 
established from Palaeolithic times (Van Wyk et al., 1997).  It is estimated that 27 
million South Africans rely on traditional medicine for their primary health care needs 
(Mander et al., 2007; Van Vuuren, 2008). 
1.2.8 New lead compounds for drug discovery and development 
There has been an increased interest in investigating medicinal plants for the 
discovery of new lead compounds for potential drug development (Eloff and McGaw, 
2014; Rout et al., 2009).  Indeed, extracts derived from medicinal plants have been 
used for a very long time for the management and prevention of many diseases.  
Despite the rise of synthetic chemistry as an integral part of lead discovery process, 
natural products still play a major role as starting material for drug discovery (Katiyar 
et al., 2012; Saleem et al., 2010).  According to Newman and Cragg (2007), of the 
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974 small molecules used as therapeutic drugs, 63% were natural product-derived or 
semi-synthetic derivatives of natural products. The number continues to increase 
annually, such that 48.6% of anti-cancer drugs are either natural products or plant-
derived entities (Newman and Cragg, 2010).  Veeresham (2012) stated that 11% of 
the 252 drugs presented by WHO originates from flowering plants.  
Emergence of drug-resistant organisms, ease of accessibility of traditional medicines 
and high cost of conventional health care systems as well as traditional beliefs are 
among the factors that continue to promote and sustain interest in alternative forms 
of medical care in non-industrialized countries (Cerella et al., 2013; Gurib-Fakim, 
2006) including developed countries (WHO, 2002).  It is further stated that 75% of 
people living with HIV/AIDS use traditional medicine for therapeutic purposes in 
South Africa (WHO, 2002).  Plant-derived substances are used as therapeutics in 
many communities in developed countries for primary health care needs.  As much 
as 50% of the populations of Europe and North America use plant-derived 
substances as supplements or primary therapeutics (WHO, 2002).  Though the pace 
of discovery of potential lead compounds and their development remains 
exceedingly slow, plants are still good sources because of their ability to synthesize 
secondary metabolites in response to microbial infection (Cowan, 1999).  Although 
the efficacy of plant-derived extracts for disease treatment has been known for 
centuries, the first isolation of a bioactive compound from a medicinal plant species 
was only achieved in the 19th century (Phillipson, 2001).  Despite the implied 
potential of natural products, only a fraction of medicinal plant species has been 
tested for bioactivity (Gautam et al., 2007).  The rich diversity of compounds with 
novel structures and biological activity make them a source of different types of 
drugs. 
Plant extracts contain multiple component mixtures of active, partially active and 
inactive substances.  This includes primary metabolites, such as sugars and amino 
acids, found in all plants and secondary metabolites, while some are found only in a 
particular genus or species (Hussain et al., 2012; Vanisree et al., 2004).  This 
explains the variation in isolating a compound from a specific species within a genus 
or family while it may be absent in the rest. 
 34 
 
The secondary metabolites and pigments that have potential therapeutic actions in 
humans can be refined to produce drugs (Pandey et al., 2011).  The activity of the 
plant extract is the sum of the activities of the individual phytochemicals as well as 
the interaction between them.  This approach has led not only to the introduction of 
many important drugs but still forms the basis of studying lead compounds from 
plants (Efferth and Koch, 2011; Habib-ur-Rehman et al., 2007).  Some of the drugs 
that are currently used originated from the diverse structures and the intricate carbon 
skeletons of natural products (Rout et al., 2009).  Innovations in phytochemical 
analysis and the ability to synthesize them have allowed scientists to modify 
structures in order to enhance certain characteristics such as solubility, efficiency 
and stability in the human body (Ji et al., 2009).  Out of many families of secondary 
metabolites, the alkaloids have contributed the largest number of drugs to the 
modern pharmacopoeia.  The terpenoids (including steroids) have made equally 
important contributions to human health (Raskin et al., 2002; Wang et al., 2005).  
Tannins, polyphenols, saponins, flavonoids and phytates have been isolated and 
studied at the cellular and molecular levels but in general, these compounds were 
not useful in treating antimicrobial infections (Singh et al., 2003). 
Interesting compounds have been isolated from plant species, bacteria and fungi 
and have a broad spectrum of biological actions.  Among many others, 
naphthoquinones have been reported for their antibiotic, antiviral, anti-inflammatory, 
antipyretic and anti-proliferative properties (Babula et al., 2009). 
Plant species still serve as a rich source of many novel biologically active 
compounds, as very few plant species have been thoroughly investigated for their 
medicinal properties (Gautam et al., 2007; Jiménez-Arellanes et al., 2013; Jimenez‐
Arellanes et al., 2003; Newman et al., 2003).  Several plants such as Buddleja 
saligna have been screened for their antimycobacterial activity (Bamuamba et al., 
2008).  Several plant extracts have been found to be active against M. tuberculosis 
and other model mycobacteria such as M. aurum, M. smegmatis and M. fortuitum 
(Aro et al., 2015; Gautam et al., 2007; Green et al., 2010; Kabongo‐Kayoka et al., 
2016). 
Ethnobotanical information has also shown that plants claimed to treat diseases 
such as TB inhibit the growth of Mycobacterium tuberculosis in culture (Tabuti et al., 
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2010).  Mycobacterium aurum has been reported as a good model for M. 
tuberculosis due to its low pathogenicity potential and rapid growth rate.  
Mycobacterium  aurum has the same sensitivity profile as M. tuberculosis as their 
fatty acid chains in the cell wall are of similar length which plays an important role in 
susceptibility of mycobacteria (Chung et al., 1995).  Mycobacterium aurum, 
therefore, has been used frequently in drug screening where the actual pathogens 
cannot be grown without risk of contamination and infection (Chung et al., 1995; 
Mukanganyama et al., 2015; Shawar et al., 1997).  Diospyrin (from Diospyros 
montana Roxb) has been explored as a potential drug efflux inhibitor for the 
treatment of tuberculosis (Mukanganyama et al., 2015).  Diospyrin and some of its 
derivatives were found to inhibit mycobacterial growth and enhanced accumulation 
of drugs inside the bacteria (Mukanganyama et al., 2015).  Other secondary 
metabolites such as alkaloids have been reported to have antimycobacterial activity 
(Camacho-Corona et al., 2009). 
1.2.9 Antimycobacterial activity of South African medicinal plants and 
bioactive compounds 
In South Africa, many people still rely on traditional medicine for their primary health 
care and due to socio-economic challenges some of those medicines are sold in 
informal markets (McKean and Mander, 2007).  Therefore, the scientific validation of 
the biological activities of South African plants is still justified though a considerable 
amount of work has been reported on the antimicrobial activity to verify some of the 
traditional claims (Fennell et al., 2004; Light et al., 2005).  Very few have reported 
antimicrobial activity against Mycobacterium spp. causing tuberculosis.   
The Phytomedicine Programme at the Faculty of Veterinary Science at the University 
of Pretoria is a multidisciplinary and collaborative research programme that 
investigates the use of medicinal plants growing in Africa for the benefit of its people 
and animals.  Acetone leaf extracts of more than 500 southern African plant species 
have been evaluated for activity against eight important bacterial and fungal 
pathogens for general antimicrobial activity; investigating the possibility that extracts 
could be used in the primary health care of rural people (Pauw and Eloff, 2014).  
Some leaf extracts of different plant families were also evaluated specifically against 
Mycobacterium spp. for antimycobacterial activity aiming at finding potential leads for 
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the treatment of tuberculosis.  These acetone leaf extracts included Euclea species 
and plants from the Rubiaceae and Anacardiaceae families (Aro et al., 2015; 
Kabongo‐Kayoka et al., 2016; McGaw et al., 2008a).  Other studies have also 
reported potential antimycobacterial activity for plants belonging to families such as 
Scutia buxifolia (Rhamnaceae); Terminalia sericea (Combretaceae); Warburgia 
salutaris (Canellaceae); Asclepias fruticosa (Apocynaceae) and others (Boligon et 
al., 2012; Green et al., 2010; Mariita et al., 2010). 
Essential oils, alkaloids, terpenoids, phenolic acids, peptides, flavonoids, tannins and 
coumarins represent the principal groups of compounds extracted from plants with 
antimycobacterial properties reported in the literature (Andrade-Ochoa et al., 2015; 
Kishore et al., 2009; McGaw et al., 2008a; Santhosh and Suriyanarayanan, 2014). 
Many bioactive compounds have been isolated from plant species which had 
promising activities during the preliminary phase, from different plant families (Eloff 
et al., 2008).  The bioactive compounds isolated to date were relatively non-polar.  
Therefore, the tendency is to focus on non-polar compounds due to complexity of 
phytochemical compounds in a plant.  Although isolation of most compounds has 
been reported elsewhere, some of the compounds have been isolated from leaves 
tested for antimicrobial activity and cytotoxicity for the first time in the Phytomedicine 
Programme.  For example, two novel terpenoid compounds have been isolated from 
Combretum imberbe and Combretum padoides (Katerere et al., 2003). 
1.2.10 Selection of potential medicinal plants for drug development 
There are several strategies for selecting medicinal plants suitable for 
pharmacological studies.  These include traditional use (ethnobotany or 
ethnopharmacology), chemical content, toxicity, randomized selection or a 
combination of several criteria (Blondeau et al., 2010; Rates, 2001; Santhosh and 
Suriyanarayanan, 2014; Schwikkard and Mulholland, 2014; Soejarto et al., 2012; 
Ramesha et al., 2011; Williamson et al., 1996).  The ethno pharmacological 
approach is often the preferred method because of the rich information on how 
medicinal plants are used by different ethnic groups.  The preparation procedure by 
the traditional practitioners provides vital information or indication of the best 
extraction method and the mode of administration when the chosen plant species 
has promising in vitro pharmacological activity that warrants further investigation 
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using animal models.  The best way of selecting potential medicinal plants is to use a 
combination of several approaches (Rates, 2001). 
Another imperative demand imposed on scientific investigation is that the result 
should be repeatable (Hedberg, 1993).  Medicinal plants harvested from the wild 
generally vary in quality and consistency of the active secondary metabolites due to 
genetic, ecological and environmental differences (Bopana and Saxena, 2007).  
Factors such as plant age, seasonal variation and geographical deviation contribute 
towards variation in pharmacological activity.  Medicinal plants are in great demand 
in developing countries and at times mature trees or plants cannot be found, then the 
young ones are used, which results in inconsistency of plant material of the same 
species and conditions (Street et al., 2008).  In order to develop an antimicrobial 
drug, it is important to be able to achieve the same level of activity in the source 
material.  For sustainability, plant leaves are a more viable option compared to the 
use of other parts of the plants such as root, bark, stem or fruits, especially if the 
bioactive phytochemicals are the same.  The extinction of vulnerable species is also 
a danger when using vital parts such as roots, bark and stem.  This explains why 
botanical gardens have become sources of collection of plant material used in many 
scientific investigations.  
Despite many publications on antimicrobial activity of plants extract, it has not yet led 
to the development of a new commercial antimicrobial compound (Gertsch, 2009).  
One of the reasons for this failure could be that scientists selected plant species for 
research based on traditional knowledge.  Traditional healers have mainly water 
available as an extractant while it has been established that aqueous extracts 
generally have little to no antimicrobial activity (Eloff et al., 2005; Kotzé and Eloff, 
2002).  Therefore, random screening of antimicrobial activities of acetone leaf 
extracts of more than 500 representative tree species belonging to different families 
was undertaken in the Phytomedicine Programme against eight microbial pathogens 
including Mycobacterium smegmatis as leads for in-depth research (Pauw and Eloff, 
2014).  Based on the good antimicrobial activity of plant species from some families 
including the Anacardiaceae, the selection was extended to other members of the 
same family to evaluate them for antimycobacterial activity (Kabongo‐Kayoka et al., 
2016). 
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1.3 PROBLEM STATEMENT 
Tuberculosis has increased worldwide during the last century and the incidence of 
this contagious and deadly disease reached a peak in 2005 while the total number of 
new TB cases is still increasing.  The positive case numbers of human 
immunodeficiency virus (HIV) and multidrug resistant patients also increased 
(Dorman and Chaisson, 2007; WHO, 2007; Shah et al., 2007).  Besides TB, other 
species of non-tuberculous mycobacteria causing disease have also been isolated 
from non-HIV and HIV-affected patients including M. avium (Biet et al., 2005; Katale 
et al., 2014). 
In humans, childhood acquired immunity for TB has been obtained through 
vaccination using the Bacille Calmette Guerin (BCG) vaccine which is an attenuated 
bovine strain.  But, studies have reported that the vaccine is only partially effective 
(Andersen and Doherty, 2005; WHO, 2015; Trunz et al., 2006; Young and Dye, 
2006).  To explore possibilities of drug development and vaccines, it is essential to 
make accurate diagnosis and conduct experiments using not only reference strain 
cultures from known culture collection databases such as the American Type 
Collection Culture (ATCC) or National Collection Type Cultures (NCTC) but also 
using current isolates as mutations might take place in this ever changing 
environment.  The continuous monitoring of Mycobacterium spp. infections in 
humans as well as in animals for any change in antimicrobial patterns is therefore 
necessary to evaluate the development of resistance against existing antimicrobial 
drugs, bearing in mind that tuberculosis is a zoonotic disease.  In 2010, the WHO 
stated that managing and responding to risks related to zoonoses and some high 
impact diseases require multi-sectoral and multi-institutional cooperation.  
Strengthening collaboration in human and animal health is essential.  The Food and 
Agriculture Organization (FAO), Office International des Epizooties (OIE) and WHO 
(2010) suggested among others the development of a joint framework to address 
gaps and strengthen collaboration in human and animal health laboratory activities. 
Therefore, the approach in this research project has been multi-inter-
transdisciplinary (MIT). 
For more than 50 years, there has not been a new molecule discovery of antibiotics.  
Most new drugs are modifications of the existing antibiotics except the newly 
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reported drug bedaquiline (Biuković et al., 2013; Diacon et al., 2012, 2009; 
Sacksteder et al., 2012).  The excessive use of antibiotics in treatment, the food 
industry and improper administration has led to an increase of antibiotic resistance in 
the market (Burnet et al., 2000).  Treatment of tuberculosis has become a challenge 
due to emerging multi-drug resistant strains (Tomioka, 2006).   
The long duration (6-9 months) of treatment and the adverse effects of 
chemotherapy are some of the reasons for lack of adherence to the completion of 
the treatment regime.  This situation has led to the increased emergence of MDR-TB 
and XDR-TB.  In South Africa, MDR-TB has also been identified (Wilkinson et al., 
1996) and tuberculosis was declared an emergency after an outbreak due to an 
extremely deadly resistant strain (XDR-TB) that was responsible for morbidity and 
mortality in the KwaZulu-Natal Province (Andrews et al., 2008; Basu et al., 2007).  It 
is therefore imperative to conduct periodic studies on characterization of 
mycobacterial species, antibiogram profiles and identification of other potential 
antibiotic drugs from natural resources. 
During the first global XDR-TB task force that WHO held in Geneva from 8-9 October 
2006, the following areas were identified as urgent research priorities: 
epidemiological characterization, relationship between strains and resistance, 
virulence and drug resistance, full understanding of the current disaster and 
Mycobacterium tuberculosis identification and drug susceptibility testing as well as 
needs to identify alternative treatments besides current available drugs (WHO, 
2007).  Plants have formed the basis of many traditional medicine systems 
throughout the world for centuries and continue to provide mankind with new 
remedies.  Numerous useful drugs were developed from lead compounds 
discovered from medicinal plants.  This strategy remains an essential route to new 
pharmaceuticals (Newman et al., 2003).  There are few publications showing activity 
of certain plants against the pathogenic mycobacteria, non-pathogenic M. bovis BCG 
and rapidly growing or non-tuberculous Mycobacteria namely M. aurum, M. 
smegmatis and M. fortuitum.  Further investigation with emphasis on pathogenic 
mycobacteria, namely M. bovis and M. tuberculosis, is still needed to provide a 
broader database of potential plant species as candidates for possible 
antimycobacterial drug development.  
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1.4 AIMS AND OBJECTIVES  
This study comprised two phases: phase I included the isolation of Mycobacterium 
spp. from samples of animals suspected of being infected with TB after 
tuberculination or showing lesions suggestive of tuberculosis and characterization of 
some of the isolates.  During phase II, selected plant species of the family 
Anacardiaceae were tested for antimycobacterial activity using some isolates from 
phase I and strains of non-tuberculous mycobacteria.   
The aims of this research project were: 
• Phase 1: To isolate and characterize M. bovis and M. avium strains from 
animal samples;  
• Phase 2: To test some first-line antimicrobial drugs and selected plant extracts 
against isolates from phase I and strains of non-tuberculous mycobacteria for 
antimicrobial sensitivity. 
The abovementioned aims were achieved through the following objectives: 
• To process samples from animals suspected of tuberculosis and isolate 
Mycobacterium species; 
• To identify and characterize the above isolates; 
• To test some of these isolates for antimycobacterial sensitivity using first-line 
drugs; 
• To select 15 plant species from a list of previously screened plants (in the 
family Anacardiaceae) with good activity against Mycobacterium smegmatis.   
• To collect the leaves from the selected plants and prepare crude acetone 
extracts from dried leaf materials; 
• To determine in vitro antimycobacterial activities and cytotoxicity of crude 
acetone extracts of the selected plant species;  
• To select the most active extract for bioassay-guided isolation of 
antimycobacterial active compounds; 
• To perform solvent-solvent fractionation of the most active crude acetone 
extract and run a second screening on the fractions for antimycobacterial 
activity;  
• To select the most active fraction/s for compound isolation; 
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• To isolate and determine the molecular structure of at least one compound 
responsible for antimycobacterial activity; 
• To determine the antimycobacterial activity and cytotoxicity of the isolated 
compounds. 
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1.5 HYPOTHESIS 
New Mycobacterium species can still be isolated in the current ever-changing 
environment.  The selected plant extracts may contain chemical compounds with in 
vitro antimycobacterial activity.  
1.6 SCOPE OF THE THESIS 
1.6.1 Isolation and characterization of mycobacteria 
To explore possibilities of drug development and vaccines, it is essential to make 
accurate diagnosis and conduct experiments using not only reference strain cultures 
but also using the current clinical isolates as mycobacterial mutations might have 
occurred in this ever-changing environment.  The treatment of tuberculosis is still a 
challenge due to emergence of MDR and XDR strains.  Therefore, there is a need to 
characterize and establish the genetic diversity of the current isolates used in 
bioassays while exploring the development of alternative drugs for tuberculosis.  The 
continuous monitoring of Mycobacterium spp. infections in humans as well as in 
animals for any change in antimicrobial patterns is therefore necessary to evaluate 
the development of resistance against existing antimicrobial drugs, bearing in mind 
that tuberculosis is a zoonotic disease.  Samples from slaughtered animals 
suspected of being infected with tuberculosis or presenting lesions suggestive of 
tuberculosis were processed for Mycobacterium spp. isolation and characterization.  
1.6.2 Antimycobacterial activity of plant extracts 
Previous screening of some tree species from the Anacardiaceae family revealed the 
presence of good antimicrobial activity against Mycobacterium smegmatis (Pauw, 
2014).  Leaf extracts of 15 Anacardiaceae tree species were screened for 
antimycobacterial activity against the pathogenic Mycobacterium bovis, multidrug 
resistant M. tuberculosis, drug sensitive M. tuberculosis (H37Ra), M. bovis BCG 
vaccine strain and strains of non-tuberculous mycobacteria, namely M. aurum, M. 
fortuitum and M. smegmatis. 
1.6.3 Cytotoxicity assay of plant extracts 
For a plant extract or compound to be considered for drug development or as an 
alternative for therapeutic use it should be more toxic to the target organism than the 
patient’s cells. The cytotoxicity of the active crude extract, its fractions and pure 
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active compounds was investigated and the selectivity index was calculated to 
achieve this aim. 
Once the antimycobacterial activity of the 15 plant extracts was established, isolation 
of the pure active compounds from one of the most active and least toxic plant 
species on normal cells was carried out.  Cytotoxicity was evaluated using Vero 
monkey kidney cells, human hepatoma liver cells and murine macrophages.  
1.6.4 Isolation, purification and identification of the active compound(s) from 
Searsia undulata  
Out of the 15 plant species tested for antimycobacterial activity, 5 had moderate to 
good activity.  Of these five plant species; Searsia undulata had good 
antimycobacterial activity and low cytotoxicity to normal cells (but was toxic to the 
C3A hepatoma cells).  According to the literature review, leaves of Searsia undulata 
are chewed by the Nama (Khoisan) for chest colds and leaf decoctions are 
administered for post partem problems.  The plant is a shrub widely distributed along 
the west coast of the Cape and occurs in a range of different habitats (Van Wyk et 
al., 1997).  This information supported the decision to focus on this plant species 
first.  
The objective was to isolate active compound(s) and evaluate the minimum inhibitory 
concentration with the different fractions and finally with the pure compound(s) 
against pathogenic mycobacteria and non-tuberculous mycobacteria. Through 
bioassay-guided fractionation, ten compounds active against mycobacteria were 
observed using bioautography but only three compounds could be isolated in 
sufficient quantity within the time frame allocated to the completion of this research 
for the degree purpose as compounds were closely related to each other and difficult 
to separate.  Due to time constraints the three compounds were only tested against 
the non-tuberculous mycobacteria. 
1.7 STRUCTURE OF THE THESIS 
Chapter 1 provides an overview related to the general aspects of the disease 
caused by mycobacteria spp. and the use of plants as alternative medicine and 
potential leads for drug development.  Epidemiology, causes, pathogenesis, clinical 
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signs, diagnosis, control, treatment and zoonotic aspects of the diseases are 
covered.  
Chapter 2 deals with samples from different animal species suspected of being 
infected with tuberculosis. Isolation of mycobacteria spp. using solid medium, 
Löwenstein-Jensen agar and liquid medium tubes using the BACTECTM MGITTM is 
described.  Isolates were identified and characterized using Ziehl-Neelsen staining, 
the line probe assay from the GenoType CM/AS kit, multiplex PCR, spoligotyping, 
variable number tandem repeat.  Antimycobacterial susceptibility testing using a 
commercial kit, Genotype® MTBDRplus against first line drugs was also conducted 
on some isolates.  Results of mycobacteria spp. identified and antimycobacterial 
activity of drugs against some isolates are reported. 
Chapter 3 describes the novel Mycobacterium avium complex isolated from black 
wildebeest samples suspected of tuberculosis. Isolation using solid medium, 
Löwenstein-Jensen slants, and liquid medium tubes using the BACTECTM MGITTM 
are reported.  Identification using biochemical tests, the line probe assay from the 
GenoType CM/AS, gene sequencing of all four genes 16S rRNA, 16S-23S rRNA 
(ITS), rpoB and hsp65 and phylogenetic analyses are discussed.   
Chapter 4 analyses results obtained from the screening of 15 plant species against 
pathogenic and rapidly growing mycobacteria.  Cytotoxicity evaluation of selected 
plants with good antimycobacterial using a colorimetric assay against Vero monkey 
kidney, human hepatoma and murine macrophage cells is discussed. Results 
justifying the selection of Searsia undulata as the plant of interest for further studies 
are presented. An incidental finding related to the potential anticancer property of S. 
undulata is reported. 
Chapter 5 provides results of the bioassay-guided fractionation of the bulk plant 
extract leading to the isolation of compounds.  Results of antimycobacterial activity, 
cytotoxicity assays and structure elucidation of isolated compounds using MS and 
NMR spectroscopy are reported.  The physio-biological properties of one of the 
compounds are provided.  
Chapter 6 covers the highlights of results obtained from each previous chapter in a 
coherent manner.  Assessment of each objective is discussed; challenges 
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encountered during the course of this research are provided, and future perspectives 
and recommendations in terms of work subsequent to this PhD research are also 
provided.  
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CHAPTER 2: 
MOLECULAR PROFILE OF MYCOBACTERIUM SPP. ISOLATES 
FROM CATTLE AND OTHER ANIMAL SPECIES 
ABSTRACT 
Mycobacterium bovis causes tuberculosis in cattle and other animals and its 
incrimination in human tuberculosis has been recognized since the beginning of the 
twentieth century. Tuberculosis caused by M. bovis or M. tuberculosis presents the 
same clinical picture. The treatment of tuberculosis is currently a challenge due to 
emergence of multi-drug and extensively drug resistant strains.  Therefore, there is a 
need to characterize and establish the genetic diversity of the current isolates used 
in antimycobacterial bioassays while exploring the development of alternative drugs 
for tuberculosis.  Consequently, a purposive sampling was conducted and a total 
number of samples (n=80) were processed for Mycobacterium spp. isolation that 
included 31 samples from 10 cattle; 26 samples from 12 black wildebeest 
(Connochaetes gnou) which were received in two different batches, 20 samples from 
20 warthogs (Phacochoerus africanus), 1 sample from an impala (Aepyceros 
melampus) and 2 samples from 1 rabbit (Oryctolagus cuniculus).  The isolation, 
multiplex PCR, spoligotyping, variable number of tandem repeat (VNTR) and 
antimicrobial susceptibility test of some of the isolates against first-line TB drugs 
using Genotype® MTBDRplus kit (Hain Life Science GmbH, Nehren, Germany) were 
investigated.   
In this chapter, samples (n=64) are described, which includes the second batch of 
samples (n=10) from 3 black wildebeest.  The findings from the first sample batch 
(n=16) from black wildebeest are reported in Chapter 3.  The 64 samples which 
yielded 36 isolates of Mycobacterium spp. included samples (n=10) from 3 black 
wildebeest that yielded M. avium subsp. hominissuis,  samples (n=20) from 20 
warthog that yielded M. bovis (n=14), M. avium (n=1) and M. intracellulare (n=1), 
samples (n=2) from a rabbit that yielded M. avium subsp. hominissuis (n=1), sample 
(n=1) from 1 impala  yielded M. bovis (n=1) and samples (n=31) from 10 cattle that 
yielded M. bovis (n=15).  
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The non-tuberculous mycobacteria isolated from the rabbit, black wildebeest 
samples and warthogs (M. intracellulare and M. avium) are potentially zoonotic as 
they have been incriminated in diseases in humans.  
The isolates from cattle were further analysed by spoligotyping and yielded two 
spoligotypes.  Ten out of 15 M. bovis isolates were typed as SB0121 (67%) and 5 
out of 15 were typed as SB 1235 (33%).  SB0121 was obtained from different 
animals and it has been isolated from several countries including South Africa 
whereas SB1235 seemed to relate to UK strains and was recently reported in South 
Africa.  A spoligotype strain is an indication of the scope of the movement of cattle 
and it is a useful epidemiological tool.  All isolates had an identical VNTR type 1 
which meant that the isolates were from the same origin.   The antimicrobial 
sensitivity test of M bovis isolates revealed that 8 out of 15 (53%) isolates were multi-
drug resistant (MDR) as they were resistant to the first-line drugs INH and RIF used 
routinely in the tuberculosis regimen in humans whereas 7 out of 15 (47%) were 
sensitive to both drugs.  The presence of MDR of M. bovis in cattle is of concern 
considering the emergence of MDR-TB strains in humans and the lack of data on the 
prevalence and incidence of tuberculosis caused by M. bovis in humans in South 
Africa. 
2.1 INTRODUCTION 
Tuberculosis (TB) is the most common cause of death in this century.  In 1993, the 
World Health Organization (WHO) declared TB to be a global emergency.  
Mycobacterium tuberculosis and Mycobacterium bovis are the main causative 
agents associated with the disease in humans.  They belong to the Mycobacterium 
tuberculosis complex (MTC) which includes other species, namely M. africanum, M. 
canetti, M. pinnipedii, M. caprae, M. microti, M. mungi, Dassie bacillus, M. orygis 
(Oryx bacillus) and M. surricatae.  These species are pathogenic and can cause 
tuberculosis in mammalian hosts (Alexander et al., 2010; Helden et al., 2009; Pittius 
et al., 2012; ; Vos et al., 2001).  In industrialized countries, human infection with M. 
bovis has been largely controlled through pasteurization of cow’s milk, abattoir 
inspection and culling of cattle positive reactors to the compulsory tuberculin test.  
Despite these control measures, cases of human tuberculosis caused by M. bovis 
associated with or without HIV/AIDS have been reported (CDC, 2005; De Kantor et 
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al., 2010; Evans et al., 2007; Gallivan et al., 2015; Hlavsa et al., 2008; Olea-Popelka 
et al., 2016) as well as cases of co-infection with both M. bovis and M. tuberculosis 
(Silva et al., 2013).  Cases of animal tuberculosis caused by M. tuberculosis have 
also been reported (Michel et al., 2013; Ocepek et al., 2005).  The incidence of 
tuberculosis caused by M. bovis in humans is underestimated in most cases due to 
the difficulty of differentiating M. tuberculosis from M. bovis with limited diagnostic 
tools such as culture medium and Ziehl-Neelsen stained smears.  Adding to this, 
human tuberculosis caused by either M. tuberculosis or M. bovis is clinically 
undistinguishable (Cousins, 2001; De la Rua-Domenech, 2006; Grange, 2001).  
Airborne human to human transmission of M. bovis has been reported in the UK 
(Evans et al., 2007). 
It was estimated that between 2002 and 2020, one billion people would be newly 
infected, 200 million people would get sick, and 35 million would die of TB if proper 
control measures were not instituted (WHO, 2002).  The treatment of tuberculosis is 
still a challenge due to emergence of multi-drug and extensively resistant strains 
(Bateman, 2015; Hoang et al., 2015; WHO, 2015).  Several authors have reported 
outbreaks of multi-drug resistant (MDR) M. bovis and M. tuberculosis strains 
(Bateman, 2015; Samper et al., 1997).    
These outbreaks highlight the importance of accurate diagnosis of Mycobacterium 
spp. for effective management of the disease.  Besides the solid culture medium, 
Löwenstein-Jensen (LJ) with glycerol that is routinely used in medical laboratories, it 
is recommended to include LJ with pyruvate which will promote the growth of M. 
bovis and prevent missing cases of M. bovis (Silva et al., 2013).  Beyond culture 
isolation and Ziehl-Neelsen staining, other methods of differentiation are used to 
identify Mycobacterium spp. namely MIRU-VNTR (Mycobacterial Interspersed 
Repetitive Units-Variable Number of Tandem Repeat), Restriction Fragment Length 
Polymorphism (RFLP) typing, gene sequencing, spoligotyping and antimicrobial 
susceptibility (Laniado-Laborín et al., 2014; Michel et al., 2013; Ocepek et al., 2005).  
Antimicrobial sensitivity profile can assist in the differentiation between M. 
tuberculosis and M. bovis while providing the susceptibility pattern against 
antimycobacterial drugs for an effective drug choice.   For example M. bovis is 
known to be resistant to pyrazinamide; such isolates should further be analysed to 
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rule out M. tuberculosis.  A combination of techniques is required for an accurate 
identification of the isolates.  Spoligotyping, RFLP typing, gene sequencing and 
VNTR are important as epidemiological tools to trace the origin of the infection, 
identify the strain involved and assist in disease control especially in eradication 
programmes aiming at eliminating the sources of infection (Hang’ombe et al., 2012; 
Hlokwe et al., 2013; Michel et al., 2013). 
Other challenges include adverse drug side effects, high loss of follow ups of 
patients (suboptimal treatment adherence), inadequate treatment of MDR-TB using 
fewer drugs, leading to XDR-TB, inadequate hospital capacity, poor infection control 
and limited availability of appropriate second-line drugs and inadequate national 
funds from government (Bateman, 2015; Hoang et al., 2015; WHO, 2015).  South 
Africa is ranked among the 30 countries with a high burden of multi-drug resistant 
tuberculosis (Churchyard et al., 2014; WHO, 2015).  The current antimycobacterial 
drugs include isoniazid (INH) and rifampin (RIF) as most common first-line drugs and 
fluoroquinolones as second-line drugs; patients diagnosed with MDR-TB do not 
respond to the treatment with first-line drugs (INH and RIF) and therefore they will 
have to be treated with second-line drugs.  The current recommendation from WHO 
for MDR and XDR is a minimum of 20 months therapy using 3 or 4 drugs in 
combination (WHO, 2015) but lower cure rates of MDR and XDR-TB have been 
observed, ranging from 50 to 70% which have led to high morbidity and mortality 
rates (Gandhi et al., 2012). 
In the absence of a preventative vaccine, more effective diagnostic tools and novel 
therapeutic interventions are needed.  An understanding of the relationship between 
strains and resistance, virulence and drug resistance, is necessary to fully 
understand the current disaster as well as needs to identify alternative treatments 
besides current available drugs (WHO, 2010b). 
There are different approaches to explore alternative treatment for TB namely, 
modification of current molecules of drugs already on the market and exploration of 
natural resources such as plants (Jimenez‐Arellanes et al., 2003; Newman et al., 
2003).  Plants have been the basis of many traditional medicine systems throughout 
the world for centuries and continue to provide mankind with new remedies. Besides 
synthetic chemistry, plants are still an important natural source of pharmacologically 
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active compounds with many drugs derived directly or indirectly from plants 
(Newman et al., 2003; Veeresham, 2012). 
When conducting the different bioassays exploring alternative treatments for 
tuberculosis, it is relevant to make use of new isolates of Mycobacterium spp. from 
the changing environment as well as reference cultures sourced for example from 
the American Type Culture Collection (ATCC) strains and National Collection of 
Type Cultures (NCTC).  Therefore, there is a need to characterize and establish the 
genetic diversity of the current isolates that can be used in bioassays exploring the 
development of alternative drugs for tuberculosis.  This will also allow detection of 
any changes in circulating strains and epidemiological traceability of Mycobacterium 
spp. causing disease.   
2.2 MATERIALS AND METHODS 
2.2.1 Study area 
In South Africa, nine provinces exist but due to the vast land mass of the country, it 
was necessary to select some study areas based on reported cases and 
accessibility to samples within the time frame allocated to this research.  
Mpumalanga Province was selected as the area of study based on previous 
publications reporting TB in wildlife and livestock (Bengis et al., 1996; Michel et al., 
2007; Vos et al., 2001) and availability of veterinary staff members experienced in 
conducting the comparative tuberculin skin test.  Mpumalanga is one of the nine 
provinces in South Africa as indicated by a red triangle on the map (Figure 2.1) and it 
is located in the north-eastern part of the country, bordering Swaziland and 
Mozambique to the East.  It embraces the southern half of the Kruger National Park, 
a vast nature reserve with abundant wildlife including big game.  It has a subtropical 
foliage supporting about 1 439 000 cattle according to the Trends in the Agricultural 
Sector (2013). 
 51 
 
 
Figure 2.1: South Africa Map with the red triangle showing Mpumalanga Province where 
samples were obtained  
Source: courtesy of www.sa.venues.com 
2.2.2 Study design and sampling 
The study was designed as a cross sectional study and specimens were collected 
from animals in the designated areas from January 2009 to January 2011.  The local 
municipalities were selected based on the number of commercial farms, proximity to 
abattoirs, and location at the human-wildlife interface and also the movement of 
animals.  The municipalities selected comprised Malelane, Nelspruit, Lydenburg, 
Ermelo, Witbank and Standerton.  The target population comprised cattle carcasses 
showing gross tuberculous-like lesions at meat inspection from positive reactors to 
tuberculin skin test at the municipality abattoirs during the study period.  Samples 
from any other animal species showing gross tuberculous-like lesions were also 
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included as convenience samples.  The sampling was purposive to increase the 
chances of isolating mycobacteria and only cattle were selected based on positive 
reaction on tuberculin skin test and pathological lesions. 
2.2.3 Sources of Samples  
Thirty-one samples randomly selected from 10 cattle (Bos taurus) from 3 different 
farms and one abattoir located in Mpumalanga were screened for Mycobacterium 
spp. isolation and identification.  This work was conducted at the National Health 
Laboratory Service (NHLS) in Pretoria, South Africa.   Samples from other animal 
species were collected based on observed tuberculosis-like lesions.  They 
comprised two samples from a rabbit (Oryctolagus cuniculus), 20 samples from 20 
warthogs (Phacochoerus africanus), a different batch of 10 samples from 3 black 
wildebeest and 1 sample from an impala (Aepyceros melampus).  Different organs 
and lymph nodes on ice were received (Table 2.1).   
All samples were accompanied by a sample submission form that contained 
information about the animal, owner and location.  The history of each animal was 
provided by the state veterinarian in charge.  Cattle samples were from positive 
reactors to tuberculin test and that had lesions suggestive of tuberculosis at 
slaughter.  Yellowish granulomatous lesions of different sizes with calcification and 
gritty sensation when cutting through the granulomas were observed.   
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Table 2.1: Types of samples from different animal species 
                                                                   Tissue samples                                                                                             Total  
                            
 Colon Liver Lung Kidney Br   Ext. Il Ing Hep Med Par Pres Retro Mand  Animal species               Black wildebeest (n=3) 0 0 0 0 5 0 0 0 5 0 0 0 0 10 
Cattle (n=10) 0 2 2 2 10 2 2 0 2 3 2 2 2 31 
Impala (n=1) 0 0 0 0 1 0 0 0 0 0 0 0 0 1 
Rabbit (n=1) 1 0 0 0 0 1 0 0 0 0 0 0 0 2 
Warthog (n=20) 0 0 0 0 5 0 0 2 0 3 0 5 5 20 
Total per category 1 2 2 2 16 3 2 2 2 6 2 7 7 64 
 
Br: bronchial; Ex IL: External iliac; Ing: Inguinal; Hep: Hepatic; Med: Mediastinal; Par: Parotid; Pres: Prescapular; Retro: Retropharyngeal; Man: Mandibular  
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2.2.4 Mycobacterial isolation  
Samples were kept frozen at -20°C until processing at NHLS under biosafety 
measures (Figure 2.2).  Direct impression smears were made from lesions and were 
stained using the Ziehl-Neelsen method.  Tissue samples taken in a sterile manner 
from the inside of granulomatous lesions at the border between healthy and fibrous 
tissues were finely cut using a sterile scalpel blade and homogenized using sterile 
glass beads by vortexing as described by Bengis et al. (1996) and Warren et al. 
(2006)  with some modifications.  To maximize the mycobacterial yield, specimens 
were subjected to a digestion and decontamination procedure using N-acetyl-L-
cysteine-sodium hydroxide (NALC-NaOH) solution with NaOH at a final 
concentration of 2% (Chatterjee et al., 2013).  The specimens were left at room 
temperature for 15 min during the decontamination process and thereafter 
neutralized with phosphate buffer pH 6.8, centrifuged (Beckman Coulter) at 3000 x g 
for 15 min at 4°C, and the supernatant decanted and pellet suspended into 1 mL of 
phosphate buffer.  The sediment was inoculated onto two LJ slants, supplemented 
with pyruvate and glycerol and an antibiotic mixture of polymyxin B, amphotericin B, 
carbenicillin and trimethoprim (PACT) (National Health Laboratory Service, South 
Africa, and Becton Dickinson, Germany) using a 0.01 mL calibrated loop.  A further 
0.5 mL of the sediment was inoculated with a graduated Pasteur pipette into a 
prepared liquid medium tube (BBLTM MGITTM Mycobacterium Growth indicator tubes) 
enriched with OADC and containing 800 µl of PANTATM antibiotic mixture (BDTM).  
This was incubated in the BACTECTM MGITTM 960 (Figure 2.2) mycobacterial 
detection system at 37°C (Warren et al., 2006).  The system was monitored for a 
maximum period of 42 days for bacterial growth whereas LJ slants were observed 
for colony growth and any other contaminants at two week intervals for 10 weeks.  
Tubes detected as positive within that period were further processed using Ziehl-
Neelsen staining and examined microscopically for the presence of acid-fast 
organisms and morphology, thereafter subcultured on LJ slant supplemented with 
glycerol and pyruvate.  For identification purposes, a single colony was subcultured 
on a fresh LJ slant to obtain pure colonies. The same was repeated with two other 
colonies on different LJ slants to rule out the possibility of missing a different 
organism.  Reference cultures of M. avium (ATCC 25291), M. bovis BCG and M. 
tuberculosis (ATCC 25177) were used as positive controls.  Stored DNA extracts 
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were preserved in a final concentration of 1 mM EDTA 24 hours prior to being taken 
to Japan. Disodium salts dehydrate, EMD Biosciences, inc. La Jolla, CA 92039-2087 
was used as a preservative.  
 
                                (a)                                                       (b) 
Figure 2.2: Samples processed in a biosafety cabinet (a) and incubated in BACTECTM               
MGITTM 960 system (b) 
2.2.5 Mycobacterial identification 
2.2.5.1 DNA extraction and primary molecular identification  
DNA extracts were prepared based on the GenoType CM/AS reverse line blot assay 
(Hain Life Science, Gmbh Nehren, Germany).   DNA was extracted from colonies on 
LJ slants by heating at 95°C for 20 min in a water bath.  Primers provided by the 
manufacturer’s kit (Hain Lifescience, Nehren, Germany) were used.  The formula for 
the PCR assay per tube mixture contained 1.1 µL of ultra-pure water, 5 µL of 10 x 
buffer, 3.6 µL of MgCl2 (25 mM), 35 µL of primer/nucleotide mix from the kit and 0.3 
µL of hot Taq polymerase.  The thermocycler was programmed to initiate the PCR as 
follows: one cycle of 15 min at 95°C, followed by 10 cycles of 30 sec at 95°C, 2 min 
at 58°C, 25 sec at 95°C; then 20 cycles of 40 sec at 53°C and 40 sec at 70°C with a 
final cycle of 8 min at 70°C.  The hybridization was then followed as per 
manufacturer’s instructions using the strips provided in the kit (DNA strip 
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Mycobacterium identification species).  Part of each DNA extract was also stored at -
20°C prior to further investigations in Japan. 
2.2.5.2 Antimicrobial susceptibility test 
The antimicrobial susceptibility test and identification of mutations responsible for 
resistance against rifampin (RIF) and isoniazid (INH) were conducted at NHLS 
according to in house standard operating procedure using a commercial kit, 
Genotype® MTBDRplus kit (Hain Life Science, Gmbh Nehren, Germany), following 
the manufacturer’s instructions.  Biotinylated primers provided with the kit were used 
to amplify 5 µl of DNA with hot-start Taq DNA polymerase (Qiagen, Pretoria, South 
Africa).  Amplification was performed using a thermal cycler MyCyclerTM (Bio-Rad, 
Cape Town, South Africa).  The thermocycler was programmed as described under 
section 2.2.5.1. Then hybridization steps were followed using hybridization trays 
(Hain Life Science, Gmbh Nehren, Germany) according to the manufacturer’s 
instructions.  The following genes were targeted for detecting the sensitivity of the 
isolates to a specific antimycobacterial drug namely eight rpoB wild-type probes 
named WT1-WT8 and four mutant probes named MUT1, MUT2A, MUT2B and 
MUT3 were used to detect resistance against RIF.  One katG wild type (katG WT) 
and two mutant probes (MUT1 and MUT2); plus two inhA wild type (WT1 and WT2) 
and four mutant probes (MUT1, MUT2, MUT3A and MUT3B) for the detection of 
resistance against INH.  According to the manufacturer, when all WT probes stained 
positive and no mutation band formed, the result was interpreted as susceptible to 
the specific anti-TB drug (Figure 2.3).  The resistance towards a specific antibiotic 
was indicated by the absence of a band for at least one of the WT probes.  Each 
pattern deviating from the wild type pattern indicates a resistance of the tested strain.  
The banding pattern obtained with rpoB probes allows a conclusion to be drawn 
about a rifampicin resistance of the strain tested whereas the banding pattern 
obtained with the katG probes allows a conclusion to be made about a high level 
isoniazid resistance; the banding pattern obtained with the inhA probes allows a 
conclusion to be drawn about a low level of isoniazid resistance of the strain tested 
respectively. 
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2.2.5.3 MTC discrimination by multiplex PCR  
The Mycobacterium tuberculosis complex-discriminating multiplex PCR (MTCD-
MPCR) targeting genetic regions cfp32 (a specific gene for MTC), RD4 (region of 
difference 4 which is present in M. tuberculosis and M. africanum but absent in M. 
bovis was used for species differentiation according to the method described by 
(Parsons et al., 2002) with slight modifications.   The reaction mixture consisted of 
7.4 μL H20, 2 μL 10 x Taq buffer, 2 μL dNTPs (2.5 mM each), 0.2 μL Taq (Takara 
Bio Inc, Shiga, Japan), 1 μL of DNA sample, 2.2 μL of 10 μM cfp32 primers, 0.7 μL 
of 5 μM RD4 primers.  The PCR was performed using the following program: 
denaturation for 1 min at 98°C followed by 35 cycles of 5 sec at 98°C, 20 sec at 58°C 
and 1 min at 68°C with final elongation at 72°C for 5 min in a thermal cycler (iCycler, 
Bio-Rad Laboratories Inc., Hercules, CA). Mycobacterium bovis BCG Pasteur 
vaccine, M. bovis BCG Tokyo and M. bovis AF2122/97 were used as positive 
controls and distilled water as negative control.  The PCR products were separated 
by electrophoresis on a 2% agarose gel in TAE buffer, and then visualized after 
staining with ethidium bromide.  RD4 Flank F and RD4 flank R gave a product of 
about 446 bp. 
2.2.5.4 Spoligotyping  
Spoligotyping of M. bovis isolates using microarray was performed according to the 
procedure by Kamerbeek et al. (1997) with slight modifications.  Forty-three spacer-
sequence probes were covalently bound to the membrane (Pall Co., NY, USA).  
PCR products were generated using primers DRa (GGTTTTGGGTCTGACGAC) and 
DRb (CCGAGAGGGGACGGAAAC).  The PCR mixture included 7.3 µL of deionized 
water, 5 X 3 µL colourless GoTaq buffer (Promega TM, Fitchburg, WI), 1.5 µL of 
PCR DIG Labelling Mix (Roche), 1 µL of 10 µM Fw primer, 11 µL of 10 µM Rv 
primer, 0.2 µL of GoTaq DNA Polymerase (5 units/µL, Promega) and 1 µL of DNA 
sample in a total volume of 15 µL of mixture per tube.  The thermocycler was 
programmed to initiate denaturation at 98°C for 60 sec, followed by 40 cycles of 5 
sec at 98°C, 10 sec at 55°C, 10 sec at 55°C, 30 sec at 72°C and a post run for 60 
sec at 72°C.  The PCR product that was diluted 500 times in hybridization buffer was 
heat denatured at 95°C for 5 min and immediately cooled on ice to obtain the single 
stranded DNA.  The probe solutions for spotting were prepared by adjusting the 
concentration with TE buffer to 50 µM of spacer probe and 10 µM of DR probe 
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(positive control).  Then the membrane was cut to an appropriate size and marked to 
distinguish the side to be spotted.  The membrane was held with forceps to avoid 
binding of protein, which could interfere with probe DNA attachment on the 
membrane.  Then 0.5 µL of each probe solution was spotted on the membrane and 
heated at 70°C for 30 min, followed by pouring of the blocking buffer on the 
membrane.  It was then allowed to stand at room temperature for 1 hour with 
intermittent gentle shaking.  
The hybridization was carried out by immersing the membrane in the hybridization 
solution at 60°C for 1 hour. Then, the membrane was washed in warm TBST-E 
(0.1% Tween-20 and 1 mM EDTA-2Na in tris-buffered saline) and incubated for 10 
min at 60°C then washed for the third time in warm TBST-E.  The membrane was 
then dried at room temperature.  The POD and TMB solutions were prepared as per 
manufacturer’s instructions.  The nitrocellulose membranes were covered with a 
1000 times diluted Ant-Digoxigenin-POD [poly], Fab fragments (Roche) in a dish and 
incubated at room temperature for 30 min. Thereafter, the membranes were 
sequentially washed three times in TBST-E at room temperature for 1 min, 10 min 
and 1 min as per protocol (Hang’ombe et al., 2012).  Then, POD on the membranes 
was detected through colour development by adding TMB solution (TMB Peroxidase 
Substrate Kit, Vector Labs Inc. TM, Burlingame, CA) according to the manufacturer’s 
protocol. The membrane was then washed with deionized water (DIW) and scanned 
(Figure 2.4).  The spoligotype patterns observed were compared to the patterns 
available in the spoligotype M. bovis database (www.mbovis.org) 
2.2.5.5 Variable number of tandem repeat (VNTR) typing 
The M. bovis isolates were further genotyped by PCR amplification using primers 
targeting a wide range of tandem repeat loci (Table 2.2).  Two different PCR reaction 
mixtures were conducted according to the loci and the PCR primer sequences used 
are outlined in Table 2.2.  Locus MIRU10, 16, 24, 26, 27, 39, 40, ETR-B, F, VNTR-
424, 3690 were done under betaine 1.0 M, whilst locus MIRU2, 4, 20, 23, 31, ETR-A, 
C, QUB- 11a, 11b, 26, 3232, 3336, VNTR-1955, 2401, 4156 were performed under 
GCII buffer (Takara). The PCR reaction mixture under 1.0 M betaine buffer was 
conducted in a mixture consisted of 6.3 μL H2O, 0.4 μL of dNTP (10 mM each), 3.0 
μL of 5x colourless Go Taq buffer, 3.0 μL of betaine (5 M), 0.6 μL of Primer 1 and 0.6 
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μL of Primer 2, 0.1 μL of Go Taq (5 units/ μL) DNA Polymerase, and 1 μL of DNA 
sample.  An initial denaturation step of 95°C for 5 min was followed by 32 cycles at 
95°C for 15 sec, 58°C for 20 sec and 72°C for 1 min with a final elongation step at 
72°C for 1 min in a thermal cycler.  The PCR reaction mixture under the GCII buffer 
consisted of 4.8 μL H2O, 0.4 μL of dNTP (10 mM each), 7.5 μL of 2 x GCII buffer, 0.6 
μL of primers, 0.1 μL of Go Taq (5 units/μL) DNA Polymerase (Promega), and 1 μL 
of DNA sample.  All the PCR samples were electrophoresed on a 2% agarose gel to 
identify the repeat numbers; a 100 bp ladder PLUS (Thermo Scientific, USA) was 
included for the estimation of the size (Hang’ombe et al., 2012) (Table 2.3). 
Table  2.2: Variable number of tandem repeat (VNTR) loci and forward and reverse primers (5'-
3') sequences used for the typing of M. bovis isolates (Le Fleche et al., 2002) 
ON-No Locus No Common names Primer sequence Mer 
749 
13 
MIRU4F GCGCGAGAGCCCGAACTGC 19 
750 MIRU4R GCGCGAGCAGAAACGCCAGC 20 
751 
1 
MIRU10F GTTCTTGACCAACTGCAGTCGTCC 24 
752 MIRU10R GCCACCTTGGTGATCAGCTACCT 23 
753 
2 
MIRU16F TCGGTGATCGGGTCCAGTCCAAGT 24 
754 MIRU16R CCCGTCGTGCAGCCCTGGTAC 21 
755 
3 
MIRU26F CCCGCCTTCGAAACGTCGCT 20 
756 MIRU26R TGACATAGGCGACCAGGCGAATA 24 
757 
4 
MIRU31F ACTGATTGGCTTCATACGGCTTTA 24 
758 MIRU31R GTGCCGACGTGGTCTTGAT 19 
759 
5 
MIRU40F GGGTTGCTGGATGACAACGTGT 22 
760 MIRU40R GGGTGATCTCGGCGAAATCAGATA 24 
761 
9 
ETR-A1 AAATCGGTCCCATCACCTTCTTAT 24 
762 ETR-A2 CGAAGCCTGGGGTGCCCGCGATTT 24 
763 
10 
ETR-C1 GTGAGTCGCTGCAGAACCTGCAG 23 
764 ETR-C2 GGCGTCTTGACCTCCACGAGTG 22 
765 
11 
QUB11b1 CGTAAGGGGGATGCGGGAAATAGG 24 
766 QUB11b2 CGAAGTGAATGGTGGCAT 18 
767 
12 
QUB26-1 GGCCAGGTCCTTCCCGAT 18 
768 QUB26-2 AACGCTCAGCTGTCGGAT 18 
769 
6 
VN424F CTTGGCCGGCATCAAGCGCATTATT 25 
770 VN424R GGCAGCAGAGCCCGGGATTCTTC 23 
771 
14 
VN2401F CTTGAAGCCCCGGTCTCATCTGT 23 
772 VN2401R ACTTGAACCCCCACGCCCATTAGTA 25 
773 
8 
VN3690F CGGTGGAGGCGATGAACGTCTTC 23 
774 VN3690R TAGAGCGGCACGGGGGAAAGCTTAG 25 
775 
15 
VN4156F TGACCACGGATTGCTCTAGT 20 
776 VN4156R GCCGGCGTCCATGTT 15 
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777 
7 
VN1955F AGATCCCAGTTGTCGTCGTC 20 
778 VN1955R CAACATCGCCTGGTTCTGTA 20 
779 
16 
MIRU2F TGGACTTGCAGCAATGGACCAACT 24 
780 MIRU2R TACTCGGACGCCGGCTCAAAAT 22 
781 
17 
MIRU20F TCGGAGAGATGCCCTTCGAGTTAG 24 
782 MIRU20R GGAGACCGCGACCAGGTACTTGTA 24 
783 
18 
MIRU23F CAGCGAAACGAACTGTGCTATCAC 24 
784 MIRU23R CGTGTCCGAGCAGAAAAGGGTAT 23 
785 
19 
MIRU24F CGACCAAGATGTGCAGGAATACAT 24 
786 MIRU24R GGGCGAGTTGAGCTCACAGAA 21 
787 
20 
MIRU27F TCGAAAGCCTCTGCGTGCCAGTAA 24 
788 MIRU27R GCGATGTGAGCGTGCCACTCAA 22 
789 
21 
MIRU39F CGCATCGACAAACTGGAGCCAAAC 24 
790 MIRU39R CGGAAACGTCTACGCCCCACACAT 24 
791 
22 
ETR-B1 GCGAACACCAGGACAGCATCATG 23 
792 ETR-B2 GGCATGCCGGTGATCGAGTGG 21 
793 
23 
ETR-F1 CTCGGTGATGGTCCGGCCGGTCAC 24 
794 ETR-F2 GGAAGTGCTCGACAACGCCATGCC 24 
795 
24 
QUB11a1 TTCAGGGGGGATCCGGGA 18 
796 QUB11a2 CCCATCCCGCTTAGCACATTCGTA 24 
797 
25 
QUB3232-1 CAGACCCGGCGTCATCAAC 19 
798 QUB3232-2 CCAAGGGCGGCATTGTGTT 19 
799 
26 
QUB3336-1 ATCCCCGCGGTACCCATC 18 
800 QUB3336-2 GCCAGCGGTGTCGACTATCC 20 
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Table 2.3: Band sizes (bp) and corresponding tandem repeat numbers 
      Tandem repeat number for M. bovis                 
No Locus name Unit (bp) 0 1 2 3 4 5 6 7 8 9 10 
1 MIRU10 53 482 537 590 643 696 749 802 855 908   
2 MIRU16 53 565 618 671 724 777 830 883 936 989   
3 MIRU26 51 461 512 563 614 665 716 767 818 869   
4 MIRU31 (ETR-E) 53 492 545 598 651 704 757 810 863 916   
5 MIRU40 54 354 408 462 516 570 624 678 732 786   
6 VN424 (Mtub04) 51 538 589 640 691 742 793 844 895 946   
7 VN1955 (Mtub21) 57 149 206 263 320 377 434 491 548 605   
8 VN3690 (Mtub39) 58  330 388 446 504 562 620 678 736   
9 ETR-A(VN2165) 75 195 270 345 420 495 570 645 720 795 870 945 
10 ETR-C(VN577) 58 44 102 160 218 276 334 392 450 508   
11 QUB11b(VN2163b) 69  136 205 274 343 412 481 550 619   
12 QUB26(VN4052) 111  264 375 486 597 708 819 930 1041   
13 MIRU04 (ETR-D) 77 or 53  252 329 406 483 560 637     
14 VN2401 (Mtub30) 58 247 305 363 421 479 537 595 653 711   
15 VN4156n(QUB4156) 59  563 622 681 740 799 858 917 976   
16 MIRU02 53 402 455 508 561 614 667 720 773 826   
17 MIRU20 77  514 591 668        
18 MIRU23 53 558 608 661 714 767 820 873 926 979   
19 MIRU24 54 395 447 501 555 609 663 717 771 825   
20 MIRU27 53  551 604 657 710 763 816 869 922   
21 MIRU39 53 536 591 646 701 756 811 866 921 976   
22 ETR-B 57 121 178 235 292 349 406 463 520 577   
23 ETR-F 79 263 342 421 500 579 658 737 816 895   
24 QUB11a(VN2163a) 69  374 443 512 581 650 719 788 857 926 995 
25 QUB3232 56 423 479 535 591 647 703 759 815 871   
26 QUB3336 59   171 230 289 348 407 466 525 584 643 702 
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2.3 RESULTS AND DISCUSSION 
2.3.1 Mycobacterial isolation 
Out of the 20 samples received from 20 warthogs, 16 different types of lymph nodes 
namely bronchial, mandibular, parotid and retropharyngeal yielded either rough or 
smooth colonies on LJ slants with pyruvate inoculated with the sediment from 
positive MGIT tubes.  One out of the 2 samples (external iliac lymph node) from a 
rabbit yielded smooth colonies as well as 3 out of 10 samples from 3 black 
wildebeest, 15 samples out of 31 samples from 10 cattle yielded rough colonies.  All 
isolates were slow-growing organisms and acid-fast rods under the microscope.  
Isolates were further identified as Ziehl-Neelsen staining alone cannot differentiate 
Mycobacterium species. In medical laboratories, it was observed that LJ with 
glycerol is routinely used; introducing LJ with pyruvate in the routine diagnostic will 
increase the opportunity to isolate M. bovis.   
2.3.2 Primary molecular identification 
The isolates from 3 black wildebeests were identified as M. avium subsp. 
hominissuis (n=3) out of the 10 samples;  16 isolates from the 20 warthogs were 
identified as M. bovis (n=14), M. avium (n=1) and M. intracellulare (n=1), one isolate 
from rabbit (n=1) was also identified as M. avium subsp. hominissuis, the isolate 
from an impala (n=1) was identified as M. bovis  and 15 isolates from 10 cattle were 
identified as M. bovis (Table 2.4) using commercial kits, the GenoType 
Mycobacterium CM/AS (Hain Lifescience GmbH, Nehren, Germany).  Cattle isolates 
were further processed as species of interest for the next phase of the research 
project whereas those from other animal species were stored at -80°C for use in 
future studies.  
The isolation of non-tuberculous mycobacteria namely M. avium subsp. hominissuis, 
M. avium and M. intracellulare are of concern as these species are potentially 
zoonotic and have been reported as causes of disease in humans.  In South Africa, 
the level of involvement of non-tuberculous mycobacteria in disease-causing 
conditions in animals and humans should be fully investigated.  In the medical 
laboratory where the study was conducted, these mycobacteria were referred as 
“MOTT” and are not given much attention. 
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Table 2.4: Mycobacterium species isolated from the different animals 
Animal species (n=5) Mycobacterium spp. 
Black Wildebeest M. avium subsp. hominissuis 
Cattle M. bovis 
Impala M. bovis 
Rabbit M. avium subsp. hominissuis 
Warthog M. bovis, M. intracellulare and M. avium 
2.3.3 MTC discrimination by multiplex PCR 
Out of 31 samples, 15 isolates were primarily identified as M. bovis using the 
GenoType Mycobacterium CM/AS (Hain Lifescience).  They were all confirmed by 
MTC-MPCR as belonging to the M. tuberculosis complex and as M. bovis by the 
absence of RD4. 
2.3.4 Antimicrobial susceptibility test 
Eight out of 15 (53%) were resistant to INH and RIF whereas 7 out the 15 isolates 
(47%) of M. bovis were sensitive to INH and RIF.  Figure 2.3 shows the appearance 
of bands as sensitivity to the drugs and absence of bands as resistance to the 
specific drug.  None of the INH and RIF resistant samples harboured mutations in 
the katG gene or the InhA gene.  In South Africa, Silaigwana et al. (2012) reported 
on a similar study and found the presence of MDR-TB isolates on a dairy farm.  More 
studies to assess the prevalence of M. bovis MDR-TB strains are needed because of 
public health implications of TB caused by M. bovis in both humans and animals.  
Mycobacterium bovis is known to be resistant to pyraminazide and have shown 
different susceptibility patterns to anti-TB drugs (Bobadilla-del Valle et al., 2015).  
These results have a clinical and epidemiological significance and further studies 
focusing on genes coding for resistance should be investigated.  
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Figure 2.3: WT probes and mutation genes targeted to determine the susceptibility of an       
isolate towards first line drugs 
2.3.5 Spoligotyping 
The 15 isolates of M. bovis from cattle consisted of two strains, namely SB0121 and 
SB1235.  Most isolates, 10 out of 15 were SB0121 (67 %) and 5 out of 15 (33%) 
were SB1235.  SB1235 lacked spacers 3, 6, 8, 9, 10, 11, 12, 16, 37-43 (Figure 2.4 
A) whereas SB0121 was characterized by lack of spacers 3, 9, 16, 21, 39-43 (Figure 
2.4 B).  SB0121 is the most frequently isolated spoligotype.  Spoligotyping is used as 
an epidemiological tool to trace the origin of the strain causing the disease and 
hence can facilitate implementation of appropriate control measures. A consistent 
characteristic of M. bovis is the lack of spacers 39-43 (Figures 2.4 and 2.5).  
Isolates from cattle were confirmed and further characterized using spoligotyping 
and VNTR.  The spoligotype patterns revealed the presence of a strain recently 
reported in South Africa, SB1235 (Hlokwe et al., 2014), whereas SB0121 is known to 
be the most common type which has been reported in several other countries, 
namely Argentina, Belgium, Brazil, Spain, Great Britain, Italy, Mexico, Sweden, USA 
and South Africa (Hlokwe et al., 2014; Musoke et al., 2015; Parreiras et al., 2012; 
Rodriguez-Campos et al., 2013).  They were all VNTR type 1 which means they 
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have the same origin.  Samples were from one province, Mpumalanga, although 
from different farms.  
SB1235 seems to relate to UK strains, and the importation by breeders of cattle from 
Europe could explain the introduction of this strain (http://www.sussex.co.za; 
http://www.afrikanerbees.com).  Spoligotype strains are an indication of how wide is 
the movement of cattle worldwide.  SB1235 was originally isolated in Northern 
Ireland whereas SB0121 seems to be the most common spoligotype in South Africa 
as reported by Hlokwe et al., (2014).  It has also been isolated worldwide from 
Argentina, Belgium, Brazil, Spain, Great Britain, Italy, Mexico, Sweden, USA, New 
Zealand and Sweden (Rodriguez-Campos et al., 2013; Sahraoui et al., 2009). 
 
 
   
Figure 2.4: Spoligotype SB1235 (A) and spoligotype SB0121 (B), deleted spacers that are 
common to all M. bovis are 39 to 43. SB1235 lack spacers 3, 6, 8, 9, 10, 11, 12, 16, 37-43 
whereas SB0121 lacks spacers 3, 9, 16, 21, 39-43 –The deleted spacers are marked with red 
stars 
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Figure 2.5: Schematic representation of spoligotype patterns of M. bovis cattle isolates from South Africa 
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2.3.6 Variable number of tandem repeat (VNTR) typing 
The typing of the 15 isolates was based on the 13 VNTR loci and yielded only one 
type, VNTR-1.  This meant that the isolates were all from the same origin. 
2.4 CONCLUSION 
The presence of MDR in M. bovis in cattle is of concern taking into consideration the 
emergence of MDR tuberculosis strains in humans. In medical laboratories, the 
tendency is to rule out M. tuberculosis, other mycobacteria are considered as MOTT 
and not given much attention.  Introducing LJ with pyruvate in the routine diagnostic 
will increase the opportunity to isolate M. bovis.  Attention should also be given to the 
non-tuberculous mycobacteria referred to as MOTT as they have been reported as 
the main cause of the disease in some cases.  The identification of MDR-M. bovis 
isolates is of concern due to public health implications.  Mycobacterium bovis causes 
tuberculosis in humans which is clinically undistinguishable from M. tuberculosis.  
The presence of MDR-MTB complex in dairy cattle in South Africa has been reported 
by Silaigwana et al. (2012).  Mycobacterium bovis is known to be resistant to 
pyraminazide and has shown different susceptibility patterns to anti-TB drugs 
(Bobadilla-del Valle et al., 2015).  Drug susceptibility and accurate identification of 
isolates in both animals and humans need attention as there are no current data on 
the prevalence and incidence of human tuberculosis caused by M. bovis in South 
Africa (Bobadilla-del Valle et al., 2015). 
Genetic typing of M. bovis has contributed greatly to the improved knowledge of 
inter-bovine and interspecies transmission of bovine tuberculosis (Durr et al., 2000).  
The understanding of genetic typing is important for the effective management of 
bovine tuberculosis control schemes and the wildlife–livestock interface in countries 
where wildlife reservoirs for M. bovis have been identified, including South Africa 
(Haddad et al., 2004; Vos et al., 2001).  The most widely used DNA typing 
techniques for M. bovis include IS6110 and PGRS restriction fragment length 
polymorphism (RFLP) typing, spoligotyping and variable number of tandem repeat 
(VNTR) typing (Reddington et al., 2011).  In South Africa, spoligotyping and variable 
number of tandem repeat typing have been used (Hlokwe et al., 2014; Michel et al., 
2007).  The two methods had a high discriminatory power of over 90% (Kremer et 
al., 2005). 
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Another finding relates to non-tuberculous mycobacteria.  Their importance has been 
emphasized during the last decade and it was interesting to isolate M. avium subsp. 
hominissuis (MAH) from the rabbit, pig samples and other samples from black 
wildebeest.  This is the most prevalent MAC involved in human infection.   Rónai et 
al. (2016) reported that M. avium subsp. hominissuis was an important member of 
the M. avium complex with a high diversity among M. avium subsp. avium and 
hominissuis and they are both potentially zoonotic.  The evidence for MAH as 
causative agent of lymphadenitis and sometimes disseminated granulomatous 
inflammation in animals is supportive of virulence of the organism (Despierres et al., 
2012).  This will need some attention as M. avium infection is a severe condition in 
humans whereas in pigs it causes a subclinical infection.  MAH has been isolated 
from swine gastrointestinal samples, from lymph nodes of tuberculin positive swine 
(Agdestein et al., 2012, 2011; Kriz et al., 2014; Yoav, 2012).  It has also been 
incriminated as a cause of mesenteric lymphadenitis and sometimes disseminated 
granulomatous lesions in different species namely pigs, cattle, dogs and parrots 
(Campora et al., 2011; Kriz et al., 2014).   
Arrazuria et al. (2015) stated that rabbits are susceptible to infection by different 
species of the genus Mycobacterium, namely Mycobacterium avium subsp. avium 
and Mycobacterium avium subsp. paratuberculosis but microbiological data on rabbit 
meat is lacking and more specifically reports of mycobacterial presence in 
industrially reared rabbit for human consumption have not been published.   
In this research, colonic granulomatous lesions from a rabbit yielded colonies that 
were characterized as M. avium subsp. hominissuis (MAH) and this species is the 
most prevalent subtype among human MAC infection.  A recent study has reported 
on the presence of MAH in rabbit (Arrazuria et al., 2015).  This isolate has been 
stored for further investigation. 
The isolates from pigs were not further characterized but have been stored for other 
studies especially M. intracellulare and M. avium isolates. 
Some of the isolates will be used in testing of plants for antimycobacterial activity in 
other chapters. 
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Post script  
The next chapter (Chapter 3) has been published in the Journal Transboundary and 
Emerging Diseases.   
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CHAPTER 3: 
NOVEL MYCOBACTERIUM AVIUM SPECIES ISOLATED FROM 
BLACK WILDEBEEST (CONNOCHAETES GNOU) IN SOUTH AFRICA  
ABSTRACT  
A study was undertaken to isolate and characterize Mycobacterium species from 
black wildebeest suspected of being infected with tuberculosis in South Africa. This 
led to the discovery of a new Mycobacterium avium species, provisionally referred to 
as “Gnou isolate” from black wildebeest (Connochaetus gnou).  Sixteen samples 
from nine black wildebeest were processed for Mycobacterium isolation.  Following 
decontamination; samples were incubated in an ordinary incubator at 37°C on 
Löwenstein-Jensen slants and in liquid medium tubes using the BACTECTM MGITTM 
960 system respectively.  Identification of the isolate was done by standard 
biochemical tests and using the line probe assay from the GenoType® CM/AS kit 
(Hain Life Science GmbH, Nehren, Germany).  The DNA extract was also analysed 
using gene sequencing.  Partial gene sequencing and analysis of 16S rRNA gene, 
16S-23S rRNA (ITS), rpoB and hsp65 and phylogenetic analyses by searching 
GenBank using the BLAST algorithm were conducted.  Phylogenetic trees were 
constructed using four methods, namely Bayesian inference, maximum likelihood, 
maximum parsimony and neighbor-joining methods.  The isolate was identified as 
Mycobacterium intracellulare using the GenoType® CM/AS kit and as Mycobacterium 
avium complex (MAC) by gene sequencing.  The gene sequence targeting all the 
genes, ITS, 16S rRNA, rpoB and hsp65 and phylogenetic analyses indicated that 
this isolate presented a nucleotide sequence different from all currently published 
sequences, and its position was far enough from other MAC species to suggest that 
it might be a new species. 
3.1 BACKGROUND 
In late 2006, animals from a commercial game farm reserve in Mpumalanga 
Province in South Africa were harvested for game meat exportation.  During meat 
inspection, the animal carcasses showed lesions suspicious of tuberculosis which 
was supported by histopathological results.  The exact cause of the disease was not 
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determined and the farm was put under quarantine for suspected bovine 
tuberculosis.   
In February 2009, 158 animals were harvested. A high number of animals (n = 135) 
showed gross-visible tuberculosis-like lesions and lesions from 6 animals processed 
for mycobacterial cultures yielded non-tuberculous mycobacteria.   
Samples (n = 16) from 9 animals were submitted to the National Health Laboratory 
Service (NHLS, Pretoria, South Africa) for mycobacterial isolation and a non-
tuberculous mycobacterium (NTM) was isolated and identified as Mycobacterium 
intracellulare using a commercial kit and as Mycobacterium avium complex (MAC) 
by gene sequencing.  The results were submitted to the Department of Agriculture, 
Forestry and Fisheries (DAFF, South Africa) as M. intracellulare, and 
characterization of the isolate was then done in Japan.   
The complete history of the herd including the pathology report described well-
developed encapsulated granulomatous lesions observed on the different samples of 
organs as very suspicious for bovine tuberculosis (BTB).  Other lesions observed 
which were not typical of M. bovis (pseudotuberculosis) comprised lack of caseous 
necrosis and liquefaction in the granulomas.  The inspissated material from within 
the capsules could almost be squeezed out in total, leaving behind an empty “shell”.  
There were also several smaller granulomas with a typical onion ring appearance, 
but absence of calcification and liquefaction with no gritty sensation on cut section of 
these capsules. .   
The genus Mycobacterium contains more than 170 species 
(http://www.bacterio.net/mycobacterium.html), most of which are classified as NTM 
or potentially pathogenic mycobacteria (PPM) (Chege et al., 2008; Kim et al., 2014; 
Malama et al., 2014; Tortoli, 2014) and mycobacteria belonging to the 
Mycobacterium tuberculosis complex (MTC).  MTC comprises M. tuberculosis, M. 
bovis, M. africanum, M. canetti, M. pinnipedii, M. caprae, M. microti, M. mungi, 
Dassie bacillus, M. orygis (Oryx bacillus), M. surricatae and the attenuated M. bovis 
Bacille-Calmette-Guerin (BCG) vaccine strain.  With the exception of BCG, these 
species are pathogenic and can cause tuberculosis (TB) in mammalian hosts 
(Alexander et al., 2010; Helden et al., 2009; Pittius et al., 2012; Vos et al., 2001).   
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The M. avium-intracellulare complex is the most commonly encountered group of 
NTM, and the clinically most important members are M. intracellulare and M. avium 
(Biet et al., 2005).  Mycobacterium intracellulare has not been subdivided into 
subspecies whereas M. avium consists of four subspecies, namely M. avium subsp. 
avium, M. avium subsp. hominissuis, M. avium subsp. silvaticum and M. avium 
subsp. paratuberculosis.  Mycobacterium Avium Complex (MAC) includes 10 
different species, namely M. avium, M. intracellulare, M. colombiense, M. 
bouchedurhonense, M. timonense, M. arosiense, M. chimaera, M. vulneris, M. 
yongonense and M. marseillense  (Tortoli, 2014). 
The importance of NTM has received attention during the past decade, especially in 
humans.  NTM are found in environmental systems (such as various soil and water 
systems) near human settlements and can be associated with colonization, serious 
infection or pseudo-outbreaks with a wide variety of presentations (Biet et al., 2005; 
Kankya et al., 2011; Katale et al., 2014).  Indeed in humans, the isolation of NTM 
from clinical samples of patients presenting with pulmonary symptoms as suspected 
cases of tuberculosis has increased over the years and has been observed in 
different countries in Africa, America and Europe (Kankya et al., 2011; Katale et al., 
2014; Mirsaeidi et al., 2014a, 2014b; Moore et al., 2010) whereas in animals the 
clinical significance of NTM has yet to be elucidated in the disease causing process 
(Chege et al., 2008; Kankya et al., 2011; Katale et al., 2014).  The members of the 
genus Mycobacterium are genetically closer to each other than the microorganisms 
belonging to other genera, making identification a difficult and challenging task.  The 
management, treatment and infection control measures differ significantly between 
M. tuberculosis and NTM infections.  
More than one hundred and fifty species of NTM have been reported worldwide, of 
which more than 60% are pathogenic to animals or humans (Kim et al., 2014; Tortoli, 
2014).  In South Africa, reports on the isolation of NTM in animals, humans and 
environment and their effects in disease-causing processes are limited (Gcebe et al., 
2013; Kabongo-Kayoka et al., 2015; Michel et al., 2007; Müller et al., 2011). 
Black wildebeest (Connochaetus gnou), known in Afrikaans as “Swartwildebees” and 
in German as “Weisschwanzgnu”, have been hunted in South Africa for meat and 
hides.  The overall research project was mainly on tuberculosis, so samples from 
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black wildebeest suspected of being infected with tuberculosis were processed as 
part of phase I of the project focusing on prevalence and molecular studies of 
mycobacteria.  The emergence of multi-drug and extremely drug resistant 
Mycobacterium tuberculosis strains was one of the main justifications of the project.  
This work resulted in the reporting of a novel Mycobacterium avium complex species 
from wildebeest in South Africa, which is expected to add to the corpus of knowledge 
and extend the frontiers of research on NTM. 
3.2 MATERIALS AND METHODS 
3.2.1 Study area 
Mpumalanga Province was selected as the area of study based on previous 
publications reporting TB in wildlife and livestock (Bengis et al., 1996; Michel et al., 
2007; Vos et al., 2001) and availability of veterinary staff members experienced in 
conducting the comparative tuberculin skin test.  Mpumalanga is one of the nine 
provinces in South Africa which is located in the north-eastern part of the country, 
bordering Swaziland and Mozambique to the East.  It embraces the southern half of 
the Kruger National Park, a vast nature reserve with abundant wildlife including big 
game. It has a subtropical foliage supporting about 1 439 000 cattle according to the 
Trends in the Agricultural Sector (2013). 
3.2.2 Study design and sampling 
The study was designed as a cross-sectional study sampling animals in the 
designated area from January 2009 to January 2011.  The local municipalities were 
selected based on the number of commercial farms, proximity to abattoirs, and 
location at the human-wildlife interface and the movement of animals as well.  The 
municipalities selected comprised Malelane, Nelspruit, Lydenburg, Ermelo, Witbank 
and Standerton.  The target population comprised cattle carcasses showing gross 
tuberculous-like lesions at meat inspection from positive reactors to tuberculin skin 
test at the municipality abattoirs during the study period.  Samples from any other 
animal species showing gross tuberculous-like lesions were also included as 
convenience samples.  The sampling was purposive to increase the chances of 
isolating mycobacteria and animals were selected based on positive reaction to the 
tuberculin skin test and suggestive lesions at the abattoir upon meat inspection. 
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3.2.3 Sources of samples  
Samples from black wildebeest were received as part of phase I of a research 
project related to “Prevalence and molecular studies of Mycobacteria”.  The samples 
were processed at the National Health Laboratory Service (NHLS) as part of a joint 
collaboration between University of Pretoria and NHLS.  The history of the case was 
provided by the state veterinarian in charge.  During a hunting period in February 
2009 on a commercial game reserve located in Mpumalanga (South Africa), game 
animals (n=158) were randomly harvested and processed in the local abattoir 
according to standard operating procedures.  These animals comprised black 
wildebeest (Connochaetes gnou) (n=137), blesbok (Damaliscus dorcas phillipsi) 
(n=15), blue wildebeest (Connochaetes taurinus) (n=2), red hartebeest (Alcelaphus 
buselaphus caama) (n=2) and springbok (Antidorcas marsupialis) (n=2).  The 
animals lagging behind were the main target as well as females.  During routine 
meat inspection of these animals, a high number of black wildebeest (n=135) 
showed granulomatous lesions in one or more lymph nodes or organs and this is the 
reason why samples were selected from this antelope species.  Sixteen samples 
randomly selected from nine black wildebeest showing fresh lesions suggestive of 
tuberculosis infection were submitted to NHLS for isolation and identification of 
Mycobacterium spp.  The samples included different organs and lymph nodes 
transported on ice (Table 3.1). 
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Table 3.1: Type of tissue samples from Black Wildebeest processed at NHLS 
 
Animals  Tissue samples  
 Liver Lung Med Total ID*     BWB 1 1 0 0 1 
BWB 2 0 0 1 1 
BWB 3 1 1 0 2 
BWB 4 0 1 1 2 
BWB 5 1 1 0 2 
BWB 6 0 1 0 1 
BWB 7 1 1 0 2 
BWB 8 0 1 1 2 
BWB 9 1 1 1 3 
Tot 5 7 4 16 
 
*ID: identity, BWB: Black Wildebeest, Med: Mediastinal lymph nodes 
3.2.4 Mycobacterial isolation  
Samples were frozen at -20°C until processing at NHLS.  Direct impression smears 
were made from lesions and smears were stained using the Ziehl-Neelsen method.  
Tissue samples taken in a sterile manner from the inside of granulomatous lesions at 
the border between healthy and pathological tissues were finely cut using a sterile 
scalpel blade and homogenized using sterile glass beads by vortexing as described 
by Bengis et al. (1996) and Warren et al. (2006) with some modifications.  To 
maximize the mycobacterial yield, specimens were subjected to a digestion and 
decontamination procedure using N-acetyl-L-cysteine-sodium hydroxide (NALC-
NaOH) solution with NaOH at a final concentration of 2% (Chatterjee et al., 2013).  
The specimens were left at room temperature for 15 min during the decontamination 
process and thereafter neutralized with phosphate buffer, centrifuged (Beckman 
Coulter) at 3000 x g for 15 min at 4°C, and the supernatant decanted and pellet 
suspended into 1 mL of phosphate buffer.  The sediment was inoculated onto two LJ 
slants supplemented with pyruvate and glycerol and an antibiotic mixture of 
polymyxin B, amphotericin B, carbenicillin and Trimethoprim (PACT) (National Health 
Laboratory Service, South Africa, and Becton Dickinson, Germany) using a 0.01 mL 
calibrated loop.  A further 0.5 mL of the sediment was inoculated with a graduated 
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Pasteur pipette into a prepared liquid medium tube (BBLTM MGITTM Mycobacterium 
Growth indicator tubes) enriched with OADC and containing 800 µL of PANTATM 
antibiotic mixture (BDTM).  This was incubated in the BACTECTM MGITTM 960 
mycobacterial detection system at 37°C (Warren et al., 2006).  The system was 
monitored for a maximum period of 42 days for bacterial growth whereas LJ slants 
were observed for colony growth and any other contaminant at two week intervals for 
10 weeks.  Tubes detected as positive within that period were further processed 
using Ziehl-Neelsen staining and examined microscopically for the presence of acid 
fast organisms and morphology.  Thereafter, they were subcultured on LJ slant 
supplemented with glycerol and pyruvate.  For identification purposes, a single 
colony was subcultured on a fresh LJ slant to obtain pure colonies.  The same was 
repeated with two other colonies on different LJ slants to rule out the possibility of 
missing a different organism.  Reference cultures of M. avium (ATCC 25291), M. 
bovis BCG and M. tuberculosis (ATCC 25177) were used as positive controls. 
3.2.5 Mycobacterial identification 
3.2.5.1 Biochemical profile  
Colonies were suspended in Middlebrook 7H9 (M7H9) broth enriched with OADC 
and inoculated into the different biochemical substrates according to the 
manufacturer’s instructions (Mycobacterium identification kit, Kyokuto 
Pharmaceutical Industrial Co., Ltd., Japan).    
3.2.5.2 DNA extract and primary molecular identification  
DNA extracts were prepared based on the GenoType CM/AS reverse line blot assay 
(Hain Life Science, Gmbh Nehren, Germany).  DNA was extracted from colonies on 
LJ slants by heating at 95°C for 20 min in a water bath.  Primers provided by the 
manufacturer’s kit (Hain Life Science, Gmbh Nehren, Germany) were used.  The 
formula for the PCR assay per tube mixture contained 1.1 µL of ultra-pure water, 5 
µL of 10 x buffer, 3.6 µL of MgCl2 (25 mM), 35 µL of primer/nucleotide mix from the 
kit and 0.3 µL of hot Taq polymerase.  The thermocycler was programmed to initiate 
the PCR as follows: one cycle of 15 min at 95°C, followed by 10 cycles of 30 sec at 
95°C, 2 min at 58°C, 25 sec at 95°C; then 20 cycles of 40 sec at 53°C and 40 sec at 
70°C with a final cycle of 8 min at 70°C.  The hybridization was then followed as per 
manufacturer’s instructions using the strips provided in the kit (DNA strip 
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Mycobacterium identification species).  Part of each DNA extract was also stored at -
20°C prior to further investigations in Japan. 
3.2.6 Gene sequencing 
The DNA extract obtained during the primary identification was processed further by 
sequencing analysis; targeting hsp65, rpoB, 16S rRNA genes and 16S-23S rRNA 
internal transcribed spacer (ITS) for identification of the bacterial species.  
3.2.6.1 16S ribosomal RNA gene and ITS    
The 16S ribosomal RNA gene and flanking 16S–23S rRNA ITS region was amplified 
with a primer pair of Bact-rrs-F: 5’-AGAGTTTGATCCTGGCTCAG- 3’ and myco ITS-
23S-Rv: 5’-CGGTTGACAGCTCCCCGAGGC- 3’. Amplification reaction mixture 
consisted of 0.5 μM of each primer pair, 1× ExTaq buffer (Takara Bio Inc., Japan), 
0.5 M betaine, 0.25 mM each of dNTPs, 1 U of ExTaq DNA polymerase (Takara Bio 
Inc.), 1 μL of target DNA solution and milli-Q water to adjust the final volume to 20 
μL. Amplification was performed in a thermal cycler with a pre-heat step at 98°C for 1 
min, 38 cycles of denaturation at 98°C for 10 sec, annealing at 55°C for 10 sec and 
extension at 72°C for 110 sec followed by a final extension at 72°C for 5 min. The 
amplicon was electrophoresed on a 1% agarose gel and a band of approximately 1.9 
Kbp was excised and purified with Wizard SV Gel and PCR Clean-Up System 
(Promega Corp., USA). The sequence of the 5’ region of the 16S ribosomal RNA 
gene and ITS were read with primers Bact-rrs-F and myco ITS-23S-Rv, respectively, 
by ABI PRISM 3130xl Genetic Analyzer (Life Technologies Corp., CA, U.S.A.) 
according to the manufacturer’s instructions. 
3.2.6.2 rpoB   
Partial rpoB gene was amplified and sequenced with primers Myco-F and Myco-R 
designed by Ben Salah et al. (2008)  PCR reaction mixture was comprised of 0.5 μM 
of each primers, 1× GoTaq buffer (Promega Corp., USA), 0.5 M betaine, 0.25 mM 
each of dNTPs, 1 U of GoTaq DNA polymerase (Promega Corp.), 1 μL of target DNA 
solution and milli-Q water to adjust the final volume to 20 μL. Amplification was 
performed with an initial denaturation at 96°C for 1 min, 38 cycles of denaturation at 
96°C for 10 sec, annealing at 60°C for 10 sec and extension at 72°C for 45 seconds 
followed by a final extension at 72°C for 5 min.  The amplicon was electrophoresed 
on a 1% agarose gel and a band with a size of 761 bp was excised and purified. The 
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sequence was read by ABI PRISM 3130xl Genetic Analyzer (Life Technologies 
Corp.) according to the manufacturer’s instructions. 
3.2.6.3 hsp65    
Partial hsp65 gene was amplified and sequenced with primers Myco-hsp65F (565-
585): 5’- AGGGTATGCGGTTCGACAAG- 3’ and MAC hsp65R (Turenne et al., 
2006).  Amplification was performed with an initial denaturation at 96°C for 1 min, 38 
cycles of denaturation at 96°C for 10 sec, annealing at 53°C for 10 sec and 
extension at 72°C for 45 sec followed by a final extension at 72°C for 5 min in the 
same reaction mixture content described in section 3.2.6.2.  The band with a size of 
1067 bp was excised and sequencing was performed by the same procedure as in 
section 3.2.6.2. 
The obtained sequences were compared with the GenBank nucleotide database by 
the blastn program (National Center for Biotechnology Information: 
http://www.ncbi.nlm.nih.gov). 
3.2.7 Phylogenetic analyses 
The datasets for the different genes (ITS, 16S, hsp65 and rpoB) were collated by 
searching GenBank (http://www.ncbi.nlm.nih.gov) using the BLAST algorithm, an 
acronym for the Basic Local Alignment Search Tool (Altschul et al., 1990).  BLAST 
searches various databases, as specified by the user, to look for similar sequences, 
and then uses a similarity matrix to measure the similarity between sequences and 
the possibility that the similarity could be due to chance based on the nucleotide 
sequence of the query versus its target. There are several types of searches 
available but for these analyses “blastn” was used which searches nucleotide 
databases with a nucleotide query. These sequences were then downloaded into a 
local database using BioEdit version 7.2.1 (Hall, 1999).  Sequences were aligned 
using MAFFT version 7 (Katoh et al., 2005, 2002) 
http://www.mafft.cbrc.jp/alignment/server/) with default parameters.  Multiple 
Alignments by Fast Fourier Transformation (MAFFT) utilizes an iterative algorithm, 
unlike previous progressive alignment methods.  Where necessary, small 
adjustments were made to the alignments manually to minimize hypothesized 
insertion/deletion events, again using BioEdit software (Hall, 1999).  The programme 
jModelTest 2.1.6 (Darriba et al., 2012) was run for each gene separately, as well as 
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the concatenated dataset, to determine the best evolutionary model to use for each 
dataset. Phylogenetic trees were constructed for all data sets by four different 
methods, Bayesian inference (BI), maximum likelihood (ML), maximum parsimony 
(MP) and neighbor-joining (NJ). This not only allowed independent confirmation of 
results, but also the benefit of different methods with different strengths, weaknesses 
and sensitivities. NJ and MP analyses were conducted with MEGA 5 (Molecular 
Evolutionary Genetic Analysis) (Tamura et al., 2011).  PhyML (Guindon et al., 2010) 
was used to carry out ML analyses on all the datasets and Mr. Bayes v3.2.5 
(Ronquist et al., 2012) was used on the concatenated dataset. Both NJ and ML 
analyses used the relevant evolutionary model as given in jModelTest. All analyses, 
except those by Bayesian inference, consisted of 1000 bootstrap replications 
(Felsenstein, 1985), a statistical method for testing the reliability of all the groupings 
within the various trees.   
3.2.8 Statistical analyses 
The agreement between databases was calculated using Cohen’s Kappa. To 
compare the results obtained from each gene and combination of two genes, only 
the databases identified with better performance in the first analysis were used.  One 
thousand bootstrap replications were used for testing the reliability of all the 
groupings within the various trees (Hallgren, 2012; Joao et al., 2014). 
3.2.9 GenBank accession numbers 
The sequences generated in this study were deposited in the GenBank database 
under accession number KR856202 for hsp65, KR856203 for rpoB, KR856204 for 
16S rRNA and KR856205 for 16S-23S rRNA ITS. 
3.3 RESULTS 
3.3.1 Mycobacterial isolation  
A mediastinal lymph node (from 1 animal) out of 16 samples (from 9 animals) yielded 
similar smooth colonies of slow growing microorganisms on LJ slants inoculated with 
the sediment from positive MGIT tubes.  The acid-fast rods were observed under the 
microscope. 
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3.3.2 Biochemical characteristics 
The phenotypic characteristics, including growth rate (fast/slow), production of 
pigment, growth at different temperatures and biochemical reactions with relevant 
substrates were evaluated. Colonies were identified as MAC slow growers with no 
pigment on specific substrates. They were positive for tellurite reduction, stimulation 
by pyruvate and heat-stable catalase but negative for niacin production, nitrate 
reduction, urease, acid phosphatase activity, Tween 80 hydrolysis (7 and 14 days) 
and urease (Table 3.2); (Cook et al., 2003). 
Table 3.2: Growth and biochemical characteristics of the isolate  
Growth rate  
27°C Positive 
37°C Positive (Slow growth) 
45°C Negative 
  
Stimulation by pyruvate Positive 
Pigmentation No pigmentation 
Niacin production Negative 
Nitrate reduction Negative 
Catalase production Positive 
Tellurite reduction Positive 
Urease Negative 
Acid phosphatase activity Negative 
Tween 80 hydrolysis (7  
and 14 days) Negative 
3.3.3 Primary molecular identification  
The isolate was identified as Mycobacterium intracellulare using a commercial kit 
routinely used at NHLS, the GenoType Mycobacterium CM/AS (Hain Life Science, 
Gmbh Nehren, Germany).  
3.3.4 Phylogenetic analyses 
3.3.4.1 ITS sequences 
Alignment of the 16S-23S rRNA ITS of Mycobacterium “Gnou isolate” with the other 
sequevars of the MAC show that the Gnou isolate is most closely related to the  
MAC-T sequevar with only three nucleotide differences. 
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Phylogenetic analyses of these data by NJ, MP and ML, placed the Gnou isolate 
within the MAC and more closely related to MAC-T, with MAC-M, MAC-I and MAC-L 
forming a sister group.  All three methods placed the Gnou isolate in the same place 
with varying degrees of bootstrap support.  
3.3.4.2 16S rRNA, hsp65 and rpoB analyses. 
All three datasets by every method grouped the Gnou isolate with M. vulneris, M. 
bouchedurhonense, and M. colombiense with M. arosiense included in the group by 
just the MP analysis of hsp65.  However, all other analyses placed M. arosiense 
close to the Gnou isolate grouping.  With the similarity between the various trees the 
four genes were combined into one dataset to give a concatenated tree (Figure 3.1).  
Generally the groupings all have good bootstrap support.  All the species above M. 
mantenii in this phylogeny are members of the MAC. 
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Figure 3.1: Phylogenetic tree obtained by NJ analysis of concatenated nucleotide sequences 
of 16S rRNA, 16S-23S rRNA, hsp65 and rpoB.  Bootstrap values (1000 replicates) are given 
above the branches for NJ/ML and below for MP. Branch support values on the nodes are 
shown in percentage and the values less than 60% are not shown.  The tree is rooted with M. 
fortuitum and M. insubricum.   
3.4 DISCUSSION AND CONCLUSION  
This is the first report in South Africa of the discovery of a novel Mycobacterium 
avium complex species from black wildebeest which has been named “Gnou isolate” 
to reflect the species name of the wildebeest from which it was isolated.  Our isolate 
was identified using analysis of 16S rRNA gene, hsp65, rpoB and ITS.  A number of 
studies suggest that 16S rRNA gene sequencing provides genus identification in 
most cases (>90%) but less so with regard to species (65 to 83%) (Janda and 
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Abbott, 2007; Joao et al., 2014).  Although 16S rRNA gene sequencing is highly 
useful in regards to bacterial classification, it has low phylogenetic power at the 
species level and poor discriminatory power for some genera (Janda and Abbott, 
2007).  It has also been reported that analysis of 16S rRNA gene alone is insufficient 
for the accurate identification of NTM (Joao et al., 2014); it was thus proposed that a 
stepwise algorithm combining 16S rRNA and hsp65 gene analysis by multiple public 
databases could be used to identify NTM at the species level.  In some cases, 16S 
rRNA gene sequence data cannot provide a definitive answer since it cannot 
distinguish between recently diverged species.  While it is impossible to be 
completely accurate when modelling all evolution that has occurred between a set of 
sequences, several parameters appear to be particularly important. These are 
corrections for substitution patterns (nucleotide substitution matrices) and correction 
for different evolutionary rates at different sites, most accurately corrected using a 
gamma distribution model, the shape parameter α of which is calculated by 
jModelTest.  It has been established that NTM cause disease (Kim et al., 2014), but 
the significance of NTM in the disease processes in animals should be investigated 
further as the presence of a small number of a specific pathogen does not correlate 
with the virulence of the pathogen nor its economic importance.  Organisms act in 
synergy, potentiating the colonization by other bacteria.  Although mixed infection 
with NTM has been reported, attention should be given to NTM in the future as 
several studies have recognized the significance of NTM as a major public health 
issue around the world (Kankya et al., 2011; Kim et al., 2014; Malama et al., 2014; 
Moore et al., 2010; Temmerman et al., 2014).  Furthermore, NTM have been found 
to interfere with the diagnosis of TB in cattle; indeed, some cross reactions between 
the antigens of NTM with those used for diagnostic purposes such as M. avium and 
M. fortuitum may compromise the diagnosis and control of bovine tuberculosis (De la 
Rua-Domenech et al., 2006; Gcebe et al., 2013). 
To our knowledge, this is the first report of this new isolate of NTM, “Gnou isolate”, 
sampled from black wildebeest (Connochaetes gnou) in South Africa.  The diagnosis 
of NTM should be standardized as the isolate was identified as Mycobacterium 
intracellulare using DNA strip according to Hain’s method at National Health 
Laboratory Service and confirmed as a new species of MAC by gene sequencing at 
Research Center for Zoonosis Control at Hokkaido University in Japan.  Tortoli et al. 
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(2010) reported the misidentification of NTM using commercial kit assays as we have 
also experienced with this study.  The partial sequencing of 16S rRNA gene alone is 
not sufficient to fully identify NTM to species level; algorithm analysis combining all 
four genes should be considered as well as biochemical identification.  One of the 
characteristics of this isolate was slow growth. The role of NTM, in particular slow 
growing MAC, should be further investigated in the disease-causing process as they 
could potentiate colonization by other rapidly growing microorganisms. The isolation 
and identification at species level of some NTM should be performed to establish 
their clinical relevance in animals and humans.  Countries should also be 
encouraged to register new species on the international data bank for purposes of 
adding to the epidemiological knowledge of this genus.  
Postscript 
The next chapter comprises the start of phase 2 of the project whereby extracts of 
plant species from the family Anacardiaceae were tested for antimycobacterial 
activity against a panel of Mycobacterium species, both rapidly growing saprophytic 
and slow-growing pathogenic species. Cytotoxicity of the extracts was also tested 
against various cell lines. The chapter has been published in the Journal 
Phytotherapy Research.  The article is attached in Appendix C. 
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CHAPTER 4: 
ANTIMYCOBACTERIAL ACTIVITY AND CYTOTOXICITY OF LEAF 
EXTRACTS OF SOME AFRICAN ANACARDIACEAE TREE SPECIES 
ABSTRACT 
Treatment of tuberculosis (TB) is a challenge due to multi- and extremely drug 
resistant strains of Mycobacterium tuberculosis.  Plant species contain antimicrobial 
compounds that may lead to new anti-TB drugs.  Previous screening of some tree 
species from the Anacardiaceae family revealed the presence of antimicrobial 
activity, justifying further investigations.  Leaf extracts of 15 Anacardiaceae tree 
species were screened for antimycobacterial activity using a twofold serial 
microdilution assay against the pathogenic Mycobacterium bovis and multidrug 
resistant M. tuberculosis and rapidly growing mycobacteria, M. smegmatis, M. 
fortuitum and M. aurum. The vaccine strain, M. bovis and an avirulent strain, M. 
tuberculosis H37Ra, were also used.  Cytotoxicity was assessed using a colorimetric 
assay against Vero kidney, human hepatoma and murine macrophage cells.  Four 
out of 15 crude acetone extracts showed significant antimycobacterial activity with 
minimum inhibitory concentration (MIC) values varying from 50 to100 µg/mL.  
Searsia undulata had the highest activity against most mycobacteria, followed by 
Protorhus longifolia.  Mycobacterium fortuitum was the strongest predictor of activity 
against MDR-TB (correlation coefficient = 0.65).  Bioautography against M. aurum 
and M. fortuitum worked well as indicators of the Rf values of active compounds 
yielding strong zones of inhibition.  The leaf extracts of S. undulata and P. longifolia 
each had more than ten different antimycobacterial compounds and had low 
cytotoxicity with LC50 values above 100 µg/mL.   
4.1 INTRODUCTION 
Tuberculosis occurs in humans, cattle, wild animals and many other domesticated 
species.  The Mycobacterium tuberculosis complex (MTC) comprises M. 
tuberculosis, M. bovis, M. africanum, M. canetti, M. pinnipedii, M. caprae, M. microti, 
M. mungi, Dassie bacillus, M. orygis (Oryx bacillus), M. surricatae and the attenuated 
M. bovis Bacille-Calmette-Guerin (BCG) vaccine strain.  With the exception of BCG, 
these species are pathogenic and can cause tuberculosis (TB) in mammalian hosts 
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(Alexander et al., 2010; Kabongo-Kayoka et al., 2015; Pittius et al., 2012; Vos et al., 
2001).   
Despite the fact that TB can be cured, this disease remains a worldwide public 
health threat due to the emergence of multi- and extremely drug resistant strains and 
subsequent poor response to current antibiotics.  One third of the world’s population 
is infected with Mycobacterium tuberculosis (MTB) and is hence at risk of developing 
active TB (WHO, 2015).  In the order of 9.6 million people every year develop TB 
and 1.5 million die from the disease. This includes 0.4 million TB deaths among HIV 
positive people (WHO, 2015).  From the 9.6 million, only 12% were HIV positive and 
it was also estimated that 480 000 cases of multidrug-resistant TB (MDR-TB) have 
occurred in 2014 (WHO, 2015).  This confirms that TB alone is still a major 
challenge.  
There is currently no effective vaccine to protect against TB.  In humans, control of 
the disease relies heavily on detecting infectious cases and treating them for at least 
six months with a combination of antibiotics.  The course of antibiotics involves the 
administration of first-line anti-TB drugs, which are combinations of isoniazid (INH), 
rifampicin (RIF), pyrazinamide and ethambutol for 2 months to kill the rapidly growing 
bacteria. The treatment is continued in the next 4 months with a combination of INH 
and RIF because of their sterilizing activity to eliminate bacilli which are dormant in 
the macrophages, or slow growers (Rivers and Mancera, 2008).  Toxicity associated 
with these first-line drugs and the long duration of treatment has led to low patient 
compliance, giving rise to drug-resistant strains.  Multidrug-resistant mycobacteria 
are resistant to INH and RIF whereas extensively drug-resistant mycobacteria are 
resistant to second-line drugs such as fluoroquinolones and to at least one injectable 
drug in addition to INH and RIF.  Hence, there is a need to find new anti-tubercular 
agents with novel modes of actions (Chinsembu, 2016). 
It is most likely that the emergence of resistant Mycobacterium isolates will continue 
in the future, exhausting the current range of effective antibiotics available.  
Therefore, new classes of anti-TB agents are urgently needed, and research projects 
seeking for alternative therapeutics have been encouraged.  Natural resources have 
been explored to develop new antibiotics.  Substances that can either inhibit the 
growth of pathogens or kill them while having little or no toxicity to host cells are 
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considered good candidates for developing new antimicrobial drugs (Nguta et al., 
2016). 
Medicinal plants are used in many parts of the world to treat different ailments 
including TB-related symptoms such as chest complaints, respiratory ailments, fever 
and coughing (McGaw et al., 2008a, 2008b).  Relevant reviews of traditional 
medicinal use of plants in Africa are available (Hutchings et al., 1996; Kuete, 2010; 
Maroyi, 2013; Nguta et al., 2016; Stark et al., 2013; Van Wyk et al., 1997). 
South Africa possesses the richest temperate flora in the world, with an estimated 24 
000 species and intraspecific taxa in 368 families more than 10% of the world’s 
vascular plant flora (Germishuizen and Meyer, 2003).  There is much potential for 
discovery of structurally interesting metabolites with activity against Mycobacterium 
species from these plants.   The existence of a strong cultural reliance on traditional 
medicines within South African communities justifies the importance of studying their 
safety and efficacy (Fennell et al., 2004). 
In a study conducted on Indian medicinal plants, Gautam et al. (2007) reported that 
with many of the plant species examined, there was a strong positive correlation 
between antimycobacterial activity and ethnomedicinal use for TB and TB-related 
diseases.  Although this provides support for investigating plants customarily used in 
other cultures to treat symptoms relating to TB, other plants tested for 
antimycobacterial activity using indicator organisms such as M. smegmatis and M. 
bovis BCG should also be investigated (McGaw et al., 2008a).  Testing plant 
material not only against ATCC strains but against current isolates is crucial as these 
microorganisms are part of the changing environment harbouring emerging resistant 
strains. 
The Anacardiaceae, cashew or Sumac is a tropical family that comprises flowering 
plant bearing fruits that are drupes and in some cases producing urushiol which is an 
irritant substance (Mabberley, 1997).  The Anacardiaceae comprises several genera 
and species of economic importance as shown in Figure 4.1 (a-l) namely Cashew 
(Anacardium occidentale), Mango (Mangifera indica), Poison Ivy (Toxicodendron 
radican, Smodingium argutum), Sumac (Searsia species), Smoke tree (Cotinus 
coggygria, Cotinus obovatus), Marula (Sclerocarya birrea), Yellow mombin 
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(Spondias mombin, Spondias purpurea var. lutea), Cuachalalate (Amphipterygium 
adstringens) and Pistacia (Pistacia lentiscus, Pistacia integerrima).  This family, 
which belongs to the order Sapindales, is represented by 77 genera and 600 species 
mostly distributed in tropical, subtropical, and temperate areas (Mabberley, 1997).  
Very few plant species of the Anacardiaceae family have been investigated for 
antimycobacterial activity.  One of the objectives of this study was to investigate in 
vitro antimycobacterial activities as well as cytotoxicity of selected plant species from 
the Anacardiaceae family.  These plants were selected mainly based on a 
preliminary broad antimicrobial screening (Pauw, 2014). 
A summary on ethnobotanical use of the selected plant species from the 
Anacardiaceae family is presented in Table 4.1.  Eight out of the 15 plants, namely 
Lannea discolor, Loxostylis alata, Ozoroa mucronata, Ozoroa paniculosa, Protorhus 
longifolia, Searsia chirindensis, Searsia lancea and Sclerocarya birrea, have 
antimicrobial properties mainly against Gram-negative and Gram-positive organisms 
(Ahmed et al., 2014; Hutchings et al., 1996; Mosa et al., 2014; Stark et al., 2013; 
Van Wyk et al., 1997).  Three species (Searsia chirindensis, Searsia undulata and 
Smodingium argutum) have good anti-inflammatory activity (Hutchings et al., 1996; 
Ojewole, 2008; Stark et al., 2013).  It would be useful to identify plant species with 
both antimycobacterial and anti-inflammatory efficacy as both acute and chronic 
inflammation are induced during the course of tuberculosis disease progression 
(Volpe et al., 2006). 
4.2 MATERIALS AND METHODS 
4.2.1 Source of plant materials and extraction 
Leaves of the 15 plant species were collected in November 2009 from the Lowveld 
National Botanical Gardens in Nelspruit, the University of Pretoria Botanical Gardens 
and the Pretoria National Botanical Garden, South Africa in terms of a signed 
material transfer agreement.  Leaves were kept in labelled bags with full 
identification and collection dates.  Voucher specimens were kept in the Lowveld 
National Botanical Gardens (Nelspruit), HGWJ Schweickerdt Herbarium of the 
University of Pretoria and Phytomedicine Programme, University of Pretoria (Table 
4.1).   The leaves were air-dried at room temperature suspended in bags of net 
material in a ventilated room (refers Figure 4.1a), ground to a fine powder in a 
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Macsalab Mill (Model 200 LAB Eriez®, Bramley, Johannesburg, South Africa) and 
stored in closed glass containers away from light until needed.  Three grams of each 
plant were extracted in 30 mL of acetone (technical grade, Merck, Darmstadt, 
Germany) in a 50 mL polypropylene centrifuge tube.  Acetone was used as the 
extracting solvent due to its ability to extract a wide range of compounds and low 
toxicity on different microorganisms (Eloff, 1998a).  The tube was vigorously shaken 
for 30 min on an orbital shaker, then centrifuged at 4000 × g for 10 min and the 
supernatant was filtered using Whatman No.1, 110mm diameter filter paper, before 
being transferred into pre-weighed glass containers as shown in Figure 4.1 (b) (Eloff, 
1998a).  The extraction was repeated thrice on the same plant material and the 
solvent was removed by evaporation under a stream of air in a fume hood at room 
temperature to produce the dried extract.  Extracts were made up to a concentration 
of 10 mg/mL in acetone for use in relevant tests.  
 
(a)                                                              (b) 
Figure 4.1: Air drying of leaves suspended in bags (a), filtration of the acetone extracts    
for preliminary assays (b)
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Table 4.1: Ethnomedicinal use and known isolated compounds of selected species of the Anacardiaceae family 
Botanical names  Common names Voucher 
number 
Plant part used Ethnomedicinal 
use 
Phytochemical constituents 
/pharmacological activities 
References 
              
Harpephyllum caffrum 
Bernh. 
Wild plum (Eng); 
wildepruim (Afr.); 
Umgwenya (X, Z)  
PRU2583 Bark, leaves and 
roots 
Purifying blood, 
skin problems  
scarifications 
around sprains and 
fractures and leg 
paralysis due to 
poison 
Polyphenolic and 
flavonoids/anticonvulsant  
Hutchings et al., 
1996; Van Wyk et al., 
1997  
Heeria argentea Meisn. Cape Rockwood, 
Wild Apricot 
(Eng.); Kliphout 
(gom) and Wilde-
Naelboom (Afr.) 
PMDN751 Gum Gum mixed with 
sweet oil used as 
plaster for burns, 
wounds, tender 
nipples and 
powdered herb 
with fat applied to 
ulcers 
__ Hutchings et al., 1996 
Lannea discolor (Sond.) 
Engl.   
Live long (Eng); 
Dikbas (Afr.); 
Isiganganyane (Z) 
PMDN565 Bark, roots and 
leaves 
Treatment of 
diarrhoea, 
abscesses, 
infertility in women, 
menorrhagia, 
gonorrhea, swollen 
legs, whooping 
cough, counteract 
effect of lightning 
and sore eyes 
Phenolic flavone/antimicrobial Hutchings et al., 
1996; Maroyi, 2013; 
Van Wyk et al., 1997 
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Loxostylis alata A. Spreng. 
ex Rchb. 
Wild pepper tree, 
tarwood (Eng); 
teerhout, tierhout 
(Afr); Ufutho, 
ufuthu (Z) 
PRU3526 Bark and leaves Used at childbirth 
boost immunity  
Phenolic lipids, cardanol and 
ginkgolic acid; lupeol 1 and B-
sitosterol 2; antimicrobials 
Ahmed et al., 2014 
Ozoroa mucronata (Bernh.) 
R. Fern. & A. Fern.  
No common 
names associated 
with this taxon 
yet.  Mvunda-
Jukunu in 
Tanzania 
NEL71/1993 Leaves and roots Diarrhoea, 
dysentery, 
stomach troubles, 
gonorrhea, 
bilharzia and 
antidote for snake 
bite 
Anacardic acid; flavonoids, 
phenols, tannins/antimicrobial 
Ahmed et al., 2014 
Ozoroa paniculosa (Sond.) 
R. Fern. & A. Fern. 
Red resin tree 
(Eng.) 
PMDN568 Bark and roots Diarrhoea and 
abdominal pain  
Flavonoids, phenols, tannins 
Anacardic acid, ginkgoic acid 
and triterpenes/antimicrobial  
Ahmed et al., 2014; 
Stark et al., 2013 
Protorhus longifolia (Bernh.) 
Engl. 
Red beech (Eng), 
rooiboekenhout 
(Afr.); 
umkhomizo, 
unhlangothi (Z) 
PRU120030 Leaves, stem bark 
and seeds 
Heartburn, 
bleeding from 
stomach,  
depilatories,            
Heartwater, 
dysentery and 
diarrhoea in cattle  
Triterpenes, lanosteryl 
triterpen/antimicrobial, 
Antihyperlipidemic and 
antihyperglycemic 
Mosa et al., 2014 
Searsia chirindensis (Baker 
f.) Moffett 
Red currant 
(Eng.); 
Bostaaibos (Afr.), 
umHlabamvubu 
(Z) 
PMDN333 Stem Bark Heart, stomach 
ailments, 
diarrhoea, 
strengthen the 
body, stimulate 
circulation, 
rheumatism and 
mental  
disturbances 
Saponins, tannins 
triterpenoids and flavonoids/ 
Inflammatory, analgesic and 
anticonvulsant   
Ojewole,  2008 
Searsia lancea (L.f.) 
F.A.Barkley 
Karee (Eng.), 
umHlakotshane 
(X) 
PMDN750 Bark and roots Diarrhoea, 
gallsickness  
Flavonoids and 
tannins/antimicrobial 
Stark et al., 2013 
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Searsia leptodictya (Diels.) 
T.S.Yi., A.J.Mill.& J.Wen  
Mountain karee 
(Eng.), bergkaree 
(Afr.) 
Motshotlwane 
(Tsw) 
NEL94/1969 Bark, leaves and 
roots 
Diarrhoea and pain Phenols, tannins and 
flavonoids  
Ahmed et al., 2014; 
Stark et al., 2013 
Searsia magaliesmontana 
(Sond.) Moffett  
 NEL68/1997 __ __ __ __ 
Searsia pyroides (Burch.) 
Moffett 
Wildcurrant 
(Eng.); 
Brandtaaibos, 
(Afr.); 
Inhlokoshiyane 
(Z) 
PMDN570 Leaves, roots and 
stem bark 
Treatment of 
epilepsy and 
cough medicine 
Flavonoids  bichalcones  Maroyi, 2013  
Searsia undulata (Jacq). 
T.S.Yi, A.J.Mill. & J.Wen  
T’kuni (khoi); Kuni 
bush, (Eng.); 
Koenibos (Afr.) 
PRU120031 Bark, leaves and 
roots 
Post-parturient 
problems and 
treatment for chest 
colds  
Apigenin 7,4´-dimethyl ether, 
flavone/ Anti-inflammatory  
Fourie and Snyckers, 
1984; Hutchings et 
al., 1996) 
Sclerocarya birrea subsp. 
caffra (Sond.) Kokwaro 
Cider tree, marula 
(Eng.); Maroela 
(Afr.); Umganu (Z)   
NEL103/1967 Bark, leaves and 
roots 
Diarrhoea, 
dysentery, pain, 
stomach problems, 
fever, cough, 
malaria, tonic,  
diabetes  and sore 
eyes  
Gallotannins, Flavonoids, 
epicatechin, alkaloids,  
triterpenoids and vitamin c  
/Anticonvulsants;  
antidiarrhoeal, antidiabetic, 
anti-inflammatory, 
antimicrobial and antioxidant  
Maroyi, 2013; Stark et 
al., 2013; Van Wyk et 
al., 1997 
Smodingium argutum E. 
Mey. ex Sond. 
African poison ivy 
(Eng.); Pynbos 
(Afr.); 
Umthomvane (Z)  
PMDN188 Bark, leaves and 
roots 
Diarrhoea and 
diabetes   
Catechols, phenolic lipids 
(cardanol and ginkgolic acid) 
/Antidiarrhoeal, 
hypoglycaemic effects and 
anti-inflammatory 
 Hutchings et al.,  
1996 
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(a)                                        (b) 
Figure 4.2: Leaves, flowers and fruits of Anacardiacea occidentalis (Cashew tree) (a) and 
Lannea discolor (b) 
Source: courtesy of www.zipcodezoo.com and www.tropical.theferns 
              
(c)              (d) 
  Figure 4.3: Leaves and fruits of Mangifera indica (c) and Ozoroa paniculosa (d) 
Source: courtesy of www.alamy.com 
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(e)                   (f) 
Figure 4.4: Leaves of Ozoroa mucronata (e) and leaves and fruits of Heeria argentea (f) 
Source: courtesy of www.ispotnature.org 
                
(g)                                       (h) 
Figure 4.5: Leaves and fruits of Searsia chirendensis (g) and leaves of Searsia lancea (h) 
Source: courtesy of www.plantzafrica.com and www.redlist.sanbi.org 
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(i)                                            (j) 
Figure 4.6: Leaves of Searsia magaliesmontana (i) and Smodingium argutum (j).  
Source: courtesy of www.operationwildflower.org.za 
                  
(k)       (l) 
Figure 4.7: Leaves and flowers of Searsia pyroides (k) and Protorhus longifolia (l).  
Source: courtesy of www.bidorbuy.co.za 
4.2.2 Antimycobacterial activity 
The antimycobacterial activity of the acetone crude extracts of leaf powder was 
determined using bioautography and the two-fold serial microdilution method.  The 
pathogenic and rapidly growing mycobacteria were test microorganisms used for 
antimycobacterial activity.  
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4.2.2.1 Pathogenic mycobacteria 
4.2.2.1.1 Mycobacterium tuberculosis multi-drug resistant isolates (MDR-TB) 
Two clinical isolates of multi-drug resistant Mycobacterium tuberculosis (MDR-TB) 
were used.  Both isolates were obtained from patients admitted to the MDR-TB ward 
at Tshepong Hospital in Klerksdorp, North West Province of South Africa in 
December 2012.  The patients were a 34 year old female and an 18 year old male.  
Samples of sputum had been submitted to the National Health Laboratory Service 
(NHLS) in Pretoria for culture in liquid medium and PCR/Line Probe Assay.  Both 
isolates were resistant to isoniazid and rifampicin.   
4.2.2.1.2 Mycobacterium bovis 
Mycobacterium  bovis cultures were isolated from field samples of cattle from herds 
that tested positive on tuberculination skin test during the period January 2009 to 
January 2011(Kabongo-Kayoka et al., 2015) as described in Chapter 2 under section 
2.3.2.  
4.2.2.2 Rapidly growing mycobacteria 
Mycobacterium bovis BCG (Pasteur strain P1172) was obtained from the 
Tuberculosis Laboratory at the ARC-Onderstepoort Veterinary Institute and M. 
tuberculosis H37Ra, which is routinely used as reference material at NHLS, was 
obtained from the American Type Culture Collection (ATCC) number 25177.  Other 
reference strains used included a M. aurum strain from the National Collection of 
Type Cultures (NCTC), a culture collection of Public Health England, M. aurum 
(NCTC 10437), M. smegmatis (ATCC 1441) and M. fortuitum (ATCC 6841). 
4.2.2.3 Maintenance of cultures 
Fresh cultures were used in the relevant assays.  The pathogenic isolates of 
Mycobacterium spp. were kept at room temperature on LJ slants supplemented with 
glycerol, or pyruvate in the case of the M. bovis BCG cultures, and were used within 
a month.  Prior to each assay, cultures were reactivated in liquid medium, 
Middlebrook 7H9, using MGIT 960 tubes which were incubated at 37°C in the 
BACTEC MGIT 960 instrument, in which they were automatically monitored each 
hour for fluorescence development for 42 days or until a positive signal developed.  
Bacterial suspensions from MGIT tubes were then subcultured on solid medium LJ 
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slants with pyruvate for M. bovis and LJ slants with glycerol for M. tuberculosis.  LJ 
tubes were then incubated in a walk-in incubator at 37°C for 4 to 6 weeks.  A stained 
Ziehl-Neelsen smear was made from the sediment of the MGIT tube and the slant of 
LJ medium.  Reference cultures of M. avium (ATCC 25291), M. bovis BCG and M. 
tuberculosis H37Ra (ATCC 25177) were used as positive controls. 
The rapidly growing Mycobacterium species were maintained on Middlebrook 7H10 
agar prepared according to the manufacturer instructions (Merck) and kept in a 
fridge at 4°C until used within a month.  Mycobacterium aurum and M. fortuitum were 
revived using Middlebrook 7H9 broth with glycerol and tween and supplemented with 
OADC (Oleic acid Albumin Dextrose Catalase) whereas M. smegmatis was revived 
using MH broth (Merck).  Bacterial suspensions were inoculated on MH agar plates 
for M. smegmatis and the rest on Middlebrook 7H9 agar.  All agar plates were then 
incubated at 37°C until colony growth was visible within 24 to 72 hours depending on 
the growth rate of the specific mycobacterial species.   The final density of 1 x 105 
CFU/mL used was confirmed after spreading an inoculum of 100 μL of tenfold serial 
dilutions of the bacterial suspensions at McFarland No 1 onto Middlebrook 7H10 
(M7H10) agar plates incubated at 37°C and counting colonies.  
4.2.2.4 Minimum inhibitory concentration (MIC) determination  
The MIC values were determined using the serial microplate method developed by 
Eloff (1998b) and slightly modified for mycobacteria by McGaw et al. (2008b).  The 
MIC value was the lowest concentration of the tested extract or sample inhibiting the 
growth of the Mycobacterium species under investigation.   
Mycobacterial suspensions were prepared from a pure culture of fresh colonies from 
solid medium and suspended in Middlebrook 7H9 (M7H9) liquid medium 
supplemented with 10% OADC.  These colonies were transferred into a sterile 
screw-capped tube containing 3 mL of M7H9 broth and homogenized by placing the 
tube on a Vortex mixer for 5 minutes.  After the larger particles had settled, the 
mycobacterial suspension was adjusted to McFarland no.1 turbidity standard by 
adding more broth (Lall and Meyer, 1999). 
The assay was performed using sterile 96-well microplates with rounded bottoms.  
The sample to be tested (plant extract, drug or fraction) was prepared at a 
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concentration of 10 mg/mL before serial dilution.  One hundred microliters of M7H9 
broth or MH broth was added to all the wells then, 100 µl of the sample to be tested 
were added in three adjacent column wells in the first row whereas other wells 
included standard drug positive controls to assess bacterial growth, solvent control, 
broth to be inoculated and clean broth for sterility check.  Two samples of crude 
extract and one standard drug were tested per plate.  A two fold serial dilution was 
carried out leaving 100 µl of different concentrations of diluted tested samples in 
each well starting with a concentration of 2.5 mg/mL in the first wells.  Then 100 µl of 
the test bacterial suspension were added to all the wells except column 12 (negative 
control) containing pure broth to make sure that there was no contamination of the 
broth.   Each dose was run in triplicate and the experiment repeated at least six 
times.  The standard antibiotics (reference drugs) included ciprofloxacin, rifampicin, 
isoniazid and streptomycin starting with a concentration of 100 µg/mL.  The 
microplates were covered and sealed in plastic bags, placed in humid chambers to 
minimize the evaporation of the culture medium and incubated at 37°C for 24 hours 
(M. smegmatis), 48 hours (M. fortuitum) and 72 hours (M. aurum).  For the 
pathogenic mycobacteria, microplates were incubated for a period of 7 to 15 days. 
At the end of incubation, a volume of 40 µl of 0.2 mg/mL of iodonitrotetrazolium 
chloride (INT) was added to each well, plates were incubated for 30 minutes or 
longer at 37°C and the development of colour observed.  A coloured red-purple 
formazan or pink colour indicated the reduction of INT by metabolizing organisms 
whereas a yellow colour or decrease in colour indicated the inhibition of bacterial 
growth Eloff (1998b).  If the colour development was not strong enough for slow 
growing organisms, plates were incubated much longer and monitored.  The 
correlation assessing the relationship between the MIC values of the 7 mycobacterial 
species used (Table 4.3) was calculated using Microsoft Excel 2010 software 
(Microsoft, Redmond, WA, USA). 
4.2.3 Thin Layer Chromatography (TLC) analysis and Bioautography 
Ten microliter from 10 mg/mL of relevant extracts (containing 100 μg of extract) was 
loaded on aluminium-backed TLC plates (Merck silica gel F254) in lines of about 1 
cm wide.  The TLC plates were eluted in three different mobile solvent systems that 
included ethyl acetate/methanol/water (EMW) 10:1.35:1, chloroform/ethyl 
acetate/formic acid (CEF) 10:8:2 and benzene/ethanol/ammonia (BEA) 18:2:0.2 
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(Kotzé and Eloff, 2002).  Chromatograms were examined under ultraviolet light at 
wavelengths of 254 and 366 nm to visualize UV active compounds that fluoresce 
and might not be visible after vanillin spray; the plates were then sprayed with a 
solution made of 0.1 g vanillin in 28 mL of methanol and 1 mL of sulphuric acid 
(vanillin–methanol-sulphuric acid) and heated at 110°C with a heat gun for colour 
development and visualization of UV inactive compounds present in the plant 
extract.  More than 10 compounds of different polarities were observed. These 
compounds were very close to each other in both the solvent systems BEA and 
CEF.  In general, the active plants had different activities against different 
Mycobacteria.  Active compounds included both polar and non-polar compounds 
based on the Rf values determined in bioautography.  In the non-polar solvent BEA, 
the non-polar compounds travelled some distance up the plate with clear zones of 
inhibition on plates sprayed with different Mycobacterium species whereas in the 
polar solvent system EMW, non-polar compounds were pushed towards the solvent 
front and polar compounds off the baseline.  The CEF solvent system led to a better 
separation of some compounds (B in Figure 4.3). 
    
    PL (A)              PL (B)                   HC (A)                  HC (B)                SU (A)                 SU (B)   
    PL: Protorhus longifolia, HC: Harpephyllum caffrum, SU: Searsia undulata 
Figure 4.8: Bioautograms (A) of the three plants extracts with low MIC values and thin layer 
chromatograms eluted in chloroform/ethyl acetate/formic (CEF) solvent system sprayed with 
vanillin sulphuric acid (B) showing varied chemical constituents.  Bioautogram of the extracts 
against Mycobacterium aurum. 
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For bioautography, only the rapidly growing organisms were used, namely M. aurum, 
M. fortuitum and M. smegmatis, because the pathogenic mycobacteria present a 
high biohazard risk if handled in a spray format. Aerosols of pathogenic species 
increase risk of possible contamination of the environment and human exposure.  
Duplicate chromatograms prepared as described above were left uncovered in a 
dark place and air dried until solvents were completely evaporated for at least 24 
hours or overnight.  A saturated bacterial culture was centrifuged at 3000 x g for 10 
min and the pellet resuspended in fresh appropriate liquid growth medium and 
prepared at McFarland No 1.  The TLC plates were then sprayed with active 
bacterial suspension (18 to 72 h old cultures depending on the growth rate of the 
particular Mycobacterium species) until completely moist using a glass spray gun 
linked to a vacuum pump.  The moist plates were incubated at 37°C in a humidified 
chamber under 100% relative humidity for 24 h for M. smegmatis, 48 h for M. 
fortuitum and 72 h for M. aurum.  The plates were then sprayed with 2 mg/mL of INT 
(iodonitrotetrazolium violet) (Sigma, Johannesburg, South Africa) in distilled water 
and incubated for a further 30 min to few hours until the development of clear zones 
against a purple-red background. The emergence of purple-red colour resulting from 
the reduction of INT into formazan indicated the presence of viable microorganisms 
whereas clear zones against the purple-red background indicated inhibition of 
mycobacterial growth indicating the Rf values of antimycobacterial compounds 
separated on the thin layer chromatography plates (Hamburger and Cordell, 1987). 
4.2.4 In vitro cytotoxicity assay and selectivity index 
The cytotoxicity of crude acetone extracts from plants with good MIC values and 
clear zones of inhibition on bioautography was determined using a tetrazolium-based 
colorimetric assay, 3-(4, 5-dimethylthiazol)-2, 5-diphenyl tetrazolium bromide (MTT 
assay) described by Mosmann (1983) and slightly modified by McGaw et al. (2007).  
Vero African monkey kidney cells were obtained from the cell culture collection of the 
Department of Tropical Diseases (University of Pretoria), cancer liver cells 
(hepatoma C3A) were purchased from the American Type Culture Collection 
(ATCC), Manassas, USA, CRL-10741 and murine macrophage (RAW 264.7) cells 
purchased from ATCC, ATCC®TIB71TM were used.  Cells were cultured in Minimal 
Essential Medium Eagle with L-Glutamine (EMEM) (BioWhittaker, Lonza, Belgium) 
supplemented with 0.1% gentamicin (Genta50) (Virbac, Centurion, South Africa) and 
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5% foetal calf serum (Highveld Biological, Sandton, Modderfontein, South Africa) for 
Vero cells and 5% sodium pyruvate (Adcock Ingram, Midrand, South Africa) and 
10% of foetal calf serum were added for C3A cells.  For C3A and Vero cells, a 5 day 
old confluent culture in 75 cm2 flasks were harvested and centrifuged at 200 × g for 2 
min, and the pellet resuspended in growth medium to a density of 0.1 ×106 cells/mL 
whereas RAW 264.7 cells were mechanically scraped, plated at a density of 4 × 105 
cells/mL onto 96-well plates containing 100 μL of Dulbecco’s Modified Eagle Medium 
(DMEM) (BioWhittaker, Lonza, Belgium) and incubated in a 37°C, 5% CO2 incubator 
for 24 h prior to exposure.  The following procedure was the same for all the different 
types of cells.  A sterile 96-well microplate was used; cell suspension (100 µL) was 
added into each well of columns 2–11.  Columns 1 and 12 were used as blanks with 
200 µL of growth medium to minimize the “edge effect” and maintain humidity.  The 
plates were incubated for 24 h at 37 °C in a 5% CO2 incubator and cells were 
observed until they reached the exponential phase of growth.  The cells were then 
exposed to different concentrations of the extract sample as well as to doxorubicin 
hydrochloride (Adriblastina CSV, Pfizer, Johannesburg, South Africa) as positive 
control and acetone as negative control.  From a concentration of 100 mg/mL of the 
extract sample, different concentrations using growth medium as a diluent were 
prepared, namely 1, 0.75, 0.5, 0.25, 0.1, 0.075, 0.05 and 0.025 mg/mL.  The 
microplates were then incubated for 48 h.  After this period of incubation, the 
medium was removed from the wells containing the cells using a multichannel 
pipette attached to a pump via a plastic tube; cells were rinsed with 200 µL 
phosphate buffered saline (PBS, Sigma-Aldrich, Johannesburg, South Africa) and 
replaced with 200 µL of fresh medium.  Then thirty microliters (30 µL) of a 5 mg/mL 
solution of 3-(4, 5-dimethylthiazol)-2, 5-diphenyl tetrazolium bromide (Sigma-Aldrich, 
Johannesburg, South Africa) in PBS was added to each well.  The plates were 
incubated for a further 4 h at 37˚C in the CO2 incubator.  After incubation, the 
medium was carefully removed using the same multichannel pipette connected to a 
pump without disturbing the MTT formazan crystals in each well.  Then 50 µL of 
dimethyl sulfoxide (DMSO) was added to each well to dissolve the MTT crystals. 
Absorbance values were read immediately using a microplate reader (BioTek 
Synergy HT, Analytical and Diagnostic Products, Johannesburg, South Africa) at a 
wavelength of 570 nm.  Columns 1 and 12 were used as blank.  The different 
concentrations were tested in quadruplicate and the assay was repeated at least 
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three times. The LC50 values were calculated as the concentration of plants extracts 
where 50% of cells were still viable compared to untreated cells in columns 2 and 11.  
In Table 4.4, the selectivity index of the active plants was calculated using LC50 
values divided by MIC values (LC50/MIC). 
4.2.5 Statistical analysis 
All experiments were conducted in triplicate and values expressed as mean ± 
standard deviation. For the MIC values, re-evaluation of the growth inhibition was 
conducted where a wide variation within the three experiments was noticed. The 
relationship between the different mycobacterial MIC values was calculated using 
the Pearson’s correlation coefficient (r).  
4.3 RESULTS AND DISCUSSION 
4.3.1 Acetone extract plant yield 
The extraction yield of the plant species ranged from 0.8 to 18.8% (Table 4.2).  The 
highest percentage was observed with Searsia magaliesmontana (18.8%) followed 
by Searsia undulata (12.5%) and Protorhus longifolia (8.3%).  Heeria argentea had 
the lowest yield of 0.8%.  The extraction yield and bioactivities of extracts using 
different extractants vary strongly (Kotzé and Eloff, 2002), hence the choice of 
acetone in this study. 
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Table 4.2: Minimal inhibitory concentration (MIC in mg/mL) and total activity (TA in mL/g) of acetone leaf extract from 15 plants of the 
Anacardiaceae family against M. bovis and M. tuberculosis 
    
MBCG H37Ra MBfield MDR-Tb 
      
  
     
Plant species Voucher number 
Extraction 
yield Mass yield (mg) MIC ± SD TA MIC ± SD TA MIC ± SD TA MIC ± SD TA 
            Harpephyllum caffrum PRU2583 4.6 138 0.11 ± 0.05 1255 0.16 ±  0 863 0.13 ± 0.05 1062 0.21 ± 0.09 657 
Heeria argentea PMDN 751 0.8 24 0.26 ± 0.09 92 0.52 ± 0.18 46 0.26 ± 0.09 92 0.21 ± 0.09 114 
Lannea discolour PMDN 565 5.7 171 0.11 ± 0.05 1555 0.11 ± 0.05 1555 0.21 ± 0.09 814 0.52 ± 0.18 329 
Loxostylis alata PRU3526 4.9 147 0.21 ± 0.08 700 0.24 ± 0.08 613 0.52 ± 0.18 283 0.52 ± 0.18 283 
Ozoroa mucronata NEL71/1993 1.7 51 0.625 ± 0 82 0.625 ± 0 82 0.51 ± 0.17 100 0.51 ± 0.17 100 
Ozoroa paniculata PMDN 568 7.7 231 0.52 ± 0.18 444 0.52 ± 0.18 444 0.51 ± 0.17 453 0.51 ± 0.17 453 
Protorhus longifolia PRU120030 8.3 249 0.11 ± 0.05 2264 0.07 ± 0.02 1186 0.11 ± 0.05 1915 0.11 ± 0.05 2264 
Searsia Chirindensis PMDN 333 3.1 93 0.16 ± 0 581 0.11 ± 0.05 845 0.31 ± 0.01 300 0.26 ± 0.09 358 
Searsia leptodictya NEL94/1969 6.1 183 0.13 ± 0.05 1408 0.42 ± 0.18 436 0.22 ± 0.0.8 832 0.26 ± 0.09 704 
Searsia magaliesmontana NEL68/1997 18.8 564 0.17 ± 0.02 3318 0.17 ± 0.02 3318 0.52 ± 0.18 1085 0.52 ± 0.18 1085 
Searsia pyroides PMDN 570 3.8 114 0.13 ±0.05 877 0.13 ± 0.05 877 0.21 ± 0.09 543 0.21 ± 0.09 543 
Searsia undulata PRU120031 12.5 375 0.07 ± 0.02 3409 0.05 ± 0.02 3409 0.11 ± 0.05 3409 0.11 ± 0.05 2885 
Sclerocarya birrea NEL103/1967 6 180 0.11 ± 0.05 1636 0.11 ± 0.05 1636 0.22  ±  0.08 818 0.22  ± 0.08 818 
Smodingium argutum PMDN 188 3.7 111 0.26  ± 0.09 427 
0.26  ± 
0.09 427 0.13  ± 0.05 854 0.13  ± 0.05 854 
Searsia lancea L PMDN 750 10.6 318 0.26  ± 0.08 1223 
0.26  ± 
0.08 1223 0.26  ± 0.08 1223 0.26  ± 0.08 1223 
CIP (µg/mL)  
   
0.013 ± 
0.006 
 
0.10 ± 0.05 
 
0.013 ± 
0.006 
 
>10 
 INH (µg/mL 
   
10.42 ± 3.61 
 
2.08 ± 0.90 
 
10.42 ± 3.61 
 
>100 
 RIF µg/mL 
   
1.04 ± 0.45 
 
0.26 ± 0.11 
 
1.04 ± 0.45 
 
>100 
 Strep µg/mL 
   
>100 
 
0.33 ± 0.11 
 
>100 
 
>100 
 Acetone mg/mL       >2.5   >2.5   >2.5   >2.5   
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4.3.2 Biological activity of extracts 
Bioautography of extracts using two (M. aurum and M. fortuitum) out of the three 
rapidly growing mycobacteria led to strong clear zones of inhibition.  This also 
corresponded with low MIC values obtained ranging from 0.05 to 0.1 mg/mL.  
Extracts with MIC values ≤ 0.1mg/mL were considered to have significant activity; 
moderate activity was between 0.1 and 0.625 mg /mL and weak or poor activity  with 
MICs >0.625 mg/mL (Kuete, 2010).  All 15 plant extracts had good to moderate 
antimycobacterial activity against rapidly growing and pathogenic mycobacteria 
ranging from 0.05 to 0.590 mg/mL. Searsia undulata extracts had significant 
antimycobacterial activity with the lowest MIC value of 0.07 mg/mL for M. aurum and 
M. fortuitum followed by M. smegmatis with MIC of 0.09 mg/mL.  Protorhus longifolia 
extracts also had significant antimycobacterial activity against all three non-
tuberculous mycobacteria with MIC values of 0.11 mg/mL for both M. aurum and M. 
fortuitum and 0.07 mg/mL for M. smegmatis.  Searsia lancea, Sclerocarya birrea and 
Harpehyllum caffrum had moderate activity of 0.420 mg/mL, 0.520 mg/mL and 0.590 
mg/mL against M. aurum respectively whereas the same plant species had 
moderate activity with low MIC values of 0.21 and 0.11 mg/mL; 0.13 and 0.21 mg/mL 
and 0.21 and 0.11 mg/mL against M. fortuitum and M. smegmatis, respectively.  
Searsia undulata had significant activity against all mycobacteria including M. bovis 
and MDR-TB isolates with MIC ranging from 0.05 to 0.11 mg/mL, and the lowest 
value of 0.05 mg/mL against M. tuberculosis ATCC strain H37Ra.   
Positive correlation was observed between the pathogenic isolates, M. bovis and 
MDR-TB, with M. fortuitum with (r) coefficient correlation values of 0.62 and 0.65 
respectively whereas negative correlation with value of -0.005 was observed with M. 
aurum.  Good correlation was observed between the ATCC strain, H37Ra and 
rapidly growing mycobacteria with values of 0.92, 0.87 and 0.37 for M. fortuitum, M. 
aurum and M. smegmatis respectively and the highest coefficient correlation value of 
0.98 between MDR-TB isolate with the pathogenic M. bovis isolate (Table 4.3).   
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Table 4.3: Pearson’s correlation coefficient (r) between MIC values of tested Mycobacteria 
  Ma Mf Ms H37Ra Mb 
MDR-
TB 
       Ma 1 
     Mf 0.62 1 
    Ms 0.62 0.20 1 
   H37Ra 0.87 0.92 0.37 1 
  Mb -0.005 0.62 0.26 0.34 1 
 MDR-
TB -0.06 0.65 0.10 0.35 0.98 1 
       
Ma, Mycobacterium aurum; Mf, Mycobacterium fortuitum; Ms, Mycobacterium smegmatis; 
H37Ra, Mycobacterium tuberculosis ATCC strain 25177; Mb, Mycobacterium bovis; MDR-TB, 
Multi-drug resistant Mycobacterium tuberculosis.  The values in bold represent the correlation 
between rapidly growing mycobacteria and pathogenic mycobacteria. 
The total activity value of an extract from a plant indicates which species could be 
the candidates for organic production of active extracts for use by communities 
because it takes into account not only the MIC of the extract but also the yield of the 
extract.  By dividing the extraction yield in mg/g by the MIC in mg/mL the total activity 
is calculated in mL/g (Eloff, 2000).  This provides the volume in mL that the extract 
from 1 g of dry material can be diluted and still kills the pathogen.  Searsia undulata 
had the lowest MIC values (significant activity) with the highest % yield and highest 
total activity of 5 357 mL/g on M. fortuitum and 2 885 mL/g on MDR-TB followed by 
Protorhus longifolia showing the highest total activity of 3 557 mL/g on M. smegmatis 
and 2 264 mL/g on MDR-TB.  The results of total activity using rapidly growing 
mycobacteria are not shown due to limitation on number of tables.  These two plants 
are the best candidates for further investigation due to their low cytotoxicity and more 
than 30 antimycobacterial compounds observed using bioautography.  In addition, 
(Mosa et al., 2014) reported that Protorhus longifolia had antibacterial activity 
towards resistant clinical isolates of Gram negative (Pseudomonas aeruginosa) and 
Gram positive (Staphylococcus aureus) whereas Searsia undulata has been used to 
treat chest cold (Hutchings et al., 1996).  Specific antimicrobials targeting Gram-
negative and Gram-positive bacteria are useful but this does not eliminate the need 
for broader spectrum antimicrobials.  However, other plants with moderate activity 
are worthy of investigation as studies have shown that there is synergy among 
different compounds within an extract and once fractionated, different 
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fractions/compounds might be more active than the crude extract (Awouafack et al., 
2013). 
4.3.3 Bioautography and thin layer chromatography analysis 
Although all selected plant species had significant to moderate activity against all 
Mycobacterium species tested, plants showing at least MIC below 0.1 mg/mL or 
close to 0.1 mg/mL for any of the mycobacteria tested were selected to be 
investigated by bioautography.  Five plants were selected namely Heeria argentea, 
Lannea discolor, Protorhus longifolia, Searsia undulata and Sclerocarya birrea.  Only 
three plant species, Harpephyllum caffrum, Protorhus longifolia and Searsia 
undulata, had one or more clear zones of inhibition after spraying with M. aurum or 
M. fortuitum.  Searsia undulata was the only species to show clear zones of inhibition 
with both M. aurum and M. fortuitum, with more compounds visible with M. aurum.  
Using bioautography, M. aurum was the best indicator of antimycobacterial activity 
followed by M. fortuitum.  Low MIC values might not always correlate with 
visualization of clear zones of inhibition due to the nature of separated compounds 
on the TLC plate, which may be volatile or experience loss of activity due to the 
separation of compounds that were acting in synergy in the crude extract.  The crude 
extract of Searsia undulata had several active compounds against M. aurum – 
potentially more than ten compounds as some compounds were very close to each 
other in terms of Rf values ranging from 0.05 to 0.98 in the different solvent systems 
BEA, CEF and EMW (results not shown).  Based on the MIC values and 
bioautogram patterns, the same plant extracts have shown different activities 
towards different mycobacteria species.  Mycobacterium  smegmatis also had some 
low MIC values with few or no visible zones of inhibition.   The BEA and CEF solvent 
systems gave the best separation of compounds at this initial stage (Figure 4.3).   
4.3.4 Cytotoxicity assay 
Most drugs or other substances are metabolised in the liver and excreted by the 
kidney.  Mycobacterial species causing tuberculosis multiply and hide in 
macrophages.  Therefore, three cell lines were selected to represent these organs 
namely Vero monkey kidney, human liver hepatoma (C3A) and mouse macrophage 
cells (RAW 264.7).  Cancer cells are abnormal cells, and substances showing 
cytotoxicity to C3A cells and low cytotoxicity to the Vero cells may also be good 
candidates for further investigation as anticancer preparations.  Cell-based in vitro 
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toxicity assays are performed at an early stage of the drug development process in 
order to remove high-risk materials.  Plants extracts showing sensitivity to cell lines 
with LC50 values >0.1 mg/mL are considered not cytotoxic in terms of searching for 
anticancer compounds (Kuete, 2010).   
Crude extracts (Heeria argentea, Lannea discolor, Protorhus longifolia, Searsia 
undulata and Sclerocarya birrea) with good antimycobacterial activity (from 
significant to moderate) and those that showed visible zones of inhibition on 
bioautograms were selected for cytotoxicity testing (Table 4.4).  All crude extracts 
tested showed low toxicity against all three cell lines (C3A, Vero cells and RAW 
(264.7) except Searsia undulata that had moderate toxicity to C3A cells with LC50 of 
0.034 mg/mL. This deserves further investigation as source of anticancer substance 
as C3A cells are cancer cells with abnormal metabolic activity.   
The Searsia undulata extract had LC50 of 0.50 and 0.12 mg/mL on Vero cells and 
RAW cells respectively with good selectivity indexes of 7.08 on Vero cells and more 
than 1 on RAW cells for non-tuberculous and MDR-TB mycobacteria.  Protorhus 
longifolia had an LC50 of 0.62 mg/mL on C3A cells, 0.88 mg/mL on Vero cells and >1 
mg/mL for RAW cells with highest selectivity index on Vero cells of 12.6 for M. 
smegmatis followed by 8.02 for M. aurum, M. fortuitum and MDR-TB.  Plant extracts 
with SI values less than1 mean that the extracts are relatively less toxic to the 
bacteria and more toxic to the mammalian cells (Eloff, 2000).  Therefore, extracts 
with SI >1 may be relatively safer to use in vivo (not accounting for pharmacokinetic 
parameters) as they are less toxic to mammalian cells but more toxic to the 
pathogens.   
The selectivity indexes, especially of P. longifolia with SI = 12.6 could be considered 
as very promising as a good therapeutic index for a remedy or drug should be ≥10 
(Caamal-Fuentes et al., 2011).  It is also worth noting that efficacy “in vitro” might 
differ from efficacy ‘in vivo” due to different parameters influencing 
pharmacodynamics and pharmacokinetic of drugs administered by different routes to 
humans and animals.   
In this study, Protorhus longifolia and Searsia undulata had the highest selectivity 
index against the three rapidly growing mycobacteria and pathogenic mycobacteria 
and the highest total activity (Table 4.4).  These rapidly growing species had the 
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highest total activity of 5357 mL/g for S. undulata and 3557 mL/g for P. longifolia 
which indicates the volume to which the extract from 1 g can be diluted and still 
inhibit the growth of mycobacteria.  It is also worth noting that the leaves of S. 
undulata are chewed by Khoi people to treat chest cold, indicating a potential low 
toxicity.  The mode of administration and interaction with other factors in vivo must 
be considered when assessing toxicity.  
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Table 4.4: Cytotoxicity (LC50 in mg/mL) of extracts and selectivity index against C3A liver cells, Vero kidney cells and RAW 264.7 murine macrophage cells 
                 
                 
  
SI C3 A SI Vero cells SI RAW cells 
                 Plant species   LC50 MA MF MS MDR-TB LC50 MA MF MS MDR-TB LC50 MA MF MS MDR-TB 
Heeria argentea 
 
0.314 0.627 1.045 1.206 1.493 0.499 0.998 1.663 1.919 2.375 NT NT NT NT NT 
Lannea discolor 
 
0.408 2.148 2.148 3.139 0.785 NT NT NT NT NT >1mg/mL 
    Protorhus longifolia 
 
0.621 5.642 5.642 8.866 5.642 0.883 8.024 8.024 12.609 8.024 >1mg/mL 
    Searsia undulata 
 
0.034 0.488 0.488 0.380 0.311 0.496 7.083 7.083 5.509 4.507 0.123 1.751 1.751 1.362 1.115 
Sclerocarya birrea 
 
0.169 0.326 1.304 0.807 0.770 0.499 0.959 3.836 2.375 2.267 NT 
                     
LC50: Lethal concentration 50, MA: Mycobacterium aurum, MF: Mycobacterium fortuitum, MS: Mycobacterium smegmatis, MDR-TB: Multiple 
resistant tuberculosis strain, SI: Selectivity index 
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4.4 CONCLUSION  
This is the first report on antimycobacterial activity of these tree species from the 
Anacardiaceae family in Africa.  Acetone leaf crude extracts of all the selected plants 
have shown significant to moderate antimycobacterial activity.  Harpephyllum caffrum, 
Lannea discolor, Protorhus longifolia, Searsia undulata and Sclerocarya birrea subsp. 
caffra had good antimycobacterial activity and low cytotoxicity.  Some rapidly growing 
mycobacteria may be used as indicators for detecting good antimycobacterial activity of 
plant extracts against pathogenic mycobacteria based on the correlation of MIC values.  
The best indicators of antimycobacterial activity on MIC and bioautography were M. 
aurum followed by M. fortuitum.  Protorhus longifolia and S. undulata had good 
antimycobacterial activity against all mycobacterial species.  Low cytotoxicity was 
observed on Vero cells and RAW cells.  Searsia undulata was cytotoxic to hepatoma 
cells and could be investigated further as a source of potential anticancer substances.  
Adding to results obtained from the bioautography, MIC values and cytotoxicity as well 
as ethnobotanical use, P. longifolia and S. undulata had good potential 
antimycobacterial activity worthy of further investigation.  The ethnobotanical use of 
chewing S. undulata leaves by Khoi people to treat chest colds is interesting and the 
antimicrobial activity of leaf extracts of this species supports this use although further 
study is necessary to validate this supposition.  Isolation and characterization of 
compounds from these highly promising species is underway and bioassay-guided 
isolation of fractions and compounds from Searsia undulata forms the topic of the next 
chapter. 
Postscript 
In the next chapter 5, preliminary results of two out of the 10 antimycobacterial 
compounds present in these extracts are provided and spectra obtained are presented 
in appendix B. 
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CHAPTER 5: 
BIOASSAY-GUIDED ISOLATION OF FRACTIONS AND COMPOUNDS 
FROM SEARSIA UNDULATA 
ABSTRACT 
The treatment of tuberculosis has been a challenge over the past decade due to the 
emergence of multi- and extremely drug resistant strains (MDR and XDR).  There is an 
urgent need to find alternative treatments for this deadly and highly contagious disease.  
Searsia (Rhus) undulata (Anacardiaceae) is a medicinal plant; its root has been used in 
South Africa by the Khoi as an anti-inflammatory.  Leaves are chewed to treat chest 
colds and decoction for post parturient problems.  Its crude extracts have shown good 
antimycobacterial activity in a previous study.  Therefore, the aim of this work was to 
isolate and identify active antimycobacterial compounds.  Isolated compounds from 
Searsia undulata were screened for antimycobacterial activity using a twofold serial 
microdilution assay against fast-growing saprophytic mycobacteria that included M. 
smegmatis, M. fortuitum and M. aurum.  Cytotoxicity (LC50) was assessed using a 
colorimetric (MTT) assay against Vero monkey kidney cells.  Different fractions, sub- 
fractions of Searsia undulata were prepared using column chromatography and 
analysed using thin layer chromatography and bioautography to visualize the 
antimycobacterial activity and isolated compounds.   Compounds were identified using 
MS and NMR spectroscopy.  Unknown compound was further processed by melting 
point and FITR.  The chloroform fraction showed more than 5 compounds but only two 
compounds (SLN1 and PKB) were fully identified respectively as Betulonic acid and a 
novel compound which did not match with any published data base using SciFinder 
search tool.  Mycobacterium aurum and M. fortuitum were good indicators of   
antimycobacterial activity with strong clear zone of inhibition; M. aurum showed more 
than 7 active zones of inhibitions.   Chloroform fraction showed more than 5 compounds 
on TLC, the butanol fraction extracted the least compounds.  Betulonic acid and 
compound PKB had an average MIC of 31.25µg/ml for M. aurum and M. smegmatis and 
23.44µg/ml and 31.25µg/ml for M. fortuitum respectively.  The highest concentration of 
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compound tested for cytotoxicity was 200µg/ml and compound PKB was the least toxic 
out of the two compounds.  Several active compounds were observed and correlated 
with low MIC values.  This is the first report on Searsia undulata related to 
antimycobacterial activity and first isolation of the two elucidated compounds. This plant 
has being investigated further for isolation of the rest of active compounds. 
5.1 BACKGROUND 
5.1.1 Description and taxonomy  
Searsia (Rhus) undulata plant belongs to the old Rhus genus also referred to as 
“Sumac” that was changed to “Searsia” (Moffett, 2007).  Searsia undulata is also called 
t’kuni (Khoi); Kuni-bush (English) and koeniebos, garrabos (Afrikaans).  The genus 
Searsia is heterogeneous in the Anacardiaceae family and comprises more than 200 
species (Moffett, 2007).  They are found in temperate and tropical regions worldwide.  
The Anacardiaceae family includes plants that produce gums, resins or latex from which 
antimicrobial compounds may be isolated.   
Searsia undulata is a dense, evergreen shrub or small tree of up to three meters in 
height native to South Africa (Figure 5.1.a).  The leaves are trifoliate (Figure 5.1.b), dark 
green with a shiny lacquered look arising from a narrow winged leaf stalk.  Each leaflet 
is variable in size and shape, with a pointed tip and a distinctly wavy margin hence the 
species epithet “undulata”.  Young leaves are obovate, usually shiny and resinous (very 
sticky).  The inconspicuous greenish flowers (Figure 5.1.b) are followed by small, thinly 
fleshy, green or slightly reddish berries.  Searsia undulata has been confused with R. 
burchellii as they are closely related (Palgrave et al., 2002).  The shrub is widely 
distributed along the west coast of the Cape and occurs in a wide range of different 
habitats (Moffett, 1993).   
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                                           (a)                                                          (b) 
       Figure 5.1: Shrub (a) and trifoliate leaves and greenish flowers (b) of Searsia undulata 
There are several species distributed in different geographical location.  In general, 
Rhus plants can grow in non-agricultural viable regions, and various species have been 
used by indigenous cultures for medicinal and other purposes (Van Wyk, 2008b).     
5.1.2 Traditional use of Searsia/Rhus species 
Traditionally, the leaves are chewed by the Nama (Khoisan) for chest cold and leaf 
decoctions for post-partum problems (Fourie and Snyckers, 1984).  The roots are used 
in infective gastrointestinal conditions.  Wheat (2014) reported in a survey conducted in 
Paulshoek community (Namaqualand, Cape Town) that the leaves from Searsia 
undulata called “Taaibos” are used in combination with leaves of “Salie”, “balerja” and 
“koorsbos” as tea against colds and flu whereas crushed leaves mixed with kidney fat 
are used as an ointment or plaster for boils, ringworms and abscesses.  The bark and 
leaves of several other species are used as medicine and include R. natalensis, R. 
burchellii, R. chirindensis, R. laevigata and R. viminalis (Hutchings et al., 1996). 
In Kenya and Tanzania, a decoction of boiled roots of R. longipes is used for the 
treatment of indigestion and abdominal pain and inhalation of steam vapour against 
influenza (Kokwaro, 2009).  In East Africa, the boiled extract of fruits of R. vulgaris is 
drunk to stop diarrhoea while the boiled stem extracts are applied to wounds.  A mixture 
of roots with other plants is used in pregnant women to allow easy delivery and it is also 
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used against infertility (Kokwaro, 2009)  In China, the decoction of all parts of R. 
chinensis is used for treatment of diabetes mellitus; a decoction from seeds is used for 
malaria and rheumatism (Djakpo and Yao, 2010; Duke, 1992).  Dried fruits of R. 
chinensis are used as infusion to treat diarrhoea, aching gums, toothaches and swollen 
legs whereas its boiled leaves are used in peptic ulcers, kidney stones, eruptions and 
bruises (Maina, 2011). 
In Turkey, the leaf extract of R. chinensis is used in the treatment of animal bites.  In 
North America and India, R. glabra is used for the treatment of bacterial diseases such 
as gonorrhea, urinary tract infections, dysentery, internal and external ulcers and 
sunburn (Borchardt et al., 2008; Hostettmann, 1999; Winston, 2001).  This plant is also 
used to alleviate hot flashes symptoms (Winston, 2001); the American Indians smoke 
sumac leaves for asthma (Hutton, 2010).  The dried fruits ground with salt of R. coriaria 
are used in the Mediterranean and Middle East as a spice and for wound healing 
(Rayne and Mazza, 2007; Shabbir, 2012). In Tanzania the extract of pounded roots of 
R. natalensis steeped in hot or cold water are used for influenza, abdominal pains, 
hookworm infestation and gonorrhea; the leaves are used against cough; steam from 
leaves macerated in hot water are inhaled to fight colds (Maina, 2011). 
5.1.3 In vitro biological activities 
Research undertaken on Rhus extracts to date indicates a promising potential for this 
genus to provide renewable bioproducts with beneficial bioactivities such as 
antimicrobial, antifungal, antiviral, antimalarial, antioxidant, antifibrogenic, anti-
inflammatory, antimutagenic, antithrombin, antitumorigenic, cytotoxic, hypoglycaemic 
and leukopenic (Maina, 2011; Rayne and Mazza, 2007) 
Much work has been done on the fruits of R. coriaria, a spice, which have demonstrated 
potential antimicrobial and antifungal properties   (Ali-Shtayeh et al., 2013; Bonjar, 2004; 
Gabr et al., 2014; Gabr and Alghadir, 2015).  These properties appear to be ascribed to 
polar compounds extractable with protic solvents.  The stem bark methanol extract of R 
quartiniana was found to have antibacterial activity against gonorrhoea (Neisseria 
gonorrhea) and Staphylococcus aureus; anthocyanins, coumarins, essential oils, 
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flavonoids, quinines, saponins, sterols and tannins have been isolated from this plant 
(Chhabra et al., 1987).  Biological activities of other Searsia species have been reported 
(Table 4.1 previous chapter).   
5.1.4 Isolation of compounds  
In Africa, there is no report on isolation of compounds from Searsia undulata with 
antimycobacterial activity, but in general, antimicrobial properties from other species of 
the genus Searsia (Rhus) have been reported elsewhere.  The favourable worldwide 
distribution of Searsia also suggests that desirable bio-products may be obtained locally 
with minimal transportation requirements from processing to consumer.  However, not 
all the species studied to date have been fully characterized for isolation of potential 
antimycobacterial activity.   The genus Searsia (formerly Rhus) is of great interest since 
the members have been found to possess chemical compounds that are toxic to micro-
organisms.  These compounds include flavonoids, bioflavonoids, isoquinolines and 
urushiols among others (Ahmed et al., 2001; Chhabra et al., 1987; Johns et al., 1990; 
Lin et al., 1999; Sebothoma, 2009; Songca et al., 2012; Wang et al., 2008).   
Bioassay-guided fractionation has been used for many years to isolate bioactive natural 
products.  The procedure involves repetitive fractionation of extracts and determining 
the biological activity of all the fractions (Brusotti et al., 2014).  The method provides a 
rational means to isolate bioactive compounds from a complex mixture even though it is 
consuming and labour intensive (Bero et al., 2011; Manvar et al., 2012).  It has also 
been found that the bioactive components can be extracted from Searsia using 
environmentally benign solvents that allow for both food and industrial end-uses.    
Indeed, antimicrobial compounds active against Gram-positive and Gram–negative 
bacteria have been isolated from the methanol extract of Rhus glabra, a species used in 
folk medicine in North America. Bioassay-guided fractionation led to isolation of three 
antibacterial compounds namely methyl ester of 3, 4, 5-trihydroxybenzoic acid (methyl 
gallate), 4-methoxy-3,5-dihydroxybenzoic acid and gallic acid (Saxena et al., 1994).  A 
flavone, apigenin dimethylether extracted from the roots of S. undulata, was reported to 
have anti-inflammatory properties (Fourie and Snyckers, 1984); the root methanol 
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extract from Rhus succedonea has been reported to contain compounds such as 
agathisflavone, robustaflavone, hinokiflavone, volkensiflavone, rhusflavone, 
succedaneflavone and their methylethers and acetates which were evaluated for 
antiviral activities.  Robustaflavone demonstrated strong inhibitory effects against 
influenza A and B viruses (Lin et al., 1999); the same activity was detected with 
agathisflavone and amentoflavone which also exhibited moderate anti-Herpes Simplex 
virus (HSV)-1 and anti-Herpes Simplex Virus (HSV)-2 activities.  Anti HIV-1 reverse 
transcriptase activity has been observed with robustaflavone, hinokiflavone and 
morelloflavone (Lin et al., 1999). 
Maina (2011) has reported on bioassay-guided antibacterial activity (using ATCC 
cultures and clinical isolates of Gram-positive and Gram-negative bacteria) of extracts 
from root bark, stem bark and leaves of Rhus natalensis from which the following 
compounds were isolated: rhuschromone, chamaechromone, lophirone A, calodenone, 
rhuschalone II and catechol.  
5.1.5 In vivo experiments 
The National Institute of Health of the United States under the screening programme for 
new antitubercular drugs recommends that all compounds, potentially antitubercular, be 
evaluated in both in vitro and in vivo models.  Animal models for in vivo evaluation of 
antimycobacterial activity and toxicity of compounds have been reported (Jiménez-
Arellanes et al., 2013; Nguta et al., 2016; Villar et al., 2008).  There is no report on the 
in vivo evaluation of antimycobacterial activity/toxicity of Searsia undulata.    
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5.2 MATERIALS AND METHODS 
5.2.1 Plant collection and storage 
The leaves of Searsia undulata were collected during summer (Figure 5.1.a) in 
November 2013 at the National Botanical Garden in Pretoria, South Africa.  
Coordinates: 25°44´S, 28°16´E.  The tree was identified and labelled in the botanical 
garden.   A voucher number was issued by the University of Pretoria herbarium (PRU) 
HGWJ Schweickerdt Herbarium, Department of Plant Sciences, where all research 
specimens are kept.  The leaves were air dried at room temperature suspended in bags 
of net material in a ventilated room (Figure 5.2.b), ground to a fine powder in a 
Macsalab Mill (Model 2000 LAB Eriez®) (Figure 5.3) and stored in closed jars away 
from light in the cupboards until used. 
   
           (a)                                                                (b) 
    Figure 5.2: Plant collection (a) and air drying of leaves (b) 
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Figure 5.3: Grinding processes of dried leaves of Searsia undulata using a Macsalab         
Mill 
5.2.2 Fractionation of bioactive fractions 
5.2.2.1 Bulk extraction and solvent to solvent fractionation 
Powder of Searsia undulata leaves (1.5 kg) was serially extracted (3 × 4.5 L each) with 
acetone (Ac).  In the first round, the content was left to stand overnight and mixed 
vigorously on a Labotec shaking machine for 3 h.  This process was repeated five times 
until the colour of the extract decreased.   Each time the mixture was vigorously shaken 
for 2 h on the shaking machine and the extract was filtered using Whatman No. 1 filter 
paper.  For each round, the collected filtrate of the extract was added into a round-
bottomed flask and dried using a Büchi R-114 rotary evaporator (Labotec) under 
reduced pressure (Figure 5.4).   The concentrated extract was then poured into a pre-
weighed glass beaker and left to dry under a stream of cold air from a wall fan.  
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Figure 5.4: Crude extract acetone-bulk extraction processes (left) and drying process with a 
rotary evaporator (right) 
A total amount of crude acetone extract (bulk extraction) was obtained (216.06 g).  
Eighty grams out of 216.06 g extract was taken aside and the rest stored in the fridge.  
The extract was further processed by fractionating components based on polarity as 
described (Suffness and Douros, 1979) with minor modifications.  The extract (80 g) 
was dissolved in a 1:1 mixture of chloroform and water and the two phases were 
separated in a separatory funnel to obtain the chloroform and water fractions.  The 
water fraction was then mixed with an equal volume of n-butanol in a separatory funnel 
to yield the water and n-butanol fractions (polar).     
On the other hand, the non-polar part included the chloroform fraction which was dried 
in a round-bottomed flask in a vacuum rotary evaporator and extracted with an equal 
volume of hexane and 35% of water: methanol mixture to yield the n-hexane fraction.  
Then the chloroform fraction was mixed with 35% water: methanol to yield chloroform 
and 35% water: methanol fractions.   
A bioassay-guided fractionation procedure was followed; collected main fractions (from 
solvent-solvent fractionation) were tested against rapidly growing mycobacteria and 
slow growing mycobacteria (pathogenic) to identify the active fractions that will be used 
for further fractionation.  The chloroform fraction, one of the active main fractions, was 
further processed for fractionation using silica gel columns (Figure 5.5). 
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5.2.2.2 Column chromatography (CC) 
The isolation of the bioactive compounds was carried out using the chloroform fraction 
with open mobile column chromatography and silica gel as the stationary phase (Figure 
5.5).  The silica gel powder (90.6 g) was mixed with an appropriate volume of n-hexane 
in a glass beaker in a sonicator and stirred until all bubbles disappeared.  The slurry 
mixture was then poured into a column (50 cm height, 4.5 cm diameter).  Extract 
sample was prepared the previous day: the 9.06 g of chloroform fraction was dissolved 
in 30 mL of acetone and mixed with 20 g of silica gel and the mixture was allowed to dry 
under cold air overnight.   A filter paper (Whatman no. 1) was cut to fit the inside 
diameter of the column and was put on top of the silica gel followed by the dried 
chloroform fraction sample then covered with another filter paper (Figure 5.5). 
The solvent system used to elute the different fractions was hexane/ethyl acetate, ethyl 
acetate/methanol.  The sample loaded was adsorbed and eluted starting with 100% n-
hexane with an increasing amount of ethyl acetate at an interval of 10% until 100% ethyl 
acetate at the following ratios (90:10), (80:20), (70:30), (60:40), (50:50), (40:60), 
(30:70), (20:80), (10:90) and finally 100% ethyl acetate; this was followed by 250 mL 
volumes of EtOAc-MeOH mixtures using similar ratios until (50:50), then small amounts 
of MeOH were added in the mixture with EtOAc up to 15% Me(OH) (98.5:2.5), (95:5), 
92.5:7.5, 90:10, 95:15).  The column was washed with 100% MeOH and the rest of the 
fractions collected, dried and kept in the fridge.  This was done gradually to yield 
different fractions which were collected into honey jars (250 mL).  All the fractions were 
left overnight to dry in a fume cabinet under a stream of cold air. 
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           Figure 5.5: Column chromatography used for fractionation 
The sub-fractions (F5, F6 and F7) from the chloroform fraction showing the presence of 
antimycobacterial phytochemical compounds were combined (Figure 5.13-A) and 
fractionated on a smaller column by gravity elution using hexane and ethyl acetate as 
solvent system as described above but using a much smaller gradient of 2% to separate 
compounds of interest.  Fractions collected were analysed on TLC and three 
compounds were isolated.  Later on, more of the chloroform fraction stock (33 g and 
140 g) was processed as described above; targeting the same fractions based on Rf 
values, bioautography and TLC fingerprint patterns with the aim of collecting a larger 
amount of the compounds of interest for further analysis.   
5.2.3 Thin layer chromatography (TLC) fingerprinting and bioautography of 
fractions and compounds 
The composition of fractions and compounds was determined by TLC using aluminium-
backed sheets of 20 X 20 cm (TLC Silica gel 60 F254, Merck, Germany).  Ten microliters 
from 10 mg/mL of selected fractions dissolved in acetone (containing 100 μg of extract) 
were loaded on TLC plates in lines of about 1 cm wide using a micropipette.  The lines 
were allowed to dry at room temperature in the dark.  Mobile phases of varying 
polarities were used to develop the plates, namely hexane/ethyl acetate at different 
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ratios [6:4], [7:3], [8:2], [8.5:1.5], [8.8:1.2], chloroform/ethyl acetate/formic acid (CEF) 
[10:8:2] and benzene/ethanol/ammonia (BEA) [18:2:0.2] (Kotzé and Eloff, 2002).  The 
above procedure, using the crude extracts of Searsia undulata, has been reported in 
Chapter 4 in section 4.2.3.  More than ten compounds of different polarities were 
observed.  These compounds were very close to each other in both the solvent systems 
BEA and CEF. Active compounds included both polar and non-polar compounds based 
on the Rf values determined on bioautograms.  In the non-polar solvent BEA, the non- 
polar compounds travelled some distance up the plate with clear zone of inhibition on 
plates sprayed with different mycobacteria species. The intermediate solvent system 
CEF led to a better separation of some compounds (Figure 4.3 previous chapter). 
For bioautography, only the rapidly growing organisms were used, namely M. aurum, M. 
fortuitum and M. smegmatis, because the pathogenic mycobacteria present a high 
biohazard risk if handled as a spray.  Mycobacteria used were cultured and maintained 
as described in Chapter 4 under section 4.2.2.3.  Duplicate chromatograms prepared as 
described above were left uncovered in a dark place and air-dried until solvents were 
completely evaporated for 24 h or overnight.  A saturated bacterial culture was 
centrifuged at 3000 x g for 10 min and the pellet resuspended in fresh appropriate liquid 
growth medium and diluted to a McFarland No. 1.  The chromatograms were then 
sprayed with active bacterial suspension (18 to 72 h old cultures depending on the 
growth rate of the particular Mycobacterium species) until completely moist using a 
glass spray gun linked to a membrane pressure pump.  The moist plates were 
incubated at 37°C in a humidified chamber under 100% relative humidity for 24 h for 
Mycobacterium smegmatis, 48 h for M. fortuitum and 72 h for M. aurum.  The plates 
were then sprayed with 2 mg/mL of INT (Sigma-Aldrich, Johannesburg, South Africa) in 
distilled water and incubated for a further 30 min to few h until the development of a 
purple-red background.  The emergence of purple-red colour resulting from the 
reduction of INT (Iodonitrotetrazolium violet) into formazan indicated the presence of 
viable microorganisms whereas clear zones against the purple-red background 
indicated inhibition of mycobacterial growth indicating the Rf values of antimycobacterial 
compounds separated on the TLC plates (Hamburger and Cordell, 1987).  
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5.2.4 Minimum inhibitory concentration (MIC) of Searsia undulata fractions and 
compounds 
The method was carried out as described in Chapter 4, section 4.2.2.4.  All the fractions 
comprised a mixture of phytochemical constituents and were tested at 10 mg /mL 
whereas the concentration for the purified compounds was 1 mg/mL.  The MIC of 
extracts, fractions and compounds was determined at each fractionation stage.  
5.2.5 Cytotoxicity of compounds 
The cytotoxicity assay was carried out as described in Chapter 4, section 4.2.4 and 
Vero monkey kidney cells were used (Figure 5.6). 
   
                                  (a)                                                                              (b) 
Figure 5.6: Normal Vero monkey kidney cells viewed under the microscope at magnifications of 
10X (a) and 40X (b) 
5.2.6 13C and 1H nuclear magnetic resonance (NMR)-procedures and structural 
elucidation of isolated compounds  
5.2.6.1 Isolation and characterization of compounds 
Glass columns (20-25 mm diameter) wet packed with silica gel 60 (0.040-0.063 mm) 
230-400 Mesh ASTM, Merck) were used for column chromatography, and elution was 
done with hexane, ethyl acetate, MeOH and chloroform (CHCl3).  Isolation of 
compounds from the combined semi-purified fractions, F5, F6 and F7 (Figures 5.14-A to 
5.15-B) was carried out using a small column packed with silica gel with 100% n-hexane 
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and fractions were collected into honey jars.  Hexane is a non-polar solvent that extracts 
mostly non-polar alkaloids, triterpenes, phenolics, flavonoids, steroids and volatile oils 
(Adeshina et al., 2012). 
5.2.6.2 Sample preparation of compounds 
Samples of compounds were submitted to the Department of Chemistry at the Council 
for Scientific and Industrial Research (CSIR) and the University of Pretoria, South Africa 
for structure elucidation.  
5.2.6.2.1 Compound SLN1 
The sample SLN1 was dissolved in 200 µL d6-acetone (500 µL ampoule, 99.99% 
deuterated acetone, C3D6O, Merck) and immediately transferred to a new 7″ Norell 
Select Series 3 mm i.d. NMR tube and sealed for analysis.  
5.2.6.2.2 Compound PK-B 
The sample was partially soluble in acetone; but soluble in DMSO-d6 which was then 
used as a solvent. DMSO (200 µL) was used to dissolve the sample from the vial and 
transferred immediately to a new 7″ Norell Select Series 3 mm i.d. NMR tube and 
sealed for analysis. 
5.2.6.3 NMR spectrometers and structure elucidation 
5.2.6.3.1 Compound SLN1 
Two spectrometers were used to accomplish the acquisitions, namely a Varian 
Premium Shield VNMRS triple resonance system (Direct Digital Receiver 1) operating 
at 600 MHz, and a Varian INOVA dual band system operating at 400 MHz.  The 600 
MHz system was equipped with a 5 mm room temperature H{CN}probe, and was used 
to acquire the proton spectrum of the material as well as all two dimensional spectra.  
The 400 MHz system was equipped with a 3 mm room temperature dual resonance 
indirect.  Both systems were operated using Agilent VNMRJ 4.2A software. 
Compounds at CSIR were measured on a Varian-600 NMR machine (Agilent 
Technologies, California).  Chemical shifts were recorded in σ (ppm).  All spectra were 
processed on ACD Labs Structure Elucidator 2015 software.  All signals in both one- 
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and two dimensional spectra were individually hand-selected to ensure signal purity and 
alignment.  
5.2.6.3.2 Compound PKB 
The mass spectrum was acquired by Synapt G2 high definition mass spectrometry in 
positive ESI mode. The NMR spectra were recorded on a 400 MHz Bruker AVANCEIII 
NMR spectrometer at 25oC. The chemical shifts from 1H NMR and 13C NMR spectra are 
reported in parts per million relative to the solvent residual peak. The chemical shifts 
used for referencing 1H and 13C Spectra were 2.50 ppm and 39.5 ppm, respectively. 
The coupling constants (J) were measured in Hz. Abbreviations used for the multiplicity 
of signals are as follows: singlet (s), doublet (d) and broadened (br). 
5.3 RESULTS AND DISCUSSION 
5.3.1 Bulk extraction, fractionation, thin layer chromatography and    
bioautography 
5.3.1.1 Extraction yield, thin layer chromatography and bioautography 
The 1.5 kg finely ground S. undulata leaves yielded 216.06 g of crude acetone extract 
(Figure 5.7). Eighty grams out of 216.06 g was processed using solvent-solvent 
fractionation and yielded five fractions, namely chloroform, hexane, 35% water: 
methanol, butanol and water based on polarity which varied widely (Figure 5.8).  The 
highest mass was obtained in the intermediate polarity chloroform fraction (53.27 g) with 
only 0.34 g in the non-polar hexane fraction.  The butanol fraction contained 9.2 g, the 
water fraction 3.75 g and the 35% H2O in methanol 0.34 g. more polar (intermediate 
polarity).  The yield of each fraction obtained after solvent-solvent fractionation of the 
bulk acetone extract (80 g) is presented in Figure 5.8. 
From the 80 g of acetone crude extract processed, the total mass recovered was 66.9 g 
which means about 84% recovery.  The 16% loss might have been due to the presence 
of pellicles that could not be separated and to the sticky, oily nature of the extract which 
was not easy to recover during solvent-solvent fractionation; the oily supernatant 
observed when separating hexane from chloroform fractions was filtered out.  The 
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percentage of recovery for each fraction was respectively 79.6% for chloroform, 13.75% 
for butanol, 5.6% for water and 0.51% for hexane and 35%H2O/methanol.  With 0.5 % 
of recovery for the non-polar fraction (hexane) and 80% of intermediate polarity 
(chloroform), the results from the different solvent systems showed compounds of 
intermediate polarity and variable active compounds from non-polar to polar.  The TLC 
fingerprint of the butanol fraction did not contain visible compounds after vanillin spray 
and colour development but some compounds were visible under UV light and those 
compounds were more visible on bioautograms (Figures 5.9-5.11-C).    
Initially 55 fractions were collected and analysed on TLC plates using hexane: ethyl-
acetate at ratio 7:3 and 6:4, fractions with similar profiles were combined into 12 sub 
fractions (F1-F12) (Figures 5.7, 5.12-5.13).  Fractions collected with 100% methanol are 
not included in figure 5.7 as they had no antimycobacterial activity. 
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Figure 5.7: Schematic extraction and fractionation results towards compound isolation from Searsia undulata 
1.5 Kg 
Acetone bulk extraction 
216.06 g 
Solvent to solvent 
fractionation 
80g 
Chloroform 
53.27 g 
Hexane 
0.34 g 
35% H2O 
0.34 g 
n-butanol 
9.2 g 
H2O 
3.75 g 
Column bed silica gel 
9060 mg 
F1 
417 mg 
F2 
187 mg 
F3 
421.3 mg 
F4 
479.4 mg 
F5 
295.2 mg 
F6 
280.8 mg 
F7 
443.7 mg 
F8 
504 mg 
F9 
1204 mg 
F10 
524 mg 
F11 
360 mg 
F12 
962 mg 
55 fractions were initially collected and based on TLC 
profiles; they were combined into 12 sub fractions (F1-F12) 
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Figure 5.8: Mass (g) of the five solvent-solvent fractions obtained from 80 g of S. undulata leaf 
extracts 
0
10
20
30
40
50
60
Butanol Chloroform Hexane Water
Mass (g) of five solvent fractions of SU 
35% H2O 
 129 
 
             
CHL         BUT-BEA        CHL_HE: E 60:40   MA-CHL;   MA-BUT       MF-CHL; MF-BUT         MS-CHL; MS-BUT 
Figure 5.9: Chloroform and butanol fractions- TLC fingerprinting and bioautograms of plates 
eluted in BEA and sprayed with rapidly growing mycobacteria spp.  CHL: Chloroform, BUT: 
Butanol, HE: Hexane, E: Ethyl acetate, MA: M aurum, MF: M fortuitum, MS: M smegmatis 
The solvent-solvent fractions with high yield, good MIC values and presence of 
antimycobacterial compounds in bioautograms were selected (chloroform, butanol and 
35% water fractions) and tested further to determine antimycobacterial activity against 
M. aurum, M. fortuitum and M. smegmatis (Figures 5.10 A - 5.11 C).  Antimycobacterial 
activity was observed for all three mycobacteria although MIC values were different. 
The difference in MIC may be due to the difference in concentration of inactive 
compounds in different fractions or to synergism.  Based on the bioautograms the most 
active compounds observed were non-polar and did not separate well. The chloroform 
fraction was selected for further work and fractionated by silica gel column 
chromatography then sequentially eluted with increasing polarity of n-hexane/ethyl 
acetate mixture to yield 55 fractions. The chemical composition was determined by TLC 
and fractions were combined based on similar composition (Figures 5.10 - A, 5.11 - A.1) 
and bioautograms (Figures 5.12-5.13).  The results indicated that most compounds 
were non polar; indeed a better compound separation was observed in the BEA solvent 
separation system.  
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5.3.1.2 TLC fingerprinting and bioautography of fractions and compounds 
5.3.1.2.1 Solvent-solvent fractions 
The five fractions were eluted in BEA solvent system and showed the presence of 
similar compounds.  The acetone crude extracts (ACE) showed similar compounds 
when compared to n-hexane (HE) and chloroform (CHA, CHB) fraction.  The chloroform 
and hexane fraction profiles were more similar showing a better separation.    The more 
polar water fraction, 35% water fraction in methanol (35% H2O), did not separate well in 
the non-polar eluent system as expected.  But, this fraction showed two compounds 
similar to those present in the n-hexane and chloroform fractions.  The n-butanol and 
water fractions did not show any visible compounds.  The water fraction was not further 
processed as no compounds were observed on vanillin-sprayed TLC plates and 
bioautogram; the hexane fraction was similar to chloroform fraction.  The butanol 
fraction was tested and showed clear zones of inhibitions on bioautograms although 
there were almost no visible compounds on vanillin-sprayed TLC plates eluted in the 
same solvent system BEA (Figures 5.9 - 5.11-A1).  
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Figure 5.10-A: Bioautogram of M. aurum eluted in BEA 
(Benzene/ethanol/ammonia at ratio 18:2:0.2) separated in triplicate (CHL) and 
sprayed with 2 mg/mL of INT (Iodonitrotetrazolium violet) showing solvent- 
solvent fractions of chloroform (CHL), butanol (BUT) and 35% water (H2O) of 
SU 
  
M. aurum-BEA 
      CHL         CHL           CHL           BUT           BUT     35%H2O 
Chloroform fraction 
selected for compound 
isolation 
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Figure 5.11-A1: TLC fingerprint of acetone crude extract and solvent - solvent 
fractions (Butanol, chloroform, 35% water, hexane and water) 
The phytochemical analysis and bioautograms of the solvent to solvent fractions eluted 
in the different mobile solvent systems and sprayed with the different mycobacteria 
species, namely M. aurum, M. smegmatis and M. fortuitum are shown as plates sprayed 
with M. aurum eluted in BEA (Figure 5.14-A1) and CEF (Figure 5.14-B); plates with M. 
fortuitum eluted in BEA and CEF solvent (Figures 5.15-A and 5.15-B) then the plates 
with M. smegmatis in BEA and CEF (Figures 5.16-A and 5.16-B).  The non-polar 
fractions separated well in the non-polar eluent system.  All fractions, namely 
chloroform, n-butanol and 35% water fraction showed in bioautography the presence of 
compounds inhibiting the growth of mycobacteria species although the TLC fingerprints 
of butanol did not show the presence of visible compounds. 
 
 
      ACE              BU            CHA          CHB      35%H2O      HE            H2O 
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Figure 5.11-B: Bioautogram plate eluted in BEA (Benzene/ethanol/ammonia at 
ratio 18:1:0.2) and sprayed with M. smegmatis followed by INT indicating 
antimycobacterial compounds of solvent-solvent fractions CHL: chloroform, 
BUT: butanol and 35% H2O: 35% water in methanol of SU.  Clear zones 
indicate mycobacterial growth inhibition 
M. smegmatis-BEA 
       CHL          CHL            CHL        BUT         BUT      35%H2O 
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Figure 5.11-C: Bioautogram plate eluted in BEA (Benzene/ethanol/ammonia at 
ratio 18:2:0.2) and sprayed with M. fortuitum and followed by INT indicating 
antimycobacterial compounds of solvent-solvent fractions CHL: chloroform, 
BUT: n-butanol and 35%H2O: 35% water in methanol of SU.  Clear zones 
indicate mycobacterial growth inhibition 
The isolation of the compound was bioassay-guided based on the presence of 
antimycobacterial activity observed as clear, white zones of inhibition on the 
bioautograms at each fractionation stage.  Most compounds were non-polar and close 
to each other which made the process of separation laborious (Figures 5.10 A – 5.11 
C). 
Based on the high yield of the chloroform fraction (53.27 g) and strong 
antimycobacterial activity observed on the bioautography and MIC values, the 
chloroform fraction was selected.  An amount of 9.06 g was used for further 
fractionation towards isolation of the compound in an open column on silica gel.  Fifty 
five fractions were collected in different jars at the initial fractionation; these fractions 
were combined into 12 fractions (F1-F12) and tested as previously described with M. 
aurum and M. smegmatis (Figures 5.12, 5.13, 5.14 and 5.16).  
M. fortuitum-BEA 
           CHL       CHL          CHL           BUT         BUT     35%H2O 
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Figure 5.12: Fractions (n=55) collected from the chloroform fraction were combined, tested and based on clear zone of inhibition pattern 
against M. smegmatis, combined into 12 semi-purified fractions (F1-F12) that were separated further for compound isolation 
 
 
 
 
 
 
 
        1-6         7-12         17-19      20           22          24         26       28              30                  31-33        34-39        45-49         51-55 
M. smegmatis-BEA 
Initial combined 55 fractions into 12 fractions 
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M. aurum-BEA 
          1-6          7-12          17-19           20            22            24          26           28             30           31-33   34-39 45-49 51-55  
Initial combined 55 fractions into 12 fractions 
 
Figure 5.13: Fractions (n=55) collected from the chloroform fraction were combined, tested and based on 
clear zone of inhibition pattern against M. aurum, combined into 12 semi-purified fractions (F1-F12) that 
were separated further for compound isolation 
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5.3.1.2.2 TLC fingerprinting and bioautograms of sub-fractions 
The chloroform fraction (9.06 g) yielded 12 fractions amounting to 6.0784 g which is 
about 67% recovery. The percentage of recovery below 80% represented the portion of 
fractions containing most of the targeted antimycobacterial compounds as shown on the 
different figures, Rf and MIC values.  Three out of the 12 sub-fractions, F5, F6 and F7, 
represented 16% of the collected sub-fractions (1.0197 g) (Figure 5.7).  The sub-
fractions F5 to F7 showed similar consistent patterns of strong clear zones of inhibition 
against all mycobacteria species tested - M. aurum, M. smegmatis and M. fortuitum - on 
plates eluted in BEA and CEF (Figures 5.14 to 5.16).  Adding to good MIC values 
obtained, they were combined and processed further for the preliminary isolation of 
some of the compounds (Figures 5-17, 5.18-5.19).   
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Figure 5.14-A: TLC fingerprints of the 12 pooled fractions obtained from the chloroform fraction; plate was eluted in 
BEA (Benzene/ethanol/ammonia at ratio 18:2:0.2). F5 to F7 fractions targeted for compound isolation  
      F1           F2           F3            F4          F5           F6          F7            F8         F9       F10          F11        F12 
Combined fractions 
targeted for compound 
isolation 
BEA 
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Figure 5.14-A1: Bioautogram eluted in BEA sprayed with M. aurum followed by INT indicating consistent clear zone of 
inhibition with focus on fractions F5, F6 and F7  
The different zones of inhibition appearing as white bands represent the lack of growth of the targeted Mycobacterium sp. 
These zones were rated according to the intensity of their appearance on a scale of 1 to 5 as visible bands observed on 
bioautograms.  Scale 1 representing a weak intensity and scale 5 a strong intensity.  Their Rf values were also calculated 
to locate the active chemicals in the elution solvent CEF as non-polar compounds were targeted (Tables 5.1, 5.2 and 5.3). 
In the intermediate CEF solvent system, low polarity compounds tend to have higher Rf values and are located higher on 
the TLC plate (Figures 5.14-B, 5.15-B and 5.16-B).  The intensity of some of the fractions corresponded to the lowest MIC 
values.  The presence or absence of zones of inhibition also varied from one Mycobacterium sp. to the other, confirming 
that the susceptibility of an antimicrobial varies from one microorganism to the other. 
           F1          F2         F3       F4         F5         F6         F7           F8           F9         F10         F11        F12 
M. aurum-BEA 
Combined fractions 
targeted for 
compounds isolation 
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                                (a)                                                                    (b) 
   F5                        F6                          F7                                             F5                        F6                      F7 
Figure 5.14-A2: Vanillin sprayed TLC plate and bioautogram plate eluted in BEA (Benzene/ethanol/ammonia at 
ratio 18:2:02) sprayed with M. aurum followed by INT indicating the three pooled fractions (F5, F6 and F7) that 
were separated further for isolation of compounds indicating the closeness of the active compounds 
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Table 5.1: The intensity of the zones of inhibition on a five point scale and their Rf values as observed in Figure 5.14-B 
  Rated Intensity of zone of inhibition against M. aurum on bioautography and Rf values in CEF solvent 
Rf values     F4     F5     F6     F7     F8    F9      F10     F11    F12 
  0.95 3 2 2 2 
       0.90-0.92 5 5 4 5 5 5 2 
    0.88-0.89 
 
3 2 5 
  
4 2 
   0.85-0.87 
    
5 5 4 4 
   0.81-0.83 
 
4 3 2 3 5 4 5 5 
  0.8 
           0.71-0.73 
     
5 
     0.68-0.69 1 2 2 1 
  
4 5 5 
  0.64-0.67 
     
5 5 
 
5 
  0.61                       
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Figure 5.14-B: Bioautogram eluted in CEF (Chloroform/ethyl acetate/formic acid at ratio 10:8:2) sprayed with M. 
aurum followed by INT indicating 12 pooled fractions from the chloroform with consistent clear zone of inhibition 
focusing on fractions F5, F6 and F7.  The clear zones indicate mycobacterial inhibition growth 
 
 
 
 
 
 
M. aurum-CEF 
      F1          F2          F3         F4         F5        F6         F7                F8        F9       F10         F11       F12 
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Figure 5.15-A: Bioautogram eluted in BEA sprayed with M. fortuitum followed by INT indicating 12 pooled fractions 
from chloroform with zones of growth inhibition focusing on fractions F5, F6 and F7   
         F1         F2         F3         F4           F5          F6       F7         F8         F9         F10        F11       F12 
M. fortuitum-BEA 
Combined fractions 
targeted for 
compounds isolation 
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Table 5.2: The intensity of the zones of inhibition on a five point scale and their Rf values as observed in Figure 5.15-B 
 
Rated Intensity of zone of inhibition against M. fortuitum on bioautography and Rf values in CEF solvent 
Rf values F4 F5 F6 F7 F8 F9 F10 F11 F12 
  0.95 
           0.90-0.92 1 1 
  
5 
      0.88-0.89 2 5 5 5 5 5 
     0.85-0.87 
   
5 
       0.81-0.83 2 4 3 
 
3 
      0.8 
     
5 
     0.71-0.73 
   
2 
 
4 1 1 
   0.68-0.69 
      
1 2 
   0.64-0.67 2 3 2 
 
5 4 
     0.61                       
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Figure 5.15-B: Bioautogram eluted in CEF and sprayed with M. fortuitum followed by INT indicating 12 pooled 
fractions from chloroform with zones of growth inhibition focusing on fractions F5, F6 and F7 
 
M. fortuitum-CEF 
          F1         F2         F3        F4            F5           F6        F7           F8         F9         F10        F11      F12 
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Figure 5.16-A: Bioautogram eluted in BEA and sprayed with M. smegmatis followed by INT indicating 12 pooled 
fractions from chloroform with zones of growth focusing on fractions F5, F6 and F7 
  
          F1         F2        F3           F4          F5          F6         F7          F8          F9          F10        F11        F12 
M. smegmatis-BEA 
Combined fractions 
targeted for compounds 
isolation 
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Table 5.3: The intensity of the zones of inhibition on a five point scale and their Rf values as observed in Figure 5.16-B 
 
Rated Intensity of zone of inhibition against M. smegmatis on bioautography and Rf  values in CEF solvent 
Rf values F4 F5 F6 F7 F8 F9 F10 F11 F12 
   0.95 
            0.90-0.92 3 1 
          0.88-0.89 
            0.85-0.87 
 
5 5 5 5 
       0.81-0.83 4 
   
2 2 
      0.8 
     
2 
      0.71-0.73 
        
1 
   0.68-0.69 
            0.64-0.67 
      
2 2 1 
   0.61             4 4 3       
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Figure 5.16-B: Bioautogram eluted in CEF and sprayed with M. smegmatis followed by INT indicating zones of growth   
inhibition focusing on fractions F5, F6 and F7  
Two plates were eluted in the BEA solvent for each fraction and sprayed, one with vanillin and the other with the 
mycobacterial suspension broth of Mycobacterium aurum. The plates were placed next to each other to visualize the 
compounds inhibiting the growth of mycobacteria appearing as white zones against a reddish background indicating the 
growth of the mycobacteria.  Prior to spraying the TLC plates with either vanillin or mycobacteria, they were observed 
under UV light at 254 nm and 366 nm to visualize any fluorescent compounds invisible to the naked eye.  Two fluorescent 
compounds were observed (Figure 5.17).  Fungal contamination during the period of this research was also a challenge 
which affected the quality of some plates as dark pinpoints or stains, but without jeopardizing the results.  
         F1          F2           F3          F4          F5          F6       F7            F8        F9           F10     F11    F12 
Combined fractions 
targeted for 
compounds isolation 
 
M. smegmatis-CEF 
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Figure 5.17: TLC fingerprints and bioautograms showing the different stages of isolation from the acetone crude extract to 
fractions of Searsia undulata.  Plates were eluted in BEA, TLC plates were sprayed with vanillin and bioautograms with 
Mycobacterium aurum (which was one of the best indicators of mycobacterial activity) followed by INT.  ACE: Acetone crude 
extract; CHL: Chloroform fraction; F5-F7: sub-fractions obtained from 55 fractions from the chloroform fraction 
 
Visible under UV  
ACE     ACE          CHL        CHL            F5                   F6                     F7                      F5                     F6                     F7 
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5.3.1.2.3 Sub-fractions and compounds 
Based on the MIC, TLC fingerprints, bioautograms and total activity of each fraction, 
three fractions were selected (F5, F6 and F7) to target compounds with the best 
antimycobacterial activity (Figures 5.14 - 5.16).  Two fluorescing compounds were 
observed under UV light at 366 nm wavelength (Figure 5.17) but did not show activity 
on bioautography and were not targeted for isolation during the period of this study.   
The three sub-fractions (F5-F7) showed strong clear zones of inhibition and they were 
compared to crude extracts, solvent to solvent fractions and compounds.  Observation 
on the separation of the fractions of interest from crude extract to isolation of 
compounds is easy to follow (Figures 5.17-5.18).  The bioautogram plate was sprayed 
with M. aurum which was one of the best indicators of antimycobacterial activity.  The 
chloroform fraction showed a clear zone of inhibition of a compound that is more polar 
and this compound seemed not to show inhibition when fractionated further.  This could 
be explained that further separation did take place and the fraction lost the active 
portion as the synergistic interaction of compounds within the fractions might be lost 
during the separation process.  Based on Rf values, the same compounds were present 
in all the fractions.   
The TLC fingerprint of the chloroform fraction indicated the presence of more than 20 
potential fractions whereas the crude extract showed about 10 visible fractions, which 
confirms that the process of fractionating was indeed taking place. In general, active 
fractions were close to each other as shown on all the profiles (Figures 5.9 - 5.11).  The 
isolated compounds were only tested using the MIC assay and for cytotoxicity.  More 
work is still to be done which includes testing against pathogenic mycobacteria, synergy 
with current standard anti-TB drugs and isolation and identification of more compounds 
while assessing the stability of fractions and compounds in different environmental 
conditions.  Some of the fractions deposited crystals on standing while others remained 
in the form of an oily paste.    The bioactivity of the crude acetone extract of Searsia 
undulata has been reported in Chapter 4, but results of the crude extract are shown and 
used to discuss results obtained from the fractions and compounds (Figure 5.18).  The 
55 fractions obtained from the chloroform fraction of SU were tested against M. aurum, 
 151 
 
M. fortuitum and M. smegmatis and their antimycobacterial activity determined on 
bioautography observed as clear zones of inhibition (white zones).  The results revealed 
that fractions 5, 6, and 7 (F5, F6 and F7) had the consistent inhibitory activity against all 
three mycobacteria species and indicated similar compounds.  Other fractions 
contained one or two active compounds that were not consistent with the different 
intensity of the clear zones of inhibition for all three tested mycobacteria.  Observations 
made on bioautograms eluted in BEA and sprayed with M. aurum revealed that F3 had 
3 visible clear zones of inhibition which were also present in F4 but F4 showed two 
visible active phytochemicals of which neither was present in F3 or F5, F6 and F7.  
Fractions F8 to F12 showed a similar active phytochemical but did not show the same 
compounds as observed in F5 to F7. F5, F6 and F7 were therefore selected for further 
isolation based on consistency observed (Figures 5.14 – 5.18).  
Compounds were eluted with 100% hexane with increasing polarity with 2% ethyl 
acetate resulting in sequential elution of SLN1 (26.2 mg); PK-A1 (15.4 mg), PK-B (22.4 
mg), PK-C (15.9 mg) and PK-D (8.4 mg).  PK-B was obtained by eluting the compound 
with a mixture of chloroform and methanol (Figures 5-18-5.19). 
   
 152 
 
 
 
  F5                  F6                     F7                     F5                      F6                   F7                C1         C2          C3             C4                    C5   C6  
Compounds Sub-fractions from chloroform fraction that were 
combined and further separated for isolation of 
compounds 
Figure 5.18: TLC fingerprints and bioautograms indicating targeted fractions F5-F7 to compounds isolated from Searsia undulata.  
Bioautogram were eluted in BEA solvent systems and sprayed with Mycobacterium aurum which was one of the good indicators of 
mycobacterial activity.  TLC plates for compounds were eluted in different ratios of hexane: ethyl acetate and sprayed with vanillin   
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Figure 5.19: TLC plate visualized under UV light (366 nm) showing the 
separation of compound B from compound C during the purification process   
PKB 
PKC 
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5.3.2 Minimum inhibitory concentration of fractions and compounds 
5.3.2.1 Minimum Inhibitory concentration of fractions 
The bioautography profile of the fractions achieved during the isolation of compounds 
as shown in the previous section showed different patterns of clear zones of inhibition 
against the different mycobacterial species used, namely M. aurum, M. fortuitum and M. 
smegmatis.  This corresponded with good MIC values ranging from 0.058 to 0.468 
mg/mL.   
The MIC assay was carried out as previously described against selected organisms.  
The antimycobacterial activities as MIC values were reported for the crude extract of 
Searsia undulata were reported in Table 4.2 in the previous chapter.  The MIC obtained 
for each of the 12 fractions is shown in Table 5.4.  Fractions with MIC values below 0.1 
mg/mL were considered to have significant activity; moderate activity was between 0.1 
and 0.625 mg/mL and weak activity >0.625 to 2.5 mg/mL or poor activity >2.5 mg/mL 
(Kuete, 2010).  
 
Figure 5.20: The MIC value (mg/mL) of each fraction against the different mycobacteria.  
MA: M. aurum, MF: M. fortuitum, MS: M. smegmatis 
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Fractions that included main fractions obtained from solvent to solvent fractionation and 
sub-fractions collected after elution of the chloroform fraction in the open column silica 
gel chromatography had good to moderate activity that did not always correlate with the 
presence of clear zones of inhibition on bioautograms.    
The fractions F5, F6 and F7 had significant antimycobacterial activity showing similar 
compounds and hence were selected for further column chromatography with MIC 
values of 0.117 mg/mL for M. aurum, 0.234 mg/mL for M. fortuitum and 0.058 mg/mL for 
M. smegmatis for all fractions except F7 with MIC value of 0.117 mg/mL for M. 
smegmatis.  Fraction F5 and F6 had the lowest MIC of 0.058 mg/mL observed against 
M. smegmatis.  The lowest value of MIC, the more effective is the fraction at a lower 
dosage whereas 1/MIC represent the sensitivity of the organism tested, the highest the 
value of 1/MIC, the more sensitive is the organism tested against the specific fraction.  
The MIC values of each fraction against all three mycobacteria species, sensitivity of 
each mycobacteria and the overall view of each fraction’s average activity is presented 
in Figures 5.20, 5.21 and 5.22.  Fractions F5, F6 and F7 were active against all three 
mycobacteria species.  
 
Figure 5.21: The 1/MIC values (mg/mL) of each fraction against the different mycobacteria 
species. MA: M. aurum, MF: M. fortuitum, MS: M. smegmatis 
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Figure 5.22: The average 1/MIC values (mg/mL) of each fraction against all the 
different mycobacteria species.  Fractions F5, F6 and F7 show consistent high 
activity 
The total activity value of a fraction indicates which species could be candidates for 
organic production of active extracts for use by communities because it takes into 
account not only the MIC of the extract but also the yield of the fraction.  By dividing the 
extraction yield in mg/g by the MIC in mg/mL the total activity is calculated in mL/g 
(Eloff, 2000) as represented in Table 5.4.  Among all 12 fractions, F3 had the highest 
total activity on its own of 19 765 mL/g for M aurum followed by 13 162 mL/g for M. 
fortuitum and 7 896 mL/g for M. smegmatis.  F3 also had active compounds and good 
MIC values but was not selected at this initial stage as it did not have a consistent 
similar pattern of phytochemical active compounds on bioautography when compared to 
F5 to F7 (Figures 5.14-5.18).  In future investigations, the isolation of compounds 
focusing only on fraction F3 will be undertaken.  The next fraction showing the highest 
activity was F6 with a total activity of 19 793 mL/g against M smegmatis followed by 9 
897 mL/g for M. aurum and the lowest 4 943 mL/g for M. fortuitum then F5 showing the 
highest total activity of 17154 mL/g against M. smegmatis, followed by 8 577 mL/g for 
M. aurum and 4 284 mL/g for M. fortuitum then the last fraction with lower total activity 
F7 showing 7 262 mL/g for both M. aurum and M. smegmatis and 3 627 mL/g for M. 
fortuitum (Figure 5.24).  The average total activity of the combined fractions was 27 599 
mL/g which is higher than F3 alone at 19 765 mL/g (Figure 5.23).  At this preliminary 
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stage, this determined the focus on the combination of these three fractions based on 
their MIC values against all the mycobacterial species.                  
   Table 5.4 The MIC values and total activity of each fraction 
Fractions 
 Mass     
(mg) MIC (mg/mL)  
 
Total activity 
(mL/g) 
  
  
MA Ave MF Ave MS Ave MA MF MS average 
F1 2 309 0.47 0.94 0.94 4 926 2 463 2 463 3 284 
F2 509 0.47 0.47 0.47 1,086 1 086 1 086 1 086 
F3 3 083.3 0.16 0.23 0.39 19 765 13 162 7 896 13 608 
F4 1 122.9 0.16 0.23 0.39 7 198 4 794 2 876 4 956 
F5 1 003.5 0.12 0.23 0.06 8 577 4 284 17 154  10 005 
F6 1 157.9 0.12 0.23 0.065 9 897 4 943 19 793 11 544 
F7 849.6 0.12 0.23 0.12 7 262 3 627 7 262 6 050 
F8 1 980.8 0.31 0.23 0.23 6 339 8 456 8 456 7 750 
F9 1 165.7 0.47 0.23 0.23 2 487 4 976 4 976 4 146 
F10 1 768.6 0.47 0.47 0.23 3 773 3 773 7 550 5 032 
F11 858.5 0.39 0.47 0.23 2 198 1 831 3 665 2 565 
F12 557 0.47 0.47 0.23 1 188 1 188 2 378 1 585 
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Figure 5.23:  Total activity of different fractions (mL/g); Fractions F3 and F6 had the 
highest total activity for M. aurum and M. smegmatis respectively followed by fractions F5, 
F6 and F7 that had better total activity against all the mycobacteria which also correlated 
with the intensity of active fractions indicated by the clear zone of inhibition on 
bioautograms  
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             Figure 5.24: The average total activity (mL/g) per fraction 
The chloroform fraction revealed the presence of several potential active fractions on 
the bioautogram sprayed with M. aurum whereas on the one sprayed with M. fortuitum 
there were fewer active fractions. This is explained by the different sensitivity of 
mycobacteria species towards the potential antimycobacterial phytochemical present in 
the fractions.  The Rf value, also called retardation factor, was used as a fingerprint to 
trace and identify targeted fractions that had antimycobacterial activity at different 
stages of the fractionation process.  Rf values of the chloroform fraction were calculated 
by dividing the distance travelled by either the extract or fraction or compound spotted 
on the vanillin sprayed TLC plate or bioautogram eluted in a specific mobile phase 
solvent system by the distance travelled by the solvent front.  Rf values were calculated 
for the plates eluted in BEA and sprayed with M. aurum or M. fortuitum as they were 
good indicators of antimycobacterial activity in general (Figures 5.9-5.11).  In Table 5.5, 
the different values showed the closeness of some of the active fractions such as Rf = 
0.21, 0.26 and 0.34 and 0.36.  Different fractions that have travelled the same distance 
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could have the same Rf values, namely fractions with Rf values 0.34.  The same applied 
to the different fractions F1 to F12 that had the same Rf values. 
Table 5.5 Rf values of different phytochemical bands observed on the chloroform fraction in BEA 
         M. aurum        M. fortuitum   
                  Rf values  
 
  
 1 0.05 0.34 
  2 0.17 0.45 
  3 0.21 0.52 
  4 0.26 0.38 
  5 0.34 
   6 0.36 
   7 0.47 
   8 0.52 
   9 0.61 
   
5.3.2.2 Minimum inhibitory concentration of compounds 
The antimycobacterial activity of the five compounds initially isolated yielded a variety of 
results.  Table 5.6 shows the MIC values of S. undulata compounds against different 
organisms.  Each value is the mean of three replications measured in µg/mL (test 
samples of compounds were prepared at an initial concentration of 1 mg/mL).  It is 
worth noting that some of the compounds formed a jelly like substance when inoculated 
in the growth medium.  Therefore, the growth medium was diluted with ethyl acetate or 
DMSO at different ratios and organisms’ growth was tested prior to carrying out the 
process.  All 5 compounds showed activity against rapidly growing mycobacteria with 
MIC values ranging from 23.44 to 250 µg/mL.  The first compounds 1 and 2 showed 
activity with the highest MIC values varying from 62.5 to > 250 µg/mL.  The MIC values 
were 62.5 µg/mL for M. aurum and M. fortuitum and 125 µg/mL for M. smegmatis 
whereas C2 showed the highest MIC value >250 µg/mL against M. fortuitum and M. 
smegmatis. Compound 3 (SLN1) had the lowest MIC value of 23.44 µg/mL for M. 
fortuitum; 31.25 µg/mL for M. aurum and M. smegmatis.  Compound PKB and 
compound 5 (C5 or PKC) both showed activity against all three mycobacteria with the 
highest MIC of 46.88 µg/mL for C4 against M. smegmatis. 
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Table 5.6 MIC values of compounds isolated from Searsia undulata 
  
MIC (µg/mL) and Mycobacterium species tested     
  
M. aurum 
 
M. fortuitum M. smegmatis 
 Compounds          
(µg/mL)               
  C1 62.5 
 
125 
 
125 
  
 
C2 62.5 
 
>250 
 
>250 
  
 
C3-SLN1 31.25 
 
23.44 
 
31.25 
  
 
C4-PKB 31.25 
 
31.25 
 
46.88 
    C5-PKC 31.25 
 
31.25 
 
31.25 
   
5.3.3 Cytotoxicity 
5.3.3.1 Crude extracts 
Reported in Chapter 4, under section 4.3.4 
5.3.3.2 Compounds 
Only three compounds were evaluated at the time as there were in sufficient  purified 
quantity for further testing and structure elucidation - all three compounds had low 
cytotoxicity with CP2 being the least toxic 210 µg/mL (Table 5.7).  The 50% lethal 
concentration (LC50) of the compound was determined by calculating the concentration 
of compound that will keep half the cells viable relative to the untreated control.  For 
each compound a duplicate assay was conducted (Table 5.7).  For the first compound 1 
(C1), it was found that Y was 0.955 and 0.997 and LC50 27.50 and 35.23 µg/mL for 
assays 1 and 2, respectively; for C2, Y was the same as for C1 with LC50 172.74 and 
248.33 µg/mL for assays 1 and 2 and C3 LC50 48.59 and 46.94 for each of the assays.   
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          Figure 5.25: LC50 of compound 1 where Y was 0.955 (A) and 0.997 (B) 
 
          Figure 5.26: LC50 of compound PKB where Y was 0.955 (A) and 0.997 (B) 
  
        Figure 5.27: LC50 of compound 1 where Y was 0.955 (A) and 0.997 (B) 
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Table 5.7 Cytotoxicity of compounds on Vero Monkey Kidney cells 
    Assay 1 Assay 2 Average SD 
Compound 1 (µg/mL) 27.50 35.23 31.37 5.47 
Compound 2 (µg/mL) 172.74 248.33 210.53 53.45 
Compound 3 (µg/mL) 48.60 46.94 47.76 1.16 
 
It is worth noting that the highest concentration of compound tested was 200 µg/mL and 
compound 2 was the least toxic out of the three compounds (Table 5.7).  
5.3.4 Structure elucidation and identification of compounds 
5.3.4.1 SLN1 
The initial inspection of the proton spectrum of the SLN1 compound revealed that it was 
triterpenoid in nature, based on the presence of at least six methyl groups in the 
spectrum. The compound was approximately 70% pure.  Additionally, a pair of triplet-
like signals at δ 4.72 ppm and δ 4.59 ppm, integrating to a single proton each, pointed 
to the presence of a terminal methylene system, likely a 1, 1-disubstituted alkene typical 
of the lupane pentacyclic triterpenoids. The absence of one of the seven methyl signals 
typically seen in the lupine systems indicated that one of these had been oxidized or 
modified, typical of the betulin-type lupane triterpenoids.  Direct integration of the 
material was complicated by the presence of approximately 30% of another 
compound(s), and the exact number of protons could not be deduced directly from this 
spectrum. 
Inspection of the carbon spectrum indicated the presence of a keto moiety (δ 216.57 
ppm), a carboxylate (δ 177.65 ppm) and a typical terminal 1,1-disubstituted alkene 
(δ 151.70 ppm and δ 110.10 ppm; cf. δ 146 ppm and δ 117 ppm typical of an internal 
alkene). The absence of signals between δ 65 – 90 ppm indicated that no further 
oxygenation was present in the system, indicating three oxygen atoms as part of the 
chemical formula only. Taking into account the purity of the material, 30 distinct carbon 
signals could be deduced from these data, indicating a chemical formula of C30H46O3.  
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The initial library searches of the selected carbon signals within Structure Elucidator 
indicated that sections of the typical lupane system were present, with a 3-keto group, 
17-COOH group and 19-propylene group likely, as suspected. 
gHSQC_PS in multiplicity-edited form allowed unambiguous assignment of the 
multiplicities (C, CH, CH2 or CH3) of each signal, allowing direct determination of the 
integration needed in the proton spectrum.  Based on the above, it was deduced that 
there were six methyl groups, eleven methylene groups, five methine groups and eight 
quaternary carbons, indicating a chemical formula of C30H45O3 but the presence of a 
carboxylate indicates that the formula should be C30H46O3, to account for the 
exchangeable –OH proton of the carboxylate. 
gDQCOSY (showing direct proton-proton scalar coupling in most cases) showed a clear 
cross-correlation between the methylene protons at δ 4.72 ppm and δ 4.59 ppm and a 
broad signal at δ 1.70 ppm corresponding to a methyl group, typical of the interaction 
seen between the protons on C29 and the methyl group of C30 in a lupane system. 
Other COSY scalar couplings are indicated in the diagram (Figure 5.28).  The above 
findings are summarized in Table 5.8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.28: Interactions between protons on C29 and methyl group of C30 and other COSY scalar 
couplings  
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Due to serious signal overlap in the sub-3 ppm area, many of the correlations could not 
be distinguished, accounting for the seeming dearth of correlations for the saturated 
alkane regions of some parts of the molecule.  gHMBC correlation spectroscopy 
enabled direct correlation of protons to carbon atoms three or more bonds away. In this 
way, the following correlation “map” could be built from the data: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         Figure 5.29: Atomic interactions within a network 
Each colour in Figure 5.29 refers to a specific atom interacting in a network (shown as 
either solid bonds or arrows). Significantly, the presence of the exocyclic propylene 
system C20/C29/C30 is clearly shown by correlation to C19, while the carboxylate C28 
is established as attached to C17 indirectly by correlations from H15, H16, H18, H21 
and H22. Similarly, the keto moiety at C3 is unambiguously shown from correlations to 
H1, H2, H23 and H24. The remaining systems confirm the lupane skeleton.  Compound 
SLN1 was identified as betulonic acid with formula C30H46O3 (Figure 5.30). 
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Table 5.8 1H and 13C NMR of SLN1 (betulonic acid) showing the chemical shift similarities with those obtained by Letedi et al. (2014) 
C C mult (HSQC) δx / ppm H δH / ppm H mult (J / Hz) gDQCOSY gHMBCAD 
1 CH2 40.311 1a 1.44-1.47 m - - 1b 1.86-1.93 m -  
2 CH2 34.599 2a 2.34-2.42 m H1b C1, C10 2b 2.458 ddd (16.52, 9.78, 7.15) H1a, H1b C1, C3 
3 C 216.665 - - - - H1b, H23 
4 C 48.037 - - - - H1b, H29a, H29b 
5 CH 55.608 5 1.36-1.45 m - C4, C7, C24 
6 CH2 20.459 6a 1.45-1.50 m - C1, C5, C8, C10, C25 6b 1.530 d (1.81) H6a C7 
7 CH2 34.541 7 1.44-1.48 m - C7 
8 C 41.563 - - - - H7, H26 
9 CH 50.006 9 1.661 t (11.18) H29a C4, C5 
10 C 37.755 - - - - H1b, H6b 
11 CH2 22.341 11a 1.27-1.33 m H11b, H12b C9, C12 11b 1.44-1.47 m H1b, H2a, H13  
12 CH2 26.537 12a 1.06-1.14 m H11b, H12b, H13 C18 12b 1.72-1.76 m H1a, H11a, H12a  
13 CH 39.257 13 2.34-2.42 m H12a, H12b C12, C14, C18 
14 C 43.394 - - - - H26, H27 
15 CH2 30.557 15a 1.206 dt (13.42, 3.11) H15b C13, C16, C28 15b 1.558  H15a, H16a, H18 C16 
16 CH2 32.871 16a 2.249 dt (12.80, 3.30) H15b, H16b C15 16b 1.466  H16a C15 
17 C 56.882 - - - - H21a 
18 CH 50.761 18 1.42-1.55 m - C28 
19 CH 47.788 19 3.049 br td (11.00, 5.22) H21a, H30 C13, C18, C20, C21, C29, C30 
20 C 151.698 - - - - H30 
21 CH2 31.450 21a 1.36-1.41 m H19, H21b C17 21b 1.90-1.95 m H15a C28 
22 CH2 37.624 22a 1.42-1.55 m H22b C17 22b 1.90-1.95 m H21a, H22a C18, C19 
23 CH3 27.086 23 1.034 s - C6 
24 CH3 21.396 24 0.992 s - C3, C4, C5 
25 CH3 16.380 25 0.997 s - C2, C8. C9 
26 CH3 16.446 26 0.950 s - C9, C13, C26 
 167 
 
d = doublet, ddd = doublet of doublets of doublets, dt = doublet of triplets, br = broad, t = triplet, td = triplet of doublets, s = singlet, m = multiplet, 
mult = multiplicity, J = scalar coupling constant in Hertz, δX = chemical shift of nucleus X in ppm. 
 
27 CH3 15.040 27 1.035 s - C15, C20, C24, C26, C7, C29, C30 
28 C 177.65 - - - - H16b, H22b 
29 CH2 110.097 29a 4.592 br t (1.70) H29b, H30 C19, C30 29b 4.724 br d (2.20) H29a C19, C30 
30 CH3 19.595 30 1.701 br s H13, H29b C19, C20, C29 
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            Figure 5.30: The structure of betulonic acid (SLN1) 
5.3.4.1.1 Physico-chemical properties and reported biological activities of betulonic 
acid and derivatives 
Betulonic acid can be obtained by oxidation of the following compounds: betulin, 
betulinic acid, betulonal or betulinal, but generally as starting material betulin is used, 
mainly because is highly accessible as a naturally-occurring compound (Bastos et al., 
2007; Tolstikov et al., 2005).  During this study, betulonic acid [lup-20(29)-en-3-oxo-28-
oic] was obtained as a yellow powder, highly non-polar with a formula of C30H46O3 
(Ledeţi et al., 2015; Melnikova et al., 2012).  Until the 2000s, interest in betulinic acid 
was primarily due to its role as the precursor for synthesis of betulonic acid, which is an 
effective drug against human melanoma and as an anti-inflammatory and anti-viral 
(Bastos et al., 2007; Laavola et al., 2016; Melnikova et al., 2012; Moldovan et al., 2013; 
Periasamy et al., 2014).  According to ChemFaces material safety data sheet (2015), 
betulonic acid amide isolated from the branch of Eucalyptus globulus Labill. stimulates 
the regenerative response in hepatocytes under conditions of combined toxic exposure 
characterized by a significant decrease of the degree of severity of liver fibrosis and the 
absence of cirrhotic transformation of the liver.  It was also observed that betulonic acid 
derivatives have promising cytostatic activity in vitro and could be used as potential 
leads for the development of new type of anti-cancer agents (Bastos et al., 2007; 
Gheorgheosu et al., 2014).   
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The mechanism of antiproliferative action of betulonic acid is thought to occur via 
induction of apoptosis through the mitochondrial intrinsic pathway.  Other biological 
properties are anticholestatic effects in mice, antiviral, anti-inflammatory, antimicrobial, 
hepatoprotective and immunostimulant activities (Dehelean et al., 2012; Flekhter et al., 
2000; Melnikova et al., 2012; Periasamy et al., 2014; Tolstikov et al., 2005; Yang et al., 
2015). 
Betulonic acid can be synthesized; it can be obtained by oxidation of betulin by Jones’ 
reagent made of Cr(VI) compounds in aqueous acetone (CrO3/H2SO4/acetone) on solid 
supports such as alumina, zeolites and silica gel at room temperature.  Selective 
oxidation (100%) during 30 min of betulin up to betulonic aldehyde was determined 
when silica gel support was used.  It was found that the selective oxidation to betulonic 
acid is due to the influence of Al3+ ions.   The synthesis of betulonic acid is long, not 
very profitable and requires challenging purification steps including column 
chromatography, multiple recrystallizations and extraction using very large volumes of 
solvents, making it unsuitable for extensive scale industrial application (Bastos et al., 
2007; Tolstikova et al., 2006). 
Betulinic and betulonic acid are naturally occurring triterpenes found in many plants but 
betulonic acid can be obtained from oxidation of betulinic acid with Jones’ reagent. 
Betulonic acid is a derivative of betulinic acid.  Betulinic acid is a naturally occurring 
pentacyclic triterpenoid which has antiretroviral, antimalarial and anti-inflammatory 
properties as well as anticancer activity.  It is found in the bark of several species of 
plants, principally the white birch (Betula pubescens) from which it gets its name, but 
also from the ber tree (Ziziphus mauritiana), selfheal (Prunella vulgaris), the tropical 
carnivorous plants Triphyophyllum peltatum and Ancistrocladus heyneanus, Diospyros 
leucomelas, jambul (Syzygium formosanum), flowering quince (Pseudocydonia 
sinensis, formerly Chaenomeles sinensis (koehne), rosemary and Pulsatilla chinensis.  
The pure compound of betulinic acid (oxidation product of betulin) appears as a white 
crystalline solid, melting at 295-297°C.  It was isolated from Melaleuca cajuput and was 
chromatographed on a silica gel column using chloroform as eluent (Abd Rahman et al., 
2012; Bastos et al., 2007; Cragg and Newman, 2005; Faujan et al., 2010; Mahajan and 
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Chopda, 2009; Newman and Cragg, 2007).  It exhibits limited solubility in organic 
alcohols such as methanol and ethanol, chloroform and ether and has low solubility in 
water, petroleum ether, dimethylformamide, dimethyl sulfoxide, and benzene.  It is 
highly soluble in pyridine and acetic acid (Cichewicz and Kouzi, 2004).  It is not readily 
visible on thin layer chromatography plates under UV (254 and 365 nm) (Cheng et al., 
2011; Jäger et al., 2007) but it is easily detected following exposure to iodine vapors, 
anisaldehyde-sulphuric acid, or vanillin (Periasamy et al., 2014). 
5.3.4.2 Compound-PKB 
The sample was analysed by NMR spectroscopy and high resolution mass 
spectrometry. The proposed structure is given in Figure 5.30. The structure was 
assigned on the basis of 1D (1H and 13C) and 2D (COSY, HSQC and HMBC) data.  The 
NMR data was in agreement with the proposed structure (Table 8).  The molecular 
formula was deduced as C30H18O10 on the basis of its positive MS data which showed 
the presence of an [M+H]+ ion at m/z 539.0959 as indicated in Figure 5.31.  
This compound could possibly be new as no matching structure was found from 
Scifinder search.  A second plant material collection will be planned to extract a larger 
amount of the compound for further analysis which will include crystallization, melting 
point and Fourier Transform Infrared Spectroscopy (FTIR). 
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a HMBC correlations not observed for C-8a at σC 154.0  
b Assignments may be interchanged 
 
Table 5.9: 1 D and 2 D NMR data of compound PK-B in DMSO-d6 
1H COSY HSQC 
 
HMBCa 
13.30 (1H, brs, OH-5) __ __ 60.0 (C, C-5), 109.2 (C, C-4a), 104.1 (CH, C-6) 
12.70 (1H, s, OH-5'') __ __ 161.3 (C, C-5''), 101.9 (C, C-4''a), 99.3 (C, C-6'') 
10.63 (2H, brs, 2 X OH) __ __ __ 
9.69 (1H, brs, OH) __ __ __ 
7.67 (2H, d, J = 8.8 Hz, H-2' & H-6') 6.82 (H-3' & H-5' ) 128.6 (2 X CH, C-2' & C-6' ) 165.0 (C, C-2), 161.6 (C, C-4'), 128.6 (2 X CH, C-2' & C-6') 
7.32 (2H, d, J = 8.6 Hz, H-3''' & H-5''') 6.87 (H-2''' & H-6''') 131.7 (2 X CH, C-3''' & C-5''') 157.3 (C, C1'''), 131.7 (2 X CH, C-3''' & C-5'''), 114.3 (C, C-8) 
7.04 (1H, s, H-3) __ 103.3 (CH, C-3) 183.0b (C, C-4), 165.0 (C, C-2), 120.8 (C, C-1'), 109.2 (C, C-4a) 
7.02 (1H, s, H-6) __ 104.1 (CH, C-6) 160.0 (C, C-5), 152.8 (C, C-7), 114.3 (C, C-8), 109.2 (C, C-4a) 
6.87 (2H, d, J = 8.6 Hz, H-2''' & H-6''') 7.32 (H-3''' & H-5''') 115.1 (2 X CH, C-2''' & C-6''') 157.4 (C, C1'''), 119.8 (C, C4''') 
6.82 (2H, d, J = 8.8 Hz, H-3' & H-5') 7.67 (H-2' & H-6' ) 115.9 (2 X CH, C-3' & C-5' ) 161.6 (C, C-4'), 120.8 (C, C-1') 
6.31 (1H, d, J = 2.0, H-8'') 
 
6.19 (H-6'') 
 
93.9 (CH, C-8'') 
 164.2 (C, C-7''), 154.8 (C, C-8''a), (101.9, C-4'' a), 99.3 (CH, C-6'') 
6.19 (1H, d, J = 2.0, H-6'') 
 
6.31 (H-8'') 
 
99.3 (CH, H-6'') 
 164.2 (C, C-7''), 161.3 (C, C-5''), 101.9 (C, C4''a), 93.9 (CH, C-8'') 
5.45 (1H, s, H-3'') __ 88.8 (CH, H-3'') 182.8b,  165.5, 101.9 (C, C4''a) 
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         Compound PK-B formula C30H18O10  
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           Figure 5.31: Proposed structure for sample PK-B 
5.4 CONCLUSION 
To our knowledge, this is the first report of the isolation of betulonic acid from the 
chloroform fraction of S. undulata.  The NMR data of the isolated betulonic acid was 
consistent with previous publications (Ledeti et al., 2014; Ledeţi et al., 2015; Melnikova 
et al., 2012).  Its biological properties have been reported, which include antitubercular 
and antiproliferative (antitumor activity) (Bastos et al., 2007; Dehelean et al., 2012; 
Periasamy et al., 2014; Yang et al., 2015).  Searsia undulata was found to be toxic to 
C3A (Human cancer liver cell) but less toxic to normal Vero kidney cells and this 
potential anticancer activity should be further investigated. 
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CHAPTER 6: 
SUMMARY AND CONCLUSIONS 
This study comprised two phases: phase I comprised the isolation and characterization 
of Mycobacterium spp.  During phase II, extracts of selected plant species of the family 
Anacardiaceae were tested for antimycobacterial activity using some isolates from 
phase I and strains of non-tuberculous mycobacteria.  Several objectives were 
formulated and reported results obtained from these objectives are summarized in this 
chapter: 
6.1 ISOLATION AND CHARACTERIZATION OF MYCOBACTERIUM SPECIES 
This objective was achieved through the processing of samples, isolation, identification, 
characterization and antimycobacterial activity of some of the isolates. 
The samples from slaughtered animals showing lesions suggestive of tuberculosis and 
cattle positive reactors to tuberculin test were processed. Samples received included 
five different animal species that included black wildebeest (Connochaetes gnou), cattle 
(Bos taurus), impala (Aepyceros melampus), rabbit (Oryctolagus cuniculus) and 
warthog (Phacochoerus africanus).  Methods used were isolation in culture using liquid 
medium BACTECTM MGITTM 960, and solid growth media on Löwenstein Jensen slants 
with glycerol and pyruvate.  The isolates were further identified using the commercial kit 
GenoType CM/AS reverse line blot assay and DNA strip Mycobacterium identification 
species (Hain Life Science, Gmbh Nehren, Germany), biochemical substrate, 
characterized by multiplex PCR, spoligotyping, variable number of tandem repeat 
(VNTR), gene sequencing, phylogenetic analysis and antimicrobial susceptibility test of 
cattle isolates (M. bovis) against first-line TB drugs using Genotype® MTBDRplus kit 
(Hain Life Science Gmbh Nehren, Germany).  
Samples from cattle yielded 15 isolates of M. bovis of which 53% were resistant to the 
first-line drugs INH and rifampin (MDR-M. bovis)-these findings are of concern as there 
are very few data available in South Africa related to human tuberculosis caused by M. 
bovis.  Considering that South Africa is among the list of high burden MDR/XDR-TB 
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countries, accurate diagnostic and antimicrobial sensitivity patterns are necessary for 
the implementation of effective treatment regimens.  Further investigation on the 
prevalence and incidence of M. bovis in humans and characterization of such isolates is 
needed. 
The isolates from cattle were further analysed by spoligotyping and yielded two 
spoligotypes.  SB0121 (67%) and SB 1235 (33%). The VNTR was type 1.  These 
isolates were from the same origin.  Spoligotype are interesting epidemiological tools to 
trace the origin of the strain for the control/management of the disease.   
Samples from black wildebeest yielded non-tuberculous mycobacteria: a novel 
Mycobacterium Avium Complex species and Mycobacterium avium subsp. hominissuis.  
The sample from a rabbit also yielded M. avium subsp. hominissuis.  These findings 
were of concern as meat from black wildebeest and rabbit are used for human 
consumption.  Non-tuberculous mycobacteria are among emerging mycobacteria with 
increased interest as their clinical significance in causing disease has been established 
in humans but not yet in animals.  Adding to that, some of the members of the MAC 
have been reported as potentially zoonotic which includes M. avium subsp. hominissuis.  
Further investigation is needed to establish the pathogenicity of non-tuberculous 
mycobacteria in animals beyond any doubt and deposition of new isolates at the 
international gene data bank. 
Samples from warthogs yielded a mixture of M. bovis and non-tuberculous 
mycobacteria, namely M. intracellulare and M. avium.  The sample from an impala 
yielded M. bovis.  
6.2 ANTIMYCOBACTERIAL ACTIVITY OF ACETONE LEAF EXTRACTS OF 
PLANT SPECIES FROM ANACARDIACEAE FAMILY 
This objective was achieved by selecting 15 plant species from the Anacardiaceae 
family and conducting in vitro evaluation of antimycobacterial and cytotoxicity activities 
of crude acetone extracts followed by selection of the most active extract for bioassay-
guided isolation of active antimycobacterial compounds.  Fifteen plant species were 
screened (Harpephyllum caffrum, Heeria argentea, Lannea discolor, Loxostylis alata, 
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Ozoroa mucronata, Ozoroa paniculosa, Protorhus longifolia, Searsia chirendensis, 
Searsia lancea, Searsia leptodictya, Searsia magaliesmontana subsp., Searsia 
pyroides, Searsia undulata, Sclerocarya birrea subsp caffra and Smodingium argutum).  
The acetone extraction yield of the plant species ranged from 0.8 to 18.8%.  The 
highest percentage was observed with Searsia magaliesmontana (18.8%) followed by 
Searsia undulata (12.5%) and Protorhus longifolia (8.3%).  Heeria argentea had the 
lowest yield of 0.8%.   
The antimycobacterial activity of acetone leaf extracts of each plant species was 
determined using a twofold serial dilution method against pathogenic (M. bovis, MDR-
TB), ATCC M. tuberculosis H37Ra and rapidly growing mycobacteria that included 
ATCC and NCTC cultures, M. aurum, M. fortuitum and M. smegmatis. 
The number of antimycobacterial compounds against rapidly growing mycobacteria in 
each extract was determined using bioautography.  The plates were developed in 
duplicate, one for bioautography and the other plate for visualization of phytochemicals 
present in each plant following spraying with the chromogenic reagent vanillin-sulphuric 
acid.  Bioautography of extracts using two (M. aurum and M. fortuitum) out of the three 
rapidly growing mycobacteria led to strong, clear zones of inhibition.  This also 
corresponded with low MIC values obtained, ranging from 50 to 100 µg/mL.  
All 15 plant species had good to moderate antimycobacterial activity against rapidly 
growing and pathogenic mycobacteria ranging from 50 to 590 µg/mL. This confirms the 
results obtained against M. smegmatis in the Phytomedicine Programme database.  
The following five plant species MIC values were good and showed the presence of 
antimycobacterial compounds on bioautograms: Searsia undulata extracts had 
significant antimycobacterial activity with the lowest MIC value of 70 µg/mL for M. aurum 
and M. fortuitum followed by M. smegmatis with MIC of 90 µg/mL.  Protorhus longifolia 
extracts also had significant antimycobacterial activity against all three non-tuberculous 
mycobacteria with MIC values of 110 µg/mL for both M. aurum and M. fortuitum and 70 
µg/mL for M. smegmatis.  Searsia lancea, Sclerocarya birrea and Harpehyllum caffrum 
had moderate activity of 420 µg/mL, 520 µg/mL and 590 µg/mL against M. aurum 
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respectively whereas the same plant species had moderate activity with low MIC values 
of 210 and 110 µg/mL; 130 and 210 µg/mL and 210 and 110 µg/mL against M. fortuitum 
and M. smegmatis, respectively.  Searsia undulata extracts had significant activity 
against all mycobacteria including M. bovis and MDR-TB isolates with MIC ranging from 
50 to 110 µg/mL, and the best activity with an MIC of 50 µg/mL against M. tuberculosis 
ATCC strain H37Ra.  Therefore, this species was selected for further investigation.  
Positive correlation was observed between the activity of the pathogenic isolates, M. 
bovis and MDR-TB, with M. fortuitum with (r) coefficient correlation values of 0.62 and 
0.65 respectively whereas negative correlation with value of -0.005 was observed with 
M. aurum and the pathogenic mycobacteria.  Good correlations were obtained between 
the ATCC strain, H37Ra, and rapidly growing mycobacteria with r values of 0.92, 0.87 
and 0.37 for M. fortuitum, M. aurum and M. smegmatis respectively and the highest 
coefficient correlation value of 0.98 between MDR-TB isolate with the pathogenic M. 
bovis isolate. 
6.2.1 Antimycobacterial activity of fractions and compounds of S. undulata 
6.2.1.1 Minimum Inhibitory concentration of fractions 
The twelve fractions obtained from the chloroform fraction following solvent-solvent 
fractionation and column chromatography were tested against the three rapidly growing 
mycobacteria, M. aurum, M. fortuitum and M. smegmatis.  All fractions had good 
antimycobacterial activity with MIC values ranging from 58 to 468 µg/mL which were 
related in most cases to the presence of clear zones of inhibition on bioautograms. 
The fractions F5, F6 and F7 had similar compounds on bioautograms and were 
combined for further fractionation to isolate antimycobacterial compounds.  These 
fractions had MIC of 117 µg/mL for M. aurum, 234 µg/mL for M. fortuitum and 58 µg/mL 
for M. smegmatis except F7 that had a MIC of 117 µg/mL for M. smegmatis.  Fractions 
F5 and F6 had the best activity with MIC of 58 µg/mL observed against M. smegmatis.   
6.2.1.2 Minimum inhibitory concentration of isolated compounds 
Five compounds were isolated and tested against M. aurum, M. fortuitum and M. 
smegmatis.  All 5 compounds showed activity against rapidly growing mycobacteria with 
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MIC values ranging from 23.44 to 250 µg/mL.  The first compounds 1 and 2 had the 
highest MIC values varying from 62.5 to >250 µg/mL.  The MIC values of 62.5 µg/mL 
were obtained against M. aurum and M. fortuitum and 125 µg/mL for M. smegmatis 
whereas C2 showed the highest MIC value >250 µg/mL against M. fortuitum and M. 
smegmatis. Compound 3 (C3 or SLN1) had the lowest MIC value of 23.44 µg/mL 
against M. fortuitum; 31.25 µg/mL against M. aurum and M. smegmatis.  Compound C4 
(C4 or PKB) and compound 5 (C5 or PKC) both showed activity against all three 
mycobacteria with best value of 46.88 µg/mL for C4 against M. smegmatis. 
6.3 CYTOTOXICITY OF ACETONE LEAF EXTRACTS OF PLANT SPECIES FROM 
ANACARDIACEAE FAMILY 
Most drugs or other substances are metabolised in the liver and excreted by the kidney.  
Mycobacterial species causing tuberculosis multiply and hide in macrophages.  This 
objective was achieved by selecting three cell lines to represent these organs, namely 
Vero monkey kidney, human liver hepatoma (C3A) and mouse macrophage cells (RAW 
264.7).  Crude extracts (Heeria argentea, Lannea discolor, Protorhus longifolia, Searsia 
undulata and Sclerocarya birrea) with good antimycobacterial activity (from significant to 
moderate) and those that showed visible zones of inhibition on bioautograms were 
selected for cytotoxicity testing.  The cytotoxicity was determined using a tetrazolium-
based colorimetric assay with 3-(4, 5-dimethylthiazol)-2, 5-diphenyl tetrazolium bromide 
(MTT) as the indicator.  All crude extracts tested showed low toxicity against all three 
cell lines except Searsia undulata that had moderate toxicity to C3A cells with LC50 of 
0.034 mg/mL. This deserves further investigation as a source of anticancer substances 
as C3A cells are cancer cells with abnormal metabolic activity.  The S. undulata extract 
had LC50 of 0.50 and 0.12 mg/mL on Vero cells and RAW cells respectively with good 
selectivity indexes of 7.08 on Vero cells and more than 1 on RAW cells for non-
tuberculous and MDR-TB mycobacteria.  Protorhus longifolia had an LC50 of 0.62 
mg/mL on C3A cells, 0.88 mg/mL on Vero cells and >1 mg/mL for RAW cells with the 
highest selectivity index on Vero cells of 12.6 for M. smegmatis followed by 8.02 for M. 
aurum, M. fortuitum and MDR-TB.  Plant extracts with SI values less than 1 mean that 
the extracts are relatively less toxic to the bacteria and more toxic to the mammalian 
cells.  Therefore, extracts with SI >1 may be relatively safer to use in vivo (not 
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accounting for pharmacokinetics parameters) as they are less toxic to mammalian cells 
but more toxic to the pathogens.  The selectivity indexes, especially of P. longifolia with 
SI = 12. 6 could be considered as very promising, as a good therapeutic index for a 
remedy or drug should be ≥10.   It is also worth noting that efficacy “in vitro” might differ 
from efficacy ‘in vivo” due to different parameters influencing pharmacodynamics and 
pharmacokinetics of drugs administered by different routes to humans and animals.  
Protorhus longifolia and Searsia undulata had the highest selectivity index against the 
three rapidly growing mycobacteria and pathogenic mycobacteria and the highest total 
activity.  These rapidly growing species had the highest total activity of 5 357 mL/g for 
S. undulata and 3 557 mL/g for P. longifolia which indicates the volume to which the 
extract from 1 g can be diluted and still inhibit the growth of mycobacteria.  It is also 
worth noting that the leaves of S. undulata are chewed by Khoisan people to treat chest 
colds, indicating a low toxicity.  The mode of administration and interaction with other 
factors ”in vivo” must be considered when assessing toxicity.  Plant extracts showing 
sensitivity to cell lines with LC50 values >0.1 mg/mL are considered not cytotoxic in 
terms of searching for anticancer compounds. Searsia undulata was selected as the 
preferred plant species for compound isolation based on its high cytotoxicity on 
abnormal cells (C3A) (potential candidate for anticancer agent) and low cytotoxicity on 
the normal Vero kidney cells and its good antimycobacterial activity. 
6.3.1 Cytotoxicity of compounds isolated from Searsia undulata 
The crude extract of Searsia undulata at a concentration of 100 µg/mL had low 
cytotoxicity (LC50 = 500 µg/mL) on Vero cells (Section 6.3).   Three of the compounds 
isolated from S. undulata had moderate toxicity with compound 2 (SLN1) being the least 
toxic (LC50 = 211 µg/mL) followed by compound 3 with LC50 = 48 µg/mL (PK-B) and 
compound 1 (LC50 = 31 µg/mL).  The other two compounds were not tested because 
they were not pure and not in sufficient quantity. 
6.4 ISOLATION OF BIOACTIVE FRACTIONS AND COMPOUNDS FROM THE 
LEAF OF SEARSIA UNDULATA 
The five fractions from solvent-solvent fractionation (chloroform, butanol, hexane, H2O-
35% methanol and H2O) were eluted in BEA solvent system and tested for 
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antimycobacterial activity against M. aurum, M. fortuitum and M. smegmatis and MDR-
TB and H37Ra.   Thin layer chromatography fingerprints eluted in hexane: ethyl acetate 
at different ratios was used to locate the active phytochemical compounds as mentioned 
under section 6.2.   
The chloroform fraction was selected as the fraction with the best antimycobacterial 
activity based on good MIC values and presence of more than 10 potential active 
compounds as discussed under section 6.2.1.1.  It was further fractionated using 
column chromatography packed with silica gel into 55 fractions that were combined into 
12 sub-fractions (F1-F12).  Three (F5-F7) out of the 12 fractions showing good 
antimycobacterial activity and presence of active phytochemical compounds on 
bioautography were combined and were further fractionated using column silica gel 
chromatography for isolation of compounds.   
Among all 12 fractions, F3 had the highest total activity on its own of 19 765 mL/g for M 
aurum followed by 13 162 mL/g for M. fortuitum and 7 896 mL/g for M. smegmatis. It 
also had active compounds and good MIC values but was not selected at this initial 
stage as it did not have the consistent similar pattern of phytochemical active 
compounds on bioautography and TLC when compared to F5 to F7 (Figures 5.14-5.18).  
In future investigations, the isolation of compounds from fraction F3 will be undertaken.  
The next fraction showing the highest activity was F6 with a total activity of 19 793 mL/g 
against M smegmatis then F5 showing the highest total activity of 17154 mL against M. 
smegmatis then the last fraction with lower total activity F7 showing 7 262 mL for both 
M. aurum and M. smegmatis.  The average total activity of the combined fractions was 
27 599 which is higher than F3 alone 19 765 mL.  At this preliminary stage, this 
determined the focus on the combination of these three fractions based on their MIC 
values against all the mycobacteria species. 
The Rf value, or retardation factor, was used to trace and identify targeted compounds 
with antimycobacterial activity at different stages of the fractionation process.  Rf values 
of the chloroform fraction were calculated by dividing the distance travelled by either the 
extract or fraction or compound spotted on the vanillin sprayed TLC plate or 
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bioautogram eluted in a specific mobile phase solvent system.  Rf values were 
calculated for the plates eluted in BEA solvent and sprayed with M. aurum and M. 
fortuitum as they were good indicators of antimycobacterial activity in general. 
Isolation of compounds from the combined semi-purified fractions, F5, F6 and F7 
(1019.7mg) was carried out using a small column packed with silica gel with 100% n-
hexane and fractions collected into honey jars.  Compounds were eluted with 100% n-
hexane with increasing polarity with 2% ethyl acetate resulting in sequential elution of 
SLN1 (26.2 mg), PKA1 (15.4 mg), PKB (22.4 mg), PKC (15.9 mg) and PKD (8.4 mg). 
The purified PK B was obtained by using a mixture of chloroform and methanol as 
eluent on a silica gel column at the second run.  
6.5 STRUCTURE ELUCIDATION AND IDENTIFICATION OF COMPOUNDS 
6.5.1 Compound SLN1  
This compound was collected and dried as a light yellow powder.  The initial inspection 
of the proton spectrum revealed that the material was triterpenoid in nature, based on 
the presence of at least six methyl groups in the spectrum. The material consisted of 
about 70% of the major product.  Additionally, a pair of triplet-like signals at δ 4.72 ppm 
and δ 4.59 ppm, integrating to a single proton each, pointed to the presence of a 
terminal methylene system, likely a 1, 1-disubstituted alkene typical of the lupane 
pentacyclic triterpenoids.  The compound was identified as betulonic acid, which has 
been reported previously as having antimicrobial activity.  
During the process of the isolation of compounds, it is worth noting that the work was 
carried out at room temperature and samples were exposed to oxygen and light.  
Changes observed on TLC plates indicated that certain compounds were unstable and 
decomposed. This could imply that the initial compound was betulinic acid which 
underwent oxidation to its derivative betulonic acid.  In either case, both compounds 
were reported to have similar biological activity properties. 
Betulinic and betulonic acid are naturally occurring triterpenes found in many plants but 
betulonic acid can be obtained from oxidation of betulinic acid with Jones’ reagent. 
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Betulonic acid is a derivative of betulinic acid as described above.  Betulinic acid is a 
naturally occurring pentacyclic triterpenoid which has antiretroviral, antimalarial and 
anti-inflammatory properties as well as anticancer (Dehelean et al., 2012).  This 
appears to be the first report of isolation of betulonic acid from S. undulata.   
6.5.2 Compound PK-B 
This compound was collected and dried as a slightly yellow powder. Its putative 
structure did not match any chemical structure on Scifinder.  This compound seems to 
be novel.  More of the compound needs to be isolated to enable crystallization, melting 
point and Fourier Transform Infrared Spectroscopy (FTIR) for full elucidation of the 
chemical structure.  The proposed structure is provided in section 5.3.4.2 (Figure 5.30). 
6.6 RESEARCH CHALLENGES 
• All bioassays were conducted in vitro.  There is still a need to validate the 
efficacy as well as safety in vivo.  Several parameters and interactions need to be 
considered during the in vivo metabolism of a drug which leads to its effective 
bioavailability. 
• The isolation of compounds was a laborious and difficult process due to the 
complexity of antimycobacterial active phytochemical compounds that were 
closely related.  This made the separation and purification processes challenging.  
• Delay encountered in the appointment of a phytochemist on site for guidance in 
the isolation of compounds. 
• No easy access to NMR instrument and very limited expert staff available 
therefore the high demand from researchers making use of this technique could 
not be met within the required time. 
• NMR broken probes were sent for repair in Germany (no technical local 
representation)  
• Minimum inhibitory concentration (MIC): the main challenge encountered was the 
formation of a jelly-like substance by some compounds when inoculated in the 
growth medium, preventing tested compounds from dissolving.  Therefore, the 
growth medium was diluted with solvents such as ethyl acetate or DMSO at 
different ratios and organisms’ growth was tested prior to carrying out the 
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bioactivity assay. Bioautography: the use of tested mycobacteria was only limited 
to the rapidly growing organisms and not extended to the pathogenic 
mycobacteria.  This is due to the technique as a mycobacterial suspension is 
sprayed on the TLC plates.  Pathogenic mycobacteria are highly infectious and 
air borne infection is one of the main routes of contamination/infection. The slow-
growing mycobacteria would also not be able to survive on the TLC plate for the 
extended period of time necessary for adequate growth. 
6.7 GENERAL CONCLUSION, RECOMMENDATIONS AND FUTURE 
PERSPECTIVES 
6.7.1 Isolation and characterization of mycobacterial species 
The involvement of some zoonotic Mycobacterium spp. in the disease-causing process 
has been established. There is evidence that new strains of bacteria are circulating.  It 
has also been reported that clinical signs of disease caused by M. bovis and M. 
tuberculosis are indistinguishable.  Other findings mention that radiological clinical 
pictures of some pulmonary diseases caused by non-tuberculous mycobacteria in 
humans were confused with those of tuberculosis.  Therefore, methods used in routine 
laboratory diagnostics of tuberculosis should be mixed and include culture, Ziehl-
Neelsen staining and at least one molecular technique.  For culture isolation, growth 
media that will promote the growth of both M. bovis and M. tuberculosis should be used.  
The so called MOTT, referring to mycobacteria spp. other than the targeted known 
pathogenic M. bovis and M. tuberculosis, should no longer be disregarded and should 
be identified fully as they might be primary causative agents of some tuberculosis-like 
lesions or clinical conditions/cases in both animals and humans.  Although the 
involvement of non-tuberculous mycobacteria in the disease-causing process has been 
established in humans and some animal species as well as their zoonotic aspects, this 
involvement still remains to be established in animals.  Laboratories and researchers 
should also be encouraged to deposit newly identified mycobacterial spp. in the 
international gene data bank as there have been reports on unpublished data of new 
mycobacteria spp. in South Africa (Gcebe et al., 2013; Helden et al., 2009).   
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The emergence of MDR/XDR TB strains is of concern, and adding to the target of 
accurate identification of mycobacterial isolates, reference laboratories should 
implement a routine antimycobacterial sensitivity test for accurately identified isolates 
and perhaps also partially identified mycobacteria to allow a rapid implementation of 
effective treatment regimens. Annual reports may be compiled of antimycobacterial 
pattern sensitivity observed in the laboratory.  As a long term goal, creating a national 
database on antimycobacterial sensitivity of mycobacterial isolates from humans and 
animals will be relevant as spill-over of M. tuberculosis from humans to animals has 
been reported and spill-back could also be a possibility (Michel et al., 2013; Ocepek et 
al., 2005).   Medical and veterinary laboratories should collaborate on generating 
databases for antimycobacterial sensitivity of M. bovis and M. tuberculosis isolates.  
This task could be conducted in medical laboratories as tuberculosis in animals is not 
treated.    
6.7.2 Antimycobacterial activities of leaf extracts, fractions and compounds 
isolated from plant species from the Anacardiaceae family 
Besides the above, an ultimate goal is to continue to seek for alternative treatments 
exploring natural resources (plants) at our disposal for potential leads to anti-TB drug 
development.  Natural products such as plant extracts, either as pure compounds or as 
standardized extracts, provide unlimited opportunities for new discoveries because of 
the unavailability of a chemical diversity database.  A national database should be 
created and voucher samples of isolated anti-TB compounds deposited.  This would 
allow at some stage easy traceability when networking with pharmaceutical companies 
in exploring the development of new drugs from targeted compounds. 
Extraction is a crucial step because it is necessary to extract the desired chemical 
components from the plant material.  The solvent used is equally important depending 
on the assay conducted. In the case of biological activity one must make sure that the 
solvent is not harmful to the microorganisms tested.  Many solvents inhibit the growth of 
microorganisms. When evaluating the biological activity of extracts against 
microorganisms, acetone was proven not to inhibit the growth of tested microorganisms 
(Eloff, 1998a). 
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During this study, five plant species, namely Harpephyllum caffrum, Protorhus longifolia, 
Searsia lancea, Searsia undulata and Sclerocarya birrea had good antimycobacterial 
activity, and they will be further analysed.  For the purpose of this study, one of the 
plants, Searsia undulata, contained about ten antimycobacterial compounds visible in 
bioautography. Of these, three compounds were isolated and two identified.  
Bioassay-guided isolation of compounds is laborious and demanding.  It needs a lot of 
patience and bioassays at each stage should be conducted scrupulously to identify the 
fractions in which active phytochemicals are present and to continue until isolation of 
the target compound(s).  Several challenges were encountered during this study. 
Among others some compounds were unstable as demonstrated by changing TLC 
fingerprints. Compounds also appeared to have closely related structures making them 
difficult to separate.  Adhering to certain environmental conditions from the extraction to 
isolation of compounds must be observed as some compounds are sensitive to heat; 
oxygen, temperature or light which might change their structure, therefore, avoiding 
exposure to these conditions will minimize structural changes. 
6.7.3 In vitro cytotoxicity activity of Searsia undulata leaf extracts and isolated 
compounds against Vero and human hepatoma cell lines 
In vitro cytotoxicity evaluation is important as compounds with fewer adverse effects are 
needed, considering that some of the current anti-TB drugs have undesirable side 
effects.  When evaluating plants, the use of normal and abnormal cells (cancer cells) is 
relevant as cancer is a major cause of mortality and a cure is yet to be found for 
different types of cancer.  Identifying potential antimicrobial and anticancer compounds 
can also be concurrently explored.  This is the case during this study where an 
incidental finding revealed that Searsia undulata had high cytotoxicity to cancerous liver 
cells (C3A hepatoma cells) but low cytotoxicity to normal cells (Vero monkey kidney 
cells).  This was supported by the compound isolated and identified as betulonic acid, 
which, together with its derivatives, has been reported to have anticancer, anti-
inflammatory, antiviral and antimicrobial activities. 
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6.7.4 Future perspectives 
As part of continued research relating to this project, there are many activities to be 
carried out in the future deriving from this study for publication purposes, and eventually 
drug development.  The different activities recommended will be planned as short term, 
medium and long term goals. 
6.7.4.1 Isolation and identification of compounds from Searsia undulata 
Ten antimycobacterial compounds were observed on bioautography and two 
compounds were identified.  One of the compounds, PK-B, requires further analysis to 
confirm beyond any doubt that it is indeed a novel compound.  Crystallization, melting 
point and Fourier Transform Infrared spectroscopy are among the techniques needing 
to be done.  The isolation and identification of the remainder of compounds will be 
carried out. 
6.7.4.2 In vitro safety of all compounds isolated from S. undulata 
The evaluation of the cytotoxicity of all isolated antimycobacterial compounds against at 
least three cell lines will be conducted. 
6.7.4.3 Synergistic evaluation of compounds isolated from S. undulata  
The synergy of antimycobacterial activity among the compounds and mixed with 
standard anti-TB drugs will be investigated. 
6.7.4.4 Determine the stability of each compound and fractions of S. undulata 
Observations made during this study indicate that some compounds might be unstable; 
therefore, it is important to evaluate the stability of each compound as a labile 
compound may not be useful.  The stability in solution and as powder under different 
conditions of temperature, moisture, light, and presence or absence of oxygen needs to 
be determined. 
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6.7.4.5 Determine antioxidant, anti-inflammatory and inhibition of nitric oxide 
production by fractions and compounds of S. undulata 
Testing for antioxidant activity and anti-inflammatory activities should be conducted. 
Inflammation, which evolves into chronic inflammation, as well as the production of 
oxidative radicals, takes place during the pathogenesis of acute or chronic tuberculosis.  
6.7.4.6 Determine the in vivo safety of pure compounds 
Identifying an animal model for in vivo evaluation of efficacy is an area that requires 
attention in the future. Clinical trials are also necessary to demonstrate the effectiveness 
and safety of the bioactive compounds.  In the course of drug development, determining 
acute and chronic toxicity is required. 
6.7.4.7 Develop an herbal product from S. undulata 
Considering that the development of drugs is expensive, one could first investigate in 
the local communities the current ethnobotanical use of this plant species.  The 
selection of species in this study was extended to the Anacardiaceae family based on 
few members of the family that had good antibacterial activities on Gram-positive and 
Gram-negative bacteria as well as M. smegmatis in a previous study (Pauw, 2004).  It 
was subsequently discovered in the literature that leaves are chewed by the Khoi San to 
treat chest colds and this needs further investigation.  A survey in this population to find 
out about any other information on the ethnobotanical use and observations about this 
plant species could be initiated. 
6.7.4.8 Understanding the mechanism of actions of compounds 
In the case of S. undulata, leaves are chewed to treat chest colds. Each group of 
currently-used antibiotics has a different mechanism of action - bactericidal or 
bacteriostatic on microorganisms.  The emergence of MDR-TB drugs is of concern and 
therefore focusing on mechanisms of action to prevent rapid development of resistance 
is crucial.  There is evidence that the development of resistance may be minimized 
when using plant extracts, as a combination of different compounds may exert a range 
of different activities.  In the case of tuberculosis, mycobacteria might be present in the 
latent “dormant” phase, and can be reactivated when immunity is compromised. 
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Therefore the best drug or combination of drugs should be bactericidal towards the 
mycobacteria, particularly those inside macrophages. Drugs with additional positive 
effects on the immune system are also desirable. 
6.7.4.9 Develop network with pharmaceutical companies 
Establishing network with companies interested in tuberculosis drugs will be part of the 
long term goal of this research. 
6.7.4.10 Testing of four other plant species with good antimycobacterial activity 
The other plant species (Harpephyllum caffrum, Protorhus longifolia, Searsia lancea 
and Sclerocarya birrea) that have good antimycobacterial activity will be further 
processed as mentioned under all the above sections. 
  
 188 
 
REFERENCES 
 
Abd Rahman, M., Yeap, S.K., Ali, A.M., Ahmad, F., Ng, M.K., Lam, H.Y., Alitheen, M., 
Banu, N. 2012. Immunomodulatory effects of betulinic acid isolation from the bark 
of Melaleuca cajuputi.  Pertanika Journal of Tropical Agriculture and Science 35: 
293–305. 
Adeshina, G.O., Kunle, O.F., Onaolapo, J.A., Ehinmidu, J.O., Odama, L.E. 2012. 
Antimicrobial activity of the aqueous and ethyl acetate sub-fractions of Alchornea 
cordifolia Leaf.  European Journal of Medicinal Plants 2: 31. 
Agdestein, A., Johansen, T.B., Kolbjørnsen, Ø., Jørgensen, A., Djønne, B., Olsen, I. 
2012. A comparative study of Mycobacterium avium subsp. avium and 
Mycobacterium avium subsp. hominissuis in experimentally infected pigs. 
Biomedical Veterinary Research 8: 1. 
Agdestein, A., Johansen, T.B., Polaček, V., Lium, B., Holstad, G., Vidanović, D., 
Aleksić-Kovačević, S., Jørgensen, A., Žultauskas, J., Nilsen, S.F. 2011. 
Investigation of an outbreak of mycobacteriosis in pigs.  Biomedical Veterinary 
Research 7:1. 
Ahmad, S. 2010. Pathogenesis, immunology, and diagnosis of latent Mycobacterium 
tuberculosis infection.  Clinical and Developmental Immunology 20:11. 
Ahmed, A.S., McGaw, L.J., Moodley, N., Naidoo, V., Eloff, J.N. 2014.  Cytotoxic, 
antimicrobial, antioxidant, antilipoxygenase activities and phenolic composition of 
Ozoroa and Searsia species (Anacardiaceae) used in South African traditional 
medicine for treating diarrhoea.  South African Journal of Botany 95: 9–18. 
Ahmed, M.S., Galal, A.M., Ross, S.A., Ferreira, D., ElSohly, M.A., Ibrahim, A.-R.S., 
Mossa, J.S., El-Feraly, F.S. 2001.  A weakly antimalarial biflavanone from Rhus 
retinorrhoea.  Phytochemistry 58: 599–602. 
Ålander-Damsten, Y.K., Brander, E.E., Paulin, L.G. 2003. Panniculitis, due to 
Mycobacterium smegmatis, in two Finnish cats.  Journal of Feline Medicine and 
Surgery 5: 19–26. 
Alexander, K.A., Laver, P.N., Michel, A.L., Williams, M., Helden, P.D., Warren, R.M., 
Pittius, N.C.G. 2010.  Novel Mycobacterium tuberculosis complex pathogen, M. 
mungi.  Emerging Infectious Diseases 16: 1296–1299. 
Ali-Shtayeh, M.S., Al-Assali, A.A., Jamous, R.M. 2013. Antimicrobial activity of 
Palestinian medicinal plants against acne-inducing bacteria.  African Journal of  
Microbiology Research 7: 2560–2573. 
Alland, D., Kalkut, G.E., Moss, A.R., McAdam, R.A., Hahn, J.A., Bosworth, W., Drucker, 
 189 
 
E., Bloom, B.R. 1994. Transmission of tuberculosis in New York City--an analysis 
by DNA fingerprinting and conventional epidemiologic methods.  New England 
Journal of Medicine 330: 1710–1716. 
Altschul, S.F., Gish, W., Miller, W., Myers, E.W., Lipman, D.J. 1990.  Basic local 
alignment search tool. Journal of Molecular Biology 215: 403–410 
doi.org/10.1016/S0022-2836(05)80360-2. 
Andersen, P., Doherty, T.M. 2005.  The success and failure of BCG—implications for a 
novel tuberculosis vaccine.  Nature Reviews Microbiology 3: 656–662. 
Andrade-Ochoa, S., Nevárez-Moorillón, G.V., Sánchez-Torres, L.E., Villanueva-García, 
M., Sánchez-Ramírez, B.E., Rodríguez-Valdez, L.M., Rivera-Chavira, B.E. 2015. 
Quantitative structure-activity relationship of molecules constituent of different 
essential oils with antimycobacterial activity against Mycobacterium tuberculosis 
and Mycobacterium bovis.  Biomedical Complementary Alternative Medicine 15: 1. 
Andrews, J.R., Gandhi, N.R., Moodley, P., Shah, N.S., Bohlken, L., Moll, A.P., Pillay, 
M., Friedland, G., Sturm, A.W. 2008. Exogenous reinfection as a cause of 
multidrug-resistant and extensively drug-resistant tuberculosis in rural South Africa. 
Journal of Infectious Diseases 198: 1582–1589. 
Aranaz, A., Liebana, E., Mateos, A., Dominguez, L., Vidal, D., Domingo, M., Gonzolez, 
O., Rodriguez-Ferri, E.F., Bunschoten, A.E., Van Embden, J.D. 1996. Spacer 
oligonucleotide typing of Mycobacterium bovis strains from cattle and other 
animals: a tool for studying epidemiology of tuberculosis.  Journal of Clinical 
Microbiology 34: 2734–2740. 
Aro, A.O., Dzoyem, J.P., Hlokwe, T.M., Madoroba, E., Eloff, J.N., McGaw, L.J., 2015. 
Some South African rubiaceae tree leaf extracts have antimycobacterial activity 
against pathogenic and Non-pathogenic Mycobacterium Species. Phytotherapy 
Research 29: 1004–1010 doi:10.1002/ptr.5338. 
Arrazuria, R., Sevilla, I.A., Molina, E., Pérez, V., Garrido, J.M., Juste, R.A., Elguezabal, 
N. 2015.  Detection of Mycobacterium avium subspecies in the gut associated 
lymphoid tissue of slaughtered rabbits.  Biomedical Veterinary Research 11: 1. 
Awouafack, M.D., McGaw, L.J., Gottfried, S., Mbouangouere, R., Tane, P., Spiteller, M., 
Eloff, J.N. 2013.  Antimicrobial activity and cytotoxicity of the ethanol extract, 
fractions and eight compounds isolated from Eriosema robustum (Fabaceae).  
Biomedical Complementary and Alternative Medicine 13:1.  
Ayele, W.Y., Neill, S.D., Zinsstag, J., Weiss, M.G., Pavlik, I. 2004.  Bovine tuberculosis: 
an old disease but a new threat to Africa.  International Journal of Tuberculosis and 
Lung Disease 8: 924–937. 
  
 190 
 
Azé, J., Sola, C., Zhang, J., Lafosse-Marin, F., Yasmin, M., Siddiqui, R., Kremer, K., van 
Soolingen, D., Refrégier, G. 2015.  Genomics and machine learning for taxonomy 
consensus: The Mycobacterium tuberculosis Complex Paradigm.  PLoS One 10: 
e0130912. 
Babula, P., Adam, V., Havel, L., Kizek, R. 2009. Noteworthy secondary metabolites 
naphthoquinones-their occurrence, pharmacological properties and analysis. 
Current Pharmaceutical Analysis 5: 47–68. 
Balunas, M.J., Kinghorn, A.D. 2005. Drug discovery from medicinal plants.  Life 
Sciences 78: 431–441. 
Bamuamba, K., Gammon, D.W., Meyers, P., Dijoux-Franca, M.-G., Scott, G. 2008. Anti-
mycobacterial activity of five plant species used as traditional medicines in the 
Western Cape Province (South Africa).  Journal of Ethnopharmacology 117: 385–
390. 
Baral, R.M., Metcalfe, S.S., Krockenberger, M.B., Catt, M.J., Barrs, V.R., McWhirter, C., 
Hutson, C.A., Wigney, D.I., Martin, P., Chen, S.C.A. 2006. Disseminated 
Mycobacterium avium infection in young cats: overrepresentation of Abyssinian 
cats.  Journal of Feline Medicine and Surgery 8: 23–44. 
Barnard, M., Albert, H., Coetzee, G., O’Brien, R., Bosman, M.E. 2008. Rapid molecular 
screening for multidrug-resistant tuberculosis in a high-volume public health 
laboratory in South Africa.  American Journal of Respiratory and Critical Care 
Medicine 177: 787–792. 
Bastos, D.Z.L., Pimentel, I.C., de Jesus, D.A., de Oliveira, B.H. 2007.  Biotransformation 
of betulinic and betulonic acids by fungi.  Phytochemistry 68: 834–839. 
Basu, S., Andrews, J.R., Poolman, E.M., Gandhi, N.R., Shah, N.S., Moll, A., Moodley, 
P., Galvani, A.P., Friedland, G.H. 2007.  Prevention of nosocomial transmission of 
extensively drug-resistant tuberculosis in rural South African district hospitals: an 
epidemiological modelling study.  Lancet 370: 1500–1507. 
Bateman, C. 2015. Eastern Cape treatment dysfunction boosts virulent new XDR-TB 
strain.  South African Medical Journal 105: 165–167. 
Ben Salah, I., Adekambi, T., Raoult, D., Drancourt, M. 2008. rpoB sequence-based 
identification of Mycobacterium avium complex species.  Microbiology 154: 3715–
3723 doi:10.1099/mic.0.2008/020164-0. 
Bengis, R.G., Kock, R.A., Fischer, J. 2002. Infectious animal diseases: the 
wildlife/livestock interface. Revue Scientifique, Technique Internationale des 
épizooties 21: 53–66. 
  
 191 
 
Bengis, R.G., Kriek, N.P.J., Keet, D.F., Raath, J.P., Vos, V., Huchzermeyer, H.F.A.K. 
1996.  An outbreak of bovine tuberculosis in a free-living African buffalo (Syncerus 
caffer-Sparrman) population in the Kruger National Park: a preliminary report. 
Onderstepoort Journal of Veterinary Research 63, 15–18. 
Bercovier, H., Vincent, V. 2001. Mycobacterial infections in domestic and wild animals 
due to Mycobacterium marinum, M. fortuitum, M. chelonae, M. porcinum, M. 
farcinogenes, M. smegmatis, M. scrofulaceum, M. xenopi, M. kansasii, M. simiae 
and M. genavense.  Revue Scientifique et Technique 20: 265–290. 
Bero, J., Hannaert, V., Chataigné, G., Hérent, M.-F., Quetin-Leclercq, J. 2011.  In vitro 
antitrypanosomal and anti-leishmanial activity of plants used in Benin in traditional 
medicine and bio-guided fractionation of the most active extract.  Journal of 
Ethnopharmacology 137: 998–1002. 
Best, C.A., Best, T.J. 2009.  Mycobacterium smegmatis infection of the hand.  Journal 
of Clinical Microbiology 4: 165–166. 
Bhalla, P., Forrest G.N., Gershon, A.A. 2015.  An official publication of the Infectious 
Diseases Society of America. Clinical Infectious Diseases: 61(1):143 
doi:10.1093/cid/civ338. 
Biet, F., Boschiroli, M.L., Thorel, M.F., Guilloteau, L.A. 2005.  Zoonotic aspects of 
Mycobacterium bovis and Mycobacterium avium-intracellulare complex (MAC). 
Veterinary Research 36: 411–436. 
Biuković, G., Basak, S., Manimekalai, M.S.S., Rishikesan, S., Roessle, M., Dick, T., 
Rao, S.P.S., Hunke, C., Grüber, G. 2013.  Variations of subunit ε of the 
Mycobacterium tuberculosis F1Fo ATP synthase and a novel model for mechanism 
of action of the tuberculosis drug TMC207.  Antimicrobial Agents Chemotherapy 
57: 168–176. 
Blazquez, J., de Los Monteros, L.E.E., Samper, S., Martin, C., Guerrero, A., Cobo, J., 
Van Embden, J., Baquero, F., Gómez-Mampaso, E. 1997. Genetic characterization 
of multidrug-resistant Mycobacterium bovis strains from a hospital outbreak 
involving human immunodeficiency virus-positive patients.  Journal of Clinical 
Microbiology 35: 1390–1393. 
Blondeau, S., Do, Q.T., Scior, T., Bernard, P., Morin-Allory, L. 2010. Reverse 
pharmacognosy: another way to harness the generosity of nature. Current 
Pharmaceutical Design 16: 1682–1696. 
Bloom, B.R., Murray, C.J. 1992. Tuberculosis: commentary on a reemergent killer. 
Science 257: 1055–1064. 
Bobadilla-del Valle, M., Torres-González, P., Cervera-Hernández, M.E., Martínez-
Gamboa, A., Crabtree-Ramirez, B., Chávez-Mazari, B., Ortiz-Conchi, N., 
Rodríguez-Cruz, L., Cervantes-Sánchez, A., Gudiño-Enríquez, T. 2015.  Trends of 
Mycobacterium bovis isolation and first-line anti-tuberculosis drug susceptibility 
 192 
 
profile: A Fifteen-Year Laboratory-Based Surveillance. PLoS Neglected Tropical 
Diseases Journal 9: e0004124. 
Boligon, A.A., Agertt, V., Janovik, V., Cruz, R.C., Campos, M., Guillaume, D., Athayde, 
M.L., dos Santos, A.R.S. 2012.  Antimycobacterial activity of the fractions and 
compounds from Scutia buxifolia.  Revista Brasileira de Farmacognosia 22: 45–52. 
Bonjar, G.H.S. 2004.  Evaluation of antibacterial properties of Iranian medicinal plants 
against Micrococcus luteus, Serratia marcescens, Klebsiella pneumoniae and 
Bordetella bronchoseptica. Asian Journal of Plant Sciences 3: 82–86. 
Bono, M., Jemmi, T., Bernasconi, C., Burki, D., Telenti, A., Bodmer, T. 1995.  Genotypic 
characterization of Mycobacterium avium strains recovered from animals and their 
comparison to human strains.  Applied and Environmental Microbiology 61: 371–
373. 
Bopana, N., Saxena, S. 2007. Asparagus racemosus—Ethnopharmacological 
evaluation and conservation needs.  Journal of Ethnopharmacology 110: 1–15. 
BoRam, K., JaeMyung, K., ByoungJun, K., YunHo, J., SoYoon, R., YoonHoh, K., 
BumJoon, K. 2014. Identification of nontuberculous mycobacteria isolated from 
Hanwoo (Bos taurus coreanae) in South Korea by sequencing analysis targeting 
hsp65, rpob and 16S rRNA genes.  Veterinary Microbiology 173: 385–389. 
Borchardt, J.R., Wyse, D.L., Sheaffer, C.C., Kauppi, K.L., Ehlke, R.G.F.N.J., Biesboer, 
D.D., Bey, R.F. 2008. Antimicrobial activity of native and naturalized plants of 
Minnesota and Wisconsin.  Journal of Medicinal Plants Research 2: 98–110. 
Bosne-David, S., Barros, V., Verde, S.C., Portugal, C., David, H.L. 2000.  Intrinsic 
resistance of Mycobacterium tuberculosis to clarithromycin is effectively reversed 
by subinhibitory concentrations of cell wall inhibitors.  Journal of Antimicrobial 
Chemotherapy 46: 391–395. 
Briskin, D.P. 2000.  Medicinal plants and phytomedicines. Linking plant biochemistry 
and physiology to human health.  Plant Physiology 124: 507–514. 
Brusotti, G., Cesari, I., Dentamaro, A., Caccialanza, G., Massolini, G. 2014.  Isolation 
and characterization of bioactive compounds from plant resources: The role of 
analysis in the ethnopharmacological approach.  Journal of Pharmaceutical and 
Biomedical Analysis 87: 218–228. 
Buckwalter, S.P., Olson, S.L., Connelly, B.J., Lucas, B.C., Rodning, A.A., Walchak, 
R.C., Deml, S.M., Wohlfiel, S.L., Wengenack, N.L. 2016.  Evaluation of Matrix-
Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for 
identification of Mycobacterium species, Nocardia species, and other aerobic 
Actinomycetes.  Journal of Clinical Microbiology 54: 376–384. 
BumJoon, K., SeongKarp, H., KeunHwa, L., YeoJun, Y., EuiChong, K., YoungGil, P., 
GilHan, B., YoonHoh, K. 2004. Differential identification of Mycobacterium 
 193 
 
tuberculosis complex and nontuberculous mycobacteria by duplex PCR assay 
using the RNA polymerase gene (rpoB).  Journal of Clinical Microbiology 42: 1308–
1312. 
Burnet, N.G., Benson, R.J., Williams, M. V, Peacock, J.H. 2000.  The rise in bacterial 
resistance.  Bristish Medical Journal 320: 199–200. 
Busse, H.J., Denner, E.B.M., Lubitz, W. 1996. Classification and identification of 
bacteria: current approaches to an old problem. Overview of methods used in 
bacterial systematics.  Journal of Biotechnology 47: 3–38. 
Butler, W.R., Guthertz, L.S. 2001.  Mycolic acid analysis by high-performance liquid 
chromatography for identification of Mycobacterium species.  Clinical Microbiology 
Reviews 14: 704–726. 
Caamal-Fuentes, E., Torres-Tapia, L., Simá-Polanco, P., Peraza-Sánchez, S.R., Moo-
Puc, R. 2011.  Screening of plants used in Mayan traditional medicine to treat 
cancer-like symptoms.  Journal of Ethnopharmacology 135: 719–724. 
Camacho-Corona, M. del R., Favela-Hernández, J.M. de J., González-Santiago, O., 
Garza-González, E., Molina-Salinas, G.M., Said-Fernández, S., Delgado, G., Luna-
Herrera, J. 2009.  Evaluation of some plant-derived secondary metabolites against 
sensitive and multidrug-resistant Mycobacterium tuberculosis.  Journal of the 
Mexican Chemical Society 53: 71–75. 
Campora, L., Corazza, M., Zullino, C., Ebani, V. V, Abramo, F.  2011.  Mycobacterium 
avium subspecies hominissuis disseminated infection in a Basset Hound dog. 
Journal of Veterinary Diagnostic Investigation 23: 1083–1087. 
Castellheim, A., Brekke, O.L., Espevik, T., Harboe, M., Mollnes, T.E. 2009.  Innate 
immune responses to danger signals in systemic inflammatory response syndrome 
and sepsis.  Scandinavian Journal of Immunology 69: 479–491. 
Centers for Disease Control and Prevention.  2005.  Human tuberculosis caused by 
Mycobacterium bovis--New York City, 2001-2004.  Morbidity and Mortality Weekly 
Report 54, 605. 
Centers for Disease Control and Prevention.  2003. Update: adverse event data and 
revised American Thoracic Society/CDC recommendations against the use of 
rifampin and pyrazinamide for treatment of latent tuberculosis infection--United 
States, 2003.  Morbidity and Mortality Weekly Report 52, 735. 
Cerella, C., Radogna, F., Dicato, M., Diederich, M. 2013. Natural compounds as 
regulators of the cancer cell metabolism.  International Journal of Cell Biology 
doi:10.1155/2013/639401. 
  
 194 
 
Chan, J., Fan, X.D., Hunter, S.W., Brennan, P.J., Bloom, B.R. 1991. 
Lipoarabinomannan, a possible virulence factor involved in persistence of 
Mycobacterium tuberculosis within macrophages.  Infection and Immunity 59: 
1755–1761. 
Chan, J., Xing, Y., Magliozzo, R.S., Bloom, B.R. 1992.  Killing of virulent Mycobacterium 
tuberculosis by reactive nitrogen intermediates produced by activated murine 
macrophages.  Journal of Experimental Medicine 175: 1111–1122. 
Chatterjee, D. 1997.  The mycobacterial cell wall: structure, biosynthesis and sites of 
drug action.  Current Opinion in Chemical Biology 1: 579–588. 
Chatterjee, M., Bhattacharya, S., Karak, K., Dastidar, S.G. 2013.  Effects of different 
methods of decontamination for successful cultivation of Mycobacterium 
tuberculosis.  Indian Journal of Medical Research 138: 541–548 doi:IJMR-138-541.  
Chege, G.K., Warren, R.M., Pittius, N.C.G., Burgers, W.A., Wilkinson, R.J., Shephard, 
E.G., Williamson, A.L. 2008. Detection of natural infection with Mycobacterium 
intracellulare in healthy wild-caught Chacma baboons (Papio ursinus) by ESAT-6 
and CFP-10 IFN-γ ELISPOT tests following a tuberculosis outbreak.  Biomedical 
Microbiology 8. 
Cheng, Y., Shao, Y., Yan, W. 2011.  Solubilities of betulinic acid in thirteen organic 
solvents at different temperatures.  Journal of Chemical and Engineering Data 56: 
4587–4591. 
Chhabra, S.C., Mahunnah, B.L.A., Mshiu, E.N. 1987.  Plants used in traditional 
medicine in eastern Tanzania. I. Pteridophytes and Angiosperms (Acanthaceae to 
Canellaceae).  Journal of Ethnopharmacology 21: 253–277. 
Chimponda, T., Mukanganyama, S. 2010.  Antimycobacterial activities of selected 
medicinal plants from Zimbabwe against Mycobacterium aurum and 
Corynebacterium glutamicum.  Tropical Biomedicine 27: 595–610. 
Chinsembu, K.C. 2016.  Tuberculosis and nature’s pharmacy of putative anti-
tuberculosis agents.  Acta Tropica 153: 46–56. 
Chung, G.A., Aktar, Z., Jackson, S., Duncan, K. 1995.  High-throughput screen for 
detecting antimycobacterial agents.  Antimicrobial Agents and Chemotherapy 39: 
2235–2238. 
Churchyard, G.J., Mametja, L.D., Mvusi, L., Ndjeka, N., Hesseling, A.C., Reid, A., 
Babatunde, S., Pillay, Y. 2014.  Tuberculosis control in South Africa: Successes, 
challenges and recommendations.  South African Medical Journal 104: 234–248. 
Cichewicz, R.H., Kouzi, S.A. 2004.  Chemistry, biological activity, and chemotherapeutic 
potential of betulinic acid for the prevention and treatment of cancer and HIV 
infection.  Medicinal Research Reviews 24: 90–114. 
  
 195 
 
Cingolani, A., Antinori, A., Sanguinetti, M., Gillini, L., De Luca, A., Posteraro, B., Ardito, 
F., Fadda, G., Ortona, L. 1999.  Application of molecular methods for detection and 
transmission analysis of Mycobacterium tuberculosis drug resistance in patients 
attending a reference hospital in Italy.  Journal of Infectious Diseases 179: 1025–
1029. 
Clarke, C., Van Helden, P., Miller, M., Parsons, S. 2016.  Animal-adapted members of 
the Mycobacterium tuberculosis complex endemic to the southern African 
subregion.  Journal of  South African Veterinary Association 87: 
doi:10.4102/jsava.v87i1.1322. 
Clarke, K.R., Fitzgerald, S.D., Hattey, J.A., Bolin, C.A., Berry, D.E., Church, S. V, Reed, 
W.M. 2006.  Experimental inoculation of wild turkeys (Meleagris gallopavo) with 
Mycobacterium bovis.  Avian Diseases 50: 131–134. 
Clay, H., Volkman, H.E., Ramakrishnan, L. 2008.  Tumor necrosis factor signaling 
mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage 
death.  Immunity 29: 283–294. 
Cleary-Guida, M.B., Okvat, H.A., Oz, M.C., Ting, W. 2001.  A regional survey of health 
insurance coverage for complementary and alternative medicine: current status and 
future ramifications.  Journal of Alternative Complementary Medicine 7: 269–273. 
Cloud, J.L., Neal, H., Rosenberry, R., Turenne, C.Y., Jama, M., Hillyard, D.R., Carroll, 
K.C. 2002.  Identification of Mycobacterium spp. by using a commercial 16S 
ribosomal DNA sequencing kit and additional sequencing libraries.  Journal Clinical 
Microbiology 40: 400–406. 
Cook, V.J., Turenne, C.Y., Wolfe, J., Pauls, R., Kabani, A. 2003.  Conventional methods 
versus 16S ribosomal DNA sequencing for identification of nontuberculous 
mycobacteria: cost analysis.  Journal of Clinical Microbiology 41: 1010–1015. 
Corner, L.A.L. 2007.  Bovine tuberculosis control in Australia, New Zealand and Ireland: 
wild animals and the epidemiology of tuberculosis in domestic animals.  Cattle 
Practice 15: 3–12. 
Corner, L.A.L. 2006. The role of wild animal populations in the epidemiology of 
tuberculosis in domestic animals: how to assess the risk.  Veterinary Microbiology 
112: 303–312. 
Corner, L.A.L., Murphy, D., Costello, E., Gormley, E. 2009.  Tuberculosis in European 
Badgers (Meles meles) and the control of infection with bacille Calmette-Guérin 
vaccination.  Journal of Wildlife Diseases 45: 1042–1047. 
Cosivi, O., Grange, J.M., Daborn, C.J., Raviglione, M.C., Fujikura, T., Cousins, D., 
Robinson, R.A., Huchzermeyer, H.F., De Kantor, I., Meslin, F.X. 1998.  Zoonotic 
tuberculosis due to Mycobacterium bovis in developing countries.  Emerging 
Infectious Diseases 4: 59. 
 196 
 
Cousins, D. V, 2001.  Mycobacterium bovis infection and control in domestic livestock. 
Mycobacterial infections in domestic and wild animals.  Revue Scientifique et 
Technique (Office International des Épizooties) 20: 71-85. 
Cousins, D. V, Bastida, R., Cataldi, A., Quse, V., Redrobe, S., Dow, S., Duignan, P., 
Murray, A., Dupont, C., Ahmed, N. 2003.  Tuberculosis in seals caused by a novel 
member of the Mycobacterium tuberculosis complex: Mycobacterium pinnipedii sp. 
nov.  International Journal of Systematic and Evolutionary Microbiology 53: 1305–
1314. 
Cowan, M.M. 1999.  Plant products as antimicrobial agents.  Clinical Microbiology 
Reviews 12: 564–582. 
Cragg, G.M., Newman, D.J. 2005.  Plants as a source of anti-cancer agents.  Journal of  
Ethnopharmacology 100, 72–79. 
Craker, L.E., Gardner, Z. 2003.  Dietary supplements: The new herbalism. 
HortTechnology 13: 239–242. 
Cushman, M.J., Hoffman, M.J. 2004.  Complementary and alternative health care and 
the home care population.  Home Health Care Management and Practice 16: 360–
373. 
Daffé, M., Reyrat, J.M., 2008.  The mycobacterial cell envelope.  Cold Spring Harbour 
Perspectives Medicine 4.a021105.  
Dailloux, M., Abalain, M.L., Laurain, C., Lebrun, L., Loos-Ayav, C., Lozniewski, A., 
Maugein, J., Group, F.M.S. 2006.  Respiratory infections associated with 
nontuberculous mycobacteria in non-HIV patients.  European Respiratory Journal 
28: 1211–1215. 
Dannenberg  Jr, A.M. 1989.  Immune mechanisms in the pathogenesis of pulmonary 
tuberculosis.  Reviews of Infectious Diseases 11 Suppl 2: S369–S378. 
Darriba, D., Taboada, G.L., Doallo, R., Posada, D. 2012.  jModelTest 2: more models, 
new heuristics and parallel computing.  Nature Methods 9: 772. 
de Kantor, I.N., Ambroggi, M., Poggi, S., Morcillo, N., Telles, M.A.D.S., Ribeiro, M.O., 
Torres, M.C.G., Polo, C.Ll., Ribón, W., García, V. 2008. Human Mycobacterium 
bovis infection in ten Latin American countries.  Tuberculosis 88, 358–365. 
De Kantor, I.N., LoBue, P.A., Thoen, C.O. 2010. Human tuberculosis caused by 
Mycobacterium bovis in the United States, Latin America and the Caribbean. 
International Journal of Tuberculosis and Lung Disease 14: 1369–1373. 
De la Rua-Domenech, R. 2006.  Human Mycobacterium bovis infection in the United 
Kingdom: incidence, risks, control measures and review of the zoonotic aspects of 
bovine tuberculosis.  Tuberculosis 86: 77–109. 
  
 197 
 
De la Rua-Domenech, R., Goodchild, T., Vordermeier, M., Clifton-Hadley, R. 2006.  
Ante mortem diagnosis of bovine tuberculosis: the significance of unconfirmed test 
reactors.  Government Veterinary Journal 16: 65–71. 
de Lisle, G.W., Bengis, R.G., Schmitt, S.M., O’Brien, D.J. 2002.  Tuberculosis in free-
ranging wildlife: detection, diagnosis and management.  Revue Scientifique et 
Technique 21: 317–334. 
Dehelean, C.A., Şoica, C., Ledeţi, I., Aluaş, M., Zupko, I., Gǎluşcan, A., Cinta-Pinzaru, 
S., Munteanu, M.  2012.  Study of the betulin enriched birch bark extracts effects on 
human carcinoma cells and ear inflammation.  Chemistry Central Journal 6: 1. 
Delogu, G., Sali, M., Fadda, G. 2013. The biology of Mycobacterium tuberculosis 
infection.  Mediterranean Journal of Hematology and Infectious Diseases. 5: 
2013070. 
Despierres, L., Cohen-Bacrie, S., Richet, H., Drancourt, M. 2012. Diversity of 
Mycobacterium avium subsp. hominissuis and mycobacteria causing 
lymphadenitis, France.  European Journal of Clinical Microbiology and Infectious 
Diseases 31: 1373–1379. 
Diacon, A.H., Donald, P.R., Pym, A., Grobusch, M., Patientia, R.F., Mahanyele, R., 
Bantubani, N., Narasimooloo, R., De Marez, T., Van Heeswijk, R. 2012. 
Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for 
multidrug-resistant tuberculosis: long-term outcome, tolerability and effect on 
emergence of drug resistance.  Antimicrobial Agents and Chemotherapy 56: 3271–
3276. 
Diacon, A.H., Pym, A., Grobusch, M., Patientia, R., Rustomjee, R., Page-Shipp, L., 
Pistorius, C., Krause, R., Bogoshi, M., Churchyard, G. 2009.  The diarylquinoline 
TMC207 for multidrug-resistant tuberculosis.  New England Journal of Medicine 
360: 2397–2405. 
Djakpo, O., Yao, W., 2010. Rhus chinensis and Galla Chinensis–folklore to modern 
evidence: review.  Phytotherapy Research 24: 1739–1747. 
Donald, P.R., Schaaf, H.S., Schoeman, J.F. 2005.  Tuberculous meningitis and miliary 
tuberculosis: the Rich focus revisited.  Journal of Infection 50: 193–195. 
Dorman, S.E., Chaisson, R.E. 2007.  From magic bullets back to the magic mountain: 
the rise of extensively drug-resistant tuberculosis.  Nature Medicine 13: 295–298. 
Dubey, N.K., Kumar, R., Tripathi, P. 2004. Global promotion of herbal medicine: India’s 
opportunity.  Current Science 86, 37–41. 
Duke, J.A. 1992. Handbook of phytochemical constituent grass, herbs and other 
economic plants. CRC press publications. 
  
 198 
 
Durr, P.A., Clifton-Hadley, R.S., Hewinson, R.G. 2000.  Molecular epidemiology of 
bovine tuberculosis II.  Applications of genotyping.  Revue Scientifique  et 
Technique  International des Epizooties 19: 689–701. 
Efferth, T., Koch, E. 2011.  Complex interactions between phytochemicals.  The multi-
target therapeutic concept of phytotherapy.  Current Drug Targets 12: 122–132. 
El Helou, G., Viola, G.M., Hachem, R., Han, X.Y., Raad, I.I.  2013.  Rapidly growing 
mycobacterial bloodstream infections.  Lancet Infectious Diseases 13: 166–174. 
Eloff, J.N. 2000.  On expressing the antibacterial activity of plant extracts - a small first 
step in applying scientific knowledge to rural primary health care.  South African 
Journal of Sciences 96: 116–118. 
Eloff, J.N. 1998a. Which extractant should be used for the screening and isolation of 
antimicrobial components from plants? Journal of Ethnopharmacology 60: 1–8. 
Eloff, J.N. 1998b.  A sensitive and quick microplate method to determine the minimal 
inhibitory concentration of plant extracts for bacteria.  Planta Medica 64: 711–713. 
Eloff, J.N., Famakin, J.O., Katerere, D.R.P. 2005.  Combretum woodii (Combretaceae) 
leaf extracts have high activity against Gram-negative and Gram-positive bacteria. 
African Journal of Biotechnology 4 (10): 1161-1166. 
Eloff, J.N., Katerere, D.R., McGaw, L.J. 2008.  The biological activity and chemistry of 
the southern African Combretaceae.  Journal of Ethnopharmacology 119: 686–699. 
Eloff, J.N., Masoko, P., Picard, J. 2007.  Resistance of animal fungal pathogens to 
solvents used in bioassays.  South African Journal of Botany 73: 667–669. 
Eloff, J.N., McGaw, L.J. 2014.  Using African Plant Biodiversity to Combat Microbial 
Infections, in: Novel Plant Bioresources. John Wiley & Sons publishers, 163–173 
doi:10.1002/9781118460566.ch12. 
Ergan, B., Çoplu, L., Alp, A., Artvinli, M. 2004.  Mycobacterium smegmatis pneumonia.  
Respirology 9: 283–285. 
Ernst, E., White, A. 2000.  The BBC survey of complementary medicine use in the UK. 
Complement Therapies in  Medicine 8: 32–36. 
Escalonilla, P., Esteban, J., Soriano, L., Fari  a, C., Pique, E., Grilli, R., Ramirez, J.R., 
Barat, A., Martin, L., Requena, L. 1998.  Cutaneous manifestations of infection by 
nontuberculous mycobacteria.  Clinical and Experimental Dermatology 23: 214–
221. 
Evans, J.T., Smith, E.G., Banerjee, A., Smith, R.M.M., Dale, J., Innes, J.A., Hunt, D., 
Tweddell, A., Wood, A., Anderson, C. 2007.  Cluster of human tuberculosis caused 
by Mycobacterium bovis: evidence for person-to-person transmission in the UK. 
Lancet 369: 1270–1276. 
 199 
 
Exarchou, V., Godejohann, M., van Beek, T.A., Gerothanassis, I.P., Vervoort, J. 2003. 
LC-UV-solid-phase extraction-NMR-MS combined with a cryogenic flow probe and 
its application to the identification of compounds present in Greek oregano. 
Analytical Chemistry 75: 6288–6294. 
Fabricant, D.S., Farnsworth, N.R. 2001.  The value of plants used in traditional medicine 
for drug discovery.  Environmental Health Perspectives 109: 69. 
Fanning, A. 1999.  Tuberculosis: 6. Extrapulmonary disease. Canadian Medical 
Association Journal 160: 1597. 
Faujan, N.H., Alitheen, N.B., Yeap, S.K., Ali, A.M., Muhajir, A.H., Ahmad, F.B.H., 2010. 
Cytotoxic effect of betulinic acid and betulinic acid acetate isolated from Melaleuca 
cajuput on human myeloid leukemia (HL-60) cell line. African Journal of 
Biotechnology 9: 6387–6396. 
Felsenstein, J., 1985. Phylogenies and the Comparative Method.  American Naturalist 
125: 1–15. 
Fennell, C.W., Lindsey, K.L., McGaw, L.J., Sparg, S.G., Stafford, G.I., Elgorashi, E.E., 
Grace, O.M., Staden, J. 2004.  Assessing African medicinal plants for efficacy and 
safety: pharmacological screening and toxicology.  Journal of Ethnopharmacology 
94: 205–217. 
Ferrara, G., Murray, M., Winthrop, K., Centis, R., Sotgiu, G., Migliori, G.B., Maeurer, M., 
Zumla, A. 2012.  Risk factors associated with pulmonary tuberculosis: smoking, 
diabetes and anti-TNFα drugs.   Current Opinion in Pulmonary Medicine 18: 233–
240. 
Fitzgerald, S.D., Zwick, L.S., Berry, D.E., Church, S. V, Kaneene, J.B., Reed, W.M., 
2003. Experimental inoculation of pigeons (Columba livia) with Mycobacterium 
bovis.  Avian Diseases 47:  470–475. 
Flekhter, O.B., Karachurina, L.T., Poroikov, V. V, Nigmatullina, L.P., Baltina, L.A., 
Zarudii, F.S., Davydova, V.A., Spirikhin, L. V, Baikova, I.P., Galin, F.Z. 2000.  The 
synthesis and hepatoprotective activity of esters of the lupane group triterpenoids. 
Russian Journal of Bioorganic Chemistry 26: 192–200. 
Fontana, C., Favaro, M., Pelliccioni, M., Pistoia, E.S., Favalli, C. 2005.  Use of the 
MicroSeq 500 16S rRNA gene-based sequencing for identification of bacterial 
isolates that commercial automated systems failed to identify correctly.  Journal of 
Clinical Microbiology 43, 615–619. 
Fourie, T.G., Snyckers, F.O. 1984.  A flavone with antiinflammatory activity from the 
roots of Rhus undulata.  Journal of Natural Products 47: 1057–1058. 
Frothingham, R., Meeker-O’Connell, W.A. 1998.  Genetic diversity in the 
Mycobacterium tuberculosis complex based on variable numbers of tandem DNA 
repeats.  Microbiology 144: 1189–1196. 
 200 
 
Gabr, S.A., Al-Ghadir, A.H., 2015. Phytochemical analysis and in vitro antifungal 
activities of bioactive fractions from leaves of Rhus coriaria (SUMAC).  Journal of 
Pure and Applied Microbiology 9: 559-565. 
Gabr, S.A., El-Metwally, M.M., Al-Ghadir, A.H. 2014.  Antioxidant and antibacterial 
active constituents of Rhus coriaria.  Biotechnology 13: 37. 
Gallivan, M., Shah, N., Flood, J. 2015.  Epidemiology of human Mycobacterium bovis 
disease, California, USA, 2003-2011.  Emerging Infectious Diseases 21: 435–443 
doi:10.3201/eid2103.141539. 
Gandhi, N.R., Andrews, J.R., Brust, J.C.M., Montreuil, R., Weissman, D., Heo, M., Moll, 
A.P., Friedland, G.H., Shah, N.S. 2012.  Risk factors for mortality among MDR and 
XDR-TB patients in a high HIV prevalence setting.  International Journal of 
Tuberculosis and Lung Disease 16: 90–97. 
Ganihigama, D.U., Sureram, S., Sangher, S., Hongmanee, P., Aree, T., Mahidol, C., 
Ruchirawat, S., Kittakoop, P. 2015.  Antimycobacterial activity of natural products 
and synthetic agents: pyrrolodiquinolines and vermelhotin as anti-tubercular leads 
against clinical multidrug resistant isolates of Mycobacterium tuberculosis.  
European Journal of Medicinal Chemistry 89: 1–12. 
Gautam, R., Saklani, A., Jachak, S.M. 2007.  Indian medicinal plants as a source of 
antimycobacterial agents.  Journal of Ethnopharmacology 110: 200–234. 
Gcebe, N., Rutten, V., Pittius, N.C.G., Michel, A. 2013.  Prevalence and distribution of 
non-tuberculous mycobacteria (NTM) in cattle, African buffaloes (Syncerus caffer) 
and their environments in South Africa.  Transboundary Emerging Diseases 60, 
74–84. 
Germishuizen, G., Meyer, N.L. 2003.  Plants of southern Africa: an annotated checklist. 
Strelitzia 14. 
Gertsch, J. 2009.  How scientific is the science in ethnopharmacology? Historical 
perspectives and epistemological problems.  Journal of Ethnopharmacology 122: 
177–183. 
Ghaemi, E.A., Mazandarani, M., Mansourian, A.R., Babaii Kochaksaraeii, M.  2011. 
Antimycobacterial activity of some medicinal plants used in traditional medicine in 
North of Iran.  International Proceedings of Chemical, Biological and Environmental 
Engineering 3: 26–28. 
Gheorgheosu, D., Duicu, O., Dehelean, C., Soica, C., Muntean, D. 2014.  Betulinic acid 
as a potent and complex antitumor phytochemical: a minireview. Anti-Cancer 
Agents Medicinal Chemistry 14: 936–945. 
Gilani, A.H. 2005.  Trends in ethnopharmacology.  Journal of Ethnopharmacology 100: 
43–49. 
Glickman, M.S., Cox, J.S., Jacobs  Jr, W.R. 2000.  A novel mycolic acid cyclopropane 
 201 
 
synthetase is required for cording, persistence, and virulence of Mycobacterium 
tuberculosis.  Molecular Cell 5: 717–727. 
Gopathi, N.R., Mandava, V., Makala, S. 2015. Tuberculosis and diabetes: the deadly 
duo.  International Journal of  Advance in Medical Science 2: 241–245. 
Grange, J.M. 2001.  Mycobacterium bovis infection in human beings.  Tuberculosis 81: 
71–77. 
Green, E., Samie, A., Obi, C.L., Bessong, P.O., Ndip, R.N. 2010.  Inhibitory properties 
of selected South African medicinal plants against Mycobacterium tuberculosis.  
Journal of Ethnopharmacology 130: 151–157. 
Guindon, S., Dufayard, J.-F., Lefort, V., Anisimova, M., Hordijk, W., Gascuel, O. 2010. 
New algorithms and methods to estimate maximum-likelihood phylogenies: 
assessing the performance of PhyML 3.0. Systematic Biology 59: 307–321 
doi:10.1093/sysbio/syq010. 
Gurib-Fakim, A. 2006.  Medicinal plants: traditions of yesterday and drugs of tomorrow. 
Molecular Aspects Medicine 27: 1–93. 
Habib-ur-Rehman, Yasin, K.A., Choudhary, M.A., Khaliq, N., Atta-ur-Rahman, 
Choudhary, M.I., Malik, S. 2007.  Studies on the chemical constituents of 
Phyllanthus emblica.  Natural Product Research 21: 775–781. 
Haddad, N., Masselot, M., Durand, B. 2004.  Molecular differentiation of Mycobacterium 
bovis isolates. Review of main techniques and applications.  Research in 
Veterinary Science 76: 1–18. 
Haddad, N., Ostyn, A., Karoui, C., Masselot, M., Thorel, M.F., Hughes, S.L., Inwald, J., 
Hewinson, R.G., Durand, B. 2001.  Spoligotype diversity of Mycobacterium bovis 
strains isolated in France from 1979 to 2000.  Journal of Clinical Microbiology 39: 
3623–3632. 
Hall, T.A. 1999.  BioEdit: a user-friendly biological sequence alignment editor and 
analysis program for Windows 95/98/NT, in: Nucleic Acids Symposium Series 95–
98. 
Hallgren, K.A. 2012.  Computing inter-rater reliability for observational data: An 
overview and tutorial.  Tutorials in Quantitative Methods for Psychology 8: 23–34. 
Hamburger, M.O., Cordell, G.A. 1987.  A direct bioautographic TLC assay for 
compounds possessing antibacterial activity.  Journal of Natural Products 50: 19–
22. 
Han, X.Y., Dé, I., Jacobson, K.L. 2007.  Rapidly growing mycobacteria: clinical and 
microbiologic studies of 115 cases.  American Journal of Clinical Pathology 128: 
612–621. 
Hang’ombe, M.B., Munyeme, M., Nakajima, C., Fukushima, Y., Suzuki, H., Matandiko, 
 202 
 
W., Ishii, A., Mweene, A.S., Suzuki, Y. 2012.  Mycobacterium bovis infection at the 
interface between domestic and wild animals in Zambia.  Biomedical Veterinary 
Research 8: 1. 
Harborne, A.J. 1998.  Phytochemical methods a guide to modern techniques of plant 
analysis.  Springer Science & Business Media publishers. 
Hedberg, I. 1993. Botanical methods in ethnopharmacology and the need for 
conservation of medicinal plants.  Journal of Ethnopharmacology 38: 113–119. 
Helden, P.D. van, Parsons, S.D.C., Pittius, N.C.G. van. 2009.  Emerging mycobacteria 
in South Africa.  Journal of South African Veterinary Association 80: 210–214. 
Henning, M.W. 1956. Animal diseases in South Africa: being an account of the 
infectious diseases of domestic animals. 3rd edn.  Pretoria: Central News Agency. 
Hett, E.C., Rubin, E.J. 2008.  Bacterial growth and cell division: a mycobacterial 
perspective.  Microbiology and Molecular Biology Reviews 72: 126–156. 
Hilty, M., Diguimbaye, C., Schelling, E., Baggi, F., Tanner, M., Zinsstag, J.  2005. 
Evaluation of the discriminatory power of variable number tandem repeat (VNTR) 
typing of Mycobacterium bovis strains.  Veterinary Microbiology 109: 217–222. 
Hlavsa, M.C., Moonan, P.K., Cowan, L.S., Navin, T.R., Kammerer, J.S., Morlock, G.P., 
Crawford, J.T., LoBue, P.A. 2008.  Human tuberculosis due to Mycobacterium 
bovis in the United States, 1995-2005.  Clinical Infectious Diseases 47: 168–175. 
Hlokwe, T.M., Helden, P. van, Michel, A. 2013.  Evaluation of the discriminatory power 
of variable number of tandem repeat typing of Mycobacterium bovis isolates from 
southern Africa.  Transboundary Emerging Diseases 60: 111–120. 
Hlokwe, T.M., Jenkins, A.O., Streicher, E.M., Venter, E.H., Cooper, D., Godfroid, J., 
Michel, A.L. 2011.  Molecular characterisation of Mycobacterium bovis isolated 
from African buffaloes (Syncerus caffer) in Hluhluwe-iMfolozi Park in KwaZulu-
Natal, South Africa.  Onderstepoort Journal of Veterinary Research 78: 39–44. 
Hlokwe, T.M., Van Helden, P., Michel, A.L. 2014.  Evidence of increasing intra and 
inter-species transmission of Mycobacterium bovis in South Africa: Are we losing 
the battle? Preventive Veterinary Medicine 115: 10–17. 
Hoang, T.T.T., Nguyen, N.V., Dinh, S.N., Nguyen, H.B., Cobelens, F., Thwaites, G., 
Nguyen, H.T., Nguyen, A.T., Wright, P., Wertheim, H.F.L. 2015.  Challenges in 
detection and treatment of multidrug resistant tuberculosis patients in Vietnam. 
Biomedical Public Health 15: 980 doi:10.1186/s12889-015-2338-5. 
Hoffmann, D. 2003.  Medical herbalism: the science and practice of herbal medicine.  
Inner Traditions/Bear & Co publishers. 
Hostettmann, K. 1999.  Chemistry, biological and pharmacological properties of 
medicinal plants from the Americas. Taylor & Francis publishers.  CRC press 
 203 
 
http://www.sussex.co.za [Accessed 2016-08-08] 
http;//www.afrikanerbees.com [Accessed 2016-08-08] 
http://www.bacterio.net/mycobacterium.html [Accessed 2016-10-26] 
http://www.ncbi.nlm.nih.gov [Accessed 2013-06-17]. 
http://www.mafft.cbrc.jp/alignment/server/ [Accessed 2009-12-13] 
Hussain, M.S., Fareed, S., Ansari, S., Rahman, M.A., Ahmad, I.Z., Saeed, M. 2012. 
Current approaches toward production of secondary plant metabolites.  Journal of 
Pharmacy and Bioallied Sciences 4: 10. 
Hutchings, A., Scott, A.H., Lewis, G.  1996.  Zulu Medicinal Plants: An Inventory. 
University of Natal Press.    
Hutton, K. 2010.  A comparative study of the plants used for medicinal purposes by the 
Creek and Seminole tribes.  PhD Thesis, University of South Florida, USA. 
Inderlied, C.B. 2004. Mycobacteria.  Infectious Diseases (Auckl). 2: 21–22. 
Jachak, S.M., Saklani, A. 2007. Challenges and opportunities in drug discovery from 
plants.  Current Science 92: 1251. 
Jacob, J.T., Mehta, A.K., Leonard, M.K. 2009. Acute forms of tuberculosis in adults. 
American  Journal of Medicine 122: 12–17. 
Jäger, S., Winkler, K., Pfüller, U., Scheffler, A. 2007. Solubility studies of oleanolic acid 
and betulinic acid in aqueous solutions and plant extracts of Viscum album L. 
Planta Medica 73: 157–162. 
Janda, J.M., Abbott, S.L. 2007. 16S rRNA gene sequencing for bacterial identification in 
the diagnostic laboratory: pluses, perils, and pitfalls.  Journal of Clinical 
Microbiology 45: 2761–2764. 
Jang, S.S., Hirsh, D.C. 2002. Rapidly growing members of the genus Mycobacterium 
affecting dogs and cats.  Journal of the American Animal Hospital Association 38: 
217–220. 
Jansen, R., Embden, J., Gaastra, W., Schouls, L. 2002.  Identification of genes that are 
associated with DNA repeats in prokaryotes.  Molecular Microbiology 43, 1565–
1575. 
Ji, H., Li, X., Zhang, H., 2009. Natural products and drug discovery.  EMBO Reports 10: 
194–200. 
Jiménez-Arellanes, A., Luna-Herrera, J., Ruiz-Nicolás, R., Cornejo-Garrido, J., Tapia, 
A., Yépez-Mulia, L. 2013. Antiprotozoal and antimycobacterial activities of Persea 
americana seeds.  Biomedical Complementary Alternative Medicine 13: 1. 
 204 
 
Jimenez‐Arellanes, A., Meckes, M., Ramirez, R., Torres, J., Luna‐Herrera, J. 2003. 
Activity against multidrug‐resistant Mycobacterium tuberculosis in Mexican plants 
used to treat respiratory diseases.  Phytotherapy Research 17: 903–908. 
Joao, I., Cristovao, P., Antunes, L., Nunes, B., Jordao, L. 2014. Identification of non-
tuberculous mycobacteria by partial gene sequencing and public databases. Int 
ernational Journal of Mycobacteriology 3: 144–151 
doi.org/10.1016/j.ijmyco.2014.04.001. 
Joffe, P. 2001.  Creative Gardening with Indigenous Plants: A South African Guide, 
South African Guide. Briza publications, Pretoria. 
Johns, T., Kokwaro, J.O., Kimanani, E.K. 1990. Herbal remedies of the Luo of Siaya 
District, Kenya: establishing quantitative criteria for consensus.  Economic Botany 
44: 369–381. 
Johnson, M.M., Odell, J.A., 2014. Non-tuberculous mycobacterial pulmonary infections. 
Journal of Thoracic Diseases 6: 210–220 doi:jtd-06-03-210. 
Johnson, R., Streicher, E.M., Louw, G.E., Warren, R.M., Van Helden, P.D., Victor, T.C., 
2007. Drug resistance in M. tuberculosis. Understanding the mechanisms of . drug 
Resistance in enhancing rapid molecular detection of drug resistance in 
Mycobacterium Tuberculosis 7. 
Kabongo-Kayoka, P., Obi, C.L., Nakajima, C., Suzuki, Y., Hattori, T., Eloff, J.N., Wright, 
J., Mbelle, N., McGaw, L.J., 2015.  Novel Mycobacterium avium Complex Species 
Isolated From Black Wildebeest (Connochaetes gnou) in South Africa.  
Transboundary Emerging Diseases doi:10.1111/tbed.12460. 
Kabongo‐Kayoka, P.N., Eloff, J.N., Obi, C.L., McGaw, L.J. 2016.  Antimycobacterial 
activity and low cytotoxicity of leaf extracts of some African Anacardiaceae tree 
species.  Phytotherapy Research doi: 10.1002/ptr.5706. 
Kamerbeek, J., Schouls, L., Kolk, A., Van Agterveld, M., Van Soolingen, D., Kuijper, S., 
Bunschoten, A., Molhuizen, H., Shaw, R., Goyal, M. 1997.  Simultaneous detection 
and strain differentiation of Mycobacterium tuberculosis for diagnosis and 
epidemiology.  Journal of Clinical Microbiology 35: 907–914. 
Kankya, C., Muwonge, A., Djonne, B., Munyeme, M., Opuda-Asibo, J., Skjerve, E., 
Oloya, J., Edvardsen, V., Johansen, T.B. 2011.  Isolation of non-tuberculous 
mycobacteria from pastoral ecosystems of Uganda: Public Health significance. 
Biomedical Public Health 11: 320 doi:1471-2458-11-320. 
Kaplan, G., Post, F.A., Moreira, A.L., Wainwright, H., Kreiswirth, B.N., Tanverdi, M., 
Mathema, B., Ramaswamy, S. V, Walther, G., Steyn, L.M. 2003.  Mycobacterium 
tuberculosis growth at the cavity surface: a microenvironment with failed immunity. 
Infection and Immunity 71: 7099–7108. 
Katale, B.Z., Mbugi, E. V, Botha, L., Keyyu, J.D., Kendall, S., Dockrell, H.M., Michel, 
 205 
 
A.L., Kazwala, R.R., Rweyemamu, M.M., van Helden, P., Matee, M.I. 2014. 
Species diversity of non-tuberculous mycobacteria isolated from humans, livestock 
and wildlife in the Serengeti ecosystem, Tanzania.  Biomedical Infectious Diseases 
14:10 doi: 1186/s12879-014-0616-y.  
Katerere, D.R., Gray, A.I., Nash, R.J., Waigh, R.D. 2003.  Antimicrobial activity of 
pentacyclic triterpenes isolated from African Combretaceae.  Phytochemistry 63: 
81–88. 
Katiyar, C., Gupta, A., Kanjilal, S., Katiyar, S. 2012.  Drug discovery from plant sources: 
An integrated approach.  International Journal of Research in Ayurveda and 
Pharmacy 33: 10. 
Katoh, K., Kuma, K., Toh, H., Miyata, T. 2005.  MAFFT version 5: improvement in 
accuracy of multiple sequence alignment.  Nucleic Acids Research 33: 511–518 
doi:10.1093/nar/gki198. 
Katoh, K., Misawa, K., Kuma, K., Miyata, T. 2002. MAFFT: a novel method for rapid 
multiple sequence alignment based on fast Fourier transform.  Nucleic Acids 
Research 30: 3059–3066 doi:gkf436. 
Kazda, J., Cook, B.R. 1988.  Mycobacteria in pond waters as a source of non-specific 
reactions to bovine tuberculin in New Zealand.  New Zealand Veterinary Journal 
36: 184–188. 
Keet, D.F., Kriek, N.P.J., Bengis, R.G., Michel, A.L. 2001.  Tuberculosis in kudus 
(Tragelaphus strepsiceros) in the Kruger National Park.  Onderstepoort Journal of  
Veterinary Research 68: 225. 
Kim, B.R., Kim, J.M., Kim, B.J., Jang, Y., Ryoo, S., Kook, Y.H., Kim, B.J. 2014. 
Identification of nontuberculous mycobacteria isolated from Hanwoo (Bos taurus 
coreanae) in South Korea by sequencing analysis targeting hsp65, rpoB and 16S 
rRNA genes.  Veterinary Microbiology 173: 385–389 
doi:10.1016/j.vetmic.2014.07.019. 
Kishore, N., Mishra, B.B., Tripathi, V., Tiwari, V.K. 2009.  Alkaloids as potential anti-
tubercular agents.  Fitoterapia 80: 149–163. 
Koh, W.J., Kwon, O.J., Lee, K.S. 2002.  Nontuberculous mycobacterial pulmonary 
diseases in immunocompetent patients.  Korean Journal of Radiology 3: 145–157. 
Kokwaro, J.O. 2009.  Medicinal plants of east Africa.  University of Nairobi press. 
Koranyi, K.I., Ranalli, M.A. 2003. Mycobacterium aurum bacteremia in an 
immunocompromised child.  Pediatric  Infectious Disease Journal 22: 1108–1109. 
Kotzé, M., Eloff, J.N. 2002.  Extraction of antibacterial compounds from Combretum 
microphyllum (Combretaceae).  South African Journal of Botany (Special Issue: 
Ethnobotany in South Africa) 68: 62–67. 
 206 
 
Kremer, L., De Chastellier, C., Dobson, G., Gibson, K.J.C., Bifani, P., Balor, S., Gorvel, 
J., Locht, C., Minnikin, D.E., Besra, G.S. 2005.  Identification and structural 
characterization of an unusual mycobacterial monomeromycolyl‐diacylglycerol.  
Molecular Microbiology 57: 1113–1126. 
Kriek, N.P.J., Keet, D.F., Raath, J.P., De Vos, V., Huchzermeyer, H.F.A.K., Bengis, 
R.G. 1996.  An outbreak of bovine tuberculosis in a free-living African buffalo 
(Syncerus caffer-Sparrman) population in the Kruger National Park: a preliminary 
report. 
Kriz, P., Kaevska, M., Slana, I., Bartejsova, I., Pavlik, I. 2014.  Mycobacterium avium 
subsp. avium in lymph nodes and diaphragms of pigs from one infected herd in the 
Czech Republic.  Journal of Food Protection 77: 141–144. 
Kuete, V., 2010.  Potential of Cameroonian plants and derived products against 
microbial infections: a review.  Planta Medica 76:1479–1491 doi:10.1055/s-0030-
1250027 
Laavola, M., Haavikko, R., Hämäläinen, M., Leppänen, T., Nieminen, R., Alakurtti, S., 
Moreira, V.M., Yli-Kauhaluoma, J., Moilanen, E. 2016.  Betulin derivatives 
effectively suppress inflammation in vitro and in vivo.  Journal of Natural Products 
79: 274–280. 
Laifangbam, S., Singh, H.L., Singh, N.B., Devi, K.M., Singh, N.T. 2009.  A comparative 
study of fluorescent microscopy with Ziehl-Neelsen staining and culture for the 
diagnosis of pulmonary tuberculosis.  Kathmandu University Medical Journal 7: 
226–230. 
Lall, N., Meyer, J.J. 1999.  In vitro inhibition of drug-resistant and drug-sensitive strains 
of Mycobacterium tuberculosis by ethnobotanically selected South African plants.  
Journal of Ethnopharmacology 66: 347–354. 
Laniado-Laborín, R., Muñiz-Salazar, R., García-Ortiz, R.A., Vargas-Ojeda, A.C., Villa-
Rosas, C., Oceguera-Palao, L. 2014.  Molecular characterization of Mycobacterium 
bovis isolates from patients with tuberculosis in Baja California, Mexico.  Infection, 
Genetics and Evolution 27: 1–5. 
Laurent, F.J., Provost, F., Boiron, P. 1999.  Rapid identification of clinically relevant 
Nocardia species to genus level by 16S rRNA gene PCR.  Journal of Clinical 
Microbiology 37: 99–102. 
Layre, E., Sweet, L., Hong, S., Madigan, C.A., Desjardins, D., Young, D.C., Cheng, T.-
Y., Annand, J.W., Kim, K., Shamputa, I.C. 2011.  A comparative lipidomics platform 
for chemotaxonomic analysis of Mycobacterium tuberculosis. Chemistry and 
Biology 18: 1537–1549. 
Ledeţi, I., Avram, Ş., Bercean, V., Vlase, G., Vlase, T., Ledeţi, A., Zupko, I., Mioc, M., 
Şuta, L.-M., Şoica, C. 2015.  Solid-state characterization and biological activity of 
betulonic acid derivatives.  Molecules 20: 22691–22702. 
 207 
 
Ledeti, I., Bosca, C.S., Cosma, C., Badea, V., Todea, A., Bercean, V.-N. 2014. Study on 
obtaining 3-oxolup-20 (29)-en-28-oic acid (betulonic acid) from (3β)-lup-20 (29)-en-
3, 28-diol (betulin).  Revista de Chimie Bucharest 65: 1289–1293. 
Lee, J., Repasy, T., Papavinasasundaram, K., Sassetti, C., Kornfeld, H. 2011. 
Mycobacterium tuberculosis induces an atypical cell death mode to escape from 
infected macrophages. PLoS One 6: e18367. 
 
Le Fleche, P., Fabre, M., Denoeud, F., Koeck, J.L., Vergnaud, J.L.  2002. High 
resolution, on-line identification of strains from the Mycobacterium tuberculosis complex 
based on tandem repeat typing. BMC Microbiology 2: 37. 
 
Legrand, E., Sola, C., Rastogi, N., 2000. Mycobacterium avium-intracellulare complex: 
phenotypic and genotypic markers and molecular basis of inter-species 
transmission. Le complexe Mycobacterium avium-intracellulare: marqueurs 
phénotypiques et génotypiques et les bases moléculaires de la trans. Bulletin de la 
Société de Pathologie Exotique 93: 182–192. 
León-Díaz, R., Meckes-Fischer, M., Valdovinos-Martínez, L., Campos, M.G., 
Hernández-Pando, R., Jiménez-Arellanes, M.A. 2013.  Antitubercular activity and 
the subacute toxicity of (−)-Licarin A in BALB/c mice: a neolignan isolated from 
Aristolochia taliscana.  Archives of Medical Research 44: 99–104. 
Leung, C.C., Rieder, H.L., Lange, C., Yew, W.W. 2011. Treatment of latent infection 
with Mycobacterium tuberculosis: update 2010.  European Respiratory Journal 37: 
690–711. 
Lienhardt, C., Lönnroth, K., Menzies, D., Balasegaram, M., Chakaya, J., Cobelens, F., 
Cohn, J., Denkinger, C.M., Evans, T.G., Källenius, G., Kaplan, G., Kumar, A.M. V, 
Matthiessen, L., Mgone, C.S., Mizrahi, V., Mukadi, Y., Nguyen, V.N., Nordström, A., 
Sizemore, C.F., Spigelman, M., Squire, S.B., Swaminathan, S., Helden, P.D. van, 
Zumla, A., Weyer, K., Weily, D. 2016.  Translational research for tuberculosis 
elimination: priorities, challenges, and actions.  PLoS Medicine 13: e1001965. 
Light, M.E., Sparg, S.G., Stafford, G.I., Van Staden, J. 2005.  Riding the wave: South 
Africa’s contribution to ethnopharmacological research over the last 25 years.  
Journal of Ethnopharmacology 100: 127–130. 
Lin, P.L., Flynn, J.L. 2010.  Understanding latent tuberculosis: a moving target.  Journal 
of Immunology 185: 15–22. 
Lin, Y.-M., Flavin, M.T., Schure, R., Chen, F.-C., Sidwell, R., Barnard, D.I., Huffmann, 
J.H., Kern, E.R. 1999.  Antiviral activities of biflavonoids. Planta Medica 65: 120–
125. 
Mabberley, D.J. 1997. The Plant-Book: A portable dictionary of the vascular plants. 
Cambridge University Press. 
 208 
 
Mahajan, R.T., Chopda, M.Z. 2009. Phyto-pharmacology of Ziziphus jujuba Mill-A plant 
review.  Pharmacognosy Reviews 3: 320. 
Mahomoodally, M.F., Gurib‐Fakim, A., Subratty, A.H. 2010.  Screening for alternative 
antibiotics: an investigation into the antimicrobial activities of medicinal food plants 
of Mauritius.  Journal of Food Science 75: M173–M177. 
Maina, M.H. 2011.  Phytochemical and antimicrobial studies on Rhus natalensis.  MSc 
Dissertation, University of the Western Cape, Western Cape. 
Makunga, N.P., Philander, L.E., Smith, M. 2008.  Current perspectives on an emerging 
formal natural products sector in South Africa.  Journal of  Ethnopharmacology 119: 
365–375. 
Malama, S., Munyeme, M., Mwanza, S., Muma, J.B. 2014.  Isolation and 
characterization of non-tuberculous mycobacteria from humans and animals in 
Namwala District of Zambia.  Biomedical Research Notes 7 doi: 10.1186/1756-
0500-7-622.  
Mander, M., Ntuli, L., Diedericks, N., Mavundla, K. 2007. South Africa’s traditional 
medicines industry. Available at http://www.hst.org.za/uploads/files/chapter13_07 
[Accessed 2016-08-13]. 
Manvar, D., Mishra, M., Kumar, S., Pandey, V.N. 2012.  Identification and evaluation of 
anti Hepatitis C virus phytochemicals from Eclipta alba.  Journal of 
Ethnopharmacology 144: 545–554. 
Marcotty, T., Matthys, F., Godfroid, J., Rigouts, L., Ameni, G., Van Pittius, N.G., 
Kazwala, R., Muma, J., Van Helden, P., Walravens, K. 2013.  Zoonotic tuberculosis 
and brucellosis in Africa: neglected zoonoses or minor public-health issues? The 
outcomes of a multi-disciplinary workshop.  Annals of Tropical Medicine and 
Parasitology 103 (5): 401-11 doi:10.1179/136485909X451771.  
Mariita, R.M., Orodho, J.A., Okemo, P.O., Mbugua, P.K. 2010. Antifungal, antibacterial 
and antimycobacterial activity of Entada abysinnica Steudel ex A. Rich (Fabaceae) 
methanol extract.  Pharmacognosy Research 2: 163. 
Maroyi, A. 2013.  Traditional use of medicinal plants in south-central Zimbabwe: review 
and perspectives.  Journal of Ethnobiology and Ethnomedicine 9:31doi: 
10.1186/1746-4269-9-31. 
Marx, G.E., Chan, E.D. 2011.  Tuberculous meningitis: diagnosis and treatment 
overview.  Tuberculosis Research Treatment doi:10.1155/2011/798764. 
Maslow, J.N., Mikota, S.K. 2015.  Tuberculosis in elephants-a reemergent disease: 
diagnostic dilemmas, the natural history of infection, and new immunological tools. 
Veterinary Pathology 52: 437–440 doi:10.1177/0300985814568357 
McGaw, L.J., Lall, N., Hlokwe, T.M., Michel, A.L., Meyer, J.J.M., Eloff, J.N. 2008a. 
Purified compounds and extracts from Euclea species with antimycobacterial 
 209 
 
activity against Mycobacterium bovis and fast-growing mycobacteria.  Biological 
and Pharmacological Bulletin 31: 1429–1433. 
McGaw, L.J., Lall, N., Meyer, J.J.M., Eloff, J.N. 2008b.  The potential of South African 
plants against Mycobacterium infections.  Journal of Ethnopharmacology 119: 482–
500. doi:10.1016/j.jep.2008.08.022 
McGaw, L.J., Steenkamp, V., Eloff, J.N. 2007. Evaluation of Athrixia bush tea for 
cytotoxicity, antioxidant activity, caffeine content and presence of pyrrolizidine 
alkaloids. Journal of Ethnopharmacology 110: 16–22 
doi.org/10.1016/j.jep.2006.08.029. 
McGrath, E.E., McCabe, J., Anderson, P.B. 2008.  Guidelines on the diagnosis and 
treatment of pulmonary non‐tuberculous mycobacteria infection.  International 
Journal of  Clinical Practice 62: 1947–1955. 
McKean, S., Mander, M. 2007.  Traditional medicine and the vulture trade: a case study. 
South African Health Review 197–199. 
Melnikova, N., Burlova, I., Kiseleva, T., Klabukova, I., Gulenova, M., Kislitsin, А., Vasin, 
V., Tanaseichuk, B. 2012.  A practical synthesis of betulonic acid using selective 
oxidation of betulin on aluminium solid support.  Molecules 17: 11849–11863. 
Michel, A.L., de Klerk, L.M., van Pittius, N.C.G., Warren, R.M., van Helden, P.D. 2007. 
Bovine tuberculosis in African buffaloes: observations regarding Mycobacterium 
bovis shedding into water and exposure to environmental mycobacteria.  
Biomedical Veterinary Research 3: 23 doi:1746-6148-3-23. 
Michel, A.L., Hlokwe, T.M., Coetzee, M.L., Mare, L., Connoway, L., Rutten, V., Kremer, 
K. 2008.  High Mycobacterium bovis genetic diversity in a low prevalence setting. 
Veterinary Microbiology 126: 151–159. 
Michel, A.L., Hlokwe, T.M., Espie, I.W., Zijll Langhout, M., Koeppel, K., Lane, E. 2013. 
Mycobacterium tuberculosis at the human/wildlife interface in a high TB burden 
country.  Transboundary Emerging Diseases 60: 46–52. 
Michel, A.L., Müller, B., Van Helden, P.D. 2010.  Mycobacterium bovis at the animal–
human interface: A problem, or not? Veterinary Microbiology 140: 371–381. 
Mikota, S.K., Peddie, L., Peddie, J., Isaza, R., Dunker, F., West, G., Lindsay, W., 
Larsen, R.S., Chatterjee, D., Payeur, J. 2001.  Epidemiology and diagnosis of 
Mycobacterium tuberculosis in captive Asian elephants (Elephas maximus).  
Journal of Zoo and Wildlife Medicine 32: 1–16. 
Miller, M.A. 2015. Tuberculosis in South African wildlife: Why is it important? Inaugural 
lecture, Stellenbosch University, Cape Town. 
Mirsaeidi, M., Farshidpour, M., Allen, M.B., Ebrahimi, G., Falkinham, J.O. 2014a. 
Highlight on advances in nontuberculous mycobacterial disease in North America. 
Biomedical Research International doi:10.1155/2014/919474. 
 210 
 
Mirsaeidi, M., Farshidpour, M., Ebrahimi, G., Aliberti, S., Falkinham, J.O. 2014b. 
Management of non-tuberculous mycobacterial infection in the elderly.  European 
Journal of Internal Medicine 25: 356–363 doi:10.1016/j.ejim.2014.03.008. 
Mittal, A.K., Chisti, Y., Banerjee, U.C. 2013.  Synthesis of metallic nanoparticles using 
plant extracts. Biotechnology Advances 31: 346–356 
doi:10.1016/j.biotechadv.2013.01.003. 
Moffett, R.O., 1993. Rhus ciliata and Rhus tridactyla, two hitherto confused species of 
southern African Anacardiaceae.  Botanical Journal of the Linnean Society 112: 
33–42. 
Moffett, R.O. 2007.  Name changes in the old world Rhus and recognition of Searsia 
(Anacardiaceae).  Bothalia 37, 165–175. 
Moldovan, H., Albulescu, M., Vlase, G., Bercean, V. 2013.  Synthesis of betulonic acid 
by oxidation of betulin.  Annals of West University Timisoara.  22: 89. 
Moore, J.E., Kruijshaar, M.E., Ormerod, L.P., Drobniewski, F., Abubakar, I. 2010. 
Increasing reports of non-tuberculous mycobacteria in England, Wales and 
Northern Ireland, 1995-2006.  Biomedical Public Health 10: 612. doi:1471-2458-10-
612. 
Mosa, R.A., Nhleko, M.L., Dladla, T. V, Opoku, A.R. 2014.  Antibacterial activity of two 
triterpenes from stem bark of Protorhus longifolia.  Journal of Medicinal Plants 
Research 8: 686–702. 
Mosmann, T. 1983.  Rapid colorimetric assay for cellular growth and survival: 
application to proliferation and cytotoxicity assays.  Journal of Immunological 
Methods 65: 55–63. 
Mourão, M.P.B., Kuijper, S., Dang, N.A., Walters, E., Janssen, H.-G., Kolk, A.H.J. 2016. 
Direct detection of Mycobacterium tuberculosis in sputum: A validation study using 
solid phase extraction-gas chromatography–mass spectrometry.  Journal of  
Chromatograpphy B 1012: 50–54. 
Mukanganyama, S., Chirisa, E., Hazra, B. 2015.  Antimycobacterial activity of diospyrin 
and its derivatives against Mycobacterium aurum.  Research Pharmacy 2(1): 1-13. 
Mukherjee, P.K., Venkatesh, P., Ponnusankar, S. 2010. Ethnopharmacology and 
integrative medicine – Let the history tell the future. Journal of Ayurveda and 
Integrative Medicine 1: 100–109 doi:10.4103/0975-9476.65077 
Müller, B., Dürr, S., Alonso, S., Hattendorf, J., Laisse, C.J.M., Parsons, S.D.C., Van 
Helden, P.D., Zinsstag, J. 2013.  Zoonotic Mycobacterium bovis-induced 
tuberculosis in humans.  Emerging Infectious Diseases 19: 899–908. 
Müller, B., Klerk-Lorist, L., Henton, M.M., Lane, E., Parsons, S., Pittius, N.C.G., Kotze, 
A., Helden, P.D., Tanner, M. 2011.  Mixed infections of Corynebacterium 
pseudotuberculosis and non-tuberculous mycobacteria in South African antelopes 
 211 
 
presenting with tuberculosis-like lesions.  Veterinary Microbiology 147: 340–345. 
Munyeme, M., Muma, J.B., Munang’andu, H.M., Kankya, C., Skjerve, E., Tryland, M. 
2010.  Cattle owners’ awareness of bovine tuberculosis in high and low prevalence 
settings of the wildlife-livestock interface areas in Zambia.  Biomedical Veterinary 
Research 6: 1. 
Munyeme, M., Muma, J.B., Siamudaala, V.M., Skjerve, E., Munang’andu, H.M., Tryland, 
M. 2010.  Tuberculosis in Kafue lechwe antelopes (Kobus leche Kafuensis) of the 
Kafue Basin in Zambia.  Preventive Veterinary Medicine 95: 305–308. 
Musoke, J., Hlokwe, T.M., Marcotty, T., Du Plessis, B.J.A., Michel, A.L. 2015.  Spillover 
of Mycobacterium bovis from wildlife to livestock, South Africa.  Emerging Infectious 
Diseases 21 (3): 448-451 doi:10 320/eid 2103.131690. 
Musser, J.M., 1995.  Antimicrobial agent resistance in mycobacteria: molecular genetic 
insights.  Clinical Microbiology Reviews 8: 496–514. 
Muwonge, A., Kankya, C., Johansen, T.B., DjÃ¸nne, B., Godfroid, J., Biffa, D., 
Edvardsen, V., Skjerve, E. 2012.  Non-tuberculous mycobacteria isolated from 
slaughter pigs in Mubende district, Uganda.  Biomedical Veterinary Research 8: 52 
doi:1746-6148-8-52. 
Myers, J.A., Steele, J.H. 1969.  Bovine tuberculosis.  Control in man and animals. St 
Louis, Missouri: Warren H. Green, Inc.   
Naranjo, V., Gortazar, C., Vicente, J., De La Fuente, J. 2008.  Evidence of the role of 
European wild boar as a reservoir of Mycobacterium tuberculosis complex.  
Veterinary Microbiology 127: 1–9. 
Newman, D.J., Cragg, G.M. 2010.  Natural products as drugs and leads to drugs: the 
historical perspective.  Natural Product Chemistry for Drug Discovery.  Cambridge, 
UK RSC Publ. 23–24. 
Newman, D.J., Cragg, G.M. 2007.  Natural products as sources of new drugs over the 
last 25 years.  Journal of Natural Products 70: 461–477. 
Newman, D.J., Cragg, G.M., Snader, K.M. 2003.  Natural products as sources of new 
drugs over the period 1981-2002.  Journal of Natural Products 66: 1022–1037. 
Nguta, J.M., Appiah-Opong, R., Nyarko, A.K., Yeboah-Manu, D., Addo, P.G.A., 
Otchere, I., Kissi-Twum, A. 2016.  Antimycobacterial and cytotoxic activity of 
selected medicinal plant extracts. Journal of Ethnopharmacology 
doi:10.1016/j.jep.2016.02.010. 
Nicholson, S., da G Bonecini-Almeida, M., e Silva, J.R.L., Nathan, C., Xie, Q.W., 
Mumford, R., Weidner, J.R., Calaycay, J., Geng, J., Boechat, N. 1996.  Inducible 
nitric oxide synthase in pulmonary alveolar macrophages from patients with 
tuberculosis.  Journal of Experimental Medicine 183: 2293–2302. 
 212 
 
Niederweis, M. 2003. Mycobacterial porins – new channel proteins in unique outer 
membranes.  Molecular Microbiology 49: 1167–1177. 
Nishi, J.S., Shury, T., Elkin, B.T. 2006.  Wildlife reservoirs for bovine tuberculosis 
(Mycobacterium bovis) in Canada: strategies for management and research.  
Veterinary Microbiology 112: 325–338. 
Nugent, G. 2011. Maintenance, spillover and spillback transmission of bovine 
tuberculosis in multi-host wildlife complexes: a New Zealand case study.  
Veterinary Microbiology 151: 34–42. 
O’Brien, D.J., Schmitt, S.M., Fierke, J.S., Hogle, S.A., Winterstein, S.R., Cooley, T.M., 
Moritz, W.E., Diegel, K.L., Fitzgerald, S.D., Berry, D.E. 2002.  Epidemiology of 
Mycobacterium bovis in free-ranging white-tailed deer, Michigan, USA, 1995–2000. 
Preventive Veterinary Medicine 54: 47–63. 
Ocepek, M., Pate, M., Zolnir-Dovc, M., Poljak, M. 2005.  Transmission of 
Mycobacterium tuberculosis from human to cattle.  Journal of Clinical Microbiology 
43: 3555–3557. 
Ojewole, J.A.O. 2008. Anticonvulsant effect of Rhus chirindensis (Baker F.) 
(Anacardiaceae) stem-bark aqueous extract in mice.  Journal of 
Ethnopharmacology 117: 130–135. 
Office International des Epizooties (OIE). 2014.  Bovine tuberculosis.  Available at 
(http://www.oie.int.pdf/BOVINE-TB-EN [Accessed 2016-10-13]. 
Olea-Popelka, F., Muwonge, A., Perera, A., Dean, A.S., Mumford, E., Erlacher-Vindel, 
E., Forcella, S., Silk, B.J., Ditiu, L., El Idrissi, A., Raviglione, M., Cosivi, O., LoBue, 
P., Fujiwara, P.I. 2016.  Zoonotic tuberculosis in human beings caused by 
Mycobacterium bovis -a call for action. The Lancet Infectious Diseases 
doi:10.1016/S1473-3099(16): 301-396. 
Padilla, E., Manterola, J.M., González, V., Thornton, C.G., Quesada, M.D., Sánchez, 
M.D., Pérez, M., Ausina, V. 2005.  Comparison of the sodium hydroxide specimen 
processing method with the C18-carboxypropylbetaine specimen processing 
method using independent specimens with auramine smear, the MB/BacT liquid 
culture system, and the COBAS AMPLICOR MTB test.  Journal of Clinical 
Microbiology 43: 6091–6097. 
Pai, M., Kalantri, S., Dheda, K. 2006.  New tools and emerging technologies for the 
diagnosis of tuberculosis: part II. Active tuberculosis and drug resistance.  Expert 
Review of Molecular Diagnostics 6: 423–432. 
Palgrave, K.C., Drummond, R.B., Moll, E.J., Palgrave, M.C. 2002.  Trees of Southern 
Africa.  Struik Publishers. 
Palmer, M. V, Thacker, T.C., Waters, W., Gortázar, C., Corner, L.A.L. 2012. 
Mycobacterium bovis: a model pathogen at the interface of livestock, wildlife, and 
 213 
 
humans.  Veterinary Medicine International doi.org/10.1155/2012/236205 (17 
pages). 
Pandey, M., Debnath, M., Gupta, S., Chikara, S.K. 2011.  Phytomedicine: an ancient 
approach turning into future potential source of therapeutics.  Journal of 
Pharmacognosy and Phytotherapy 3: 113–117. 
Parandhaman, D.K., Narayanan, S. 2014.  Cell death paradigms in the pathogenesis of 
Mycobacterium tuberculosis infection. Front.  Cellular and Infection Microbiology 4: 
31 doi 10.3389/fcimb.2014.00031. 
PARDO, R.B., LANGONI, H., MENDONÇA, L.J.P., CHI, K.D. 2001.  Isolation of 
Mycobacterium spp. in milk from cows suspected or positive to tuberculosis. 
Brazilian Journal of Veterinary Research and Animal Science 38(6): 284-287. 
Parreiras, P.M., Andrade, G.I., Nascimento, T. de F. do, Oelemann, M.C., Gomes, H.M., 
Alencar, A.P. de, Assis, R.A. de, Mota, P.M.P.C., Pereira, M.A. da S., Lobato, 
F.C.F. 2012. Spoligotyping and variable number tandem repeat analysis of 
Mycobacterium bovis isolates from cattle in Brazil.  Memorias do Instituto Oswaldo 
Cruz 107: 64–73. 
Parsons, L.M., Brosch, R., Cole, S.T., Somoskövi, Á., Loder, A., Bretzel, G., Van 
Soolingen, D., Hale, Y.M., Salfinger, M. 2002.  Rapid and simple approach for 
identification of Mycobacterium tuberculosis complex isolates by PCR-based 
genomic deletion analysis.  Journal of Clinical Microbiology 40: 2339–2345. 
Pauw, E.L. 2014.  Evaluating the predictive value of a database of antimicrobial 
activities of leaf extracts of 537 southern African tree species against six important 
bacterial and fungal pathogens.  PhD Thesis, University of Pretoria, Pretoria. 
Pauw, E., Eloff, J.N. 2014. Which tree orders in southern Africa have the highest 
antimicrobial activity and selectivity against bacterial and fungal pathogens of 
animals? Biomedical Complementary and Alternative Medicine 14: 317 
doi:10.1186/1472-6882-14-317 (8 pages). 
Pavlik, I., Matlova, L., Dvorska, L., Bartl, J., Oktabcova, L., Docekal, J. 2003. 
Tuberculous lesions in pigs in the Czech Republic during 1990.1999: occurrence, 
causal factors and economic losses.  Veterinarni Medicina, 55 (2): 55-59. 
Pavlik, I., Matlova, L., Dvorska, L., Shitaye, J.E., Parmova, I. 2005.  Mycobacterial 
infections in cattle and pigs caused by Mycobacterium avium complex members 
and atypical mycobacteria in the Czech Republic during 2000-2004.  Veterinary 
Medicine 50: 281. 
Periasamy, G., Teketelew, G., Gebrelibanos, M., Sintayehu, B., Gebrehiwot, M., Karim, 
A., Geremedhin, G. 2014.  Betulinic acid and its derivatives as anti-cancer agent: a 
review.  Archives of Applied Science Research 6: 47–58. 
Phillipson, J.D. 2001. Phytochemistry and medicinal plants.  Phytochemistry 56: 237–
 214 
 
243. 
Pierre-Audigier, C., Jouanguy, E., Lamhamedi, S., Altare, F., Rauzier, J., Vincent, V., 
Canioni, D., Emile, J.-F., Fischer, A., Blanche, S. 1997.  Fatal disseminated 
Mycobacterium smegmatis infection in a child with inherited interferon γ receptor 
deficiency.  Clinical Infectious Diseases 24: 982–984. 
Pittius, N.C.G., Perrett, K.D., Michel, A.L., Keet, D.F., Hlokwe, T., Streicher, E.M., 
Warren, R.M., Helden, P.D. 2012.  Infection of African buffalo (Syncerus caffer) by 
oryx bacillus, a rare member of the antelope clade of the Mycobacterium 
tuberculosis complex.  Journal of Wildlife Diseases 48: 849–857. 
Prasad, H.K., Singhal, A., Mishra, A., Shah, N.P., Katoch, V.M., Thakral, S.S., Singh, D. 
V, Chumber, S., Bal, S., Aggarwal, S. 2005.  Bovine tuberculosis in India: potential 
basis for zoonosis.  Tuberculosis 85: 421–428. 
Puttinaowarat, S., Thompson, K.D., Kolk, A., Adams, A. 2002.  Identification of 
Mycobacterium spp. isolated from snakehead, Channa striata (Fowler), and 
Siamese fighting fish, Betta splendens (Regan), using polymerase chain reaction-
reverse cross blot hybridization (PCR-RCBH).  Journal of Fish Diseases 25: 235–
243. 
Qulu, L., Daniels, W.M.U., Russell, V., Mabandla, M. V. 2015.  Searsia chirindensis 
reverses the potentiating effect of prenatal stress on the development of febrile 
seizures and decreased plasma interleukin-1ß levels. Neuroscience Research 
doi:10.1016/j.neures.2015.08.004 
Raskin, I., Ribnicky, D.M., Komarnytsky, S., Ilic, N., Poulev, A., Borisjuk, N., Brinker, A., 
Moreno, D.A., Ripoll, C., Yakoby, N. 2002.  Plants and human health in the twenty-
first century. Trends in Biotechnology 20: 522–531. 
Rates, S.M.K. 2001.  Plants as source of drugs. Toxicon 39: 603–613. 
Rayne, S., Mazza, G. 2007.  Biological activities of extracts from sumac (Rhus spp.): a 
review.  Plant Foods for Human Nutrition 62: 165–175. 
Reddington, K., O’Grady, J., Dorai-Raj, S., Niemann, S., van Soolingen, D., Barry, T. 
2011. A novel multiplex real-time PCR for the identification of Mycobacteria 
associated with zoonotic tuberculosis. PLoS One 6 
doi:10.1371/journal.pone.0023481.  
Riley, L.W. 2006.  Of mice, men, and elephants: Mycobacterium tuberculosis cell 
envelope lipids and pathogenesis.  Journal of  Clinical Investigation 116: 1475. 
Rivers, E.C., Mancera, R.L., 2008.  New anti-tuberculosis drugs in clinical trials with 
novel mechanisms of action. Drug Discovery Today 13: 1090–1098 
doi:10.1016/j.drudis.2008.09.004 
Rodriguez-Campos, S., Navarro, Y., Romero, B., de Juan, L., Bezos, J., Mateos, A., 
Golby, P., Smith, N.H., Hewinson, G.R., Domínguez, L. 2013.  Splitting of a 
 215 
 
prevalent Mycobacterium bovis spoligotype by variable-number tandem-repeat 
typing reveals high heterogeneity in an evolving clonal group.  Journal of Clinical 
Microbiolology 51: 3658–3665. 
Rónai, Z., Csivincsik, Á., Dán, Á., Gyuranecz, M. 2016.  Molecular analysis and MIRU-
VNTR typing of Mycobacterium avium subsp. avium,‘hominissuis’ and silvaticum 
strains of veterinary origin.  Infection, Genetics and Evolution 40: 192–199. 
Ronquist, F., Teslenko, M., van der Mark, P., Ayres, D.L., Darling, A., Hohna, S., Larget, 
B., Liu, L., Suchard, M.A., Huelsenbeck, J.P. 2012.  MrBayes 3.2: Efficient 
Bayesian phylogenetic inference and model choice across a large model space. 
Systematic Biology 61: 539–542 doi:10.1093/sysbio/sys029. 
Roring, S., Scott, A., Brittain, D., Walker, I., Hewinson, G., Neill, S., Skuce, R. 2002. 
Development of variable-number tandem repeat typing of Mycobacterium bovis: 
comparison of results with those obtained by using existing exact tandem repeats 
and spoligotyping.  Journal of Clinical Microbiology 40: 2126–2133. 
Roth, A., Reischl, U., Schönfeld, N., Naumann, L., Emler, S., Fischer, M., Mauch, H., 
Loddenkemper, R., Kroppenstedt, R.M. 2000.  Mycobacterium heckeshornense sp. 
nov., a new pathogenic slowly growing Mycobacterium sp. causing cavitary lung 
disease in an immunocompetent patient.  Journal of Clinical Microbiology 38: 
4102–4107. 
Rout, S.P., Choudary, K.A., Kar, D.M., Das, L., Jain, A. 2009.  Plants in traditional 
medicinal system - future source of new drugs.  International Journal of Pharmacy 
and Pharmaceutical Sciences 1: 1–23. 
Rybicki, E.P., Chikwamba, R., Koch, M., Rhodes, J.I., Groenewald, J.-H. 2012.  Plant-
made therapeutics: an emerging platform in South Africa.  Biotechnology Advances 
30: 449–459. 
Ryll, R., Kumazawa, Y., Yano, I. 2001.  Immunological properties of trehalose 
dimycolate (cord factor) and other mycotic acid‐containing glycolipids. A Review of 
Microbiology and Immunology 45: 801–811. 
Ryu, Y.J. 2015.  Diagnosis of pulmonary tuberculosis: recent advances and diagnostic 
algorithms.  Tuberculosis and Respiratory Diseases  78: 64–71. 
Sacksteder, K.A., Protopopova, M., Barry, C.E., Andries, K., Nacy, C.A. 2012. 
Discovery and development of SQ109: a new antitubercular drug with a novel 
mechanism of action.  Future Microbiology 7: 823–837. 
Sahraoui, N., Müller, B., Guetarni, D., Boulahbal, F., Yala, D., Ouzrout, R., Berg, S., 
Smith, N.H., Zinsstag, J. 2009.  Molecular characterization of Mycobacterium bovis 
strains isolated from cattle slaughtered at two abattoirs in Algeria.  Biomedical 
Veterinary Research 5: 4. 
Sakamoto, K. 2012.  The pathology of Mycobacterium tuberculosis infection.  Veterinary 
 216 
 
Pathology 49: 423–439. 
Saleem, M., Nazir, M., Ali, M.S., Hussain, H., Lee, Y.S., Riaz, N., Jabbar, A. 2010. 
Antimicrobial natural products: an update on future antibiotic drug candidates.  
Natural Product Reports 27: 238–254. 
Samper, S., Martín, C., Pinedo, A., Rivero, A., Blázquez, J., Baquero, F., Van 
Soolingen, D., van Embden, J. 1997.  Transmission between HIV‐infected patients 
of multidrug‐resistant tuberculosis caused by Mycobacterium bovis.  Aids 11: 1237–
1242. 
Santhosh, R.S., Suriyanarayanan, B. 2014.  Plants: a source for new antimycobacterial 
drugs.  Planta Medica 80: 9–21. 
Saxena, G., McCutcheon, A.R., Farmer, S., Towers, G.H.N., Hancock, R.E.W. 1994. 
Antimicrobial constituents of Rhus glabra.  Journal of Ethnopharmacology 42: 95–
99. 
Schmitt, S.M., O’brien, D.J., BRUNING‐FANN, C.S., Fitzgerald, S.D. 2002.  Bovine 
tuberculosis in Michigan wildlife and livestock.  Annals of the New York Academy of  
Sciences 969: 262–268. 
Schwikkard, S.L., Mulholland, D.A. 2014.  Useful methods for targeted plant selection in 
the discovery of potential new drug candidates.  Planta Medica 80: 1154–1160. 
Sebothoma, C. 2009. Isolation and characterization of antibacterial compounds from 
Rhus leptodictya. MSc Dissertation, University of Limpopo, Limpopo. 
Shabbir, A. 2012.  Rhus coriaria Linn, a plant of medicinal, nutritional and industrial 
importance: a review.  Journal of Animal and Plant Sciences 22: 505–512. 
Shah, N.S., Wright, A., Bai, G.-H., Barrera, L., Boulahbal, F., Drobniewski, F., Gilpin, C., 
Havelkov, M., Lepe, R., Lumb, R. 2007.  Worldwide emergence of extensively drug-
resistant tuberculosis.  Emerging infectious Diseases 13 (3): 380-387. 
Shanmuganathan, R., Shanmuganathan, I.D. 2015. Clinical manifestation and risk 
factors of tuberculosis infection in Malaysia: case study of a community clinic. 
Global Journal of Health Science 7: 110. 
Sharma, S.K., Mohan, A., Sharma, A., Mitra, D.K. 2005.  Miliary tuberculosis: new 
insights into an old disease.  Lancet Infectious Diseases 5: 415–430. 
Shawar, R.M., Humble, D.J., Van Dalfsen, J.M., Stover, C.K., Hickey, M.J., Steele, S., 
Mitscher, L.A., Baker, W. 1997.  Rapid screening of natural products for 
antimycobacterial activity by using luciferase-expressing strains of Mycobacterium 
bovis BCG and Mycobacterium intracellulare.  Antimicrobial Agents and 
Chemotherapy 41: 570–574. 
Shitaye, E.J., Beran, V., Svobodová, J., Morávková, M., Babák, V., Pavlík, I. 2009. 
Comparison of the conventional culture, the manual fluorescent MGIT system and 
 217 
 
the automated fluorescent MGIT 960 culture system for the detection of 
Mycobacterium avium ssp. avium in tissues of naturally infected hens.  Folia 
Microbiologica 54: 137–141 doi:10.1007/s12223-009-0020-y. 
Silaigwana, B., Green, E., Ndip, R.N. 2012.  Molecular detection and drug resistance of 
Mycobacterium tuberculosis complex from cattle at a dairy farm in the Nkonkobe 
region of South Africa: A pilot study.  Internationa Journal of  Environmental 
Research and Public Health 9: 2045–2056. 
Silva, M.R., Rocha, A. da S., Costa, R.R. da, Alencar, A.P. de, Oliveira, V.M. de, 
Fonseca Junior, A.A., Sales, M.L., Issa, M. de A., Soares Filho, P.M., Pereira, 
O.T.V. 2013.  Tuberculosis patients co-infected with Mycobacterium bovis and 
Mycobacterium tuberculosis in an urban area of Brazil.  Memorias do Instituto 
Oswaldo Cruz 108: 321–327. 
Singh, B., Bhat, T.K., Singh, B. 2003.  Potential therapeutic applications of some 
antinutritional plant secondary metabolites.  Journal of Agricultural and Food 
Chemistry 51: 5579–5597. 
Skuce, R.A., McCorry, T.P., McCarroll, J.F., Roring, S.M.M., Scott, A.N., Brittain, D., 
Hughes, S.L., Hewinson, R.G., Neill, S.D. 2002.  Discrimination of Mycobacterium 
tuberculosis complex bacteria using novel VNTR-PCR targets.  Microbiology 148: 
519–528. 
Slany, M., Mrlik, V., Kriz, P., Pavlik, I. 2010.  First isolation of a newly described 
Mycobacterium insubricum from freshwater fish.  Veterinary Microbiology 144: 254–
255 doi:10.1016/j.vetmic. 
Soejarto, D.D., Gyllenhaal, C., Kadushin, M.R., Southavong, B., Sydara, K., 
Bouamanivong, S., Xaiveu, M., Zhang, H.-J., Franzblau, S.G., Tan, G.T. 2012.  An 
ethnobotanical survey of medicinal plants of Laos toward the discovery of bioactive 
compounds as potential candidates for pharmaceutical development.  
Pharmaceutical Biology 50: 42–60. 
Sola, C., Filliol, I., Legrand, E., Lesjean, S., Locht, C., Supply, P., Rastogi, N. 2003. 
Genotyping of the Mycobacterium tuberculosis complex using MIRUs: association 
with VNTR and spoligotyping for molecular epidemiology and evolutionary genetics. 
Infection, Genetics and Evolution 3: 125–133. 
Songca, S.P., Sebothoma, C., Samuel, B.B., Eloff, J.N. 2012.  A biflavonoid and a 
carotenoid from Rhus leptodictya: isolation, characterization and antibacterial 
properties.  African Journal of Biochemistry Research 6: 172–178. 
Sotgiu, G., Centis, R., D’Ambrosio, L., Spanevello, A., Migliori, G.B. 2013.  Linezolid to 
treat extensively drug-resistant TB: retrospective data are confirmed by 
experimental evidence.  European Respiratory Journal 42: 288–290. 
Sreevatsan, S., Stockbauer, K.E., Pan, X.I., Kreiswirth, B.N., Moghazeh, S.L., Jacobs, 
W.R., Telenti, A., Musser, J.M. 1997.  Ethambutol resistance in Mycobacterium 
 218 
 
tuberculosis: critical role of embB mutations. Antimicrobial Agents and 
Chemotherapy 41: 1677–1681. 
  
 219 
 
Stahl, D.A., Urbance, J.W. 1990.  The division between fast-and slow-growing species 
corresponds to natural relationships among the mycobacteria.  Journal of 
Bacteriology 172: 116–124. 
Stark, T.D., Mtui, D.J., Balemba, O.B. 2013.  Ethnopharmacological survey of plants 
used in the traditional treatment of gastrointestinal pain, inflammation and diarrhea 
in Africa: future perspectives for integration into modern medicine.  Animals 3: 158–
227. 
Street, R.A., Stirk, W.A., Van Staden, J. 2008.  South African traditional medicinal plant 
trade - challenges in regulating quality, safety and efficacy.  Journal of  
Ethnopharmacology 119: 705–710. 
Suffness, M., Douros, J. 1979. Drugs of plant origin.  Methods cancer Research 16: 73–
126. 
Sunder, S., Lanotte, P., Godreuil, S., Martin, C., Boschiroli, M.L., Besnier, J.M. 2009. 
Human-to-human transmission of tuberculosis caused by Mycobacterium bovis in 
immunocompetent patients. Journal of Clinical Microbiology 47:1249–1251 
doi:10.1128/JCM.02042-08. 
Svensson, E.M., Murray, S., Karlsson, M.O., Dooley, K.E. 2014.  Rifampicin and 
rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug. 
Journal of Antimicrobial Chemotherapy  doi: 10.1093/jac/dku504. 
Swaminathan, S., Chandrasekaran, P. 2014.  Tuberculosis screening and isoniazid 
preventive therapy implementation: a Brazilian experience.  Expert Review of Anti - 
Infective Therapy 12: 289–292. 
Tabuti, J.R.S., Kukunda, C.B., Waako, P.J. 2010. Medicinal plants used by traditional 
medicine practitioners in the treatment of tuberculosis and related ailments in 
Uganda.  Journal of Ethnopharmacology 127: 130–136. 
Tamura, K., Peterson, D., Peterson, N., Stecher, G., Nei, M., Kumar, S. 2011.  MEGA5: 
Molecular evolutionary genetics analysis using Maximum Likelihood, Evolutionary 
Distance, and Maximum Parsimony Methods.  Molecular Biology and Evolution 28: 
2731–2739. doi:10.1093/molbev/msr121. 
T Ramesha, B., Gertsch, J., Ravikanth, G., Priti, V., N Ganeshaiah, K., Uma Shaanker, 
R. 2011.  Biodiversity and chemodiversity: future perspectives in bioprospecting. 
Current Drug Targets 12: 1515–1530. 
Temmerman, S., Vandekerckhove, L., Sermijn, E., Vogelaers, D., Claeys, G., 
Vaneechoutte, M., Cools, P., Callens, S. 2014.  Disseminated infection with 
Mycobacterium tilburgii in a male immunocompromised patient. Journal of Clinical 
Microbiology 52: 1777–1779. doi:03148-13. 
  
 220 
 
Thoen, C.O., LoBue, P.A., Enarson, D.A. 2014.  Tuberculosis in animals and humans -  
Zoonotic tuberculosis. Mycobacterium bovis and other pathogenic Mycobacteria, 
Third Ed. John Wiley & Sons: 3–7. 
Thoen, C.O., LoBue, P.A., Enarson, D.A., Kaneene, J.B., de Kantor, I.N. 2009. 
Tuberculosis: a re-emerging disease in animals and humans.  Veternaria Italiana, 
45 (1): 135-181. 
Thomson, J.R., Mollison, N., Matthews, K.P. 1988.  An investigation of mastitis due to S 
agalactiae, S. uberis and M. smegmatis in a dairy herd.  Veterinary Record 122: 
271–274. 
Tolstikov, G.A., Flekhter, O.B., Shultz, E.E., Baltina, L.A., Tolstikov, A.G. 2005.  Betulin 
and its derivatives: Chemistry and biological activity.  Chemistry for Sustainable 
Development 13: 1–29. 
Tolstikova, T.G., Sorokina, I. V, Tolstikov, G.A., Tolstikov, A.G., Flekhter, O.B. 2006. 
Biological activity and pharmacological prospects of lupane terpenoids: I. Natural 
lupane derivatives.  Russian Journal of Bioorganic Chemistry 32: 37–49. 
Tomioka, H. 2006.  Current status of some antituberculosis drugs and the development 
of new antituberculous agents with special reference to their in vitro and in vivo 
antimicrobial activities.  Current Pharmaceutical Design 12, 4047–4070. 
Tortoli, E. 2014.  Microbiological features and clinical relevance of new species of the 
genus Mycobacterium.  Clinical Microbiology Reviews 27: 727–752. 
Tortoli, E. 2009.  Clinical manifestations of nontuberculous mycobacteria infections. 
Clinical Microbiology and Infection 15: 906–910. 
Tortoli, E., Adriani, B., Baruzzo, S., Degl’Innocenti, R., Galanti, I., Lauria, S., Mariottini, 
A., Pascarella, M. 2009.  Pulmonary disease due to Mycobacterium arosiense, an 
easily misidentified pathogenic novel Mycobacterium.  Journal of Clinical 
Microbiology 47: 1947–1949 doi:2449-08. 
Tortoli, E., Pecorari, M., Fabio, G., Messin, M., Fabio, A. 2010.  Commercial DNA 
Probes for mycobacteria incorrectly identify a number of less frequently 
encountered species.  Journal of Clinical Microbiology 48: 307–310 doi:1536-09. 
Trunz, B.B., Fine, P.E.M., Dye, C. 2006.  Effect of BCG vaccination on childhood 
tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and 
assessment of cost-effectiveness.  Lancet 367: 1173–1180. 
Turenne, C.Y., Semret, M., Cousins, D. V, Collins, D.M., Behr, M.A., 2006.  Sequencing 
of hsp65 distinguishes among subsets of the Mycobacterium avium Complex.  
Journal of Clinical Microbiology 44: 433–440 doi:1878-05.  
Tweddle, N.E., Livingstone, P. 1994.  Bovine tuberculosis control and eradication 
programs in Australia and New Zealand.  Veterinary Microbiology 40: 23–39. 
 221 
 
Une, Y., Mori, T. 2007.  Tuberculosis as a zoonosis from a veterinary perspective. 
Comparative Immunology, Microbiology and Infectious Diseases 30: 415–425. 
van der Werf, M.J., Ködoman, C., Katalinic-Janković, V., Kummik, T., Soini, H., Richter, 
E., Papaventsis, D., Tortoli, E., Perrin, M., van Soolingen, D., Zolnir-Dovć, M., 
Thomsen, V.O. 2014.  Inventory study of non-tuberculous mycobacteria in the 
European Union.  Biomedical Infectious Diseases 14 (1): 1 doi:1471-2334-14-62.  
Van Vuuren, S.F. 2008.  Antimicrobial activity of South African medicinal plants.  
Journal of Ethnopharmacology 119: 462–472. 
Van Wyk, B.-E. 2008a.  A broad review of commercially important southern African 
medicinal plants.  Journal of Ethnopharmacology 119: 342–355. 
Van Wyk, B.-E., 2008b. A review of Khoisan and Cape Dutch medical ethnobotany.  
Journal of Ethnopharmacology 119: 331–341. 
Van Wyk, B.E., Van Oudtshoorn, B., Gericke, N. 1997.  Medicinal Plants of South 
Africa.  Briza Publications. 
Vanisree, M., Lee, C.-Y., Lo, S.-F., Nalawade, S.M., Lin, C.Y., Tsay, H.-S. 2004. 
Studies on the production of some important secondary metabolites from medicinal 
plants by plant tissue cultures.  Botanical Bulletin of Academia Sinica 45: 1–22. 
Veeresham, C. 2012.  Natural products derived from plants as a source of drugs.  
Journal of Advanced Pharmaceutical Technology and Research 3: 200. 
Villar, R., Vicente, E., Solano, B., Pérez-Silanes, S., Aldana, I., Maddry, J.A., Lenaerts, 
A.J., Franzblau, S.G., Cho, S.-H., Monge, A. 2008.  In vitro and in vivo 
antimycobacterial activities of ketone and amide derivatives of quinoxaline 1, 4-di-
N-oxide.  Journal of Antimicrobial Chemotherapy 62: 547–554. 
Volpe, E., Cappelli, G., Grassi, M., Martino, A., Serafino, A., Colizzi, V., Sanarico, N., 
Mariani, F. 2006.  Gene expression profiling of human macrophages at late time of 
infection with Mycobacterium tuberculosis.  Immunology 118: 449–460. 
Vonmoos, S., Leuenberger, P., Beer, V., De Haller, R. 1986.  Pleuropulmonary infection 
caused by Mycobacterium smegmatis.  Case description and literature review. 
Schweizerische Medizinische Wochenschrift 116: 1852–1856. 
Vos, V., Bengis, R.G., Kriek, N.P.J., Michel, A., Keet, D.F., Raath, J.P., Huchzermeyer, 
H.F.K.A. 2001.  The epidemiology of tuberculosis in free-ranging African buffalo 
(Syncerus caffer) in the Kruger National Park, South Africa. Onderstepoort Journal 
of Veterinary Research 68: 119–130. 
Wagner, D., Young, L.S. 2004.  Nontuberculous mycobacterial infections: a clinical 
review.  Infection 32: 257–270. 
Walker, L., Lowrie, D.B. 1981.  Killing of Mycobacterium microti by immunologically 
activated macrophages.  Nature 293: 69-70 doi:10.1038/293069a0. 
 222 
 
Walsh, D., McCarthy, J., O’Driscoll, C., Melgar, S. 2013.  Pattern recognition receptors - 
molecular orchestrators of inflammation in inflammatory bowel disease. Cytokine 
and Growth Factor Reviews 24: 91–104. 
Wang, G., Tang, W., Bidigare, R.R. 2005.  Terpenoids as therapeutic drugs and 
pharmaceutical agents, in: Natural Products. Springer: 197–227. 
Wang, R.-R., Gu, Q., Wang, Y.-H., Zhang, X.-M., Yang, L.-M., Zhou, J., Chen, J.-J., 
Zheng, Y.-T. 2008.  Anti-HIV-1 activities of compounds isolated from the medicinal 
plant Rhus chinensis.  Journal of Ethnopharmacology 117: 249–256. 
Wang, Y., Zhou, Q., Li, B., Liu, B., Wu, G., Ibrahim, M., Xie, G., Li, H., Sun, G. 2012. 
Differentiation in MALDI-TOF MS and FTIR spectra between two closely related 
species Acidovorax oryzae and Acidovorax citrulli.  BioMed Central Microbiology 
12: 1. 
Wani, R.L.S. 2013.  Tuberculosis 2: pathophysiology and microbiology of pulmonary 
tuberculosis.  South Sudan Medical Journal 6: 10–12. 
Ward, J.L., Baker, J.M., Beale, M.H. 2007.  Recent applications of NMR spectroscopy in 
plant metabolomics.  Federation of European Biochemical Societies Journal 274: 
1126–1131. 
Warner, D.F., Mizrahi, V. 2006.  Tuberculosis chemotherapy: the influence of bacillary 
stress and damage response pathways on drug efficacy.  Clinical Microbiology 
Reviews 19: 558–570. 
Warren, R.M., Pittius, N.C.G., Barnard, M., Hesseling, A., Engelke, E., Kock, M., 
Gutierrez, M.C., Chege, G.K., Victor, T.C., Hoal, E.G., Helden, P.D. 2006. 
Differentiation of Mycobacterium tuberculosis complex by PCR amplification of 
genomic regions of difference.  International Journal of Tuberculosis and Lung 
Disease 10: 818–822. 
Wayne, L.G. 1994.  Dormancy of Mycobacterium tuberculosis and latency of disease. 
European Journal of Clinical Microbiology and Infectious Diseases 13: 908–914. 
Wheat, N.M. 2014.  An ethnobotanical, phytochemical and metabolomics investigstion 
of plants from the Paulshoek Communal Area, Namaqualand.  PhD Thesis, 
University of Cape Town, Cape Town. 
Wilkinson, D., Davies, G.R., Connolly, C. 1996.  Directly observed therapy for 
tuberculosis in rural South Africa, 1991 through 1994.  American Journal Public 
Health 86: 1094–1097. 
Williamson, E.M., Okpako, D.T., Evans, F.J. 1996.  Selection, preparation and 
pharmacological evaluation of plant material.  John Wiley & Sons. 
Winston, D. 2001.  Nwoti—Cherokee Medicine and Ethnobotany.  Journal of the 
American Herbalists Guild 2: 45–49. 
 223 
 
Wirth, T., Hildebrand, F., Allix-Béguec, C., Wölbeling, F., Kubica, T., Kremer, K., van 
Soolingen, D., Rüsch-Gerdes, S., Locht, C., Brisse, S. 2008.  Origin, spread and 
demography of the Mycobacterium tuberculosis complex. PLoS Pathogens 4 (9): 
e1000160.doi:10.1371. 
World Health Organization.   2015.  Global tuberculosis report 2015.  Geneva, World 
Health Organization.   
World Health Organization.  2010a.  Global tuberculosis control: WHO report 2010. 
Geneva, World Health Organization. 
World Health Organization (WHO).  2010b.  Treatment of tuberculosis: guidelines.  
Geneva, World Health Organization.    
World Health Organization (WHO).  2007.  Guidelines for assessing quality of herbal 
medicines with reference to contaminants and residues.  Geneva, World Health 
Organization.   
World Health Organization (WHO).  2002.  Traditional medicine strategy 2002-2005.  
Geneva, World Health Organization. 
www.who.int  information available at (http://www.who.int/iris/9789241565059_eng 
[Accessed 2016-05-13]. 
www.intranet.tdmu.edu.ua information available at 
(http://www.intranet.tdmu.edu.ua/data/kafedra/internal/micbio/classes_stu/en/nurse/
Associate) [Accessed 2016-09-16]. 
www.microbiologyinfo.com information available at 
(http://www.microbiologyinfo.com/lowenstein-jensen-lj-medium) [Accessed 2016-
08-12] 
www.sa.venues.com information available at (http://www.sa.venues.com) [Accessed 
2016-07-13]. 
www.zipcodezoo.com information available at (http://www.zipcodezoo.com) [Accessed 
2016-08-13]. 
www.tropical.theferns information available at (http://www.tropical.theferns) [Accessed 
2016-08-13]. 
www.alamy.com information avalailable at (http://www.alamy.com) [Accessed 2016-08-
13]. 
www.ispotnature.org information available at (http://www.ispotnature.org) [Accessed 
2016-08-13) 
www.plantazafrica.com information available at (http://www.plantzafrica.com) [Accessed 
2016-08-13] 
  
 224 
 
www.redlist.sanbi.org information available at (http://www.redlist.sanbi.org) [Accessed 
2016-08-13]. 
www.operationwildflower.org.za information available at 
(http://www.operationwildflower.org.za) [Accessed 2016-08-13]. 
www.bidorbuy.co.za information available at (http://www.bidorbuy.co.za) [Accessed 
2016-08-13]. 
www.nda.agric.za information available at (http:www.nda.agric.za) [Accessed 2016-03-
12]. 
www.mbovis.org information available at (http://www.mbovis.org) [Accessed 2010-12-
13]. 
Xavier, A.S., Lakshmanan, M. 2014. Delamanid: A new armor in combating drug-
resistant tuberculosis.  Journal of Pharmacology and Pharmacotherapeutics. 5: 
222. 
Yang, S.-J., Liu, M.-C., Xiang, H.-M., Zhao, Q., Xue, W., Yang, S. 2015.  Synthesis and 
in vitro antitumor evaluation of betulin acid ester derivatives as novel apoptosis 
inducers.  European Journal of Medicinal Chemistry 102: 249–255. 
Yoav, K. 2012.  Diarrhea and colonic ulcers of unusual etiology.  Mycobacterial 
Diseases 2:112 doi:10.4172/2161-1068.1000112. 
Yokoyama, E., Kishida, K., Uchimura, M., Ichinohe, S. 2007.  Improved differentiation of 
Mycobacterium tuberculosis strains, including many Beijing genotype strains, using 
a new combination of variable number of tandem repeats loci.  Journal of Molecular 
Epidemiology and Evolutionary Genetics of Infectious Diseases 7: 499–508. 
Young, D., Dye, C. 2006.  The development and impact of tuberculosis vaccines.  Cell 
124: 683–687. 
Young, L.S. 1993.  Mycobacterial diseases and the compromised host. Clinical 
Infectious Diseases:  An Official publication of the Infectious Diseases Society of 
America 17 Suppl 2: S436–S441. 
Zahin, M., Hasan, S., Aqil, F., Khan, M.S.A., Husain, F.M., Ahmad, I. 2010.  Screening 
of certain medicinal plants from India for their anti-quorum sensing activity.  Indian 
Journal of Experimental Biology 48 (12): 1219-24. 
Zeng, W., Zhang, Y., Zhao, X., Huang, G., Jiang, Y., Dong, H., Li, X., Wan, K., He, C. 
2013.  Occurrence of non-tuberculous mycobacteria species in livestock from 
northern China and first isolation of Mycobacterium caprae.  Epidemiology and 
Infection, Special Issue: TB in wildlife. 141: 1545–1551. 
Zumla, A., Nahid, P., Cole, S.T. 2013.  Advances in the development of new 
tuberculosis drugs and treatment regimens.  Nature Reviews Drug Discovery 12: 
388–404.
 225 
 
APPENDICES 
Appendix A: Structure elucidation of compound SLN-1 
 
 226 
 
 
 
 
 227 
 
 
 228 
 
 
 229 
 
 
  
 230 
 
 
 
 
 231 
 
 
 
 232 
 
 
 
 233 
 
 
 
 234 
 
 
 
 235 
 
 
 
 236 
 
 
 
 237 
 
 
 
 238 
 
 
 
 239 
 
 
 
 240 
 
 
 241 
 
 
 
 242 
 
 
 243 
 
 
 244 
 
 
 
 245 
 
 
 
 246 
 
 
 247 
 
 
 248 
 
 
 249 
 
 
 250 
 
 
 251 
 
 
 252 
 
 
 253 
 
 
 254 
 
 
 255 
 
 
 
 256 
 
 
 257 
 
 
 258 
 
 
 259 
 
 
 260 
 
 
 261 
 
 
 262 
 
Appendix B: Structure elucidation of compound PK-B 
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[M-H]- = 537.0822 for C30H17O10 
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[M-H]+ = 539.0959 for C30H19O10 
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